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ABSTRACT 
Low implementation of cost-effective health technologies results in inefficient use of 
resources in a health system. Despite this, estimates of implementation or diffusion are not 
routine components of analyses performed within health technology assessments (HTA), 
potentially due to a lack of a) methods to obtain diffusion estimates and b) understanding 
of the impact of diffusion estimates on health economic outcomes. This thesis contributes a) 
a method to estimate health technology diffusion prior to HTA and b) a modelling 
framework that assesses the potential impact of diffusion estimates on cost-effectiveness 
and expected value of information and implementation (EVII) analysis using modelling, 
qualitative and elicitation methods. These were illustrated in a preterm birth (PTB) 
screening case study. 
The modelling framework included extensions to an existing EVII model to make it 
dynamic and allow research to affect implementation; and the development of a dynamic 
cost-effectiveness analysis (DCEA) model that reflects price changes precipitated by 
diffusion and hence, the reimbursement decision. Drivers of diffusion were identified for 
the case study technology, aiding the design of implementation strategies. The developed 
method for predicting diffusion requires transformation of elicited expert beliefs to inform 
an existing diffusion model. Application in the PTB screening model showed that the 
dynamic EVII method can 1.) help more accurately assess the losses the health care payer 
incurs when there is decision uncertainty and low implementation and 2.) provide more 
realistic assessments of implementation strategies and evidence generation schemes. The 
applied DCEA model showed that changes in price triggered by technology diffusion 
significantly affect cost-effectiveness results. The method for predicting health technology 
diffusion and the EVII and DCEA frameworks are foreseen to be relevant in the context of 
HTAs of medical devices, diagnostics and drugs; particularly when there is low 
implementation or there is potential for future price changes conditional on diffusion.  
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CHAPTER 1. INTRODUCTION: WHY DIFFUSION ESTIMATES ARE 
IMPORTANT TO HEALTH TECHNOLOGY ASSESSMENT 
1.1 Chapter outline 
The aim of this chapter is to introduce the research undertaken for this thesis. In Section 
1.2, I explain the background to this thesis. Section 1.3 presents the rationale for and the 
hypotheses to be tested in this thesis, as well as an introduction to the case study on 
electrical impedance spectroscopy for use in preterm birth screening and my philosophical 
position. In Section 1.4, I describe my research aim and objectives and Section 1.5 presents 
the structure of the thesis. 
 
1.2 Background on technology implementation and health technology 
assessment 
1.2.1 Definitions of key concepts 
First, I wish to highlight that this thesis adopts the perspective of the health care payer, 
and, to make the research questions in this thesis specific and ensure its feasibility, I focus 
on one jurisdiction, England. The National Institute for Health and Clinical Excellence 
(NICE) is the decision-making body for reimbursement of health technologies in England. 
The topic of this thesis focusses on health technology uptake. The term ‘health 
technology’ is defined as any product or activity that is ‘used to promote health, prevent and 
treat disease and improve rehabilitation and long term care’ (NIHR, 2012) and can thus 
include medicines, medical devices, procedures and screening technologies, amongst others. 
‘Uptake’ describes the number of units of a technology in use as a share of the maximum 
number of desirable units, typically at one point in time. The health economic literature 
often uses the term ‘implementation’ to describe uptake (Fenwick et al., 2008, Department 
of Health, 2011). I use the terms ‘uptake’ and ‘implementation’ interchangeably throughout 
this thesis, although different interpretations have been observed in different contexts 
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(Greenhalgh et al., 2004). The terms ‘adoptions’ or ‘utilisation’ are also commonly used to 
describe the units in use of a technology. As it is defined above, uptake is a relative measure. 
However, both terms of uptake and implementation have been used as absolute measures of 
the number of adoptions, which would ultimately be compared with the maximum number 
of attainable adoptions. Technology uptake can confusingly also be understood as a dynamic 
process. To make a clear distinction, I refer to this dynamic process as diffusion, which is a 
term that has been used to describe the process of technology uptake, for instance by Rogers 
in his book ‘Diffusion of Innovations’ (Rogers, 2003).  
The definition of the uptake concept is further complicated by the different levels of 
uptake that can occur in health technologies. To make this clearer, I use three examples: 1. 
the adoption levels of a medical device could entail a) the number of hospitals purchasing 
the device; b) the number of clinicians using the device, or alternatively, the number of 
patients being offered the device; and c) the number of patients ultimately receiving the 
device, taking patient acceptance into account. 2. The adoption process of a drug mainly 
entails the number of physicians prescribing the drug and the number of patients accepting 
it. 3. For screening technologies, the only level of uptake is often the patient level, or that of 
the general public. In this thesis, I use a medical device as a case study example. To simplify 
the illustration of the concepts developed in this thesis in the case study technology, I focus 
on a) the number of hospitals purchasing the device.  
In this thesis, I use the term ‘implementation strategies’ to refer to any initiatives and 
programmes that are aimed at increasing the uptake of health technologies (Essat et al., 
2013) in the England NHS. Other terms commonly used in the literature are ‘implementation 
initiatives’ and ‘implementation measures’ (Essat et al., 2013), and I use these 
interchangeably. 
 
1.2.2 Health technology assessment and health economic methods 
With a fixed budget for health care spending in England, resource allocation decisions 
are typically made using coherent frameworks for decision-making that are based on health 
economic principles (Drummond et al., 2005). These principles entail the maximisation of 
benefits to patients in the NHS within a given budget. Welfarism demands that overall 
welfare, measured in terms of individuals’ evaluations of their utility associated with 
different states, be maximised subject to budget constraints. Assigning monetary value to 
utilities, cost-benefit analyses are used to implement welfarism in practice (Morris et al., 
2007). There are, however, various limitations associated with welfare economics used in 
3 
 
health care. These include that welfarism is firmly based in consumer choice theory that 
makes assumptions such as consumer rationality, amongst others, which cannot be 
guaranteed in the health care setting in which market failure is commonly assumed to occur 
(Morris et al., 2007). Furthermore, individual utilities are not deemed a good measure of 
well-being (Morris et al., 2007), as the concept of utility in its classical sense relates to 
utility arising from consumption of goods.  
The most commonly used and recommended approach to resource allocation decisions 
in England is therefore based on so-called ‘extra-welfarism’, a framework that permits 
measures other than utilities, for example measures of health, in the social welfare function 
(Morris et al., 2007). With it comes an alternative to cost-benefit analysis, the so-called cost-
effectiveness analysis that allows measuring benefits in non-monetary terms (Morris et al., 
2007). This compares costs of decision options with the health gain that can be achieved, 
and if this is expressed in terms of the quality-adjusted life year (QALY), which is typically 
used in decision-making in England (NICE, 2013), then the correct term for this type of 
analysis is cost-utility analysis (Drummond et al., 2005). I will continue to use the term cost-
effectiveness analysis, as this appears to be more widely used, certainly in the context of 
NICE decision-making (NICE, 2013). The decision of whether a new health technology is a 
good use of resources compared to other options, that is, whether it is cost-effective, is made 
using a decision rule. This decision rule entails two components: first, the incremental cost 
per QALY, called the incremental cost-effectiveness ratio (ICER) of a health technology 
over an alternative is calculated. Second, the ICER is compared with a pre-specified 
threshold that represents the ceiling value that the health care payer would pay for a QALY 
given the budget constraints in the health system (Eckermann and Pekarsky, 2014). The 
threshold for most drugs is set to a range of £20,000 to £30,000 per QALY in England 
(NICE, 2013). Thresholds for other health technologies may be different, for instance the 
threshold for medical devices is £0 per QALY, expecting these to be cost-saving compared 
to current practice (NICE, 2012).  
The aim of cost-effectiveness analyses within health technology assessments is to 
provide estimates of the ICER associated with a new health technology compared with 
existing alternatives (NICE, 2013). The process for estimating costs and QALYs associated 
with different health technologies can entail complex mathematical modelling methods, the 
synthesis of evidence from different sources and simulation methods to consider the 
uncertainty associated with the input parameters (Briggs et al., 2006). Value of information 
methods, while not routinely used in the process of health technology assessment (HTA) 
(NICE, 2013), can inform the decision-maker on the opportunity loss associated with 
uncertainty in a decision and, beyond that, can inform research design decisions (Briggs et 
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al., 2006, Claxton and Posnett, 1996, Brennan and Kharroubi, 2007, Strong et al., 2015, 
Eckermann and Willan, 2007). For this, the value of information is scaled up over the 
affected patient population and accrued over future time periods up to the decision relevance 
horizon, that is, the time until which a decision remains relevant, for example until there is a 
new technology class replacing the current one. The decision relevance horizon has in the 
past been most relevant to value of information analysis (Philips et al., 2008) because future 
periods are not generally modelled in cost-effectiveness analyses (NICE, 2013). Philips et al. 
(2008) found that the nature and magnitude of change, for example in price, evidence and / 
or competition affected the length of the decision relevance horizon. 
 
1.2.3 The dynamic nature of technology implementation  
Uptake of new technologies typically follows a dynamic process (Rogers, 2003). This 
process has been much described in the marketing literature as that of new product growth or 
diffusion (Meade and Islam, 2006). A theoretical framework was developed by Rogers 
(2003) in the first edition of his book ‘Diffusion of Innovations’ in 1962 and the author 
described diffusion to follow an S-shaped curve, time being presented on the x-axis and 
cumulative per period uptake on the y-axis (illustrated in Figure 1.1).  
 
Figure 1.1 Example of an s-shaped diffusion curve according to Rogers’ theory of diffusion 
 
 
The s-shape resulted from the assumption that populations are heterogeneous in their 
propensity to innovate (Meade and Islam, 2006), with innovators having a relatively small 
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threshold to technology adoption and imitators having a relatively higher threshold. Rogers 
assumed that the threshold sizes were distributed normally among the population (Rogers, 
2003) where the size of individual thresholds could depend on various factors, among them 
income. This model mainly applies to the purchases component of uptake but it has also 
been assumed to hold for the combined levels of purchases and utilisation by clinicians in 
the context of health technology diffusion and productivity growth in the United States 
(Skinner and Staiger, 2015). When implementation appears low in the first periods after 
technology introduction, this may therefore simply reflect that the technology is early in its 
product life cycle. This is not to say that nothing can be done to increase implementation. 
For this, it is important to understand factors that can potentially influence diffusion. 
 
1.2.4 Technology diffusion in the health-care sector 
Health technology implementation varies between different technologies and in many 
countries around the world (Packer et al., 2006), as well as in England (Department of 
Health, 2011). Low implementation is recognised as a problem in England and is currently 
on the political agenda (Department of Health, 2011). The Department of Health (DH) 
committed to a variety of actions to aid the implementation of new technologies such as the 
introduction of the NICE Compliance Regime that has the aim to ensure rapid consistent 
implementation throughout the NHS (Department of Health, 2011). There is now a wide 
range of policy initiatives in use in the NHS to improve implementation, from the provision 
of financial incentives within the Quality and Outcomes Framework (QOF) and 
Commissioning for Quality and Innovation (CQUIN) scheme through to the NICE 
implementation programme that provides local organisations with tools such as ‘How to put 
NICE guidance into practice’ (Essat et al., 2013).  
To be able to devise effective implementation strategies, it is essential to understand the 
causes of low implementation. Whilst the Department of Health’s plans target the removal 
of systemic barriers to implementation and incentivise implementation through reward 
schemes, there are many possible causes for low implementation that may not be tackled 
through these broad schemes. These include technology characteristics that may lead to low 
implementation (Terris-Prestholt et al., 2016), patient characteristics such as deprivation 
(Morris et al., 2012) or financial barriers (Skinner and Staiger, 2015). As diffusion of health 
technologies appears to be heterogeneous, there is no single set of diffusion determinants 
that explains low implementation for all technologies, or health technologies for that matter 
(Greenhalgh et al., 2004). With health technologies being the focus of this thesis, I 
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concentrated on finding diffusion drivers and barriers from the health technology sector, 
thereby excluding generic sources applicable to all types of technologies such as the 
catalogue of technology uptake determinant factors created by Rogers (2003). I performed a 
scoping review of the literature on uptake and diffusion of health technologies in the United 
Kingdom (UK), which helped me inform the research questions in this thesis. I identified 
three exemplary sources with findings on diffusion determinants in health technologies 
potentially relevant to this work: one was a systematic review of so-called diffusion 
determinants conducted by Greenhalgh et al. (2004), the other the previously mentioned DH 
report (Department of Health, 2011), which identified the main barriers to implementation in 
the NHS and the third was a qualitative study on health technology diffusion determinants in 
the England NHS (Barnett et al., 2011). These three studies provide insights that are 
valuable for study design and I therefore briefly summarise their methods and findings: 
Greenhalgh et al. (2004) developed a conceptual model for determinants of diffusion in 
health service delivery and organisation based on their systematic literature review of 
diffusion determinants in health service delivery innovations. The authors used a broad 
definition of innovation in health service delivery and organisation as ‘novel set of 
behaviours, routines and ways of working that are directed at improving health outcomes, 
administrative efficiency, cost-effectiveness or users’ experience and that are implemented 
by planned and coordinated actions’. Based on the results, the authors examined different 
theoretical approaches to diffusion of innovations in order to create a conceptual diffusion 
model. The respective conceptualisation of diffusion of each theoretical approach was 
extracted. The authors developed a model of diffusion and provided a catalogue of 
categories of diffusion determinants. The high-level categories included are shown in Table 
1.1. 
Barnett et al. (2011) conducted a qualitative study in which the authors interviewed 
fifteen health care organisations, which had generated and implemented a service innovation 
and were recognised with an award. The aim was to identify diffusion determinants in the 
England NHS as perceived by the innovators and main themes are shown in Table 1.1.  
The Department of Health report ‘Innovation Health and Wealth’ (2011) summarised the 
practical experience from the England NHS in terms of barriers to the use of innovations, as 
shown in Table 1.1. 
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Table 1.1 The drivers of health technology diffusion according to three studies 
Greenhalgh et al. (2004) Barnett et al. (2011) Department of Health 
(2011) 
Characteristics of innovation: its 
relative advantage over existing 
interventions as well as its 
requirements in terms of knowledge 
and tasks required for adoption  
The role of evidence Poor access to evidence, 
data and metrics 
Adopters: needs, skills, values and 
goals, and social networks 
The role of partnerships Insufficient recognition and 
celebration of innovation 
and innovators 
Communication and influence: social 
networks and the influence of change 
agents 
The influence of 
champions and other 
human-based resources 
Financial levers do not 
reward innovators and can 
act as a disincentive to 
adoption and diffusion 
System antecedents: organisation 
structure, absorptive capacity for new 
knowledge and receptive context for 
change 
The impact of contextual 
factors, both 
organisational and 
external 
Commissioners lack the 
tools or capability to drive 
innovation 
System readiness: need, advocacy and 
opponents and the ability to evaluate 
the innovation 
 
 Leadership culture to 
support innovation is 
inconsistent or lacking 
Outer context: interorganisational 
networks, knowledge exchange, 
international spread strategies and 
policies 
 Lack of effective or 
systematic innovation 
architecture 
Implementation and routinisation: 
organisation structure, leadership and 
funding 
  
Linkage among model components: 
characteristics of links between change 
agency, developers and / or potential 
external change agents 
  
 
Owing to the different methods and inclusion of different sources, it is difficult to directly 
compare these three studies. There are similarities in the findings, but differences are 
especially evident in the level of comprehensiveness, with the Greenhalgh et al. (2004) study 
being far more comprehensive than the other two; and the level of abstractness, with the DH 
report being the least abstract of the three. Furthermore, the DH report focussed on effective 
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and even cost-effective technologies experiencing low implementation, and therefore 
ignored some of the factors mentioned by Greenhalgh et al. (2004), such as the technological 
advantage.   
This brief review demonstrated that these exemplary ‘generic’ catalogues cannot readily 
be used for identifying diffusion determinants individual to specific technologies as 
diffusion is a highly technology-specific process (Greenhalgh et al., 2004). The above 
catalogues present an aggregation of individual factors affecting uptake of a number of 
individual health technologies and, as such, present inspiration for what may affect uptake of 
an individual technology. However, no final conclusive decision on relevant uptake factors 
to an individual technology can be reached using these catalogues. Apart from this 
individuality, the development stage that the technology in question is at may affect what is 
regarded as most important uptake factors and has to be borne in mind when devising 
implementation strategies. For instance, a technology’s research evidence on effectiveness is 
likely to influence uptake at any stage of development whereas usability may only present a 
barrier to uptake once research evidence is available to show that the technology works. 
These catalogues also do not tell us anything about the design of potential implementation 
strategies.  
 
1.2.5 Health technology assessment methods and diffusion 
It appears as though implementation estimates are not routine components of analyses 
performed within health technology assessments (NICE, 2013), with the potential exception 
of the requirement for a budget impact analysis. Budget impact analyses identify an estimate 
of the total expenditure associated with a health technology. The population estimate used to 
arrive at such an estimate should be adjusted by the current technology mix in use, as was 
highlighted in the ISPOR guide to budget impact analysis (Mauskopf et al., 2007). 
Mauskopf et al. (2007) recommended obtaining data to inform this from the decision-
maker’s own database and to account for changes over time. They did not specify any 
method as to how the changes over time can be accounted for. They further recommended 
use of market research data or expert opinion on current and evolving treatment patterns in 
the absence of published information on current treatment patterns (Mauskopf et al., 2007).  
Another area in which implementation estimates have appeared in health economic 
analysis is the assessment of implementation strategies. Economic evaluations of 
implementation strategies are relatively uncommon (Essat et al., 2013) and are not part of 
standard health technology assessment processes (NICE, 2013, NICE, 2012, NICE, 2011a). 
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Essat et al. (2013) identified frameworks for the evaluation of implementation strategies 
(Fenwick et al., 2008, Mason et al., 2001, Sculpher, 2000), and identified only a few further 
developments and applications (Willan and Eckermann, 2010, Walker et al., 2010, Hoomans 
et al., 2009a).  
NICE methods guides do not recommend the use of implementation estimates within 
cost-effectiveness analyses (NICE, 2013, NICE, 2012, NICE, 2011a). Most health economic 
models focus on modelling one cohort over the lifetime of patients (Hoyle and Anderson, 
2010). The implicit assumption is that no change in parameter values occurs over the 
modelled decision relevance horizon, thereby ignoring potential correlations between 
changing implementation rates and other model parameters.  
 
1.3 Rationale for this thesis  
1.3.1 Why does diffusion matter in health technology assessment? 
In the background section, I highlighted that implementation of effective health 
technologies is often low. There are generic causes for low implementation although these 
vary for individual technologies. Health economic methods, at least in England, do not 
routinely incorporate estimates of diffusion. For the health system, or the health-care payer, 
however, low implementation of cost-effective technologies results in an inefficient use of 
resources. This is because cost-ineffective technologies remain in use when cost-effective 
technologies are not fully implemented, causing these inefficiencies. Furthermore, health 
economic models typically ignore future change. The question that came to my mind was: 
what are the implications of health technology diffusion for how we value health 
technologies? 
Four hypotheses motivated this thesis: I hypothesised (A) that consideration of low 
implementation and the resulting opportunity loss to the health care system could be 
beneficial to the reimbursement authority and the health care payer at the time of HTA, by 
enabling decision-making on implementation strategies, especially the generation of further 
research evidence; (B) that implementation estimates may be correlated with other 
parameters in the cost-effectiveness model and influence health economic outcomes; (C) that 
it is possible to acquire the knowledge of low implementation and the opportunity loss it 
causes at the time of HTA; and (D) that a better understanding of the technology-specific 
causes of low implementation is required to effect change.  
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Hypothesis (A) is derived from the thought that consideration of the opportunity loss 
caused by low implementation at the time of HTA may enable the payer or the decision-
maker to address the problem of low implementation early on, that is, before the technology 
is introduced into routine practice. The decision-making authority may be able to 
recommend implementation strategies, although NICE, for instance, can only make 
recommendations for further research to be conducted and not for other implementation 
strategies to be pursued (NICE, 2013). It therefore makes sense to examine research 
recommendations for their ability to have a positive effect on implementation. 
Hypothesis (B) refers to the potential implications for HTA where the implementation 
parameters are correlated with other parameters in the health economic model. If this is the 
case and the implementation parameter changes over time, there may be a case for 
incorporating these changes and their impact in the model. One such case is the effect of 
diffusion on price. It has been observed in medical devices that prices declined with 
increasing technology uptake, a phenomenon that is described by so-called experience 
curves (Brown et al., 2007). 
To study hypothesis (C), it is important to understand the opportunity loss to the payer 
that is caused by low implementation. This has previously been called the expected value of 
perfect implementation by Fenwick et al. (2008) and is a function of the implementation 
discrepancy (that is, how low implementation is compared to the desired ‘full’ level) and the 
expected incremental net benefit of the cost-effective technology over its alternatives. Whilst 
the former, the estimation of the implementation discrepancy, is not a routine part of HTAs, 
the estimation of the expected incremental net benefit is. Estimating the value of 
implementation at the time of HTA would provide the decision-maker with valuable 
information early on, with the only additional requirement of estimating the implementation 
discrepancy.  
Hypothesis (D) is related to developing an understanding of the technology-specific 
causes of low implementation that is required to effect change in implementation. 
Knowledge of the causes of low implementation can potentially enable stakeholders to 
design effective implementation initiatives. Such knowledge is relevant for technology 
developers and policy-makers alike. The questions that may be asked by policy-makers and 
technology developers are: what are barriers to uptake, how can they be addressed and what 
is the cost-effectiveness of addressing them? Answering these questions poses a challenge: 
when a technology is still in the development phase, uptake barriers have to be identified 
prospectively before any uptake could be observed. Furthermore, there may be an abundance 
of factors that play into the uptake decision of a diverse set of different individual and 
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institutional decision-makers. To identify technology-specific diffusion determinants and 
implementation strategies in a certain environment and before the HTA process, technology-
specific research prior to technology launch is required. As was described above, there do 
not appear to be any prescribed methods to find out about technology-specific uptake factors 
prospectively. 
 
1.3.2 Application in a case study 
The hypotheses developed in the previous section were tested in this thesis using a real 
life case study of a technology currently in development, called electrical impedance 
spectroscopy developed for preterm birth screening. The use of only one case study may be 
perceived as a limitation but I accepted this to ensure feasibility of the project within the 
time frame of a doctoral thesis while addressing all of the above-mentioned hypotheses. The 
choice of the case study technology was largely dictated by access to data of technologies in 
development. This proved easier for technologies other than drugs. I thought it adequate to 
choose a medical device over a drug because the DH report (Department of Health, 2011) 
predominantly mentioned ‘non-drugs’ for which particularly low implementation was noted. 
  
 Therapeutic area of preterm birth 1.3.2.1
In the UK, approximately 4% of all babies are born prematurely, that is before 34 weeks 
of gestation (Honest et al., 2009). Preterm birth (PTB) is a serious issue associated with 
potential health consequences for the baby, encompassing neo-natal mortality, long-term 
neurological impairment, respiratory distress syndrome, bronchopulmonary dysplasia, 
intraventricular haemorrhage, retrolental fibroplasia and developmental problems (Honest et 
al., 2009). PTB places a great emotional, psychological and financial burden on parents and 
their children and is associated with significant cost, chiefly for prolonged neo-natal care 
and health care. 
There is a variety of causes of PTB, some of which are not fully understood. Some cases 
of PTB are elective, which means that it is judged to be in the baby’s and mother’s interest 
to deliver the baby early due to complications such as hypertension or diabetes (Honest et al., 
2009). The non-elective cases are the focus of this thesis but even these are heterogeneous 
and the cause of a PTB in an individual is not always identified. Causes include 
inflammations, cervical weakness, and other environmental factors, amongst others, with 
cervical weakness being in the focus of this thesis.  
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Owing to the heterogeneity of the condition, there are many tests (a total of 22 as per the 
review by Honest et al. (2009)) that claim to predict PTB, with varying levels of accuracy. 
These include a previous history of PTB, cervicovaginal fibronectin, cervical length 
ultrasound scanning, amongst others. Not all of these specifically test for cervical weakness. 
If a pregnant woman received a positive test, then there is a range of 40 different treatment / 
prevention options (Honest et al., 2009). Many of these treatment options lack a good quality 
evidence base, but some were associated with a benefit in preventing PTB, including 
smoking cessation programmes, progesterone treatment, periodontal treatment, fish oil 
(Honest et al., 2009) and cervical cerclage (NICE, 2015). The current NICE 
recommendation for women with potential cervical weakness is to offer a choice of either 
prophylactic vaginal progesterone or prophylactic cervical cerclage to women with a history 
of PTB or mid-trimester loss and in whom ultrasound scan has revealed a cervical length 
shorter than 25 mm between weeks 16 and 24 of pregnancy (NICE, 2015). 
There are, however, limitations associated with cervical length ultrasound scans. One is 
that the predictive ability is not very good: its sensitivity was estimated at approximately 21% 
and its specificity at 98% (based on likelihood ratios provided by Honest et al. (2009)). This 
means that cervical length ultrasound scans are not very good at identifying those women 
that will go on to have a PTB, as only 21% of those that will have a PTB test positive. A 
Cochrane review (Berghella et al., 2009) has therefore highlighted the need for new and 
improved screening methods. Another limitation is that ultrasound machines are often 
working at full capacity, even without them being used for PTB screening (NICE, 2015).  
 
 Electrical Impedance Spectroscopy for use in PTB screening 1.3.2.2
Electrical Impedance Spectroscopy (EIS) is a technology that has been developed and 
used for cervical cancer screening. In this function, it is manufactured by Zilico Ltd. It is 
also currently in development for use in PTB screening at Sheffield Teaching Hospital. EIS 
measures cervical impedance, which has been observed in early tests to be predictive of PTB 
before 34 and 37 weeks of gestation in women at risk based on their previous history. EIS 
examinations are thought to occur at week 20-22 and week 26-28 of a woman’s pregnancy. 
A randomised controlled trial in women with a history of PTB is currently under way to 
establish the predictive ability of EIS. Preliminary results from a pilot based on a sample 
size of 38 women only indicate that EIS has a sensitivity of 44% and specificity of 90%, 
indicating that there may be a slight improvement over cervical length ultrasound scans in 
the reduction of false negatives. It would provide the additional advantage of being an easy 
to use, small and probably inexpensive piece of kit that could alleviate the pressure on 
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ultrasound machines. The developers envision that the main treatment strategy following a 
positive test result would be treatment with vaginal progesterone. One issue for the 
development of EIS for the purpose of PTB screening was that the device’s accuracy was 
sensitive to pressure exerted by the EIS administrator, which leads to measurement 
variability. Therefore, the device is being further developed by adding a transducer-based 
force gauge that may improve test accuracy over what was observed in the pilot study. 
 
1.3.3 Research philosophy 
A researcher’s philosophical position influences their methodology and is thus viewed as 
important to identify before embarking on a research project (Ritchie et al., 2003). My 
intuition was to use different methods in this thesis and I therefore thought it valuable to 
identify my own research position and how it influences the choice of methodology. A 
philosophical position is typically characterised by the stance a researcher adopts with 
regards to the paradigms epistemology and ontology (Ritchie et al., 2003). For this study, I 
adopted an epistemological stance of pragmatism with the ontological view of subtle realism.  
Ontology is the study of the nature of all being. It comprises a range of different 
positions between two extremes: realism acknowledges the existence of one reality that is 
independent of anyone’s beliefs, while idealism states that reality is only knowable through 
socially constructed meanings (Mason, 2002). A position between the two is subtle realism, 
which acknowledges the existence of a reality independent of people that is only accessible 
through people (Ritchie et al., 2003). In the context of this thesis, the stance of subtle realism 
signifies that while I believe in the existence of one reality and I am striving to capture this 
reality in a health economic modelling framework and through other research methods, I 
acknowledge that my understanding of it may be shaped by assumptions that are a product 
of my priorities and beliefs.  
Epistemology refers to the question of how knowledge is created. There are the two 
extremes of positivism and interpretivism, where positivism describes the researcher’s 
stance that created knowledge is independent of and unaffected by the researcher (Mason, 
2002), resulting in a preference for quantitative research methods. With the stance of 
interpretivism, in contrast, the created knowledge of the social world only exists through the 
interaction with the researcher, leading to qualitative research being viewed as appropriate 
(Mason, 2002). The choice of pragmatism as a paradigm expresses the rejection of a forced 
choice between the two and enables research methods to be chosen based on the research 
problem, rather than being dictated by the chosen position itself (Ritchie et al., 2003). The 
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rationale for choosing the pragmatist stance was that I believe that different research 
questions warrant different methods.  
 
1.4 Research aim and objectives 
The aim of this thesis was to develop a method to estimate health technology diffusion 
prior to the time of HTA and to explore the potential impact of these diffusion estimates on 
HTA methods. To achieve this, I sought to address the following objectives:  
1. To explore the potential use and impact of diffusion estimates in the health technology 
assessment context.  
2. To identify prediction methods for diffusion prior to technology introduction and 
relevant to the health technology context that yield probabilistic diffusion estimates. 
3. To develop model frameworks for incorporating diffusion estimates in relevant health 
economic analyses. 
4. To identify relevant implementation strategies for the case study technology EIS for 
use in PTB screening. 
5. To develop a method for predicting diffusion prior to technology introduction using 
the PTB screening case study. 
6. To assess the impact of diffusion on health economic model outcomes in the PTB 
screening case study.  
 
1.5 Thesis structure 
The thesis structure is described below and illustrated in Figure 1.2. Chapter 2 addresses 
Objective 1 through a series of literature reviews. These reviews comprise a scoping review 
to identify common uses of implementation estimates in health economic evaluation; a 
second review on the application of experience curves in health economic modelling; a third 
review on the use of implementation estimates in value of information analyses; and a fourth 
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review on the status quo of applications and developments of the expected value of 
implementation. 
In Chapter 3, two literature reviews are presented that address Objective 2. The first 
review aims to collect diffusion data from the UK health technology setting in order to 
assess the feasibility of evidence synthesis. The second review aims to identify a method for 
predicting diffusion prior to technology introduction. 
In Chapter 4, I present model frameworks for the potential effects of diffusion estimates 
on health economic analyses to address Objective 3. The first framework develops the value 
of implementation further by allowing for integration of the dynamics of diffusion and by 
allowing information to affect implementation. The second framework establishes the 
relationship between health technology implementation and price.  
Chapter 5 describes the qualitative study that was conducted to identify potentially 
relevant implementation strategies for the case study technology (Objective 4). Within this, I 
report on semi-structured interviews that were conducted with participants involved with the 
use or purchase of health technologies in obstetrics to identify diffusion determinants. 
Relevant diffusion determinants were then translated into two implementation strategies.  
In Chapter 6, I describe the developed diffusion prediction method and its application to 
the case study technology (Objective 5). The developed method was an elicitation of expert 
opinion using the structure of an established diffusion model.  
In Chapter 7, the expected value of information and implementation framework that is 
described and extended in Chapter 4 is applied to the health economic analysis of the case 
study technology (Objective 6). First, the cost-effectiveness model of EIS is presented. The 
values of implementation, information and further research are then calculated. 
Chapter 8 presents the application of the dynamic cost-effectiveness analysis and 
experience curve framework to a hypothetical case study based on the EIS case study setting 
(Objective 6), as it turned out that the cost-effectiveness results of EIS were insensitive to 
price. 
In Chapter 9, I discuss the novel contribution of this thesis in the context of the existing 
literature. I present how this thesis is relevant and discuss strengths, limitations and areas for 
further research. I finally provide a conclusion. 
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Figure 1.2 Thesis flow 
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CHAPTER 2. REVIEWS ON THE POTENTIAL USE OF 
IMPLEMENTATION ESTIMATES IN HEALTH ECONOMIC 
EVALUATION 
2.1 Background 
Chapter 1 highlighted that little was known about the relevance of implementation 
estimates to health technology assessment and methods for estimating implementation for 
use in health economic models. The aim of this chapter is to explore the uses of 
implementation estimates in health economic evaluation. Four reviews were performed to 
address this. One aimed to identify common uses of implementation estimates in economic 
evaluations of health technologies. The other three reviews more specifically targeted 
defined uses of implementation: identifying health economic evaluations that had modelled 
experience curves, exploring the use of implementation estimates in Expected Value of 
Information (EVI) analysis and investigating the use of the Expected Value of 
Implementation (EVIM). 
 
2.2 Implementation estimates in health economic evaluations – findings 
from an abandoned scoping review 
2.2.1 Background to implementation in economic evaluation review 
This literature review was conducted to identify common uses of implementation 
estimates in health economic evaluations, to find the reasons for including implementation, 
the methods used and to examine what effect implementation had on model results. This 
scoping review was started at the very beginning of this project and it quickly turned out that 
it was not suited to define the research questions for this thesis. This was mainly because a 
search on methods is typically difficult (more on this in Section 2.2.2). I therefore 
abandoned the review half-way through, to concentrate on more specific research questions, 
which are described and answered in Sections 2.3 to 2.5 of this chapter. However, this 
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abandoned review, while not comprehensive, resulted in some interesting findings. I 
therefore decided to include the review in this thesis. 
 
2.2.2 Methods of implementation in economic evaluation review 
A scoping review as described by Grant and Booth (2009) was considered appropriate to 
find out more about implementation estimates used in health economic methods. This review 
type identifies the nature and extent of research evidence on a subject, informing the 
researcher what additional reviews may be needed. In scoping reviews, there is some 
flexibility as to the level of completeness of the review. In the context of this thesis, the 
scoping review could help identify areas for further research. These potential topics could 
then be researched more efficiently with more targeted reviews. Methodology papers are 
notoriously challenging to identify: searches typically yield a large number of hits, of which 
only a few may be relevant (Chilcott et al., 2003). Citation searches or searching lists of 
references of key publications are a more appropriate approach to search for further 
documents on a subject where there are known deficiencies in indexing or terminology 
(Chilcott et al., 2003). 
 
 Search strategy 2.2.2.1
The search was conducted in Medline via OvidSP. The search terms were selected such 
that only studies on economic evaluations in health were considered that had concerned 
themselves in any way with implementation. To capture potential health economic 
evaluations, the terms HTA (for health technology assessment) and CTA (for constructive 
technology assessment, a concept developed in the Netherlands where implementation 
estimates play a role in some economic evaluations known to the author) were used 
alongside other terms that are commonly associated with health technology assessments. 
Largely synonymous terms with implementation were also used in the search strategy. The 
following building blocks were used: 
Facet A: (Implementation OR uptake OR diffusion) 
Facet B: (Model OR estimate) 
Facet C: (HTA OR CTA OR cost effectiveness OR economic evaluation OR technology 
assessment) 
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Search: (A AND B AND C) 
In the first phase, titles and abstracts were screened; full texts of the included studies 
were screened in the second phase. 
 
 Inclusion and exclusion criteria 2.2.2.2
Inclusion criteria were economic evaluations of health technologies that included an 
estimate of implementation. Studies that evaluated the effectiveness of initiatives to increase 
uptake were excluded, as these were dealt with in a separate review.  
 
 Data extraction 2.2.2.3
A combination of tabular and narrative analysis was used. The standardised tabular data 
extraction sought to provide an overview of the study characteristics that could potentially 
address the research questions. Answers to the research questions provided by this review 
were summarised in the narrative: 
1.) What were the technologies under assessment in the identified studies? 
2.) What was the impact of the implementation estimates on health economic outcomes? 
3.) What were the methods used to estimate implementation? 
4.) What areas for further research on implementation were identified? 
 
2.2.3 Results of implementation in economic evaluation review 
This search, which was conducted in May 2012, identified 515 publications. Two 
hundred of these publications were reviewed. The 200 reviewed publications were a pseudo-
random sample from the 515 hits, using the first letter of first authors’ surnames. At least 10% 
of hits for each first letter were reviewed. Of these, 163 publications were excluded based on 
titles and abstracts. Of the remaining 37 hits, 17 were excluded based on a full text review, 
leading to 20 included articles. One further publication, not identified through the search, 
was also included: a follow up publication on one of the studies found in the review (Entry 
19) (Retel et al., 2012). An overview of the included publications is shown in Appendix 
Table A.1. As mentioned above, this review was abandoned after 200 hits. At this point, 
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only few uses of implementation estimates in cost-effectiveness analysis citations were 
found, thus highlighting the difficulty of finding relevant publications with this type of 
search. Whilst the remaining 315 would have included further relevant citations, I thought 
that I could answer my research questions better in the reviews described in Sections 2.3, 2.4 
and 2.5. This is a consequence from the results, which are described in the next Section 2.2.3. 
The results of this scoping review suggested that estimates of implementation were 
rarely used in economic evaluations. Out of the 200 hits reviewed, only 10 percent were 
economic evaluations that had included an implementation estimate. However, as per the 
definition of the search, only economic evaluations that had mentioned implementation were 
included in the review. The proportion of economic evaluations with implementation 
estimates is therefore unclear, but is likely to be much lower than 10 percent. 
  
1.) What were the technologies under assessment in the identified studies?  
Out of 20 identified studies reported in 21 citations (as stated above, a follow-up 
publication (Retel et al., 2012) on the same study by Retel et al. (2009) was also included), 
14 were economic evaluations of infectious diseases, of which 12 were evaluations of 
vaccinations. Herd immunity was included as an outcome in three of these vaccination 
studies. Seven of the identified publications evaluated screening or diagnostic technologies, 
three of which were in infectious diseases and the remaining four in other conditions. In 
addition, one study evaluated a disease-management programme in coronary heart disease, 
and one study assessed different chemotherapy regimens.  
 
2.) What was the impact of the implementation estimates on health economic outcomes? 
In 12 studies reported in 13 publications, the implementation estimate had an effect on 
the Incremental Cost-Effectiveness Ratio (ICER) (Entries 1, 2, 3, 6, 7, 8, 10, 11, 15, 16, 19, 
20, 21 in Appendix A.1). Three studies included implementation estimates only to obtain 
estimates on population effects and / or costs (Entries 5, 17, 18 in Appendix A.1). In three 
studies, the impact of implementation was not clear (Entries 4, 13, 14 in Appendix A.1). One 
study evaluated the expected value of implementation (Entry 9 in Appendix A.1). Another 
study estimated the cost per affected pregnancy (Entry 12 in Appendix A.1).  
The mechanism by which implementation estimates affected the ICER in the 13 
identified publications varied. In three of the 13 publications in which implementation had 
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an effect on the ICER, the mechanism was by which this occurred was herd immunity 
(Entries 7, 10, 17 in Appendix A.1). With herd immunity, effectiveness grows at a greater 
rate with implementation than costs. A fourth study (Entry 21 in Appendix A.1), reported a 
similar mechanism by which the ICER varied with implementation, by effects growing at a 
greater rate with implementation than costs. While herd immunity was not specifically 
mentioned, the effects of the different chlamydia screening programmes were considered 
beyond the screened individual in a transmission model (Roberts et al., 2007a).  
In three further studies reported in four publications, the levels of implementation 
affected the ICER because implementation levels differed for the different comparator 
strategies and the ICER was calculated as a so-called ‘blended ICER’ in which costs and 
effects of each strategy were adjusted by the implementation levels of that strategy (Entries 
1, 3, 19, 20 in Appendix A.1). For instance, in the cost-effectiveness analysis of influenza 
vaccination in 50-64 year olds by Aballea et al. (2007) (Entry 1), uptake would generally be 
higher among high risk patients than among low risk patients. A cohort vaccination strategy 
would result in even higher uptake among the high risk population that exhibited a higher 
propensity to benefit from vaccination compared to a high risk only vaccination strategy. 
Because each strategy was associated with different implementation levels, the ICER was 
affected by the implementation estimate. Another study tested different uptake scenarios for 
baseline care, in this case a community eye test, to estimate the cost-effectiveness of open 
angle glaucoma (OAG) screening (Burr et al., 2007) (Entry 3 in Appendix A.1). When 
higher uptake rates of the community eye test were employed, the ICERs for OAG screening 
compared with the community eye test were larger because the cheaper community eye test 
would result in many OAG cases detected without screening for OAG specifically. One 
study that was reported in two included articles on the same constructive technology 
assessment (CTA) study on a breast cancer diagnostic test in the Netherlands focused on 
forecasting future developments, particularly diffusion (Retel et al., 2009, Retel et al., 2012) 
(Entries 19, 20 in Appendix A.1). This is a requirement of CTA studies and the rationale for 
this is to provide information to potentially influence future developments. The blended 
ICER for the new technology was therefore higher when uptake was lower, due to the less 
cost-effective comparator remaining in use when uptake was low. In another study by 
Atherly et al. (2009), on the cost-effectiveness of rotavirus vaccination compared to no 
vaccination, the mechanism by which the ICER varied with implementation was the patient 
mix of high risk and low risk groups with different propensity to benefit and different uptake 
rates (Entry 2 in Appendix A.1).  
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Among the four remaining publications out of the 13, there were three for which the 
ICER was said to be affected but the mechanism by which this occurred was unclear (Entries 
8, 15, 16 in Appendix A.1). Authors were contacted but no reply was received.  
The remaining publication was a study on a management programme for coronary heart 
disease (Chew et al., 2010) (Entry 6 in Appendix A.1). The authors found uptake relevant 
because full costs of the programme would be incurred for all patients, including those who 
did not complete the programme; while effects would not be accrued by those non-compliant 
patients. With varying uptake, the rate of non-completions would also be varied, presumably 
not proportional to the change in uptake, although this level of detail was not provided.  
 
3.) What were the methods used to estimate implementation? 
The methods of obtaining implementation estimates were relatively basic. Thirteen 
studies used historical data or data on analogous technologies, for example, general infant 
vaccination coverage rates. These assumed rates did not change over time. Out of those 13, 
four studies made adjustments to the available data based on assumptions. Six studies based 
their implementation estimates on assumptions only. One study used diffusion theory in 
discussions with experts, created qualitative diffusion scenarios with the help of these 
experts and based the quantitative estimates on various assumptions (Retel and Grimm, 
2013). For example, in one scenario, uptake would resemble that of uptake of clinical 
guidelines, in another scenario it would be at 50% for the entire duration of decision 
relevance.  
 
4.) Was any area for further research on implementation identified? 
Twelve out of the 21 publications did not mention implementation in their discussion. 
One study highlighted that the implementation estimate was only used for the Expected 
Value of Perfect Implementation (EVPIM) but not for the ICER or EVPI calculations for 
which it may be beneficial (Entry 9 in Appendix A.1). Two studies highlighted the potential 
for cost-effectiveness evaluations to assess uptake-increasing initiatives (Entries 1, 21 in 
Appendix A.1). Five studies acknowledged limitations with the way implementation levels 
were estimated and added that future research should focus on obtaining better quantitative 
estimates (Entries 3, 6, 11, 16, 20 in Appendix A.1). One study acknowledged the static 
nature of their implementation estimate of pertussis vaccination as a limitation (Entry 10 in 
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Appendix A.1) and another discussed the potential for incorporating differential uptake rates 
for different patient characteristics in the chlamydia screening study (Entry 21 in Appendix 
A.1).  
 
2.2.4 Discussion of implementation in economic evaluation review 
This scoping review found that approximately 10 percent of the search results were 
relevant to address the broadly defined research question, suggesting that, if completed, this 
review could have resulted in approximately 50 relevant publications. The review 
highlighted that it was likely that implementation estimates were not commonly used in 
health economic evaluations. Implementation estimates were used in those types of 
economic evaluations in which implementation affected health economic outcomes, such as 
in infectious diseases through herd immunity for instance, or value of implementation 
analyses. Importantly, the methods used to estimate implementation were simple: either data 
from reference technologies were used, or the estimates were based on assumption. 
These preliminary results suggested that there was not much added value in finishing the 
review or conducting a systematic review on the topic. This was because results did not do a 
particularly good job in defining further research questions. The findings from this review 
include that the inclusion of implementation estimates appeared to be fairly established in 
infectious disease modelling and in the estimation of population costs and effects, suggesting 
that there was limited scope for further research in this area, except in methods to obtain 
better implementation estimates. The ICER was predominantly affected when a blended 
ICER was calculated, where costs and effects of each comparator were adjusted by levels of 
implementation that differed for the comparator. Such a blended ICER makes intuitive sense 
in technologies for which effectiveness relies on the level of implementation. However, 
blended ICERs do not identify the most efficient technology based on their costs and health 
effects, which is arguably the prime objective of reimbursement authorities such as NICE. 
Blended ICERs are therefore not recommended by NICE (NICE, 2013). 
Another topic that was excluded as an area for further research was the inclusion of 
patient groups with different implementation levels. Subgroups or patients with different 
characteristics are better dealt with in separate economic evaluations (Sculpher, 2008). If this 
were not done, a new technology may be considered cost-effective on average, despite it 
being cost-ineffective in some subgroups (Sculpher, 2008). The distinction between patient 
compliance to treatment and implementation was another relevant issue identified. This 
thesis focusses on implementation, not compliance, and, therefore, non-compliance to 
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treatment programmes was not included as an area for further research. The expected value 
of implementation was identified as one area where further research may be beneficial and 
this is pursued in Section 2.5. No value of information analysis studies were identified in this 
review.  
The limitations of this scoping search were that it was confined to one database, 
Medline, and that it was abandoned after 200 search results were sifted through. I have 
provided justification for this in that there is not expected to be added value in continuing 
this review and that other review designs would be better in identifying relevant 
publications. However, the lack of comprehensiveness may mean that potentially interesting 
areas for further research were not identified.  
In conclusion, conventional review methods provide little value for methodological 
questions such as this one and pearl-growing and citation searches are generally considered 
more useful (Chilcott et al., 2003). However, this review has helped in identifying that 
methods of estimating implementation for use in health economic modelling were likely to 
be rudimentary and that there were potential areas for further research in the use of expected 
value of implementation analysis. 
 
2.3 Review on the use of experience curves in health economic 
evaluation 
2.3.1 Background to the experience curve review 
The previous review showed that implementation levels are not commonly used in 
economic evaluations. One reason for this might be that the impact of implementation on 
commonly used measures such as the ICER is not immediately obvious. For the standard 
(that is, the non-blended) ICER to be affected by implementation levels, implementation 
would have to affect costs and effects in a disproportionate manner. The above review 
showed that this could be the case when there is herd immunity to be achieved in infectious 
diseases. Another way this may occur is through the existence of price-volume relationships, 
which are described by so-called experience curves that were introduced in Chapter 1.  
Experience curves describe empirical evidence on price declines with increasing uptake 
of technologies. Experience curves were first described in a study by Wright (1935) but 
since then, ample evidence for such price reductions in a variety of different technologies as 
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well as from a study on 20 medical devices by Brown et al. (2007) have become available. 
The existence of experience curves is mainly explained through a technology’s competitive 
situation (Brown et al., 2007). When the conditions of perfect competition and perfect 
information are not satisfied, pricing occurs above marginal costs, especially in R&D 
intensive industries (Camejo et al., 2011). The larger a market becomes, the more likely it is 
for competitors to enter. In the health-care industry, this would typically occur after patent 
expiry but also before, through between-patent competition, which describes competition 
through close substitutes (Camejo et al., 2011). With increasing competition, prices are 
likely to fall. In addition, economies of scale, which describe reductions in costs with 
increasing production volume at the level of the market actor may also lead to reduced costs 
and prices (Brown et al., 2008, Brown et al., 2007). As both, the competitive situation and 
economies of scale (to a lesser extent as most of the health technology price would typically 
reflect development costs) may hold for drugs, experience curves may be applicable to drugs, 
although there is no evidence of such to my knowledge. 
The findings presented by Brown et al. (2007) imply that there may be value in including 
a dynamic model of product price in health technology assessments of medical devices. If 
this is not done, a technology may be rejected based on its initial price while, after a certain 
level of diffusion, the product’s final price may be lower. Importantly, these price changes 
would only materialise with a positive recommendation – if the technology is not 
implemented, no price changes will occur. If experience curves were present, 
implementation would thus influence price and cost-effectiveness. The question whether this 
relationship has been considered in economic evaluation is addressed with this review. 
  
2.3.2 Methods of the experience curve review 
I performed a citation search to identify those articles that cited the study by Brown et al. 
(2007) on medical device prices following the experience curve. The rationale behind this 
was that any study after the publishing date of Brown et al. (2007) that had used experience 
curves in health economic modelling would presumably have cited this study. 
  
 Search strategy 2.3.2.1
I performed a search in three search engines: 1. Medline, 2. Web of Science and 3. 
Google Scholar. I performed citation searches of the key journal article by Brown et al. 
(2007) in all three search engines.  
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 Exclusion criteria 2.3.2.2
Excluded were all search results that were (A) not a health economic model, (B) that had 
not used experience curves within the model or (C) were not in English.  
 
 Data extraction and analysis  2.3.2.3
Search results were screened based on their titles and abstracts in a first phase and based 
on their full texts in the second phase. Included publications were described in a narrative. 
 
2.3.3 Results of the experience curve review 
The search that was conducted in November 2015 produced 12 results. All of these were 
obtained from the Google Scholar search as the identified key publication by Brown et al. 
(2007) was not found in Medline or in Web of Science. Eight of the 12 results were 
excluded based on exclusion criterion (A), they were not health economic models, in the 
first title and abstract screening phase. One study was excluded based on exclusion criterion 
(C), with title, abstract and full text only available in Japanese.  
These led to three publications being screened in the second phase full text review. All 
three were excluded, one because it was not a health economic model (A) and the other two 
because they did not use experience curves within the model. One of these mentioned 
potential price declines in the discussion (Osnabrugge et al., 2012). The other publication 
mentioned potential future device price fluctuations as a reason for performing deterministic 
sensitivity analysis on device price (Moreno et al., 2012). Experience curves were, however, 
not used in the model.  
 
2.3.4 Discussion of the experience curve review 
This brief review showed that potential future price changes, as supported by evidence 
on experience curves in medical devices, have so far not been included in health economic 
evaluations. There may therefore be value in exploring methods of how they can be 
incorporated in economic evaluation of health technologies and exploring potential cost-
effectiveness results.  
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The limitation of this review was its small scope, using a publication as a starting point 
that was not widely cited. However, it is not very likely that an economic evaluation in 
health technologies posterior to the Brown et al. (2007) article would not have cited this 
study, as this appears to be the only study on experience curve data in the health technology 
sector.  
In conclusion, the inclusion of experience curves in health economic evaluation has not 
been widely studied and presents a valuable area for further research within this thesis. 
 
2.4 Review of implementation estimates in value of information analyses 
2.4.1 Background to implementation in EVI analysis review 
The review in Section 2.2 did not result in identification of any value of information 
analyses. However, there is the potential for implementation to affect the value of 
information, particularly through the population estimates that are commonly used to 
compare the population value of information with the cost of research. While the use of 
implementation-adjusted population estimates for costs and effects within cost-effectiveness 
was documented in the review described in Section 2.2, there was no mention of population 
estimates for EVI analysis.  
EVI is used in economic evaluations to assess the value of reducing decision uncertainty 
through further research (Briggs et al., 2006). To obtain the overall value that can be derived 
from research in a health system or society, EVI is aggregated over the population that may 
potentially benefit and the time horizon that research may be relevant for (subsequently 
called the decision relevance horizon), resulting in the population EVI (PEVI) (Briggs et al., 
2006). There has been some discussion on both, what decision relevance horizon to apply in 
EVI analyses (Philips et al., 2008) and on methods for obtaining population estimates that 
should include an estimation of the probability of implementation (Hoomans et al., 2012). 
With this background, the objective of this research was to investigate whether 
implementation estimates were used in PEVI analyses.  
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2.4.2 Methods of implementation in EVI analysis review 
 Search strategy 2.4.2.1
The search was conducted using the NHS Economic Evaluation Database (EED). Search 
terms were: ((Value of Information) OR EVI OR VOI). Titles and abstracts were screened in 
the first phase; and in the second phase, full texts of the thus far included publications were 
reviewed. Additional PEVI analyses that were known to me but did not come up through 
this small-scale search were also included. 
 
 Inclusion and exclusion criteria 2.4.2.2
Publications were excluded when they did not report PEVI analyses. Duplicates were 
also removed. 
 
 Data extraction 2.4.2.3
A tabular overview of the included studies was developed and results were discussed in a 
narrative, addressing the following research questions: 
1.) Was the population estimate for the PEVI analysis adjusted by uptake?  
2.) What methods were used to obtain the estimate of uptake?  
3.) Was the issue of uncertainty associated with the population estimate discussed? 
 
2.4.3 Results of implementation in EVI analysis review 
The NHS EED search, which was first performed in June 2012 and updated in 
November 2013, resulted in 43 hits. The titles and abstracts of all hits were screened and 10 
publications were excluded because no EVI analysis had been performed and another six 
were excluded because no population EVI had been reported. Another publication was 
excluded because it resulted from an analysis already described in another included 
publication. One publication stated that EVI analysis had been conducted but did not detail 
methods or results and instead referenced another publication. Hence, the former was 
excluded and the latter included. Three additional publications with EVI analyses that had 
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not come up through this search but were known to the author were included. A total of 29 
publications were included and examined with regards to the research questions. Results are 
shown in detail in Appendix A.2 and are described below.  
 
1.) Was the population estimate for the PEVI analysis adjusted by uptake?  
In 27 out of the included 29 publications, the population size was not adjusted by uptake 
of the cost-effective intervention. In those analyses, the population estimate was mainly 
obtained by estimating the incidence and prevalence of the condition or the number of 
annual procedures. An uptake level of 100% was implicitly assumed in those cases. Only 
two studies adjusted the population estimate by uptake. 
 
2.) What methods were used to obtain the estimate of uptake?  
One of the two studies mentioned above, on thromboembolism prophylaxis in post-hip 
replacement patients, used uptake estimates that were based on assumption (McCullagh et 
al., 2012). The second study used an uptake estimate which was obtained from a trial that 
had reported the use of trastuzumab adjuvant to chemotherapy in early stage breast cancer 
(Hall et al., 2011). Neither of the two studies used a dynamic estimate of uptake or 
accounted for uncertainty associated with it. 
 
3.) Was the issue of uncertainty associated with the population estimate discussed? 
Five studies mentioned the issue of uncertainty associated with the population estimates 
in their PEVI analysis; four in their discussion and one implicitly by reporting different 
PEVI results with varying population estimates. In one of the five studies, it was stated that 
implementation may not automatically happen once research results become available and 
further exploration of this topic was recommended. None of the five studies, however, fully 
accounted for uncertainty by modelling the population estimate probabilistically. 
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2.4.4 Discussion of implementation in EVI analysis review 
This review showed that the majority of EVI analyses do not consider uptake 
adjustments in their population estimates. The implication is that most reported values for 
the PEVI are likely to be an over-estimate of the actual value of further research as low 
uptake would cause the population benefitting from further research to be smaller than the 
potentially eligible population. As the PEVI is viewed as an upper ceiling to the value of 
further research, assuming an uptake level of 100 percent is not wrong per se. It simply 
reflects the value of further research in a full uptake scenario. The full population EVPI is 
therefore an important measure. In the context of the value of future research studies, 
however, this maximum value of further research might never be reached due to low 
implementation. In cases where an uptake level of 100 percent is unattainable, potentially 
due to the existence of implementation barriers, ignoring uptake from the PEVI estimate 
would result in a drastic over-statement of the value of further research and therefore have 
the potential to mislead decision-makers.  
Limitations of this study include the small scope of the search. It is improbable that all 
PEVI analyses in health technologies have been captured with the adopted search strategy 
and there may be further examples that incorporated uptake estimates in their analysis, 
especially after the search was last updated. With 27 out of 29 analyses estimating the 
population without an uptake adjustment and none including uptake dynamics, the main 
findings of this review are fairly representative of common practice and could be used as the 
basis for defining research questions for this thesis. 
As was suggested in the previous reviews, this review supports the finding that further 
research is needed on estimation methods for uptake, which should consider the dynamic 
nature of implementation and uncertainty. The two studies in this review that had used 
uptake estimates had obtained them from available trials and assumed that this level of 
uptake would hold up to the decision relevance horizon. As technology implementation is 
regarded as a dynamic process, there is further research potential on approaches to estimate 
uptake dynamics. 
In conclusion, based on the result that very few PEVI studies adjusted their population 
estimate by uptake and taking into account the large downward effect that uptake 
adjustments could have on the value of PEVI estimates, there is a need for discussion and 
further research around uptake adjustments in PEVI analyses. 
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2.5 Review of applications and further development of the expected 
value of implementation 
2.5.1 Background to value of implementation review 
The aim of the value of implementation review was to obtain an overview of scope for 
further development of expected value of implementation methods. Having provided a 
unified framework of both value of information and value of implementation that is 
consistent with the methods of technology appraisals, the article by Fenwick et al. (2008) 
was used as the starting point for my search.  
Fenwick et al. (2008) defined the expected value of implementation as a function of the 
incremental net benefit of health technologies and the current and perfect level of 
implementation. Together with the expected value of information, this framework could be 
used to calculate the ceiling values of conducting further research (through the EVPI) and 
investing in implementation measures (through the EVPIM), and both through the Expected 
Value of Perfection (EVP). Information and implementation were assumed to be 
independent; that is, further research evidence would not affect implementation levels. The 
authors outlined areas for further research that included: (1) relaxing the assumption of 
independence of implementation and information; (2) incorporating uncertainty around 
implementation levels in the analysis; (3) evaluating specific levels of implementation that 
are attainable with the use of implementation strategies, thereby allowing states other than 
current and perfect; (4) application of the framework in an ongoing appraisal. In addition to 
these, implementation is a dynamic process and the dynamic nature of implementation 
should also be considered when applying or developing the framework by Fenwick et al. 
(2008). 
The objective of this review was to find out about any further developments and 
applications of the expected value of implementation and information framework developed 
by Fenwick et al. (2008). 
 
2.5.2 Methods of value of implementation review 
 Search strategy 2.5.2.1
To cover both, scientific and grey literature, I performed a search in three search engines: 
1. Medline, 2. Web of Science and 3. Google Scholar. The search was a citation search; that 
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is, I performed citation searches of the named journal article by Fenwick et al. (2008) in all 
three search engines. In the first phase, title and abstracts were reviewed, and the full texts of 
included articles were reviewed in the second phase.  
 
 Exclusion criteria 2.5.2.2
Excluded were all search results that were not an application or further development of 
the framework developed by Fenwick et al. (2008). Duplicates were also removed.  
 
 Data extraction and analysis  2.5.2.3
The approaches to apply the Fenwick et al. (2008) framework and to develop it further 
are presented in the results section in a tabular overview (which also includes the Fenwick et 
al. (2008) paper) and narrative. Furthermore, I examined whether the abovementioned 
identified areas for further research had been addressed since the publication of it to date 
(October 2015), leading to the following research questions: 
1.) Has the framework developed by Fenwick et al. (2008) been applied in a practical 
example? 
2.) Has the framework developed by Fenwick et al. (2008) been developed further in any 
way? 
3.) Were implementation levels other than current and perfect considered? 
4.) Was the effect of research evidence on implementation considered? 
5.) Were implementation dynamics considered? 
6.) Was uncertainty incorporated around the levels of implementation? 
 
2.5.3 Results of value of implementation review 
The three searches, which were updated in October 2015, resulted in a total of 115 hits, 
before exclusion criteria applied. Out of those, 20 hits came from the Medline search, 16 
from the Web of Science search and 79 from the Google Scholar search. After 25 duplicates 
were removed, there were still 90 hits to be reviewed. After the title and abstract review, 70 
were excluded based on exclusion criterion (A), as they were no applications or further 
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developments of the EVPI and EVPIM framework developed by Fenwick et al. (2008). One 
further hit was excluded because the link led to a Chinese university website that appeared to 
link back to the Fenwick et al. (2008) paper. Translation was therefore not considered 
worthwhile. Out of the remaining 19 hits, 11 were excluded based on the full text, leading to 
eight included publications. Also known to the author was another report, which was 
included as Entry 8 (see Appendix A.3). A further study that was only published online in 
November 2015 and known to the author was also added as Entry 11. The 10 included 
publications as well as the publication by Fenwick et al. (2008) are described in 
chronological order and are critically appraised in Appendix A.3.  
The answers to the six research questions are summarised in the following:  
1.) Has the framework developed by Fenwick et al. (2008) been applied in a practical 
example? 
Based on the findings from this review, eight applications of the framework, additional 
to the original publication, have been identified. The identified publications have either 
calculated the EVPIM and EVP only (Hoomans et al., 2009c, Soeteman et al., 2011, Tuffaha 
et al., 2014, Revill et al., 2015) or have also produced the expected value of specific 
implementation measures (Hoomans et al., 2011, Faria et al., 2014, Whyte et al., 2014). One 
article (Willan and Eckermann, 2010) furthermore estimated the effect of information on 
implementation in two example case studies and another allowed for states other than perfect 
and current (Andronis and Barton, 2016). 
 
2.) Has the framework developed by Fenwick et al. (2008) been developed further in any 
way? 
Three publications provided extensions to the original framework. Willan and 
Eckermann (2010) presented a framework for estimating the value of information allowing 
for imperfect implementation, and by modelling the effect of research evidence on 
implementation as a function of the strength of evidence. This was done by employing a 
sliding step function for implementation, which depended upon the strength of evidence. 
The latter was represented by a certain threshold of the z-statistic; once it was surpassed, 
implementation would linearly increase until the improved implementation level was 
reached. The authors calculated the EVSI and demonstrated that the optimal research design 
could be found by maximising the expected net gain (that is, the EVSI compared to trial 
costs) associated with different designs. The authors found that the EVSI increased with 
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imperfect implementation. This was because research also has an effect on the 
implementation, thus reducing the expected opportunity loss incurred by the health care 
payer due to a proportion of patients being on a treatment that is expected to be less cost-
effective. However, the dynamic nature of implementation was not considered and 
implementation was assumed to jump to the calculated level when evidence became 
available. The relationship between information and implementation was furthermore 
assumed to be linear between the current level of evidence and a defined future level of 
evidence at which implementation would reach the highest possible level.  
The report by Walker et al. (2014) had the aim of providing a framework to allow for the 
evaluation of implementation initiatives in the England and Wales NHS. The framework was 
essentially the same as the one proposed by Fenwick et al. (2008) but the authors allowed for 
the following extensions: a) they presented a way of evaluating implementation initiatives 
that could target different subgroups of a population, accounting for different costs, benefits 
and utilisation rates; b) they allowed for multiple periods in the calculation of the value of 
implementation measures; c) they considered imperfect levels of implementation that would 
result from implementation measures using the ‘expected value of actual implementation’. 
The authors let implementation levels differ in each period and costs of the implementation 
initiative could occur in different periods of time.  
The framework by Walker et al. (2014) was applied in follow-up reports shown in Entry 
7 and 8 in Appendix A.3, in a case study on novel anticoagulants in the prevention of stroke 
and systemic embolism (Faria et al., 2014) and another application to B-type natriuretic 
peptide (BNP) testing in diagnosing chronic heart failure (Whyte et al., 2014). The latter 
study is now published as a peer-reviewed journal article (Whyte et al., 2016).  
Andronis and Barton (2016) extended the existing four-state framework by two further 
states: improved implementation and sample information. They then presented the 
‘implementation-adjusted’ EVSI and claimed that the traditional EVSI would over-estimate 
the real value of research when implementation was imperfect. This is a simplification that 
does not recognise that the ‘implementation-adjusted EVSI’ is, in fact, nothing but the value 
of a research study treated as an implementation measure, thereby disregarding the effect of 
research on decision uncertainty altogether. This is because the ‘implementation-adjusted 
EVSI’ was calculated omitting the maximisation of expected net benefits under current 
information, and the maximisation of net benefits in each simulation for the with research 
scenario, and instead uses an uptake-weighted average net benefit in both cases. The effectof 
research on uncertainty is thereby ignored. What is truly calculated is the expected value of 
implementation of the research activity. If the authors had explored a sufficiently large range 
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of implementation levels, including low ones, they would have found that their 
‘implementation-adjusted’ EVSI can, in fact, be larger than the EVSI. This is intuitive 
because EVSI and ‘implementation-adjusted’ EVSI measure different things. One measures 
the potential reduction in decision uncertainty that a research study can achieve and the other 
measures the potential reduction in the expected value of implementation that is attainable 
with the same research study. More will be said on this in Chapter 4. 
 
3.) Were implementation levels other than current and perfect considered? 
Implementation levels other than ‘current’ and ‘perfect’ were allowed in one series of 
studies (Faria et al., 2014, Walker et al., 2014, Whyte et al., 2014) and another publication 
by Willan and Eckermann (2010). Estimates for these states were based on assumption or 
derived by quantitative extrapolation methods described in Question 5.) below. Another 
article (Andronis and Barton, 2016) used static implementation estimates that were ‘elicited 
from experts’ but no uncertainty was reported. In this study, other scenarios were also tested 
in sensitivity analysis based on assumptions. 
 
4.) Was the effect of research evidence on implementation considered? 
Only two studies considered the relationship between the strength of research evidence 
and implementation levels (Willan and Eckermann, 2010, Andronis and Barton, 2016) as 
described in Question 2.). Problems with the Willan and Eckermann (2010) approach may 
lie in the fact that the strength of research evidence reflects uncertainty surrounding a 
specific parameter, rather than decision uncertainty. This may or may not be appropriate in 
reflecting a trust’s or clinician’s thought process when making the adoption decision. 
The problems with the Andronis and Barton (2016) approach relate to the authors’ 
interpretation of the ‘implementation-adjusted’ EVSI as described under Question 2.). A 
further problem relates to the way they obtained the before and after research 
implementation estimates. Experts provided point estimates of 50% for the current level of 
implementation and 75% for the with research implementation and a linear improvement in 
implementation of 5 percentage points per year for the cost-effective technology was 
assumed to occur in the following years. 
 
5.) Were implementation dynamics considered? 
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In Faria et al. (2014), linear and polynomial regression methods were used to extrapolate 
future implementation from available data over a three year period, but depending on the 
method, the resulting implementation levels after some periods of time varied widely. The 
authors concluded that it was difficult to assess which model can predict future utilisation 
accurately. The wide variation of results may have been caused by an arbitrary choice of 
methods that ignored well established methods of modelling diffusion, as reported in a 
variety of studies, including the 25-year review of diffusion modelling methods by Meade 
and Islam (2006).  
In the paper by Whyte et al. (2016), an exponential model was used to obtain future 
implementation levels that followed an s-shape, acknowledging diffusion theory (Rogers, 
2003). However, evidence was only available on two periods of utilisation, and it appeared 
as though these were not the first two periods after technology introduction. This means that 
the inflection point may not have been accurately captured as data on all periods since 
technology introduction are required for sigmoid curves to represent diffusion accurately 
(Meade and Islam, 2006). Furthermore, the maximum number of attainable adoptions was 
implicitly set at a hundred percent of the eligible patient population, which may not be 
realistic, and possibly a result of ignoring the first periods of diffusion. Both of these issues 
may result in arbitrary effects on the fitted diffusion curves, with the second effect possibly 
being the over-estimation of uptake that can potentially be achieved.  
Andronis and Barton (2016) used implementation estimates that changed linearly in the 
future. They used a sigmoid curve for implementation in a sensitivity analysis, which they 
stated was inspired by Rogers’ diffusion theory (Rogers, 2003) but they did not provide any 
further detail on it. All three applications did not use established diffusion models for which 
the fit with real world data has been shown. These are examined further in Chapter 3.  
 
6.) Was uncertainty incorporated around the levels of implementation? 
None of the included studies incorporated uncertainty in their implementation estimates. 
 
2.5.4 Discussion of value of implementation review 
The expected value of implementation review showed that the value of implementation 
was assessed in a small number of applications only. The unified framework originally 
developed by Fenwick et al. (2008) was extended further by: 1. allowing for subgroups, 2. 
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allowing the strength of research evidence to affect implementation, 3. allowing 
implementation levels other than ‘current’ or ‘perfect’ and finally 4. allowing 
implementation to change over future time periods. Whilst three included papers explored 
future diffusion with a nod to diffusion theory, none of them used established diffusion 
curves for which there is evidence on the fit with real world data. This is important because 
not all s-shaped extrapolations have demonstrable forecasting ability (Meade and Islam, 
2006). None estimated the uncertainty associated with their estimates of diffusion. 
These findings demonstrate that more research is needed in the area of obtaining 
implementation estimates. More concretely, it was shown that implementation estimates are 
needed for: 1. the ‘counterfactual’ development of implementation levels, when no 
implementation initiatives are pursued; 2. the ‘potential’ with implementation initiatives or 
with research implementation levels; and 3. implementation levels for each future period in 
both of these cases.  
Two particular weaknesses in the use of implementation dynamics were seen in the 
method used for extrapolating future implementation: 1.) in the study by Faria et al. (2014), 
the regression method used significantly influenced the maximum level of implementation 
that could potentially be achieved. 2.) The data used for the observed implementation levels 
as well as for the effect size of implementation measures were highly uncertain in the study 
by Whyte et al. (2014), and not all periods since technology launch had been incorporated in 
the analysis.  
It may be desirable from a policy perspective to identify technologies or policies with 
potentially low implementation early and to assess the value of implementation measures 
before they are introduced in the health system. This may be particularly relevant when 
research studies may have an effect on implementation, as research is more likely to be 
conducted before technology introduction. Performing such analysis before technology 
introduction could thus enable policy-makers to design research studies with the effect on 
implementation in mind, similar to a CTA approach used in the Netherlands. None of the 
included publications had attempted to estimate implementation levels before technology 
introduction. Such analysis is likely to be associated with further methodological difficulties 
of obtaining implementation estimates and identifying those technologies with potentially 
low implementation. Furthermore, the effect of research evidence on implementation should 
be made more specific than the sliding-step relationship of the z-static and future 
implementation levels employed by Willan and Eckermann (2010). 
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The strength of this review was its targeted and specific methodology. Only the addition 
of Google Scholar as another database meant that the number of search results went up to 
more than a hundred – without Google Scholar there would have been only 36 hits before 
removing duplicates. Including Google Scholar proved important: three of the included 
publications were only found by Google Scholar and two of those were especially relevant 
in that they had developed the original framework further.  
The limitation of this review was the same as the strength. Being very specific and 
limited to only three databases meant that other publications studying the value of 
implementation may have been missed, for example because of the databases not accessing 
all relevant journals. This was not considered a sufficiently large problem to warrant the 
extension of this review to other databases. Being a citation search also meant that studies on 
a similar topic that did not cite Fenwick et al. (2008) would have been missed.  
In conclusion, this review showed continuous interest in the expected value of 
implementation from the time of publication of the Fenwick et al. (2008) framework, which 
was applied and extended in 11 studies until November 2015. It also highlighted the need for 
further research, in particular around the estimation of implementation dynamics, potentially 
before technology introduction, and the relationship between research and implementation. 
 
2.6 Summary 
The reviews presented in this chapter found that implementation estimates were not 
commonly used in economic evaluation of health technologies. The uses of implementation 
estimates were limited to expected value of implementation analysis, population estimates of 
value of information, costs or effects, and the modelling of infectious diseases. When 
implementation estimates were used, the approaches of obtaining them were basic: most 
studies with few exceptions (Faria et al., 2014, Whyte et al., 2014) did not consider changing 
implementation over time and estimates were mostly based on reference data or assumption. 
These findings provided guidance in the selection of the areas for further research within 
this thesis. Most importantly, it became clear that further study of methods to obtain 
estimates of implementation over time was needed. I also identified some scope for further 
research and development of the expected value of implementation framework. Furthermore, 
price changes precipitated by the reimbursement decision and subsequent changes in 
implementation had not been included in economic evaluation. 
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The research topic was approached from different angles, using different types of 
reviews (scoping and citation searches) and different key publications as starting points. This 
ensured that a variety of research studies were included. The citation searches were narrowly 
defined but I was confident to have found the most relevant studies in the respective areas. 
The scoping review highlighted the challenges commonly associated with methodological 
research: a large number of hits was obtained of which only a fraction was relevant. It did 
help with the identification of areas for further research but the lack of comprehensiveness 
meant that not all the studies using implementation estimates were found. However, I was 
confident that no important methodological study was missed after having performed the 
other searches and reviews. Multiple presentations of this work in front of different 
academic and policy audiences did not result in any further studies being highlighted to me.  
Further research is needed in obtaining an overview of actual health technology diffusion 
data in England and to review potential methods to model health technology diffusion. 
Model frameworks are required that can facilitate the incorporation of diffusion estimates in 
value of information and implementation analysis and the modelling of the diffusion-price 
relationship through experience curves. 
In conclusion, there is scope for further research on the incorporation of diffusion 
estimates in health economic methods.  
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CHAPTER 3. REVIEWS OF METHODS TO ESTIMATE HEALTH 
TECHNOLOGY DIFFUSION PRIOR TO TECHNOLOGY 
INTRODUCTION 
3.1 Background 
The previous chapter established that diffusion estimates are relevant for economic 
evaluation of health technologies. As was highlighted in the introductory chapter, 
implementation of new technologies follows a gradual growth curve over time. This is 
explained through diffusion theory. The natural shape of health technology diffusion, 
however, is unknown. The fact that HTAs are commonly performed prior to technology 
introduction presents an additional methodological challenge in the estimation of diffusion 
for the technology to be assessed.  
The aim of this chapter was to identify a method of obtaining probabilistic estimates of 
new health technology diffusion with no existing data on uptake. This method would then be 
used to obtain diffusion estimates for the case study technology (Chapter 6) (see this 
chapter’s place in the thesis in Chapter 1, Figure 1.2). In Section 3.2, I explore available 
evidence on health technology diffusion data in the UK. The objective of this was to provide 
the information needed for generating a synthesised diffusion curve of health technologies in 
the UK, potentially controlling for influencing factors such as the effect of NICE guidance. 
Such synthesised curves could then be used for future reference, potentially with some 
adaptation, to predict new health technology diffusion. In Section 3.3, I explore existing 
sales forecasting methods and diffusion models that could help predict diffusion of 
individual health technologies. The objective was to identify a method to generate 
probabilistic estimates of diffusion of individual health technologies when no data is 
available. For this, I reviewed existing diffusion models and sales forecasting methods with 
the ability to predict diffusion curves when no data is available. 
 
3.2 Review of health technology diffusion in the United Kingdom 
3.2.1 Objective of UK health technology diffusion review 
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This literature search sought to identify publications with empirical estimates of 
diffusion curves of health technologies in the UK health care setting that could potentially 
enable evidence synthesis on health technology diffusion in the UK. I chose the UK instead 
of England for this review, to avoid exclusion of evidence that could potentially be adjusted 
to reflect England.  
 
3.2.2 Methods of UK health technology diffusion review 
 Search strategy 3.2.2.1
The search strategy followed three different branches. These branches were each 
targeted reviews to identify additional relevant publications and are described in Sections 
3.2.2.2 to 3.2.2.4. The searches were performed in January 2013. 
 
 The ERNIE database 3.2.2.2
The Evaluation and Review of NICE Implementation Evidence (ERNIE) database was 
searched for so-called NICE implementation uptake reports, which empirically estimate the 
uptake of NICE technology appraisals, clinical guidelines and public health initiatives. The 
ERNIE database also lists publications on uptake from external sources, referring to external 
publications that were related to health technologies previously assessed by NICE. There 
were references for each of the following categories: cancer service guidance, clinical 
guidelines, interventional procedures, public health guidance and technology appraisals. I 
deemed the technology appraisals and interventional procedures streams as most relevant for 
the research question. References in these two categories were therefore searched. There 
were five interventional procedures and 154 technology appraisals with a varying number of 
between one to ten external references for each of them. References for all five 
interventional procedures and all 154 technology appraisals were searched. 
A few external references contained information on various health technologies. This 
resulted in those key references being listed as external references for more than one 
technology appraisal. Those were marked as ‘duplicates’. In the case of irrelevant 
publications the reason for their irrelevance was given, whether they were duplicates or not, 
instead of marking them as duplicates first. This followed from the structure of the database 
that did not allow exporting of references. 
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 Medline 3.2.2.3
The search strategy for Medline was developed following an initial search for key 
publications and after identifying suitable search terms from their abstracts and keywords.  
Keywords for search Medline 1 were: 
(Diffusion OR Uptake OR Adoption) AND (adj3 Curve OR adj2 Data) AND (‘Diffusion 
of Innovation’) AND (geographical filter UK) 
The subject heading ‘Diffusion of Innovation’ was dropped for one search variation to 
explore whether more results would be obtained (Search Medline 2). The geographical filter 
was dropped for another variation of the search (Medline 3). Results were limited to 
publications in English language.  
 
 Restrictive Google Scholar search 3.2.2.4
A restrictive Google Scholar search was conducted using the following search terms: 
(Diffusion OR Uptake) AND curve AND health 
Only English language publications were retrieved and the search was limited from 
January 1991 to January 2013. The rationale for this was to limit the search to recent and 
therefore more comparable data. The first one hundred results were screened for relevant 
publications that might not have been picked up by the other searches, especially grey 
literature.  
 
 Inclusion and exclusion criteria 3.2.2.5
Included were publications with diffusion data in the UK health care setting. Excluded 
were publications using data from outside the UK or with a data series of less than two years. 
Publications on technologies that could not qualify as health technologies or were grouped 
rather than individual technologies were excluded. Further publications were excluded when 
the terms diffusion or uptake did not refer to diffusion of health technologies but instead to 
diffusion of other phenomena. Publications were also excluded when they were secondary 
publications of data for which the primary publication was available.  
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 Data extraction 3.2.2.6
The results of the searches were described in narrative. The resulting diffusion curves 
were categorised in terms of conditions that were grouped as cancer, acute conditions, 
chronic conditions, conditions that can be chronic and acute and others. Data for the 
condition, the technology, the measure of diffusion or proxies used, the data source, the 
length of time for which diffusion data was available and the first year diffusion data was 
extracted into tabular overviews.  
 
3.2.3 Results of UK health technology diffusion review 
 ERNIE database search results 3.2.3.1
This search identified 31 NICE implementation uptake reports, 16 of which referred to 
technology appraisals, 14 to clinical guidelines and one to a public health initiative. Out of 
the 16 reports on technology appraisals, 14 included data points on the technologies’ uptake. 
Two were excluded for containing grouped data on several medications. Nine out of the 14 
uptake reports concerning clinical guidelines yielded data points on diffusion. Five were 
excluded: one of them for not containing diffusion data; the other was a duplicate that was 
included in the technology appraisals uptake report and three contained grouped data for 
different technologies. One uptake report assessing a public health initiative was included in 
this review. In total, 24 uptake reports were thus included.  
From the search of ERNIE external references, five interventional procedures with six 
external references were listed. None of them contained data on utilisation over time and so 
were excluded from the review. For the 154 screened technology appraisals, a total of 399 
external references were listed. Out of those, 165 did not contain diffusion curves, 219 were 
duplicates of already included studies and one provided prescription volume data but only on 
drug classes instead of individual health technologies. Fourteen publications were included 
for full text review. Out of those, two were excluded because they referred to the same 
diffusion data as other publications. One was the innovation scorecard which did not yield 
diffusion curves of at least two years. One could not be found online. Ten publications were 
finally included. 
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 Medline search results 3.2.3.2
Medline search 1 yielded four records. Two of those were included in the final results 
based on the inclusion criteria. One was excluded because the data used was from Florida, 
another because it provided data for less than two years. Two of the included publications 
referred to the same technology and to the same dataset and one of them was therefore 
excluded. One publication with diffusion curves of different technologies in the UK health 
care setting was included.   
Medline search 2 yielded 16 records. None of them were included in the final results. As 
expected, the four records from Medline 1 came up again and were excluded; the 12 
additional publications did not use UK data.  
Medline search 3 yielded 169 records. After the abstract search, 139 publications were 
excluded based on their different understanding of the term diffusion which did not refer to 
diffusion of health technologies but, for instance, to the diffusion of tumour tissue. Ten 
publications were excluded because they did not contain data to inform a diffusion curve and 
two studies were excluded because their data were not from the UK. Fourteen potentially 
relevant publications were identified. As expected, the four results from search Medline 1 
were listed but excluded as duplicates. After the full text review, three publications were 
included based on the inclusion criteria. The remainder were excluded as no diffusion data 
over time was provided (10) or because of grouped data (1).  
 
 Restrictive Google Scholar search results 3.2.3.3
The Google Scholar search yielded 47,700 records and the first 100 records, sorted by 
relevance, were searched. In 68 records, diffusion or uptake was used to describe diffusion 
other than that of health technologies. Nineteen records did not contain empirical diffusion 
curves, seven records did not come from the UK and three were not health technologies. 
Two had been identified through the Medline searches and were excluded. Therefore, one 
publication was found to be relevant and it was included after full text review. No further 
searching was undertaken using Google Scholar due to this poor hit rate and the availability 
of data from the other searches. 
An overview of the number of publications retrieved by the searches and included after 
review can be found in Table 3.1. 
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Table 3.1 Overview of search results 
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 Summary of findings 3.2.3.4
A total of 164 diffusion curves were reported within the 40 included studies. Diffusion 
curves related to 52 therapeutic areas or conditions. Conditions were grouped as cancer (10), 
acute conditions (9), chronic conditions (17), conditions that can be chronic and acute (8) 
and others (8). Others included, for example, smoking cessation programmes, obesity and 
prevention of diseases.  
Diffusion was shown for a total of 127 technologies, 99 of which were drugs and 28 
were other treatments or technologies. Those other treatments or technologies encompassed 
surgical technologies such as laparoscopic surgery, therapies such as computerized cognitive 
behavioural therapy, and devices such as Magnetic Resonance Imaging (MRI) scanning. 
Diffusion data was mainly presented as absolute numbers of prescriptions or prescription 
costs. Some publications used number of patients or number of milligrams or hospital 
episodes. Most of the data was presented as absolute numbers; less frequently relative to the 
incidence or as the share over other alternative technologies.  
Different data sources informed the diffusion data in the included publications. Data 
were primarily obtained from the IMS Health Hospital Pharmacy Audit Index database, the 
electronic prescribing analysis tool (ePACT) and the prescription cost analysis (PCA) 
system. Less frequently, data were obtained from the Hospital Episode Statistics (HES) 
national data warehouse, surveys and General Practitioner (GP) records as well as 
specialised databases such as the British Pacing and Electrophysiology Group (BPEG) 
Register. 
The available time series varied in length and most publications presented data on a 
limited number of periods. The average length of time series data was 6.5 years. The average 
length of data available without guidelines was 2.75 years. The length of time series data 
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was potentially too short to observe sigmoid curves in most cases although visual inspection 
resulted in a few sigmoid candidates (for instance, oxaliplatin and capecitabine for colon 
cancer; percutaneous coronary intervention with drug eluting stents in angioplasty; or 
donepezil in Alzheimer’s disease). Characteristics of data on diffusion curves from the 
included publications – grouped as cancer, acute conditions, chronic conditions, conditions 
that can be chronic and acute and others – are provided in summary tables within Appendix 
B. As well as variation between studies in terms of conditions, diffusion measure, data 
sources and length of the time series, it was clear that contextual factors played a strong role 
in diffusion patterns. Consequently, no attempt was made at meta-analysing or summarising 
the identified curves. 
 
 How results of this review could inform further analysis 3.2.3.5
The presented search resulted in identification of relevant publications and extracted data 
that could be of potential value for estimating health technology diffusion in this thesis. The 
identified reports and articles that presented data on health technology diffusion in the UK 
did not include data on all health technologies currently in use in the UK. It was not possible 
to identify the selection criteria for health technologies for which diffusion data was reported. 
The data may therefore not be representative of the true technology diffusion in the NHS. 
Other issues relate to: 
 
a) Availability of data 
The exact data was mostly unavailable from the identified reports which mainly 
visualised diffusion in graphs. However, reasonably accurate data could be generated 
through digitising graphs using purpose-built software (e.g. Grafula). 
 
b) Range of technologies covered 
A wide range of technologies were covered by the literature. The proposed 
categorisation of technologies was to group them by conditions. In addition, drugs and other 
health technologies could be separated. There was data on only 28 technologies falling in the 
category of ‘other health technologies’. These could further be grouped as: types of surgery 
(7), diagnostics (4), devices (9) and others (8).  
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c) Heterogeneity 
Even within technology / disease groupings, diffusion curves appeared extremely diverse, 
with some stagnating at a very low level and some going through exponential growth and a 
following decline. None of the diffusion curves formed a straight horizontal line from the 
date of technology introduction. No explanation was provided for the different shapes of the 
curves. The only piece of information that was available for many of the included diffusion 
curves was the issue date of NICE guidance. Based on visual inspection, it could not be 
observed that the issue of NICE guidance resulted in a homogeneous change in the 
examined diffusion curves. Due to the lack of information on explanatory factors, meta-
analysing the extracted data would have likely produced meaningless results. With 
knowledge of these explanatory factors, diffusion curves could be grouped and aggregated 
more sensibly, which could then enable meta regression analysis. However, this would 
require in-depth research for each technology on information that is not available from this 
review. None of the included studies examined drivers of diffusion in an attempt to explain 
heterogeneity. 
 
d) Length of time series 
Ideally, time series would cover the entire life-span of a technology, or at least include 
the inflection point of the curve. However, none of the present data sets fulfil the former, and 
based on visual inspection it is difficult to assess whether the latter is given. The stage a 
technology is at in the product lifecycle is an important explanatory factor that would need 
to be identified for each set of diffusion data if they were to be analysed. However, length of 
time series is also important as it impacts on the accuracy of longer-term estimates. If the 
decision was made to only take diffusion data with more than three years of observed data 
into account, then 133 diffusion curves were still available. With greater than seven years of 
diffusion data, the number of curves dropped to 52 and greater than nine years of data 
decreased the number of diffusion curves to 25. The mean length varied over the different 
categories of conditions, with diseases that can be both acute and chronic having the longest 
diffusion curves (mean of nine years) and the cancer category having the shortest (mean of 
five years).  
As the issue of NICE guidance could have an impact on ‘natural’ diffusion, it would be 
of particular interest to analyse this, conditional on sufficient data points being available. On 
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average, diffusion curves covered two to three years before guidance was issued. Only 
analysing diffusion curves of three years before guidance was issued reduced their number 
to 32. Only six diffusion curves were left when diffusion curves with more than seven years 
before guidance were included. 
 
e) Specificity of data 
There were a few studies that showed prescription data of, for instance, proton pump 
inhibitors or statins, without specifying the condition. These were included in the present 
results but would need to be excluded for further analysis as they would not be suitable for 
assessing the diffusion of a health technology for a specific condition. 
 
f) Output variable 
Some of the included publications used prescription volume data as a measure of 
diffusion. Others used prescription costs as a proxy, which seemed reasonable under the 
conditions that prices did not change over time and that they were split by indication. 
Further studies used the proportion of usage of a technology relative to the eligible patient 
population. The latter appeared to be the most sensible option for aggregation of data across 
conditions with different population sizes. A diffusion measure relative to the total eligible 
population would, however, require further data on the expected patient population over 
time or in the case of costs, the expected total treatment costs over time.  
 
3.2.4 Discussion of UK health technology diffusion review 
This review showed that diffusion data on health technologies in the UK were available. 
The above-mentioned heterogeneity and the short length of time over which data were 
available meant that a meta-analysis would not yield sensible and usable results. While 
heterogeneity could potentially be addressed by further qualitative or quantitative analysis to 
better explain the impact of different factors influencing diffusion, the number of available 
diffusion curves with sufficient time periods of data available was likely too small to enable 
meaningful meta-analysis. This review did not yield the qualitative information necessary 
for such analysis, for example information on entry of competitors and other potential 
diffusion determinants. 
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Another option of generating a diffusion curve for a particular health technology would 
be to choose an analogous technology from this catalogue and use its diffusion curve, 
possibly with some adaptation. The caveat is that the defining features of an ‘analogous’ 
technology are not entirely clear in the context of health technology diffusion. In other 
studies, such analogous technologies are typically very narrowly defined as those in the 
same product category and with other similarities (Jiang et al., 2006). Those similarities 
could include the environment within which the product will be launched, the behaviours of 
buyers, marketing strategy and the nature of the innovation (Goodwin et al., 2014). 
The implication for the further development of this thesis was that using meta-analysed 
diffusion data was not a feasible option and that picking an analogous technology and 
adjusting its diffusion to match the context in question may be challenging. Other methods 
are therefore required to obtain diffusion estimates. With NICE publishing the 
implementation uptake report series, much more diffusion data is going to become available 
in the future, which could potentially enable the future use of analogous technologies or 
meta-analysis.  
The strengths of this study relate to the number of databases explored. This led to a 
broad range of health technology diffusion data found. Limitations were the restriction on 
the Google Scholar search to only one hundred hits and the exclusion of public health 
guidance, cancer service guidance and clinical guidelines databases for searching external 
references. However, these searches were not expected to reveal sufficient additional 
diffusion data to change the conclusion of this review. 
In conclusion, the health technology diffusion evidence available for the UK is not 
mature enough to perform meta-analysis from empirical data alone and other methods of 
estimating diffusion are required. 
 
3.3 Review of methods for predicting diffusion prior to launch  
3.3.1 Background to predicting diffusion methods review 
With observed evidence of diffusion curves not being mature enough to perform 
evidence synthesis of empirical data alone (as demonstrated in Section 3.2 of this chapter), 
another estimation method for health technology diffusion was needed. This section 
therefore sought to identify methods to predict diffusion. One starting point was having 
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informal conversations with two representatives of one medical device and one 
pharmaceutical manufacturer, with the objective to identify methods of forecasting or a body 
of literature. These did not identify formal forecasting methods but suggested that the 
prediction of future sales entailed consideration of multiple variables such as the number of 
physicians covered by sales representatives per year and the likely market share that could 
be achieved. 
Another starting point was to explore methods commonly used for sales forecasting in 
pharmaceutical or health technology companies. A scoping review was performed in the 
databases Business Source Premier via EBSCO, Medline via OvidSP and Google Scholar on 
search terms relating to sales forecasting and diffusion of health technologies. This scoping 
review produced results on a diffusion model called the Bass model of new product growth 
(Bass, 1969, Sillup, 1992, Meade and Islam, 2006, Bass et al., 2001).  
For lack of knowledge of formal forecasting methods other than the Bass model of new 
product growth, I decided to do further research on this established model. This choice was 
supported by the fact that values of model parameters were available for many different 
technologies including health technologies, and its fit with real data was demonstrated in 
several publications (these are discussed in the sections below). The Bass model of new 
product growth (Bass, 1969), developed shortly after Rogers’ theory of diffusion (Rogers, 
2003) described in Chapter 1, used a logistic model to reflect the s-shape of cumulative 
technology diffusion, with parameters adapted to reflect the degree of innovation and 
imitation as well as the overall attainable number of adoptions:  
 𝑛(𝑡) = 𝑝(𝑚 − 𝑁𝜏) +
𝑞
𝑚
𝑁𝜏(𝑚 −𝑁𝜏) 
(3.1)  
where 𝑛(𝑡) is the number of new adoptions in period t, with 𝑛(𝑡) ≥ 0, 𝑡 > 0, p the 
coefficient of innovation, and q the coefficient of imitation, with 
𝑞
𝑝
> 1 to ensure the s-shape 
(Meade and Islam, 2006), 𝑚 the total number of attainable adoptions with 𝑚 > 0, 𝑁𝜏 the 
cumulative number of adoptions up to 𝜏 with 𝜏 = 𝑡 − 1. The coefficient of innovation (p) 
can be explained as the speed of adoption in initial periods that is largely independent of 
peer influence. The coefficient of imitation (q) is the speed of adoption in later periods at 
which peer influence is the main driver. 
 
3.3.2 Methods for predicting diffusion methods review 
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 Search strategy 3.3.2.1
I performed a state-of-the-art review (Grant and Booth, 2009) to identify papers on 
methods to predict diffusion without any available data. It is worth mentioning here that a 
review of pre-launch forecasting methods was published in 2014 (Goodwin et al., 2014) that 
was found when updating this review in December 2015. This is especially relevant to this 
thesis as it focusses on pre-launch forecasting methods and includes methods other than 
diffusion models. This is going to be discussed together with other findings in Section 3.3.3.  
A state-of-the-art review is a review that prioritises most current methods to point out 
areas for further research. From the scoping review described in Section 3.3.1, one study 
was identified that predicted diffusion with no data available: a paper by Bass et al. (2001). 
Based on a systematic review by Meade and Islam (2006) that had the objective to identify 
extensions and adaptations to diffusion models (Meade and Islam, 2006), the Bass et al. 
(2001) paper was the only one predicting diffusion with no data available up to the time of 
their review. I therefore used the Bass et al. (2001) paper to perform a citation search in Web 
of Science, with the objective to identify any newer papers published since, in which 
diffusion was predicted prior to technology launch. This search was first performed in May 
2013 and updated in December 2015. 
 
 Inclusion and exclusion criteria 3.3.2.2
The titles and abstracts of identified publications were screened and papers were 
included for full text review based on the inclusion and exclusion criteria below. These 
criteria were applied again in the full text review. Papers were included when methods were 
described for predicting diffusion without any data available. Papers were excluded when (a) 
no methods for predicting diffusion were described, (b) there was some data available and (c) 
the methods were already described in the original paper that was included. 
 
 Data extraction 3.3.2.3
Included papers as well as the paper by Bass et al. (2001), the starting point to this 
search, were summarised in terms of their objectives, methods used and limitations in 
tabular format. Important developments in methods for predicting diffusion with no data 
available were additionally described in narrative. In addition to the review results, the 
critical review by Goodwin et al. (2014) was summarised in order to provide an overview of 
forecasting methods in general. 
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3.3.3 Results of predicting diffusion methods review 
 Included publications 3.3.3.1
The citation search in Web of Science resulted in 18 citations of the paper by Bass et al. 
(2001). Ten of them were excluded based on the title and abstract screening, four because 
the papers did not describe methods for predicting diffusion (a), five because the predictions 
were based on some available data (b) and one because the original paper referenced was 
already included (c) (the review by Meade and Islam (2006) that was identified before this 
review, as described above). Three more papers were excluded during the full text screening 
phase, two of which based on criterion (b) and one based on criterion (a). The full text 
review therefore resulted in five included papers. The review by Goodwin et al. (2014) was 
not included in the discussion of this review but was discussed separately (Section 3.3.3.3). 
 
 Findings from the search and review on predicting diffusion 3.3.3.2
Five out of six of the papers included in this review used a method called ‘guessing by 
analogy’ to predict diffusion of a new technology prior to technology introduction, when no 
data were available (Appendix B, Table B.7). The Bass et al. (2001) paper predicted 
diffusion of a new television technology by analogy and expert judgement was used to 
identify the most appropriate analogous product. The authors stated that it was difficult to 
choose the right analogy because little was known on how analogies should be chosen. Jiang 
et al. (2006) expanded on this stating that guessing by analogy is of limited applicability 
when few similar products are available, especially because it is difficult to find 
technologies sufficiently similar to result in similar diffusion patterns. Furthermore, data of 
analogous technologies are often truncated on either side, that is, there usually is data 
shortage on the beginning phase of diffusion or on the later periods (Jiang et al., 2006). This 
introduces bias (Jiang et al., 2006). Diffusion data may also be more likely to be published 
for successful technologies causing sample selection bias. Finally, elapsed time since the 
analogous technology was introduced may have brought about other exogenous factors that 
may influence diffusion patterns (Kim et al., 2013).  
An extension to commonly used guessing by analogy methods was presented in the 
paper by Lee et al. (2014). In their study of consumer electronics, product attributes of a 
large number of technologies in the same product category were analysed for their effects on 
product diffusion. This was achieved using statistical and machine learning-based 
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approaches. For this, the authors created databases of product attributes that were informed 
by expert judgement, and of diffusion characteristics that were achieved through non-linear 
least squares regression analysis of at least 12 years’ worth of available adoption data points 
for 80 technologies. The product attributes were developed based on a literature review and 
discussions with senior marketing managers. Four of the 17 identified attributes were valued 
on nominal scales and the others were valued on five-point Likert scales from very low to 
very high. All of the attributes were valued for each of the included technologies by industry 
experts. Among the various regression methods employed, multivariate linear regression 
performed best in terms of mean absolute error.  
While the method proposed by Lee et al. (2014) is a step in the direction of obtaining 
better diffusion estimates prior to launch based on analogous technologies, it is unlikely to 
be reproducible in health technologies. This is because a large database of similar products is 
required to establish the relationship between product attributes and diffusion characteristics. 
The degree to which technologies are similar is important: in non-health technologies, 
analogies were typically used from the same technology class, when there were no long lags 
between the launch dates of the respective technologies (Goodwin et al., 2014). This is much 
more likely to happen in consumer markets in which the protection of intellectual property 
plays a lesser role than in health care. Lee et al. (2014) used a database of 80 technologies. 
In health technologies, it is improbable that such large numbers of technologies in the same 
therapeutic area and with similar product characteristics can be found. Furthermore, to be 
able to produce relatively accurate diffusion estimates, the available adoption data need to 
encompass the peak of per period adoptions. For this reason, Lee et al. (2014) only included 
those products with more than 12 years’ worth of adoption data. Considering that the review 
presented in Section 3.2 found only 25 diffusion curves that had more than nine years of data 
available, it is unlikely that the numbers needed for such analyses can be generated in the 
health technology sector at present. 
An example of a subjective judgement method to product demand forecasting was 
presented in the paper by Kim et al. (2013). The authors proposed a survey method that 
asked for seven items associated with important data on diffusion. The seven items were: 
quantity in first period, time and cumulative quantity at take-off, time and cumulative 
quantity at peak, time and cumulative quantity at stagnant demand. The authors chose the 
time of stagnant demand over the quantity of market potential, because the latter was 
deemed difficult to estimate, being the asymptomatic value of demand over infinite time. 
These quantities could be converted to estimate the parameters of the logistic model by 
means of algebraic transformation and local searches.  
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This survey method stands in contrast to other studies that proposed using three 
questions on peak time, peak rate and market potential (Mahajan and Sharma, 1986) and 
sum of Bass model parameters p and q, initial demand and market potential (Lawrence and 
Lawton, 1981). The rationale for expanding the number of questions was to minimise the 
chance of erroneous estimates of one or more of the parameters. The authors considered 
such erroneous estimates more likely due to the vague nature of questions asked in those two 
studies. A limitation of this study was that the survey only delivered deterministic diffusion 
data and did not allow for the respondents’ uncertainty to be expressed. If this was to be 
addressed by using formal elicitation of expert opinion, then the number of questions asked 
may be too great to provide meaningful results and fit into tight schedules of experts. The 
authors used a logistic model instead of the Bass model, owing to its relative simplicity. 
They did, however, acknowledge that the Bass model is superior in its ability to accurately 
forecast, especially in technologies for which the demand pattern is asymmetrical about the 
peak of per period adoptions. This study highlighted the difficulty in finding a good balance 
of information that is easy to elicit because it is intuitive, and information that can be 
transformed into diffusion model parameters.  
 
 Summary of Goodwin critical review of new product forecasting methods 3.3.3.3
The paper by Goodwin et al. (2014) contains a critical review of different methods of 
pre-launch forecasting. While this paper does not describe any prediction method based on 
diffusion models that were not included in this review already, it is a valuable addition in 
that it discusses forecasting methods other than those based on diffusion models, a body of 
literature that I had not found before. I therefore briefly summarise the content of this paper: 
Goodwin et al. (2014) stated that the ideal scenario forecast included a probability 
distribution for adoption levels at each time period and that this had possibly never been 
accomplished. Instead, forecasting methods used included (i) management judgement, (ii) 
the analysis of judgements by potential customers and (iii) formal models of the diffusion 
process. Management judgement (i) was found to be elicited from individuals or groups, 
with aggregation methods typically spanning simple averages and Delphi methods, rather 
than more sophisticated aggregation methods such as behavioural aggregation (O'Hagan et 
al., 2006). Nothing in this review indicated that this method had ever included formal 
elicitation of expert opinion and diffusion models were also not used.  
For method (ii), potential customers were typically asked about their likelihood of 
purchasing the new technology, either in terms of binary outcomes or on five-point or 11-
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point scales. Other methods such as utility-based conjoint analyses or discrete choice 
experiments can help in establishing the probability of adoption when utility of the new 
technology exceeds that of alternatives. However, customer-based approaches are less likely 
to be applicable in the medical sector in which purchasing decisions are likely made by 
groups of people in a clinical commissioning group. 
For approach (iii), Goodwin et al. (2014) described in detail only the Bass model of 
diffusion and stated that it was based on a firm theoretical rationale. The authors mentioned 
other possible models such as the Gompertz, logistic and Weibull functions as alternatives. 
The authors also reported alternatives, namely system dynamics models and agent-based 
modelling, but also highlighted that these had not been widely used and therefore lacked 
data on effectiveness in forecasting. The paper concluded with stating that formal diffusion 
models should be at the core of new product forecasting and were preferred to unstructured 
judgements.  
 
3.3.4 Discussion of predicting diffusion methods review 
This state-of-the-art review found that there are two types of methodologically and 
theoretically validated methods for predicting diffusion prior to launch: guessing by analogy 
and expert judgement on quantities informing diffusion models. Both methods have their 
limitations. Guessing by analogy is unlikely to deliver accurate forecasts in health 
technologies because of the limited number of appropriate analogies, even in its more 
sophisticated form that was proposed by Lee et al. (2014). The problem with expert 
judgement has been that only deterministic judgements have been elicited so far and that 
transforming intuitive quantities into diffusion model parameters can be tricky. There is 
therefore scope for developing expert judgement methods further to elicit probabilistic 
estimates and try and overcome the issue of transforming elicited quantities into model 
parameters. 
A limitation of this search was the restriction to Web of Science as the only database 
searched. Diffusion literature is notoriously difficult to search for. Web of Science had 
previously been shown to include the most relevant search hits in a review described in 
Chapter 2.5 and had the feature of conducting citation searches. With the focus on peer-
reviewed methods, Google Scholar was not considered relevant for this search. A quick 
browse through the 88 hits when performing the same citation search on Google Scholar 
suggested that the inclusion of Google Scholar as a database would not lead to the addition 
of publications with additional information. Furthermore, the critical review of pre-launch 
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forecasting by Goodwin et al. (2014) confirmed that no formal diffusion model estimation 
methods were missed.  
In conclusion, expert judgement methods based on formal diffusion models appear to be 
the most appropriate method of predicting health technology diffusion when no data are 
available. This was because one alternative, guessing by analogy, is associated with the 
following problems when applied in the context of health technologies: a) the fact that there 
typically are few comparators in health technologies; b) that vast heterogeneity has been 
observed in health technologies, even those in the same class; c) the difficulty in finding 
truly analogous technologies in general; d) that large numbers of analogous technologies 
would be required to  perform a more sophisticated guessing by analogy study in the spirit of 
Lee et al. (2014); e) even fewer analogies are available when stipulating that available time 
series data include the inflection point; and f) the introduction of bias when using immature 
diffusion estimates. Expert judgement methods are associated with problems of a) not using 
established diffusion models for which evidence of superior forecasting accuracy was 
available; b) the introduction of bias that is caused by unstructured estimation of parameters; 
and c) the use of vague questions. When using expert judgement methods based on formal 
diffusion models, there is also scope for further development in obtaining probabilistic 
estimates, for example through formal expert elicitation methods.  
In conclusion, scope for developing a better method for pre-launch forecasting lies in the 
area of an elicitation of expert beliefs about diffusion that uses the structure of an established 
diffusion model.  
 
3.4 Identifying the most appropriate diffusion model for this thesis 
Having decided that elicitation of expert opinion will be used on the structure of an 
existing diffusion model, I will give a brief overview of different diffusion models and then 
more specifically the Bass model of diffusion, as well as extensions and adaptations that 
may be relevant to this thesis.  
 
3.4.1 Use of the Bass model compared with alternatives 
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In their 25-year review of diffusion modelling, Meade and Islam (2006) describe a 
number of different diffusion models, the so-called epidemic models, that include the Bass 
model, the generalised Bass model, different logistic models, exponential models, the 
Gompertz model and Weibull models, amongst others. The authors also describe the use of 
individual level models, often simply called probit models, as reported by Geroski (2000), 
amongst others. Probit models provide the advantage of incorporating heterogeneity between 
adopting institutions while maintaining the ability to generate s-shaped curves (Geroski, 
2000). More specifically, probit models allow modelling of certain individual threshold 
values that, if surpassed, lead to the adoption decision. Examples of such threshold values 
that were explored in the literature included firm size and purchasing costs.  
Differences between these modelling techniques are important, as some have a better 
track record in accurately forecasting diffusion than others (Meade and Islam, 2006). In 
comparative studies of different forecasting models, the Bass model consistently performed 
well although other models such as the local logistic, the Gompertz and the logistic model 
also performed well (Meade and Islam, 2006). I chose the Bass model because it had the 
greatest number of applications and validation studies (Meade and Islam, 2006). Other than 
that, the choice of the Bass model over other well-performing models was, to a certain extent, 
arbitrary. It is therefore important to observe some quality-control. Criteria for good practice 
that should be observed in making predictions about product growth curves were described 
as (Meade, 1984): 
- Model validity: there should be an upper bound to the saturation level. This could 
naturally be set at 100% of the eligible population, but is likely to be lower than that in 
most settings, given that alternative technologies are available. If the saturation level is 
not carefully estimated, this could result in a large bias in the resulting diffusion curve. 
- Statistical validity: estimated model parameters should be tested for significance. 
Where model parameters are not obtained from observed data but using prediction, 
Bayesian methods can be used as an alternative to significance testing. This could entail 
the use of Bayesian reference priors, for example elicited from expert opinion. This is 
important because it increases the chance that true uptake values are captured in the 
distribution.  
- Demonstrable forecasting ability and validity: contextual plausibility should be 
demonstrated and some measure of uncertainty shown. Again, this can help ensure that 
true uptake values are reflected in the estimates. Contextual plausibility could be 
established by eliciting the opinions of experts, that is, of people who may be involved 
in the purchase of the technology.  
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3.4.2 Bass model extensions useful for predicting diffusion prior to technology 
introduction 
Since Bass’ model in 1969, many adaptations to this model have been explored. Meade 
and Islam (2006) provide a useful overview of the different extensions and adaptations. 
These encompass extensions to incorporate diffusion in different countries, different 
technology generations and explanatory variables. In this thesis I focus on England, and also 
on the first generation device of EIS only, making the first two mentioned extensions 
irrelevant. The inclusion of explanatory variables, however, may be of interest. 
One of the objectives of this thesis was to quantify the effect of implementation 
strategies on diffusion. This would require the elicitation of different diffusion curves, one 
for a scenario in which no implementation strategies are used, and multiple other diffusion 
curves for the number (and combinations) of different implementation strategies. That 
means, for each scenario, Bass model parameters p, q and m would need to be estimated. 
Including implementation strategies as explanatory variables in the Bass model could 
potentially help in reducing the number of quantities to elicit. It would therefore be desirable 
to establish the effects of different implementation strategies and different scales of these 
implementation strategies on Bass model parameters p, q and m. There is a small literature 
on explanatory variables impacting on diffusion that was summarised by Meade and Islam 
(2006). While a few studies attempted to make Bass model parameters p, q and m functions 
of explanatory variables such as advertising and price (those were the two main factors 
included as explanatory variables), Bass, Krishnan & Jain (1994) proposed the introduction 
of a multiplicative term, summarising the effect of explanatory variables in what they called 
the ‘generalised Bass model’ (GBM). The authors demonstrated that adding a multiplicative 
term comprising both price and advertising strategies performed better in several 
retrospective case studies than estimating the Bass model parameters as functions of price 
and advertising separately. The advantage of the GBM was seen in that constant 
environmental effects led to the GBM reducing to the ‘basic’ Bass model. However, in the 
GBM, external strategies only affect parameters p and q, but the total attainable number of 
adoptions m remains unaffected. Assuming that some implementation strategies make a 
technology more attractive for potential purchasers, this is an unrealistic feature of the GBM.  
Subsequent studies found that, rather than predicting explanatory variables, 
incorporating the time-varying nature of all Bass model parameters could improve 
forecasting accuracy (Putsis, 1998); and that there was little evidence of an improvement in 
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forecasting accuracy because of the inclusion of explanatory variables (Bottomley and Fildes, 
1998). The authors thought that this may be partly owed to the fact that any changes in those 
explanatory variables were predictions at the time of product forecasting. 
While it is possible to incorporate a functional relationship of different explanatory 
variables and diffusion in the Bass model, the limitations are that a) it is not clear whether 
this would improve forecasting accuracy compared to the elicitation of different scenarios; 
and b) it does not appear to reduce the number of quantities to elicit. These developments 
would be more complex and for the purposes of this study not necessary.  
 
3.4.3 Addressing limitations of the Bass model 
There are problems associated with the use of the Bass model when used to predict 
diffusion with no data available. One is that estimates of the Bass model parameters are 
correlated with each other so that estimating them from univariately elicited summaries may 
yield unrealistic diffusion curves. This will be explained in more detail in Chapter 6. 
Another problem is the discrete nature of uptake data which is represented in a time-
continuous function in the classic Bass model (Equation 3.1). This could lead to over- and 
under-estimation of the difference equation from one period to another, given certain values 
for parameters p and q. While this is not a problem in the majority of cases, it could result in 
an ‘oscillating’ cumulative diffusion curve in a small number of cases where parameters p 
and q adopt a combination of extreme values. This will also be explained in more detail in 
Chapter 6. 
In search of a solution to this problem, I found a paper by Satoh (2001) that addressed 
these problems. This did not come up in the previous search because that search was 
specifically designed to find publications on pre-launch forecasting. I therefore performed a 
google scholar search on this issue and identified the paper by Satoh (2001). The Satoh 
approach is a transformation to the Bass model that applies a discrete analogue of a 
quadratic first order equation proposed by Hirota (1979) to the Bass model to make it 
discrete in time, rather than continuous in time. This is supposed to avoid the problem of 
‘oscillating’ diffusion curves in extreme values for p and q. The Satoh approach is described 
in more detail in Chapter 4 and is applied and tested for its performance in terms of 
predicting diffusion in comparison with the classic Bass model in Chapter 6. 
 
3.4.4 Parameter estimation 
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Although I decided against the use of diffusion data from analogous technologies or 
from meta-analysis to inform the diffusion curve of EIS, it is worth noting sources of 
evidence on the diffusion model in different technologies, for purposes of comparison with 
the elicited diffusion curves and future reference when analysts lack the time for an 
elicitation exercise.  
A meta-analysis of a variety of diffusion curves from the 1950s to 1980s was conducted 
by Sultan et al. (1990). Mean values for p and q were reported, however, significant 
variation was observed between technologies and no standard deviations were reported. The 
authors explained that part of the variation (up to 50%) was systematic and explainable. 
Results included that the main factors influencing parameter estimates were the type of 
innovation, the country and the variables included. Sultan et al. (1990) specifically 
highlighted that diffusion was not an ‘automatic’ process and that inclusion of 
environmental variables such as marketing activities was clearly indicated. The authors also 
reported ranges for p and q that had been observed in other studies: p ranged from 0.000021 
to 0.03297 and q from 0.2013 to 1.67260. These may give an indication of what value 
ranges p and q will probably fall into but also highlight the great variation that was observed 
with different types of technologies. The results from their own meta-analysis were mean 
values of 𝑝 = 0.03 and 𝑞 = 0.38. In another meta-analysis of 52 consumer durables in 28 
countries (van den Bulte and Stremersch, 2004), the authors found mean values of 𝑝 =
0.027 and 𝑞 = 0.419. 
In health technologies, reported Bass model parameters are hard to find but there are a 
few applications in health that are potentially relevant. In a study by Sillup (1992), the Bass 
model was used to retrospectively predict product growth of several medical technologies, 
including computerised tomography scans, MRI and ultrasound. Unfortunately, relevant 
parameter values were not reported. Another application of the Bass model was in a new 
neuro-monitoring device that reported the concentration of certain biomarkers in the blood 
(Gobok et al., 2009). At the development stage, no decision on the use of this technology 
had been made and a variety of settings were evaluated using the Bass model. The settings 
included stroke monitoring in intensive care units, traumatic brain injury monitoring, sepsis 
monitoring and neonatal paediatric monitoring. The authors used estimates for parameters p 
and q for ultrasound imaging in the medical industry (which were reported to be 𝑝 = 0.0013 
and 𝑞 = 0.6196 (Lilien and Rangaswamy, 2004) based on sales data available from 1965 to 
1978) and adapted these using a scoring system to reflect the potential differences in 
diffusion of the neuromonitoring device. They then arrived at their final predicted values for 
sepsis, stroke, neonatal monitoring and traumatic brain injury, respectively: 𝑝 = 0.0052 and 
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𝑞 = 0.8328, 𝑝 = 0.0041 and 𝑞 = 0.7062, 𝑝 = 0.0009 and 𝑞 = 0.6995, 𝑝 = 0.0051 and 
𝑞 = 0.8061. P and q values for another health technology were reported by Meade and 
Islam (2006) who showed predicted time-varying p and q values for the adoption of 
mammography in US hospitals. 
 
3.5 Summary 
This chapter identified no feasible and existing methods for obtaining probabilistic 
estimates of health technology diffusion prior to technology introduction, when no uptake 
data were available. Synthesising available evidence from the UK health technology sector 
would have been associated with challenges difficult to overcome, because of heterogeneity 
of the data, small numbers of analogous technologies and short lengths of time series. 
Forecasting methods have mainly focussed on guessing by analogy, a method that, given the 
limited available data in the health technology sector, was not deemed suitable. While expert 
judgements were another method occasionally used for pre-launch forecasts, the resulting 
diffusion estimates reported in the literature were not probabilistic and issues were reported 
in converting elicited quantities into parameters of the most established diffusion model, the 
Bass model of new product growth. It was highlighted that formal diffusion models such as 
the Bass model should provide the structure for an expert judgement exercise. The Bass 
model was chosen for further research because it was well established in forecasting tasks, 
values of model parameters were available for many different technologies including health 
technologies, and its fit with real data was demonstrated in many publications.  
The reviews presented in this chapter were important in identifying a research gap and 
developing the scope and methods for this thesis. The consulted diffusion model and 
forecasting literature together with a review of available UK health technology diffusion 
data suggested that replicating existing methods was not feasible or would likely not yield 
accurate estimates. Instead, this chapter established the need for an expert judgement method 
that can provide probabilistic estimates of diffusion and that can elicit quantities that can be 
transformed to yield the Bass model parameters.   
A strength of this chapter was that both the use of synthesised diffusion data and 
methods for estimating individual technology diffusion were considered. I was therefore 
confident that the decision to develop an expert elicitation study using a diffusion model was 
worth further research efforts, providing scope for improving forecasting accuracy in health 
62 
 
technologies. A limitation is that it was not entirely clear whether the Bass model was the 
best diffusion model for such an exercise. However, its advantages were clearer than those 
associated with other diffusion models and there was indication that its limitations could 
potentially be addressed using the Satoh adaptation.  
In conclusion, the reviews presented in this chapter informed the decision to focus on 
developing a formal elicitation of expert opinion method to obtain probabilistic diffusion 
estimates based on the Bass model for individual health technologies prior to technology 
introduction.  
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CHAPTER 4. MODELLING FRAMEWORK FOR INCORPORATING 
DIFFUSION ESTIMATES IN HEALTH ECONOMIC METHODS 
4.1 Background 
In Chapter 2, four literature reviews were conducted through which I identified how 
health technology diffusion could affect health economic outcomes. While other effects are 
possible, the main areas to be studied in this thesis were the value of implementation and the 
effect of diffusion on health technology pricing through experience curves. In Chapter 3, I 
identified an established diffusion model: the Bass model of new product growth.  
The aim of this chapter was to develop a model framework that allows incorporation of 
diffusion estimates in health technology assessments. For this, I develop several extensions 
to the expected value of information and implementation (EVII) model in Section 4.2. In 
Section 4.3, I present the dynamic cost-effectiveness analysis (DCEA) and experience curve 
model. In Section 4.4, I present the diffusion models used for this thesis: the Bass model of 
new product growth and the Satoh adaptation of it. I end with a discussion and conclusion in 
Section 4.5. The place of this chapter within this thesis is illustrated in Figure 1.2 in Chapter 
1. 
 
4.2 The dynamic value of information and implementation framework 
As was identified in Chapter 2, there is an existing framework, the unified EVII 
developed by Fenwick et al. (2008) that analyses the expected opportunity loss associated 
with low implementation and uncertainty. As was mentioned before, the authors developed a 
four-state model where both implementation and information could adopt the states ‘current’ 
and ‘perfect’. The limitations of this existing framework were (a) that it did not allow for 
states in between current and perfect; (b) that the potential effect of evidence generation 
schemes on implementation was ignored; and (c) that the framework did not allow for the 
dynamics of diffusion. Existing extensions identified in the review in Chapter 2 did not fully 
address these issues. One study attempted to relax assumption (a) but did not do so correctly 
(Andronis and Barton, 2016). Another framework was identified that relaxed assumption (b) 
(Willan and Eckermann, 2010). While this was done successfully, the Willan and 
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Eckermann work had the limitation that the effect of research on implementation was 
modelled using strong assumptions (a threshold value of the z-static at which 
implementation would jump to a certain value), and that implementation was static. Three 
studies attempted to relax assumption (c) but did not do so using established diffusion 
models (Andronis and Barton, 2016, Whyte et al., 2016, Faria et al., 2014). 
The aim for this section was to develop the unified EVII framework further to enable the 
analysis of particular implementation strategies: first, by capturing their effect on 
implementation and second, to assess their value in terms of the reduction of the value of 
implementation. In this framework, I also allow research studies to have an effect on 
implementation. A further objective was to incorporate the dynamics of health technology 
diffusion in this framework and to allow for implementation measures to take effect with 
delayed timings. To achieve this, I illustrate the dynamic value of implementation 
framework in a hypothetical example. 
 
4.2.1 The existing EVII framework  
 The expected value of implementation 4.2.1.1
The Expected Value of Perfect Implementation (EVPIM) was developed by Fenwick et al. 
(2008). This framework described the expected opportunity loss associated with low 
implementation of a cost-effective health technology. The authors also described the 
relationship between further evidence generation and investment in implementation 
measures, treating them as two alternative strategies with the potential to add value to a 
health system. The framework uniquely enables a reimbursement authority to assess where 
the greatest potential for adding further value lies: in improving implementation or in 
reducing uncertainty through further generation of evidence.  
As is shown in Equation (4.1), the EVPIM consists of two components. The right hand 
side after the minus sign is the uptake-weighted mean of the expected net benefits of all 
technologies in one appraisal. This mean expected net benefit that is attainable for the health 
system under current (or anticipated) uptake levels is then subtracted from the maximum 
expected net benefit among the different decision options in the appraisal. It is worthwhile 
mentioning here that when I mention the net benefit in this thesis I generally refer to the net 
monetary benefit of a technology, although all of the following value measures could also be 
reflected in terms of net health benefits. 
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𝐸𝑉𝑃𝐼𝑀 = 𝑚𝑎𝑥𝑑𝔼𝜃𝑁𝐵(𝑑, 𝜃) −∑ 𝜌𝑑
𝐶𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
 
(4.1)  
where 𝜌𝑑
𝐶 is the probability of implementing technology d with current information, 
𝑁𝐵(𝑑, 𝜃) is the expected net monetary benefit of technology d given the uncertain model 
input parameters 𝜃. 
The EVPIM is important because, if unresolved (that is, when full implementation is not 
achieved), it gives a value to inefficiencies in the health system that are caused by cost-
ineffective technologies remaining in use. 
 
 The expected value of information 4.2.1.2
The expected value of information, or the payer uncertainty burden as it was most 
recently called (Grimm et al., 2016), is an established concept that describes the expected 
opportunity loss associated with a decision made under uncertainty. Expected Value of 
Information (EVI) methods estimate the magnitude of uncertainty on a cost or health scale 
and can help identify the drivers of that uncertainty, thus determining the areas in which 
further research may be required (Briggs et al., 2006). The Expected Value of Perfect 
Information (EVPI) is the expected value of reducing all uncertainty present in a decision 
(Briggs et al., 2006). The EVPI is calculated by subtracting the maximum expected net 
benefit among the different decision options in the appraisal from the expectation of the 
maximum net benefit in each iteration of the probabilistic sensitivity analysis (PSA). Note 
that the part of the equation after the minus sign in Equation (4.2) equals the part of the 
equation before the minus sign in Equation (4.1). 
 
 𝐸𝑉𝑃𝐼 = 𝔼𝜃𝑚𝑎𝑥𝑑𝑁𝐵(𝑑, 𝜃) − 𝑚𝑎𝑥𝑑𝔼𝜃𝑁𝐵(𝑑, 𝜃) (4.2)  
The EVPI is relevant because most technology appraisals are associated with 
considerable uncertainty that may result from an evidence base that has not been fully 
developed. Uncertainty may also stem from other sources of evidence such as the value 
assigned to certain health states or the cost of a service outside clinical trials. When a 
decision is made under uncertainty, there is a risk of making the ‘wrong’ decision, that is, 
recommending a health technology that does not provide the true maximum net benefit 
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(Grimm et al., 2016). The cost of making this decision under uncertainty, the EVPI, is 
therefore composed of the risk of making the ‘wrong’ decision and the consequences of 
making that decision in terms of costs or health foregone (Grimm et al., 2016). 
 
 The expected value of perfection 4.2.1.3
When there is uncertainty and low implementation, the payer faces a combined burden 
of uncertainty and implementation that is described by the Expected Value of Perfection 
(EVP) (Fenwick et al., 2008). The EVP, being the sum of the EVPI and the EVPIM, is 
calculated by subtracting the second part of Equation (4.1) from the first part of Equation 
(4.2), which is shown in Equation (4.3).  
 𝐸𝑉𝑃 = 𝔼𝜃𝑚𝑎𝑥𝑑𝑁𝐵(𝑑, 𝜃) −∑ 𝜌𝑑
𝐶𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
 (4.3)  
The EVP is important because it highlights the opportunity loss experienced by a health 
system if a decision is made without resolving uncertainty and without improving 
implementation. The goal of a decision-maker could be to recommend measures to resolve 
the EVP, or reduce it as far as possible. 
 
4.2.2 Extension to assess the value of specific implementation measures 
I propose an extension to the Fenwick et al. (2008) framework to assess the expected 
value of specific implementation measures (EVSIM) by allowing for states other than current 
and perfect. The term EVSIM was proposed by Fenwick et al. (2008) but the authors did not 
demonstrate how this was calculated.  
States other than current or perfect have been incorporated in value of information 
methods for a long time by calculating the expected value of sample information (EVSI), in 
which particular designs of research studies can be assessed. A parallel can be drawn 
between assessing the value of sample information and the value of implementation 
measures. For this reason, I first discuss how the EVSI is commonly calculated and will then 
present the calculation of the EVSIM.   
To calculate the EVSI, it is required to simulate the data to be collected in the future. To 
do this, one needs to specify a statistical model that describes the data to be collected. This 
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model can be used to draw from in a large number of simulations, to generate the data to be 
collected conditional on the PSA results of the parameter(s) of interest. To add the simulated 
data to the evidence available so far, it is necessary to calculate the posterior distribution for 
the parameter(s) of interest (Brennan and Kharroubi, 2007, Ades et al., 2004, Strong et al., 
2015). This can be a complex exercise because Markov Chain Monte Carlo simulation was 
typically required to calculate the posterior when an analytic solution was not available 
(Brennan and Kharroubi, 2007). Recent developments have simplified the step of calculating 
the posterior by using nonparametric regression methods (Strong et al., 2015). The EVSI is 
then the difference between the expected value of the best decision with sample information 
and the best decision’s expected value without sample information, as shown in Equation 
(4.4): 
 𝐸𝑉𝑆𝐼 =  𝔼𝑋[𝑚𝑎𝑥𝑑𝔼𝜃|𝑋{𝑁𝐵(𝑑|𝜃)}] −𝑚𝑎𝑥𝑑[𝔼𝜃{𝑁𝐵(𝑑, 𝜃)}] (4.4)  
where data X are informative for the input parameters 𝜃. 
Prior to calculating the EVSI, it is therefore useful to determine how much individual or 
grouped input parameters used in the cost-effectiveness model contribute to decision 
uncertainty. Expected Value of Perfect Parameter Information (EVPPI) calculations can be 
performed to achieve this. The EVPPI indicates the expected value of reducing all 
uncertainty on a specified parameter or group of parameters (Strong et al., 2014) and is 
presented in Equation (4.5):  
 𝐸𝑉𝑃𝑃𝐼 =  𝔼𝜃𝑖[𝑚𝑎𝑥𝑑𝔼𝜃−𝑖|𝜃𝑖{𝑁𝐵(𝑑, 𝜃𝑖|𝜃−𝑖)}] − 𝑚𝑎𝑥𝑑𝔼𝜃𝑁𝐵(𝑑, 𝜃) (4.5)  
where 𝜃𝑖 is the parameter of interest and 𝜃−𝑖 are the remaining input parameters. 
Assessing the value of specific implementation measures is more straightforward. 
Instead of a simulation of data, all that is needed are estimates of the implementation levels 
achievable before and after implementation. The EVSIM is then the difference between the 
expected net benefits weighted by the achieved implementation before and after 
implementation measures, as shown in Equation (4.6): 
 
𝐸𝑉𝑆𝐼𝑀 =  ∑𝜌𝑑
𝐼𝑀𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
−∑𝜌𝑑
𝐶𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
 
(4.6)  
where 𝜌𝑑
𝐼𝑀 is the with-implementation measure implementation of technology d.  
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If implementation had effects on the net benefit, for example in the case of vaccinations 
or where learning effects could improve effectiveness, this could be incorporated into 
Equation (4.6) by making the net benefit function conditional on implementation.  
Uncertainty over uptake is not considered in this equation, but can be incorporated by 
simulating the EVSIM drawing from the probability distributions over 𝜌𝑑
𝐼𝑀 and 𝜌𝑑
𝐶. When 
this is done, it is possible to perform a value of information analysis on the implementation 
estimate using the EVSIM function as the objective function and performing an EVPPI 
analysis on the implementation parameter.  
The EVSIM would need comparing with costs of the implementation strategy. It is then 
important to consider not only fixed costs, but also potential variable costs that arise with the 
uptake. In such a case, the cost function would also contain an estimate of 𝜌𝑑
𝐼𝑀. 
 
4.2.3 Disentangling the effect of research on value of implementation and the 
effect of implementation on value of information 
The assumption made by Fenwick et al. (2008) and subsequent papers identified in 
Chapter 2 (with a few exceptions mentioned in the following) was that the effect of research 
studies on the EVPIM was zero. The authors acknowledged that research could have an 
effect on implementation and that it would be worthwhile exploring the value of 
implementation of research studies. They also provided an exploratory analysis in which 
they let information affect implementation, which I describe below. Only two studies have 
incorporated the effects of information on implementation at the time of writing. The study 
by Willan and Eckermann (2010) focused on establishing a functional relationship between 
the strength of research evidence and potential implementation. The recent study by 
Andronis and Barton (2016) developed the implementation-adjusted EVSI but interpreted it 
incorrectly. I will demonstrate this in this section, by investigating the effect of research on 
the value of implementation.  
To fully understand the effects of research on implementation, it is useful to examine in 
more detail how the EVPI and EVSI work. In EVPI calculations, we follow two simple steps: 
1. we assess the value of a decision we would make with full information. In fact, given full 
information, we would choose the optimal decision option every time (for example, in every 
run of the PSA, and given that we are rational and utility maximising). 2. We compare the 
expected net benefit of making this optimal decision every time with the expected net 
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benefit of choosing one decision option over the others once, based on current information 
expected values, and then stick with this decision every time (that is, in every run of the 
PSA). It follows that the value of information is entirely derived from the expected value of 
the discrepancy between the optimal and sub-optimal decision (the incremental net benefit) 
and the number of times a sub-optimal decision would be chosen under current knowledge.  
Incorporating implementation in an EVPI formula alters this and makes the number of 
times we make the sub-optimal decision independent of the expected net benefit. 
Implementation therefore removes the value of the reduction of uncertainty component. So, 
if we incorporate technology implementation in the EVPI equation, we are not capturing the 
effect of uncertainty, because now, despite having full information on which technology to 
adopt, we are not choosing this technology every time. Equally, despite believing in the 
maximum expected net benefit of one technology over the other under current knowledge, 
we do not choose this technology every time but instead only choose it some of the time. 
The term ‘realisable EVPI’ that was employed by Fenwick et al. (2008) is therefore 
misleading as it may evoke the impression that the concept describes the value of 
information of a research study under imperfect implementation rather than the value that a 
research study contributes through its effect on implementation. The authors’ explanation of 
the realisable EVPI as ‘the expected value of research that is realizable without actively 
undertaking strategies to change implementation’ is perhaps more intuitive than the term 
‘realisable EVPI’. Equally, and probably following from a misunderstanding of the term, the 
Andronis and Barton (2016) interpretation of the implementation-adjusted EVSI is incorrect.  
This is important: it means that by including implementation in EVPI, EVPPI or EVSI 
calculations we are not assessing the value of reducing uncertainty any longer. We instead 
capture the value of the reduction of uncertainty in terms of improving implementation. Both 
effects are dissimilar and unrelated. I therefore suggest separating these two effects by 
making a clear distinction between value of information and implementation measures. To 
make this distinction, when research can affect implementation, the expected value of 
perfection which previously consisted of the EVPI and EVPIM can now be divided up into 
three components: 1. The expected value of perfect information. 2. The expected value of 
perfect implementation resolvable by research (I call this the Research EVPIM, or shorter, 
the 𝐸𝑉𝑃𝐼𝑀𝑅). 3. The expected value of perfect implementation resolvable through other 
implementation measures (𝐸𝑉𝑃𝐼𝑀𝐼𝑀).  
The EVP, being a measure of both values of information and implementation, can be 
reduced by implementation measures and research. When perfect implementation of the 
most cost-effective technology has been achieved without doing any research, the EVP 
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reduces to the EVPI. (Of course, the EVP with perfect implementation, or the EVPI, may be 
reduced if part of the activities to achieve perfect implementation was research.) 
Mathematically, this is because the second part of Equation (4.3) (shown on the left hand 
side below) would become the second part of Equation (4.2) (shown on the right hand side 
below), thus converting Equation (4.3) (the EVP) into Equation (4.2) (the EVPI): 
 ∑ 𝜌𝑑
𝐶𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1 = 1 ∗ 𝔼𝜃𝑁𝐵(𝑑
∗, 𝜃) + ∑ 0 ∗ 𝔼𝜃𝑁𝐵(𝑑′, 𝜃)
𝐷′
𝑑′ = 𝑚𝑎𝑥𝑑𝔼𝜃𝑁𝐵(𝑑, 𝜃),  
where 𝑑∗ is the decision option expected to be most cost-effective, 𝑑′ is a set of other 
cost-ineffective decision options and 𝜌𝑑
𝐶 = 1 𝑓𝑜𝑟 𝑑∗, 𝜌𝑑
𝐶 = 0 𝑓𝑜𝑟 𝑑′ . 
When perfect information has been achieved first, in contrast, the EVP in theory reduces 
to the EVPIM, because all uncertainty is resolved and all that is left to do is to improve 
implementation. Mathematically, this can be shown by the first part of Equation (4.3) (EVP, 
shown on the left hand side below) that would become the first part of Equation (4.1) 
(EVPIM, shown on the right hand side below): 
 𝔼𝜃𝑚𝑎𝑥𝑑𝑁𝐵(𝑑, 𝜃) = 𝑚𝑎𝑥𝑑𝑁𝐵(𝑑, 𝜃) = 𝑚𝑎𝑥𝑑𝔼𝜃𝑁𝐵(𝑑, 𝜃).  
However, effects of research on implementation may result in a with-research residual 
EVP that is lower than the original EVPIM. This is because a part of the EVPIM, the 
Research EVPIM, can be resolved through research. This Research EVPIM is what was 
called the realisable EVPI by Fenwick et al. (2008). The distinction may be subtle, but it is 
important: the term realisable EVPI implies that the full value of the EVPI cannot be reached 
due to the low implementation. This is, however, not the case, as the Research EVPIM could 
be larger than the EVPI. This was shown in the exploratory analysis by Fenwick et al. 
(2008) and is also demonstrated in the following equations. The Research EVPIM is shown 
in Equation (4.7): 
 𝐸𝑉𝑃𝐼𝑀𝑅 = 𝔼𝜃∑𝜌𝑑
𝑃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
−∑𝜌𝑑
𝐶𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
 (4.7)  
The fact that the Research EVPIM can exceed the expected value of perfect information 
(and indeed exceeded it in the exploratory analysis by Fenwick et al. (2008)) is explained by 
the following: the first term of the Research EVPIM Equation (4.7) (𝔼𝜃 ∑ 𝜌𝑑
𝑃𝑁𝐵(𝑑, 𝜃)𝐷𝑑=1 ) 
converges to the first term of the EVPIM Equation (4.1) (𝑚𝑎𝑥𝑑𝔼𝜃𝑁𝐵(𝑑, 𝜃)) when 
implementation of the cost-effective technology approaches a level of 100%; and the second 
term of both Research EVPIM and EVPIM equations are equal. The value of research can 
therefore be much larger than the EVPI alone and the term realisable EVPI is therefore 
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misleading. For this reason, I continue to use the expression ‘expected value of perfect 
implementation that is resolvable with research’ or short the Research EVPIM, and the 
contrasting ‘expected value of perfect implementation that is resolvable through other 
implementation measures’ or the ‘implementation measure (IM) EVPIM’. The EVPIM is the 
sum of the Research EVPIM and the implementation measure EVPIM: 
 𝐸𝑉𝑃𝐼𝑀 = 𝐸𝑉𝑃𝐼𝑀𝑅 + 𝐸𝑉𝑃𝐼𝑀𝐼𝑀 (4.8)  
Fenwick et al. (2008) further established that when implementation with perfect 
information equals implementation under current information (𝜌𝑑
𝑃 = 𝜌𝑑
𝐶), the Research 
EVPIM equals zero. This is because the expected value of a decision under perfect  
information is the same as under imperfect information (Fenwick et al., 2008). When 
implementation at perfect information 𝜌𝑃equals one, the Research EVPIM equals the 
EVPIM. Of course, this holds only as long as both measures use the same value of current 
implementation 𝜌𝑑
𝐶 as the baseline.  
4.2.4 Extension to calculate the expected value of research 
It follows from the above that a research study can be assessed in terms of both its effect 
on implementation and its effect on information. Willan and Eckermann (2010) implicitly 
calculated the joint effect of both in their EVSI analysis but did not make the different 
effects of implementation and information explicit. Modelling these different effects 
explicitly, however, results in greater transparency that could be useful for decision-makers. 
I therefore propose the Expected Value of Research (EVR), which measures the effect of 
research on both the reduction of uncertainty and the change in implementation. The EVR is 
simply the sum of the EVSIM of the research study and the EVSI of the same study, shown 
in Equation (4.9):  
 𝐸𝑉𝑅 = 𝐸𝑉𝑆𝐼𝑀𝑅 + 𝐸𝑉𝑆𝐼 (4.9)  
The EVR is thus: 
 
𝐸𝑉𝑅 =  ∑ 𝔼𝑋[𝜌𝑑
𝑋𝔼𝜃𝑁𝐵(𝑑, 𝜃)]
𝐷
𝑑=1
−∑𝜌𝑑
𝐶𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
+ 𝔼𝑋[𝑚𝑎𝑥𝑑𝔼𝜃|𝑋{𝑁𝐵(𝑑|𝜃)}]
− 𝑚𝑎𝑥𝑑[𝔼𝜃{𝑁𝐵(𝑑, 𝜃)}] 
(4.10)  
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where 𝜌𝑑
𝑋 is implementation of technology d with availability of data X. 
The Research EVSIM can be written similarly to any other EVSIM because the effects 
of the reduction of uncertainty cancel out with the inclusion of implementation, as is shown 
in Equation (4.11). The difference to EVSIMs associated with implementation strategies, 
however, is that diffusion is also influenced by the outcomes of the study, which are not pre-
planned. 𝜌𝑑
𝑋 is therefore associated with uncertainty and a dependent covariate of net benefit. 
 
𝐸𝑉𝑆𝐼𝑀𝑅 = 𝔼𝑋 [∑ 𝜌𝑑
𝑋𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}
𝐷
𝑑=1
]
−∑ 𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝑋[𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}]
= [∑ 𝔼𝑋[𝜌𝑑
𝑋𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}]
𝐷
𝑑=1
]
−∑ 𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝑋[𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}]
= [∑ 𝔼𝑋[𝜌𝑑
𝑋𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}
𝐷
𝑑=1
]]
−∑ 𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝜃𝑁𝐵(𝑑, 𝜃) 
(4.11)  
 
If we were only interested in the effect of the strength of research evidence on diffusion, 
assuming that study results were more or less the same as our prior expectation of them, then 
𝜌𝑑
𝑋 can be treated as independent of the net benefit function. Equation (4.11) then reduces to: 
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𝐸𝑉𝑆𝐼𝑀𝑅 = 𝔼𝑋 [∑ 𝜌𝑑
𝑋𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}
𝐷
𝑑=1
]
−∑ 𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝑋[𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}]
= [∑ 𝜌𝑑
𝑋𝔼𝑋[𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}]
𝐷
𝑑=1
]
−∑ 𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝑋[𝔼𝜃|𝑋{𝑁𝐵(𝑑, 𝜃)}]
= [∑ 𝜌𝑑
𝑋𝔼𝜃{𝑁𝐵(𝑑, 𝜃)}
𝐷
𝑑=1
] −∑ 𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝜃𝑁𝐵(𝑑, 𝜃) 
(4.12)  
 
More intuitively, and as was discussed in the previous section, the effect of uncertainty 
reduction is now not captured in the Research EVSIM: including implementation has 
removed the term that accounted for the effect on uncertainty, which is the difference 
between the maximisation and the number of times the sub-optimal decision would have 
been made based on choosing the decision option with the highest expected net benefit 
under current information. With the EVSI, the maximum expected net benefit conditional on 
the new data was chosen. With the EVSIM of research, however, the expected net benefit is 
accrued for a certain part of the population, and the newly generated data plays no role in its 
calculation, except in the change of the implementation estimate. This clarifies where 
Andronis and Barton (2016) went wrong: what they called the implementation-adjusted 
EVSI was in fact the Research EVSIM shown in Equation (4.11). Their interpretation of it 
was that the effect of research on the EVPI would be dampened by low implementation. In 
contrast, I have shown above that the Research EVSIM has to be understood as the effect of 
research on implementation. The authors further stated that the implementation-adjusted 
EVSI would always be lower than the EVSI and even claimed that the value of research was 
systematically over-estimated if not adjusted by implementation. I show the opposite: if 
research has an effect on implementation, then its value may be under-estimated when only 
the EVSI is calculated. 
Similar to the EVPPI, the value of resolving all uncertainty caused by one or more 
parameters can also be assessed in terms of the effect on implementation using the Research 
EVSIM for perfect parameter information (𝐸𝑉𝑆𝐼𝑀𝑅𝑝𝑝) shown in Equation (4.13). This 
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enables calculating the ceiling value of the potential value of implementation of research 
studies on certain groups of parameters. As such, its calculation is no different from other 
EVSIM calculations. The 𝐸𝑉𝑆𝐼𝑀𝑅𝑝𝑝 thus answers the question of how much the value of 
implementation would reduce if we removed all uncertainty surrounding a (group of) 
parameter(s). 
 
𝐸𝑉𝑆𝐼𝑀𝑅𝑝𝑝 = ∑ 𝜌𝑑
𝑅𝑝𝑝𝔼𝜃𝑖{𝑁𝐵(𝑑, 𝜃𝑖)}
𝐷
𝑑=1
−∑𝜌𝑑
𝐶
𝐷
𝑑=1
𝔼𝜃𝑁𝐵(𝑑, 𝜃) 
(4.13)  
where 𝜌𝑑
𝑅𝑝𝑝
 is the with perfect parameter information implementation of technology d. 
 
4.2.5 Extension to make the EVII dynamic 
The analyses described above took neither implementation dynamics nor timings of 
research and implementation measures into account. In this section, I describe in what way 
implementation dynamics can be used in the calculation of the expected value of 
implementation measures. Calculations of the EVPI, the EVPPI and the EVSI remain 
unaffected as implementation is not considered in them. 
With implementation varying over periods of time, all the value of implementation 
measures will accrue different values for each period up to the defined decision relevance 
horizon. These can be shown individually in a tabular overview, such as in the example 
shown in the first column of Table 4.1. Using the 𝐸𝑉𝑃𝐼𝑀𝑅 as an example, if utilisation of 
intervention A was at 2% in the first year, then utilisation of the only other two comparators 
B and C in the same model would be at 49% each (assuming equal utilisation for the two 
remaining technologies, due to a lack of knowledge that suggests otherwise), and the 
𝐸𝑉𝑃𝐼𝑀𝑅 would be calculated accordingly. In the second year, implementation of A might 
be at 10%, resulting in 45% of implementation of B and C, and so on.  
To obtain these different values of the 𝐸𝑉𝑃𝐼𝑀𝑅 in each period of time, I let the 
implementation estimate be time variable as shown in Equation (4.14). The same principles 
apply to the calculation of the 𝐸𝑉𝑃𝐼𝑀𝐼𝑀, the 𝐸𝑉𝑆𝐼𝑀𝑅𝑝𝑝 and the EVSIM.   
 𝐸𝑉𝑃𝐼𝑀𝑅𝑡 = 𝔼𝜃∑𝜌𝑡,𝑑
𝑃 𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
−∑𝜌𝑡,𝑑
𝐶 𝔼𝜃𝑁𝐵(𝑑, 𝜃)
𝐷
𝑑=1
 (4.14)  
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where t=1,…,T is the time period up to the defined decision relevance horizon T, in 
years.  
 
4.2.6 Accruing value measures over population and decision relevance horizon 
EVII measures are typically presented accrued over the affected patient population and 
the decision relevance horizon, for example until there is a new technology class replacing 
the current one. This is commonly done by simply adding up the values of the EVPI (or any 
other value measure) over the future time periods up to the decision relevance horizon. 
Using the example of the EVPIM, it can be multiplied by the discounted population in each 
period as is shown in Table 4.1. 
 
Table 4.1 Tabular overview of example dynamic EVPIM 
Time t Individual (per 
person) 𝐸𝑉𝑃𝐼𝑀 
Discounted 
population affected 
𝐸𝑉𝑃𝐼𝑀 accrued over 
population 
1 𝐸𝑉𝑃𝐼𝑀1 𝛿1𝜋1 𝛿1𝜋1𝐸𝑉𝑃𝐼𝑀1 
2 𝐸𝑉𝑃𝐼𝑀2 𝛿2𝜋2 𝛿2𝜋2𝐸𝑉𝑃𝐼𝑀2 
3 𝐸𝑉𝑃𝐼𝑀3 𝛿3𝜋3 𝛿3𝜋3𝐸𝑉𝑃𝐼𝑀3 
where 𝛿 is factor describing discounting at 
1
(1+𝑟)𝑡
, with r being the discount factor and 𝜋𝑡  
is the number of affected patients in period t.  
For the evaluation of specific implementation measures, the use of the discounted 
population measure without any adjustment for implementation would over-estimate the 
value of implementation. This is because only the patients that will receive the most cost-
effective technology will benefit from the success of the implementation measure. When 
calculating the per period EVSIM, the population estimate should therefore be adjusted by 
the achievable implementation in each period, as illustrated in Table 4.2. This was not done 
in Table 4.1 because, arguably, when calculating the EVPIM, the decision-maker is 
interested in the maximum value of resolving the EVPIM.   
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Table 4.2 Tabular overview of example dynamic EVSIM – adjusting the patient population by 
implementation 
Time t Individual 
(per person) 
EVSIM 
Discounted 
population 
affected 
Implementation of 
cost-effective 
technology 
EVSIM accrued over 
implementation-
adjusted population 
1 𝐸𝑉𝑆𝐼𝑀1 𝛿1𝜋1 𝜌1,𝑑 𝜌1,𝑑𝛿1𝜋1𝐸𝑉𝑆𝐼𝑀1 
2 𝐸𝑉𝑆𝐼𝑀2 𝛿2𝜋2 𝜌2,𝑑 𝜌2,𝑑𝛿2𝜋2𝐸𝑉𝑆𝐼𝑀2 
3 𝐸𝑉𝑆𝐼𝑀3 𝛿3𝜋3 𝜌3,𝑑 𝜌3,𝑑𝛿3𝜋3𝐸𝑉𝑆𝐼𝑀3 
 
It is furthermore noteworthy that the EVSIM calculation in the future relies on the 
expected net monetary benefit in the future periods. If net benefit changes in future periods, 
for example due to the incorporation of experience curves, learning curves or other changes 
in model parameters over time, then this can easily incorporated in the EVSIM calculation 
by making net benefit time-dependent.  
To facilitate comparison with static per patient analysis, as opposed to above population 
analysis, which is typically presented for the first year, the average taken over all periods can 
be used to represent an annual per patient estimate of the dynamic value measures. Using the 
EVSIM as written in Equation (4.6) as an example, I do not take discounting into account in 
the calculation of the average future EVSIM because it is designed to compare with the 
static EVSIM which does not consider discounting: 
 𝐸𝑉𝑆𝐼𝑀𝑑𝑦𝑛 =
1
𝑇
∑𝐸𝑉𝑆𝐼𝑀𝑡
𝑇
𝑡=1
 (4.15)  
If the population value of this 𝐸𝑉𝑆𝐼𝑀𝑑𝑦𝑛  was of interested, it can be calculated by 
accruing it over the uptake-adjusted population. I assume here that the devised 
implementation measure is designed to increase implementation for the intervention with the 
largest expected net benefit. The discounted population is therefore adjusted by the 
implementation in t that is attainable for the technology in question conditional on the 
implementation measure being used: 
 𝑝𝑜𝑝. 𝐸𝑉𝑆𝐼𝑀𝑑𝑦𝑛 =
1
𝑇
∑𝜌𝑡,𝑑NB.max 
𝐼𝑀 𝜋𝑡
𝑇
𝑡=1
𝐸𝑉𝑆𝐼𝑀𝑡  (4.16)  
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with 𝜌𝑡,𝑑NB.max 
𝐼𝑀  being the attainable implementation (with the implementation measure in 
question) in each time period t of the technology with the maximum expected net benefit.  
Population estimates can also be adjusted for implementation in EVPI calculations. This 
can make sense, for example, in the case that implementation was at a certain level and it 
was unlikely that anything could be done about it. The realistic EVPI if implementation is a 
given can only be accrued for the part of the patient population that will receive the cost-
effective technology: 
 𝑝𝑜𝑝.𝐸𝑉𝑃𝐼𝑑𝑦𝑛 =
1
𝑇
∑𝜌𝑡,𝑑NB.max 
𝑃  𝜋𝑡
𝑇
𝑡=1
𝐸𝑉𝑃𝐼𝑡 (4.17)  
with 𝜌𝑡,𝑑NB.max 
𝑃  being the implementation at perfect information of the technology with 
the maximum expected net benefit in each time period t. 
 
4.2.7 The timing of implementation measures and their effects  
When assessing the expected value of implementation measures in a dynamic analysis, 
the timing of the measure itself and its effects are crucial. These two effects are separate. For 
instance, if an implementation measure is a research study that takes two years to report 
from the time of decision-making, the existing EVPI will only be reduced at the time that a 
new decision is made that is based on that new research. It may also be that the improvement 
of implementation occurs with a delayed effect. Accounting for these two effects is simple: 
for the periods until the research reports, the EVII with current information is used. The EVP 
reduces by the value of sample information at the time that research reports (assuming that a 
new decision is made straight away) and it reduces further at the time when implementation 
improvements take effect. 
 
4.2.8 Proposed presentation of the EVII framework using an illustrative 
example 
To illustrate the potential use of the dynamic EVII framework in health technology 
assessments, I present a hypothetical analysis of an illustrative example technology A. New 
technology A is cost-effective compared to existing technology B; however, there is 
uncertainty associated with the decision that is reflected in a positive EVPI. Available 
78 
 
estimates of natural diffusion for technology A suggest that A will not achieve perfect 
implementation over a decision relevance horizon of 10 years. EVPPI analysis suggests that 
further research evidence on one parameter 𝜃𝑖 can reduce decision uncertainty and that this 
exact research study (called Study X) has a positive effect on implementation. Diffusion 
estimates for a scenario in which this research has been conducted are available. It would 
also be possible to improve implementation with an implementation strategy S; and 
diffusion estimates for this scenario are available.  
The resulting value of perfection and value of research can then be presented in the EVII 
analysis chart, which is shown in Figure 4.1. This shows the EVP, split into the EVPI, the 
Research EVPIM and the implementation measure EVPIM for current information and 
implementation in the first stacked bar. The second stacked bar shows the residual EVP with 
Study X and it can be seen that doing this research study would result in a reduction of both 
the EVPI and the Research EVPIM. Performing implementation measure S results in a 
reduction of the implementation measure EVPIM, but does not achieve the same overall 
reduction of the EVP as Study X. Both Study X and Strategy S reduce the EVP the most. 
With the effects of both being independent of each other, Study X and Strategy S have an 
additive effect on the reduction of the EVP.  
 
Figure 4.1 The EVII analysis chart of example technology A 
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4.2.9 Summary 
Summarising Section 4.2, I extended the existing EVII framework and its further 
developments by a) presenting an approach to calculating the expected value of specific 
implementation strategies; b) reflecting the effects of the reduction of uncertainty on 
implementation; and c) making the framework dynamic by incorporating diffusion estimates. 
I conclude that whether the burden on the health system that results from low 
implementation is large depends on three factors: 1. how low implementation is going to be 
compared to what it could be, that is, the implementation discrepancy, 2. the magnitude of 
the incremental net benefit of the new cost-effective technology over its comparators, 3. the 
size of the patient population that is affected. Furthermore, the values of information and 
implementation are separate entities, but overlap occurs where research affects 
implementation. Then, the value of research will be composed of the value of information 
and the value of implementation of that research study. All expected value of information 
and implementation measures are summarised in Table 4.3. 
 
Table 4.3 The expected value of information and implementation measures 
 Value measure Description 
U
n
c
er
ta
in
ty
 
EVPI The value of resolving all decision uncertainty 
EVPPI 
The value of resolving all uncertainty related to individual 
or grouped model parameters 
EVSI 
The value of a proposed research study design in reducing 
uncertainty  
Im
p
le
m
e
n
ta
ti
o
n
 EVPIM  
The value of achieving perfect implementation (from 
current ‘baseline’ level)  
EVPIM
R 
The value of improving implementation by resolving all 
decision uncertainty 
EVSIM
(R+IM) 
The value of improving implementation with a proposed  
implementation measure or research study design 
B
o
th
 
EVP 
The value of achieving perfect implementation and 
resolving all decision uncertainty 
EVR 
The value of a proposed research study design in 
improving implementation and reducing uncertainty  
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4.3 The dynamic cost-effectiveness analysis framework and the 
experience curve model 
4.3.1 The experience curve model 
As was explained in Chapter 2, experience curves describe empirical evidence for price 
declines with increasing uptake of technologies. There is ample evidence for such price 
declines in a variety of different technologies as well as in health technologies in a study on 
20 medical devices by Brown et al. (2007). As was described in Chapter 2, experience 
curves are mainly explained by a technology’s competitive situation but potentially also 
through economies of scale (Brown et al., 2007). Experience curves therefore relate 
technology price to uptake. More specifically, it has been observed in a number of studies 
that prices decline to a percentage of the technology’s initial price every time initial 
production volume doubles (Brown et al., 2007): 
 𝑃𝑁𝑡 = {
𝑃𝑁0 𝑓𝑜𝑟 0 < 𝑁𝑡 < 2𝑁0
∝𝛽 𝑃𝑁0 𝑓𝑜𝑟 𝑁𝑡 ≥ 2𝑁0
 (4.18)  
where 𝑁𝑡 is the cumulative uptake or sales volume up to period t, with 𝑃𝑁𝑡 being the 
price at 𝑁𝑡, 𝑃𝑁0 is the price that was set at initial quantity 𝑁0 which is maintained until 
 𝑁𝑡 ≥ 2𝑁0, 𝛼 is the experience curve parameter or the percentage of the technology’s initial 
price with 0 <  𝛼 < 1, and 𝛽 is the number of times that the initial quantity had doubled, 
with 𝛽 = 𝑙𝑜𝑔2 [
𝑁𝑡
𝑁0
]. 
Equation (4.18) reflects the fact that prices remain stable until the initial production 
quantity has doubled for the first time. Price is essentially dependent on technology uptake 
through 𝛽, the number of times that the initial quantity had doubled, rather than on time, 
requiring estimates of diffusion to inform this model.  
 
4.3.2 The dynamic cost-effectiveness analysis model 
To incorporate experience curves in health economic evaluation, the cost calculations in 
the cost-effectiveness model must be performed over several time periods up to the decision 
relevance horizon. Costs and benefits of health technologies are typically average values 
assumed to reflect at least one cohort of patients or an average of future cohorts. The 
standard measure of assessing a technology’s value is the ICER which represents average 
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incremental costs over average incremental quality-adjusted life-years (QALYs) gained with 
one technology over another.  
 𝐼𝐶𝐸𝑅 =
𝑐𝑖 − 𝑐𝑗
𝑒𝑖 − 𝑒𝑗
 (4.19)  
where 𝑐𝑖 , 𝑐𝑗 and 𝑒𝑖 , 𝑒𝑗 are the expected costs and effects of interventions i and j, with 
𝑐, 𝑒 ≥ 0. 
The dynamic cost-effectiveness analysis (DCEA) model incorporates the effects of 
experience curves and diffusion by modelling future periods up to the decision relevance 
horizon and using the experience curve and uptake models in the dynamic ICER calculation. 
I assume that, given a positive reimbursement decision, uptake would grow, and given a 
negative reimbursement decision, the technology would not be implemented at all. Costs in 
period t are now dependent on price and cumulative uptake up to period t through the 
experience curve model. Contrary to other studies (Hoyle, 2011, Hoyle, 2010, Hoyle and 
Anderson, 2010), I have refrained from weighting the dynamic ICER by uptake as weighting 
would lead to a blended ICER that assesses a mix of technologies rather than identifying the 
most efficient technology based on costs and health effects. The dynamic ICER is shown in 
Equation (4.20). 
 
𝐼𝐶𝐸𝑅𝑑𝑦𝑛 =
∑ ∆𝑐𝑗(𝑃𝑁𝑡)𝛿
𝑇
𝑡
∑ ∆𝑒𝑗(𝑡)𝛿
𝑇
𝑡
 
(4.20)  
where ∆c(PNt) is the difference in costs between interventions j, as a function of price 
and uptake and 𝑒𝑗(𝑡)  are effects in each period of time, both summed up over the number of 
periods up to decision relevance horizon 𝑇 and discounted at a discount factor of 𝛿 =
1
(1+𝑟)𝑡
  
with r as the discount rate, with cj(P), e(t) ≥ 0, r ≥ 0.  
To my knowledge, a price increase with falling uptake has not been observed. This 
means that no upwards price effects, which may be caused by falling implementation of 
technology j when uptake of technology i rises are accounted for in this model. 
Changes in the expected net monetary benefit that now are dependent on uptake and 
experience curve as well as the decision relevance horizon adopted can then be written as in 
Equation (4.21). 
 𝑁𝐵 = 𝜆∑𝑒𝑗(𝑡)𝛿
𝑇
𝑡=1
−∑𝑐𝑗(𝑃𝑁𝑡)𝛿
𝑇
𝑡=1
 (4.21)  
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where 𝑁𝐵 is the net monetary benefit, and 𝜆 is the threshold with 𝜆 > 0.  
Of course, incorporating experience curves in the model affects the EVPI through the net 
monetary benefit calculations. It is likely that adding uncertain parameters on future price 
change and uptake would increase the decision uncertainty reflected in the probabilistic 
sensitivity analysis. EVPPI analysis can be used to identify to what extent these parameters 
contribute to decision uncertainty.  
 
4.3.3 Summary 
In this section, I have provided a simple extension to cost-effectiveness analysis that 
allows modelling future periods and reflecting price changes that are precipitated by 
diffusion. I conclude that estimates of diffusion and the expected price changes conditional 
on expected diffusion are required to reflect such future price changes in the DCEA 
framework. 
 
4.4 The diffusion model 
Estimates of diffusion are needed for both frameworks presented in Sections 4.2 and 4.3. 
In Chapter 3, I identified the Bass model of diffusion to be the most established and 
validated existing model of diffusion. I briefly presented this model in Chapter 3.3 but 
provide a more detailed presentation on it in this section. In Chapter 3, I also highlighted 
potential problems with the Bass model used to predict diffusion with no data available and 
found a proposed solution by Satoh (2001).  
As a side note, what is truly needed to inform the EVII and DCEA frameworks is a 
market share curve over time for each of the decision options considered. This could be 
represented by, for example, a multinomial logistic model. Diffusion models focus on only 
one technology. For the remaining technologies in a market or therapeutic area, an 
assumption therefore needs to be made on the share of the remaining technologies. Because 
diffusion models have a greater evidence base, I focus on these. However, further 
exploration of market share models is considered as an important area for future research. 
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4.4.1 The Bass model of diffusion 
The new product growth model developed by Bass (1969) (often simply referred to as 
the Bass model) is an adapted logistic model that incorporates the effects of ‘innovation’ and 
‘imitation’. Bass distinguished between innovators and imitators which he noted was 
‘consistent with the characterisation of the behaviour of these groups in the social science 
literature’ (Bass, 1980). Innovators were considered to be those adopters who adopt the 
technology without being influenced by peers and imitators were those mainly taking the 
adoption decision because of their peers. Influence not exerted by peers was called external 
influence and that exerted by peers internal influence. To name examples, external influence 
could be direct communication by the manufacturer such as advertising; internal influence 
could be word-of-mouth. The Bass model typically follows an s-shaped curve for the 
cumulative number of adoptions and a bell-shaped curve for the per-period number of 
adoptions. The per-period number of adoptions are represented by Equation (4.22): 
 
𝑛(𝑡) = 𝑝(𝑚 − 𝑁𝜏) +
𝑞
𝑚
𝑁𝜏(𝑚− 𝑁𝜏) 
(4.22)  
where 𝑛(𝑡) is the number of per-period adoptions in period t and 𝑁𝜏 is the cumulative 
number of adoptions up to time 𝜏 = 𝑡 − 1, p the coefficient of external influence and q the 
coefficient of internal influence, 𝑚 the total number of attainable adoptions with 𝑚 > 0.  
It can alternatively be written as the probability of adoption in each period t: 
 
𝑃(𝑡) = 𝑝 +
𝑞
𝑚
∗ 𝑁𝜏 
(4.23)  
where 𝑃(𝑡) is the probability of adoption in period t. 
It is unclear from the literature what the restrictions for parameters p and q are. A few 
meta-analyses reported the ranges that they had found for parameters p and q (van den Bulte 
and Stremersch, 2004, Sultan et al., 1990), which were reported in Chapter 3. When I 
attempted to find natural boundaries of parameters p and q, I found that the model performed 
well with parameter values of 0.0001<p<0.1 and 0<q<0.9999. I observed that values 
outside these ranges may cause the diffusion curve to oscillate. However, this only happens 
for certain combinations of the p and q parameters and the impact of this is explored further 
in Chapter 6. 
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In a review of diffusion models, Meade and Islam (2006) stated that 𝑝 + 𝑞 controls the 
scale and that 
𝑞
𝑝
 controls the shape, with 
𝑞
𝑝
> 1 ensuring the s-shape of the cumulative 
diffusion curve. This implies that parameters p and q are negatively correlated. When 
eliciting data to inform the Bass model, correlated parameters will have an impact on the fit 
of the elicited data. The extent of correlation of the Bass model parameters and its 
implications for further analysis will be explored in Chapter 6.  
The shape of diffusion when using the Bass model is illustrated in Figure 4.2 using 
parameter values for p and q (p=0.0009 and q=0.6995) that were estimated for a biomedical 
device in the US (Gobok et al., 2009), and a hypothetical value for the market size m.  
 
Figure 4.2 Illustration of the per period and cumulative diffusion curves estimated with the Bass model 
 
 
The classic Bass model requires knowledge of uptake in the previous period to estimate 
uptake of any given period. The value of zero for uptake in the previous period results in the 
future period uptake to be zero, too. To estimate uptake in the first period after technology 
introduction, another estimation method is therefore required. The following approximation 
to the number of adoptions in the first period after launch has been used (van den Bulte and 
Stremersch, 2004, Mahajan et al., 1990): 
 𝑁1 =
𝑚(1 − 𝑒−(𝑝+𝑞))
(1 +
𝑞
𝑝 ∗ 𝑒
−(𝑝+𝑞))
 (4.24)  
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where 𝑁1 reflects the purchases in year 1. 
Another known quantity that describes the Bass model and is useful for the elicitation 
exercise in Chapter 6 is the time period at which the inflection point of the Bass model s-
shaped curve occurs (Mahajan et al., 1990, Sultan et al., 1990): 
 𝑡′ =
1
𝑝 + 𝑞
∗ ln (
𝑞
𝑝
) (4.25)  
where 𝑡′ is the point of inflection, or the time in number of years at which the number of 
adoptions starts to decline.  
 
4.4.2 The Satoh approach to modelling diffusion 
I highlighted in Chapter 3 that there are two potential problems with the use of the 
classic Bass model in an elicitation exercise to predict diffusion without any available data. 
The Bass model limitations were a) that parameters are correlated and this correlation is not 
captured when parameters are elicited univariately; b) the representation of discrete uptake 
data in a time-continuous fashion. These problems together may result in unrealistic 
diffusion curves. The alternative approach which was proposed by Satoh (2001) is a 
transformation of the Bass model that uses a discrete analogue of the Riccati equation 
proposed by Hirota (1979) to apply to the Bass model and make it discrete.  
A Riccati equation is any quadratic first-order differential equation such as this one: 
 𝑑𝑢
𝑑𝑡
= 𝑎(𝑡) + 2𝑏(𝑡)𝑢 + 𝑐(𝑡)𝑢2 
(4.26)  
where 𝑎(𝑡), 𝑏(𝑡) and 𝑐(𝑡) are given functions of t. 
Hirota obtained a discrete analogue of the Riccati equation that has an exact solution for 
u(t) when a, b and c are constant over time (Satoh, 2001, Hirota, 1979): 
 𝑢(𝑡 + 𝛿) − 𝑢(𝑡 − 𝛿)
2𝛿
= 𝑎 + 𝑏(𝑢(𝑡 + 𝛿) + 𝑢(𝑡 − 𝛿))
+ 𝑐𝑢(𝑡 + 𝛿)𝑢(𝑡 − 𝛿) 
(4.27)  
with δ being the constant time-difference length. 
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Assuming a, b and c to be constant, Satoh (2001) set them equal to the following terms 
consisting of Bass model parameters: 
 𝑎 = 𝑚𝑝 (4.28)  
 𝑏 =
𝑞 − 𝑝
2
 (4.29)  
 𝑐 = −
𝑞
𝑚
 (4.30)  
Putting these back into the Hirota discrete analogue yields (Satoh, 2001): 
 𝑁𝑛+1 −𝑁𝑛−1
2𝛿
= 𝑝(𝑚 −
𝑁𝑛+1 − 𝑁𝑛−1
2
)
+
𝑞
𝑚
(
𝑚
2
(𝑁𝑛+1 +𝑁𝑛−1)−𝑁𝑛+1𝑁𝑛−1) 
(4.31)  
with 𝑛 =
𝑡
𝛿
.  
The solution to this is: 
 
𝑁𝑛 = 𝑚
(
 
 1 − (
1 − 𝛿(𝑞 + 𝑝)
1 + 𝛿(𝑞 + 𝑝))
𝑛
2
1 +
𝑞
𝑝 (
1 − 𝛿(𝑞 + 𝑝)
1 + 𝛿(𝑞 + 𝑝))
𝑛
2
)
 
 
 
(4.32)  
 
Reflecting that each time period is one year, the parameter 𝛿 can be set to 𝛿 = 1 and 
Equation (4.32) simplifies to: 
 
𝑁𝑡 = 𝑚
(
 
 1− (
1 − (𝑞 + 𝑝)
1 + (𝑞 + 𝑝))
𝑡
2
1 +
𝑞
𝑝(
1 − (𝑞 + 𝑝)
1 + (𝑞 + 𝑝))
𝑡
2
)
 
 
 
(4.33)  
 
It is immediately obvious, that 𝑁𝑡 now is independent of the number of adoptions in the 
previous period and therefore the Satoh approach enables estimation of the number of 
adoptions in the first period 𝑁1 directly, without using an alternative estimation approach. 
The performance of the Satoh approach compared with the classic Bass model will be 
compared in Chapter 6. 
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4.4.3 Summary 
The Bass model of diffusion and the adaptation by Satoh provide a structure for 
incorporating diffusion estimates in EVII and DCEA analysis. 
 
4.5 Discussion 
4.5.1 Findings 
In this chapter, I proposed a modelling framework for the incorporation of diffusion 
estimates in health economic evaluation. These frameworks included the dynamic EVII 
model, the dynamic CEA model and the diffusion model.  
 
4.5.2 Relevance  
The dynamic EVII framework allows decision-makers to assess the opportunity loss to 
the health system that is caused by recommending a technology under uncertainty and 
imperfect implementation. As such, this framework can help direct investments to the most 
valuable activities, whether they be research studies or implementation measures. At the 
time this framework was developed it was the only one that allowed diffusion dynamics to 
be incorporated in these analyses. It remains the only one doing so using an established 
diffusion model with behavioural parameterisation. It also is the first to appropriately 
consider the relationship between implementation and information and its implications for 
decision-makers.  
I have demonstrated within my framework that other authors’ assumptions and 
interpretations used in and derived from value of implementation methods were incorrect. 
Since the time I developed this framework, one study appeared that claimed to consider the 
effect of implementation on the value of information (Andronis and Barton, 2016). This 
study had several limitations that I addressed with my framework. One of those limitations 
was that their proposed way of incorporating time-varying implementation estimates was 
simplistic, as they made assumptions of linearity. More importantly, the authors 
misunderstood the concept of the realisable EVPI developed by Fenwick et al. (2008) and 
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subsequently their interpretation of the implementation-adjusted EVSI was incorrect. I have 
provided proof that adjusting the EVSI calculation itself by implementation results in 
calculating the EVSIM of research. One reason that may have contributed to the 
misunderstanding is the term ‘realisable EVPI’ that characterised the maximum value of 
implementation that can be resolved through research. I therefore purposefully called this the 
Research EVPIM instead, to avoid this possible confusion.  
The DCEA framework has the potential to help decision-makers assess cost-
effectiveness of a technology that may experience price changes in the future. This can 
potentially prevent a situation in which a technology is rejected based on its current price, 
which would have become cost-effective in the future, in cases in which the price change is 
precipitated by the reimbursement decision.  
 
4.5.3 Strengths and limitations 
The strength of this modelling framework relates to the fact that it is based on diffusion 
theory and established diffusion models to incorporate the dynamics of implementation. 
Furthermore, the dynamic EVII framework establishes more clearly and hopefully more 
intuitively than it was done in the past what the true effect of information on implementation 
can be and how it can be calculated. The strength of the DCEA framework is that it 
formalises a phenomenon that exists (at least in some health technologies, namely medical 
devices) that has not been widely considered in the context of HTAs. 
A limitation of this chapter is that the implementation modelling framework has not been 
applied in a case study. This is going to be done in Chapters 7 and 8. Another limitation is 
that only one diffusion model (and one adaptation of it) is considered in this framework. It 
was shown in Chapter 3 that other diffusion models are possible. However, the Bass model 
was chosen on the basis that it was the most widely used and established model, with 
predictive accuracy shown in many studies. 
 
4.5.4 Conclusion 
This chapter has provided a framework for incorporating diffusion estimates in health 
economic modelling for use in HTA decision-making. This framework can enable more 
informed decision-making and potentially direct investments to where the greatest value to 
the health system can be achieved. Further research is needed to apply this framework in a 
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case study with the objective to assess its feasibility and potential range of results and to 
explore any issues that may arise with its use. 
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CHAPTER 5. IDENTIFYING POTENTIALLY EFFECTIVE 
IMPLEMENTATION STRATEGIES FOR EIS IN PTB SCREENING 
5.1 Introduction  
One of the objectives in this thesis was to identify relevant implementation strategies for 
the case study technology Electrical Impedance Spectroscopy (EIS) for use in preterm birth 
(PTB) screening. The methods for estimating implementation have been reviewed in 
Chapter 3 and the model framework for the evaluation of implementation strategies has been 
developed in Chapter 4. To facilitate estimating the effect of an implementation strategy on 
the uptake of EIS in Chapter 6 and evaluate its cost-effectiveness in Chapter 7, relevant 
implementation strategies are identified in this chapter. The results will ultimately be used to 
calculate the expected value of implementation of the identified strategies. Figure 1.2 in 
Chapter 1 illustrates the flow of the thesis. 
The rationale for the study presented in this chapter is that there is currently no 
knowledge of potentially relevant implementation strategies for EIS in PTB screening. As 
discussed in Chapter 1, it is not possible to use readily available strategies from other 
technologies because there is a wealth of factors influencing diffusion of health technologies 
rather than a well-defined set of main drivers. It is also plausible that different 
implementation strategies exhibit different levels of effectiveness at different stages of the 
product lifecycle. 
The aim of this chapter is to identify relevant implementation strategies for the use of 
EIS for PTB screening in the England NHS at an early stage of technology life. Qualitative 
research methods that enable asking open-ended questions and provide the depth to explore 
why phenomena occur (Ritchie et al., 2003) were therefore deemed ideal for this study. This 
chapter is structured as follows: in Section 5.2, I describe the selection of the methods used, 
the sampling frame, interview design, data analysis and methods used to identify 
implementation strategies that are relevant at the current stage of the technology life cycle. I 
then present the results from the interviews in the Results Section 5.3, including the 
transferability of results and triangulation with the subsequent elicitation study and present 
the selected implementation strategies. I conclude with a discussion and conclusion in 
Section 5.4. 
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5.2 Methods 
5.2.1 Method selection 
In this section, I present how I identified potential implementation strategies in two 
stages. The first phase entailed an exploratory study to identify potential uptake determinants 
for the case study technology EIS. In a second step I chose implementation strategies 
relevant to EIS at its lifecycle stage. 
 
 Stage 1: Identifying potential uptake determinants for EIS using qualitative 5.2.1.1
research  
The research question in this part of the chapter was to identify potential factors 
influencing the uptake of EIS. It may not be possible to turn all uptake determinants into an 
implementation strategy. However, there were two reasons for keeping the research question 
this broad: first, the desire not to limit respondents unnecessarily in their responses. The 
more restrictive the design of the topic guide, the smaller the likelihood that respondents 
would think broadly and name relevant factors that do not come to mind easily. Second, so 
as not to miss potentially valuable information. While some named uptake determinants 
might not translate into implementation strategies, they might give a qualitative description 
of how best to design those strategies.  
Semi-structured interviews with experts were deemed the most appropriate format to 
elicit information on determinants of uptake. Semi-structured interviews allow asking open-
ended questions while providing a structure to guide the researcher and interviewee through 
the interview (Britten, 2006). I adopted a topic-centred approach, that is, there was an 
interview guide that covered certain topics to make sure these topics were discussed but it 
also allowed themes to emerge when they had not been considered previously (Britten, 
2006). This method also provided the flexibility to probe about past points or more detail. 
Individual interviews with experts were chosen over focus groups to capture the full scope 
of individual experiences, including differences between different professional profiles and 
settings. The adoption decision to be investigated is likely to occur at the level of individuals, 
such as individual clinicians or business managers, and individual interviews are more likely 
to capture individual thoughts and nuances. Focus groups do not offer the same opportunity 
for eliciting individual thoughts (Ritchie et al., 2003) and I therefore considered them less 
relevant for this study. One advantage of focus groups over individual interviews would be 
the opportunity of reaching consensus among experts with regards to the most important 
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uptake factors. This advantage is, however, offset by the fact that individual additions of 
themes are less likely to be captured. In addition, focus groups are associated with more 
practical complexity because they require gathering experts together at the same time. Study 
participants may not be available at the same time, and travelling to a meeting location 
would require additional time from the experts; hence, individual interviews at the work 
place of the participant were considered the most appropriate method. 
 
 Stage 2: Selection of implementation strategies  5.2.1.2
The intention was to choose potentially effective implementation strategies that made 
sense, rather than investigating all possible implementation strategies. Ideally, one would 
want to elicit the effects of all possible implementation strategies and optimise the decision 
to achieve the optimum strategy in terms of effects on implementation and costs, but this 
was not feasible within the scope of this project, nor did it serve the main purpose of 
illustrating the use of the proposed extension to the expected value of implementation 
framework. I therefore do not claim comprehensiveness in the selected implementation 
strategies, nor do I claim that these are the best implementation strategies in terms of their 
impact or cost-effectiveness. I nevertheless made sure that relevant implementation 
strategies were chosen by basing the choice upon the findings from the qualitative study and 
then applying selection criteria to those findings. This process is shown in Figure 5.1 and 
described in more detail below. 
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Figure 5.1 Process of identifying implementation strategies for EIS 
 
 
5.2.2 Sampling 
The population of interest, or the sampling frame, was based upon the inclusion of those 
individuals that would be involved in the selection, purchase and use of new technologies in 
obstetrics at the Sheffield Teaching Hospitals NHS Foundation Trust, Barnsley Hospital 
NHS Foundation Trust or Rotherham NHS Foundation Trust. With those three trusts, both 
hospital types in England, that is, University Teaching Hopsitals (UTH) and District General 
Hospitals (DGH) were covered. The restriction to three trusts ensured feasibility and 
facilitated recruitment. The sampling approach adopted was purposive sampling to cover a 
relevant range of contexts or phenomena (Mason, 2002, Ritchie et al., 2003) that would 
enable reflection of different ranges of experience.  
Professions and different types of hospitals were chosen as the categorising factors for 
this sampling frame because it was expected that different professions and professional 
settings might contribute different views on the adoption decision. The sampling categories 
included obstetricians and business managers from either UTHs or DGHs. Obstetricians 
would be using EIS and would be the most crucial in proposing new devices to purchase. 
Business managers on the other hand would provide further insight into financial 
determinants in the purchasing decision. It was anticipated that affiliations with the different 
hospital types might shape individuals’ experiences and thoughts on adoption decisions. To 
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cover the different categories, an absolute minimum of six respondents was needed (Table 
5.1). 
 
Table 5.1 The sampling frame for the semi-structured interviews 
Category  Number of individuals 
Obstetricians (DGH) At least 1 
Obstetricians (UTH) At least 4 
Business manager (DGH or UTH) At least 1 
Total At least 6 
 
The required sample size for qualitative interviews is determined by the point at which 
theoretical saturation is achieved; that is, when no new themes or data emerge (Guest et al., 
2006). For fairly homogeneous samples, six to eight interviews have been described as 
potentially sufficient (Guest et al., 2006, Kuzel, 1992). Consensus theory developed by 
Romney, Batchelder and Weller (1986) as cited in Guest et al. (2006) suggests that the 
degree of expertise among the study participants, which may be defined by certain 
qualifications or experience, can ensure homogeneity of responses. This also suggests that 
for expert interviews fewer respondents are needed than for interviews with novices. As 
Guest et al. (2006) argue, a homogeneous sample of experts, together with a relatively 
narrow objective, may cause saturation to be achieved sooner. In this case, the degree of 
expertise was regarded as high as the sampling frame was narrowly defined. The objective 
of identifying a shared perception of the most relevant uptake factors was seen as relatively 
narrow, which justifies the relatively small minimum sample of six participants. Despite 
these theoretical justifications, the degree of saturation was monitored after conducting a 
number of interviews by examining how many new themes still emerged. 
The sample was generated through snowballing. Snowballing refers to a process of 
asking people who have been interviewed to identify other potential participants who match 
the selection criteria (Ritchie et al., 2003). Contacts with one person from each trust were 
established at the start of the process. Selection criteria were shared with the individuals that 
were willing to participate. These individuals then contacted potential participants and 
provided the details of those who might be interested in taking part.  
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Interviews with 10 experts involved in purchase decisions and use of obstetrics 
technologies were conducted between June and October 2013. These included obstetricians 
from both UTHs (7) and DGHs (2) and one business manager. All themes and sub-themes 
had emerged at the sixth interview, achieving theoretical saturation. Although there was a 
possibility that further themes would emerge with more interviews, the additional marginal 
benefit was deemed too little to continue the interviews as it was not expected that the 
overall results would change. I also considered the impact of a potential lack of saturation to 
be small due to the objective of this research to inform an elicitation exercise in contrast to 
developing a comprehensive understanding of uptake determinants. 
 
5.2.3 Interview design  
An interview guide was created to ensure that all interviews followed a similar format. 
The interview guide started out with broad questions and became more specific to ease the 
interviewee into the topic, as recommended by Legard et al. (2003). In the introductory part, 
background on the study was provided. An explanation of uptake of health technologies was 
provided. The information sheet was discussed (respondents had received it in advance of 
the interview) and any questions the participants had were addressed. The introductory part 
concluded with warming up questions about general practice.  
This was followed by the main part in which the interviewees were asked about anything 
that might influence uptake within certain categories. To develop these categories I 
considered consulting existing catalogues of diffusion determinants by Greenhalgh et al. 
(2004), the DH report (Department of Health, 2011) and the qualitative study by Barnett et 
al. (2011), that were described in Chapter 1 and by thinking about what was going to be 
easiest for participants to think about, without prompting them. Most categories named in 
the Greenhalgh study were quite abstract and not intuitive enough to use as guiding 
questions in an interview schedule. The categories named by the DH report, on the other 
hand, were very concrete and were likely to prompt participants if included in the interview 
guide. These categories were also too narrowly defined, making assumptions on the 
effectiveness and cost-effectiveness of the technology in question. I therefore decided not to 
adopt any of these catalogues, but to use them as inspiration and design the interview guide 
based on categories that were intuitive enough to provide a guide for participants to direct 
their thought while attempting to cover a wide range of topics.  
96 
 
The final questions asked about factors influencing diffusion were related to: the 
technology; the users; the purchaser; the organisation; the external environment; and 
anything else that could increase uptake if low uptake was noted. I included the question on 
technology-specific factors influencing uptake because the Greenhalgh et al. (2004) study 
emphasised the role of the technological advantage in diffusion. Equally, the questions on 
the organisation and the external environment were included because of the importance 
placed on these in the Greenhalgh study, the qualitative study and the DH report. The other 
questions were designed to include all factors influencing different stakeholders in their 
decision-making (the user and purchaser). This design allowed for any thoughts to come up 
without prompting, with subsequently aiding the stream of thoughts by allowing the 
questions to be more specific and targeted. Finally, respondents were asked to name the two 
to three factors thought to be the most influential on uptake of EIS out of all those that they 
had mentioned. If required, all the factors they had mentioned before were repeated to them 
(this was made possible through taking field notes) but it turned out that most respondents 
had a very clear idea of what was most important in their opinion. 
All interviews were conducted by me. This ensured familiarisation with the interviewees’ 
different responses and picking up on nuances as well as learning about how best to 
approach different topics. Most interviews lasted 30-40 minutes, but the shortest was 28 
minutes long and the longest one hour and six minutes. Interviews were audio-recorded and 
field notes of important points were taken. I transcribed all interviews and double-checked 
transcripts for accuracy. 
A pilot was conducted with one respondent. This facilitated the review of the interview 
guide for its effectiveness in eliciting the information needed and served as practice in 
performing interviews as this was the first time I ever conducted semi-structured interviews. 
The interview guide was not changed posterior to the pilot interview and as a result of this I 
decided to include the findings from the pilot in the data analysis. 
 
5.2.4 Ethical considerations 
The study had obtained ethics approval by the University of Sheffield Research Ethics 
Committee (UREC), as well as NHS R&D governance by the Sheffield Teaching Hospitals 
NHS Foundation Trust, the Rotherham NHS Foundation Trust and Barnsley Hospital NHS 
Foundation Trust. Interviews were held face to face at the respondents’ work place to ensure 
convenience and safety. Written informed consent was obtained from all study participants 
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after questions raised by respondents were addressed before the start of data collection. The 
information sheet, informed consent form and interview guide can be found in Appendix C. 
 
5.2.5 Data analysis using framework 
Data analysis was performed using ‘Framework’ in order to identify and categorise the 
factors influencing uptake of EIS that are hidden in the data. Framework is an analytical 
process with various structured phases (Ritchie and Spencer, 2002). It is a matrix-based 
analytic method and a way of using labels and categories to organise and analyse the data 
(Ritchie et al., 2003) whilst enabling the researcher to move between different levels of 
abstraction. This is done by using cross-sectional code and retrieve methods (Mason, 2002) 
by which a system of categories is first devised and then applied to the data. A study will 
thus have a thematic framework, with data organised into key themes and divided into sub-
themes. Framework has been developed for use in policy research and since been used 
widely in health and policy research because of its pragmatic outlook that makes it 
particularly suitable to help answer policy questions (Pope et al., 2006, Gale et al., 2013). 
Framework was chosen over other types of thematic analysis because of its differentiating 
step of charting themes. These charts display themes in the shape of a matrix that allows 
analysis within cases and within themes. With the preservation of individual accounts, 
framework facilitates comparisons across individuals (Gale et al., 2013). This appeared to be 
particularly useful in visualising the data, and categorising it.  
After interview data has been transcribed, framework comprises five main phases 
(Ritchie and Spencer, 2002) shown in Figure 5.1; the first phase is that of familiarisation. 
Having conducted and transcribed all interviews myself helped with the first steps of 
familiarisation; and listening to the tapes and reading through the transcripts twice aided the 
process. More familiarisation with the data occurred throughout all phases of data analysis 
while coding, sorting and charting the data. In phase two the thematic framework, consisting 
of recurring themes and ideas, was identified through examining the range of responses to 
questions. A numerical index was created at that stage, which referred to ideas or themes 
that were close to the original verbatim rather than imposing existing theoretical structure at 
this point (Ritchie et al., 2003). Themes were sorted and grouped under higher categories. 
Indexing, that is applying codes to the data, was conducted in phase two, by printing 
transcripts and marking phrases and sentences of verbatim with the respective index in the 
margins of the transcripts. After a first round of indexing, an initial framework was 
established (phase three) based on abstracting from verbatim to develop themes. The 
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framework was then revised based on a second round of indexing in which themes were 
added and others were grouped if there was some overlap. At this stage, 49 codes were 
created and applied to the data. The codes were aggregated into a number of four themes.  
With the framework developed, phase four entailed charting data thematically. For each 
theme abstracted summaries of respondents’ statements were chosen and presented in a chart 
with one row for each respondent and one column for each sub-theme and page references 
for each summary. I attempted neither to over-simplify nor to include too much data. Row 
heights and column widths were kept the same for each chart in order to facilitate easy 
comparison across respondents. The charts were reviewed and compared with the initial 
framework to check whether any data were missing. In phase five I returned to the aim of 
this study and described the range and nature of factors influencing uptake of EIS and 
identified patterns and connections. Associative analysis, that is finding links and 
connections between phenomena and explaining why those associations exist, was 
conducted as there was evidence of some themes appearing in clusters. For this, associations 
were explored as pointers to further analysis, as recommended by Ritchie et al. (2003). 
It was tempting to include the recurrence or the frequency with which a factor was 
named as a measure of importance. As highlighted by Ritchie et al. (2003), frequency should 
not be presented as a primary finding as it does not have any statistical value. On the other 
hand, the authors also argue that frequency of occurrence should not be ignored but 
explanations be sought for this phenomenon. It was for this reason that counts of 
respondents mentioning a factor were presented at times and explanations sought when some 
importance was placed on those counts. 
 
5.2.6 Validation of findings 
The relevance of validity as a concept has been disputed in qualitative research (Lewis 
and Ritchie, 2003). It traditionally consists of internal and external validity. The former 
relates to whether the research explores what the researcher claims to be investigating and 
the latter to whether the findings are applicable to other parts of the population which makes 
it a part of generalisation (Lewis and Ritchie, 2003). The questions posed in qualitative 
research differ from those in quantitative research (Lewis and Ritchie, 2003) and could be 
represented better by exploring whether the respondents’ perceptions were accurately 
reflected. Having adopted a pragmatist stance and using a mix of qualitative, elicitation and 
modelling techniques within this study, I considered this study to share features with mixed 
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methods studies. The question posed in a pragmatist mixed methods study is more that of 
‘transferability’ than of generalisation or context (Morgan, 2007). Examining transferability 
refers to investigating which factors can make these findings applicable to other settings. 
One way of achieving that would be to compare the identified themes to existing research. In 
this case the themes were compared to the broader diffusion model components developed 
by Greenhalgh et al. (2004), the barriers to implementation identified by the Department of 
Health report (Department of Health, 2011) and diffusion determinants in the England NHS 
elicited in a qualitative study (Barnett et al., 2011). At the centre of this comparison were the 
following questions: Were named factors able to fall into the same model components? If 
not, are there any evident explanations for them lying outside the existing model? If they did 
not cover all of the model components, was there any evident explanation for that? Findings 
from this comparison were then used as pointers to the factors that could influence the 
transferability of results to other settings. 
Multiple assessment, that is, assessment by another researcher to ensure that themes 
were identified correctly, was considered but not used. There were a few reasons for not 
using it: there are limitations with this because no individual interview will match the 
abstract framework fully (Mays and Pope, 2006). As such, multiple assessment is not 
advised as a check on validity but rather as a type of error reduction in each interview (Mays 
and Pope, 2006). Another reason was that a degree of subjectivity is accepted in mixed 
methods research (Morgan, 2007) and that researchers outside this project would not know 
the data and meaning as well as me. Instead, transparency in analysing the data can help the 
reader in judging the way that conclusions were drawn (Mays and Pope, 2006). Framework 
helps in transparency by charting data from the interviews within the identified themes. 
Further validation was performed through triangulation. Triangulation refers to 
comparing results from different methods of data collection and enables testing the 
comprehensiveness of findings (Mays and Pope, 2006). Hence, the qualitative explanations 
obtained in the elicitation study were compared with the findings of the present qualitative 
study to check for any deviations in what respondents regarded as important influencing 
factors to uptake. For this, all qualitative observations from the elicitation study were 
compared with all themes from the qualitative study described in this chapter. 
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5.2.7 Identifying potential implementation strategies 
With factors influencing the uptake of EIS identified through semi-structured interviews 
and framework analysis, I turned to the second objective of this chapter: identifying 
potentially effective implementation strategies that could be assessed for their effectiveness 
in the subsequent elicitation study. This part of this chapter does not claim to identify the 
most effective or cost-effective implementation strategies – this could only be achieved 
through quantitative analysis of all of them. However, I attempted to identify 
implementation strategies relevant for EIS at the current stage of product lifecycle; that is, 
before its introduction. 
I first reviewed answers to the final question asked in the interviews. In that question, 
participants were encouraged to name three factors they thought to have the greatest 
influence on uptake. It was assumed that ease of recall in this particular question truly 
reflected the importance of the factor. Second, I re-examined the language used by 
respondents and printed in the framework charts to identify what was described as vital or 
most important by respondents to check for any divergence from the respondents’ identified 
uptake factors. Third, I placed greater emphasis on those uptake factors likely to be relevant 
at an earlier stage of product development. A chart of factors influencing the uptake of EIS 
and their relevance in the technology life cycle was therefore developed based on the 
different stages of product lifecycle (Kotler and Keller, 2012) and the respondents’ 
statements. 
 
5.3 Results 
In Sections 5.3.1 to 5.3.4, themes are described in detail including their sub-themes and 
charts of representative summaries of respondents’ comments belonging to each included 
theme and sub-theme are shown in Appendix C. The transferability of these findings is 
discussed in Section 5.3.5 and findings are triangulated with those of the elicitation study in 
Section 5.3.6. In Section 5.3.7, potentially effective implementation strategies are presented. 
 
5.3.1 Research evidence 
Research evidence was identified as a key theme with three sub-themes (Figure 5.2) and 
representative summaries of respondents’ comments relating to its three sub-themes of 
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evidence for ‘predictive ability of EIS’, evidence for the ‘progesterone treatment effect’ 
relative to no treatment after screening with EIS and the ‘quality’ of the evidence are shown 
in Appendix C.4.  
Evidence for the predictive ability of EIS was mentioned as a crucial factor by all 
respondents and evidence for the progesterone treatment effect was mentioned separately by 
all but one respondents. All but two respondents also mentioned quality of the research in 
some shape or form as a potential determinant to uptake. These three sub-themes included 
statements on its different aspects which are depicted branching out from the sub-themes in 
Figure 5.2. Each of the sub-themes with their different aspects are now described in further 
detail. 
 
Figure 5.2 Theme 1: Research evidence 
 
 
The predictive ability of EIS was also named as evidence ‘that it works’. Most 
interviewees thought that the predictive ability of EIS would be demonstrated in a study 
among high risk women but some others emphasised the desirability of showing predictive 
ability in the wider population of all pregnant women. This would enable a change in the 
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general perception that a predisposition to giving birth preterm can only be discovered in 
women with risk factors. Those risk factors entail a history of previous preterm births or 
miscarriages. It would obviously be desirable to prevent premature births also in women 
who have not experienced losses or premature deliveries of babies before.  
‘If it works we could screen all pregnant women at their 20 week scan.’ (Participant 
1) 
‘There has to be overwhelming evidence, e.g. likelihood ratios in the 10s and 20s 
and good reproducibility.’ (Participant 2) 
‘...without trial evidence noone is going to introduce anything.’ (Participant 3) 
‘Research has to show sensitivity and specificity to make sure that clinicians will use 
it correctly.’ (Participant 8) 
‘The biggest thing would be the evidence, that it works, and if there was clear 
evidence on what the true positives, negatives and false positives, negatives were, 
that could drive uptake.’ (Participant 10) 
 
If EIS could be shown to reliably predict PTB also in women without a history, then this 
would increase its utility to clinicians since such a tool is not available at present. Whether 
EIS would be used in a high-risk population only or in the wider population of all pregnant 
women would of course have huge implications for its absolute uptake. On the other hand, 
screening every pregnant woman, including women who would otherwise remain in 
midwifery-led care, would have clinical pathway and financial implications.  
‘The ability for it to be used by all pregnant women would be crucial for uptake.’ 
(Participant 1) 
‘If the evidence came out that you would be screening every pregnant woman, that 
would have quite big training and logistical issues.’ (Participant 4) 
‘If you start using it in high risk groups, will it translate to low risk groups, will it 
get false positives, so I think you need a lot more studies.’ (Participant 5) 
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The sub-theme of evidence on the progesterone treatment effect was also expressed as 
the desirable outcome of delivering ‘happy healthy babies’. The rationale behind this was 
that participants questioned the effectiveness of progesterone treatment, especially in 
combination with EIS screening. The evidence base for treatments in general is relatively 
immature, with progesterone therapy deemed to be the most promising treatment available at 
present (Honest et al., 2009). However, existing evidence only shows progesterone 
effectiveness in preventing PTB after cervical length scans. More studies to show the 
effectiveness of progesterone after EIS screening were desirable from the point of view of 
some respondents and some stated that trials on the prevention of PTB with progesterone 
treatment after testing with EIS were needed. 
 ‘If you see that it saves lives, and you get results in clinical practice.’ (Participant 3) 
 ‘Happy healthy babies is a valid endpoint.’ (Participant 4) 
 ‘If it gives us better health outcomes, it will be taken up quickly.’ (Participant 6) 
‘Other people are not convinced that the existing treatment works and may need 
more evidence.’ (Participant 4) 
‘If you could prove that there was an intervention to improve the overall outcome, 
then that would send up the uptake.’ (Participant 10) 
 
The summaries in Appendix C.4 highlight that respondents placed great importance on 
both types of evidence, using key phrases such as ‘the main thing…’, ‘the biggest thing…’ 
and making judgement statements about uptake such as ‘… it may not be adopted’ and 
‘…that would send up the uptake’. 
The third sub-theme was quality of the evidence. Any research study should ideally fulfil 
different dimensions of quality. The robustness of the study design was mentioned as a key 
factor, with a randomised controlled trial considered the gold standard and sufficient patient 
numbers to power the study emphasised by a few respondents. A double-blind study was 
mentioned as desirable, albeit difficult to implement with EIS. Respondents wanted initial 
research to be validated in multi-centre studies across different settings and some mentioned 
that evidence on the performance of EIS compared with a comparator would be desirable. A 
few emphasised that they would want the reproducibility of results to be shown by the 
research. By reproducibility of results respondents meant a demonstration of achieving the 
same results if the same person was screened twice on the same day. 
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 ‘It'll need validation in multi-centre studies across different settings.’ (Participant 1) 
‘Evidence in the shape of randomised-controlled trials, double-blind in fact, is 
essential.’ (Participant 5) 
‘Good research could convince me of whether this could make a difference. It has to 
be a good-sized study with adequate power. And it needs to be randomised. I'm not 
bothered about lots of trials as long as it's good quality and it's big enough and not 
biased in any way by the people who are trying to make it.’ (Participant 9) 
 
Respondents would also like to see whether screening with EIS was safe and well-
tolerated. One respondent mentioned that it would be important to consider the 
psychological morbidity that may be associated with screening of pregnant of women. 
‘Actually, there is a morbidity associated with this, putting patients under some 
degree of stress and telling some of them that they may have a PTB, a psychological 
morbidity that it could ruin your pregnancy.’ (Participant 8) 
 
5.3.2 Product and service characteristics 
The second key theme identified was ‘Product and service characteristics’, which 
included the three sub-themes of ‘easy to use design’, ‘costs’ and ‘marketing’ (Figure 5.3). 
The ease of use of the device was important to the majority of the respondents and was 
mentioned as one of the major factors to uptake. A design that could facilitate ease of use 
comprises many different aspects. Disposable probes were one such aspect, as it was not 
deemed feasible to send the device for sterilisation after every use. 
‘It needs to have a disposable cover.’ (Participant 4) 
 
The look of the device was important to the respondents, who did not want it to look too 
‘menacing’ and thought that a sleek design would encourage usage and therefore uptake.  
‘It must not look menacing or too big, if it looks sleek and nice it is likely that people 
would take it up.’ (Participant 1) 
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‘The design is probably quite important, it should look sleek and easy to use and not 
big and threatening.’ (Participant 5) 
 
Figure 5.3 Theme 2: Product / service characteristics 
 
 
Equally, it was important to respondents that the device be ergonomic in the hand of its 
user as an ‘ergonomic design is a big factor to uptake’. An ergonomic design was seen to 
entail a small size which would make it easier to handle.  
‘I've had issues in the past with devices that were too big and did not fit my hand.’ 
(Participant 4) 
 
A smaller size would also make it more portable. Portability was mentioned as important 
because that would enable its operation in different rooms without having to purchase a 
large number of devices. Another design feature that would make it more portable was the 
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preference for a battery-driven device rather than one that has to be connected to a charger 
overnight.  
‘Portability would influence the decision.’ (Participant 7) 
 
Four respondents also made statements regarding ‘easy data transfer’. The desirability of 
wireless data transfer to connect with any computer was mentioned along with the 
possibility of having a docking station for the device from which data could be transferred. 
‘It would be great if it had a docking station and you put it in and it downloads data 
to the computer.’ (Participant 4) 
‘If you've got a probe that will link to a computer by bluetooth or wifi, people think 
that's wonderful.’ (Participant 6) 
 
The robustness of the device was highlighted by one respondent who thought that 
purchasers may be put off by a device that breaks easily.  
‘I'd want to know how robust is the piece of kit.’ (Participant 6) 
 
Finally, respondents saw an advantage in EIS in that it could provide quick 
measurements and save time over other types of screening such as ultrasound scans. It was 
thought that speed of measurement would help bring it ‘into clinical practice’. 
 ‘If it's easy and quick to use it would influence uptake.’ (Participant 5) 
 
The sub-theme of easy to use design was mentioned together with evidence by some 
respondents as in below example statements. This association of evidence and ease of use 
seems to highlight the relevance of those particular factors to clinicians. 
‘As long as the evidence said it was good and it was good in everybody's hands 
because it was easy to use, then I can see the potential.’ (Participant 9) 
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‘An ergonomic and easy to use look is the greatest factor [to uptake], along with the 
evidence for its use.’ (Participant 10) 
 
The other sub-theme was the ‘costs’ associated with the purchase of EIS. Different types 
of costs were thought to have an effect on uptake. Based on the participants’ statements it 
appears that the most important types of costs were the capital costs, that is the cost of 
purchasing the device, and the consumable costs, that is the cost of the disposable probes.  
‘When things are expensive they are not taken up…’ (Participant 6) 
‘How usable it was would depend on the initial outlay…’ (Participant 9) 
‘It would make a big difference if you had to think very carefully about consumable 
cost.’ (Participant 5) 
 
One respondent mentioned that the purchasing price mattered because with a price 
higher than £5,000 the decision would be made by the capital investment team, rather than 
the local directorate. It was also thought that if the cost of the disposable probes was too 
high, that is ‘10s of pounds, [for example] £30 every time’, then clinicians would think 
carefully about the use of EIS in clinical practice. One respondent mentioned ‘that some 
companies will work with you to achieve that [low consumable costs]’. 
Other costs that were mentioned included training costs, replacement, maintenance, 
manpower and implementation costs. All respondents mentioned some type of costs and 
they placed some importance on them. Some stated that, in the current economic climate and 
given the NHS’ reluctance to change, costs presented a very important factor.  
 ‘Cost is the biggest thing at the minute because all trusts are under pressure.’ 
(Participant 9) 
 
Because costs were placed in context with the effectiveness of the device or the wider 
financial impact the device could have, the financial impact was another aspect to the ‘costs’ 
sub-theme. Many participants mentioned that the cost of EIS would have to be outweighed 
by the savings or the benefit EIS could contribute in clinical practice and in terms of health 
outcomes.  
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‘Why should we spend X amount of money, if we are not going to improve 
efficiency?’ (Participant 2) 
‘If something can save money as well, the business case is a lot easier.’ (Participant 
3) 
‘The biggest thing would be evidence and working out the cost benefit, if you could 
save 3-5 PTBs per year, the impact that would have on drugs, special care baby 
units and long-term effects.’ (Participant 10) 
 
One respondent associated the cost-benefit of EIS with the use of EIS on all pregnant 
women: 
‘… if we had a simple device that costs just £5,000 that we could use on everybody 
and predict the ones that deliver before 28 weeks, then we could have some impact.’ 
(Participant 4) 
 
Several other aspects of the product and service characteristics were mentioned that were 
grouped under the sub-theme of ‘marketing’. Within this sub-theme, it was mentioned that 
reduction of costs through training or maintenance packages offered for free by the 
manufacturer could have a positive effect on uptake. Trial periods in which the device is 
provided for free were seen as an initiative likely to increase uptake.  
‘It would have to be minimal outlay or it would be for the company to say we will 
give you this on trial, completely free, with X many refills for 6 months...’ 
(Participant 2) 
‘It's how good care the manufacturer gives, that is also things like training 
packages.’ (Participant 9) 
 
Furthermore, the skills of the sales representative, their enthusiasm and persuasiveness 
were seen to affect the uptake decision by individual clinicians. 
‘I think it's how enthusiastic the sales person is, if they believe in what they do and 
they can put that over to you...’ (Participant 6) 
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5.3.3 Organisational set-up 
The theme of the ‘organisational set-up’ contained the sub-themes of ‘clinician’, 
‘practicalities’, ‘midwives’ support’ and ‘budget’ (Figure 5.4).  
 
Figure 5.4 Theme 3: Organisational set-up 
 
 
There were two aspects to the ‘clinician’ theme: their knowledge and awareness and 
their motivation. Clinicians’ potential ignorance of new evidence was mentioned as a 
potential barrier to adoption. It was also mentioned that some gynaecologists working in 
obstetrics may be less aware of recent developments in obstetrics and that junior staff on 
rotation may not be aware of procedures.  
‘It's got mostly to do with awareness of how good the technology is.’ (Participant 9) 
 
The motivation aspect emerged in eight interviews. It was never mentioned to be a very 
important factor but interviewees did seem to think that it could affect uptake. Respondents 
described enthusiasm for innovations or the lack of it as well as the effect that the career 
stage or age could have on the clinicians’ attitude towards new technologies. The burden of 
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increasing workload through adopting new products or processes was also mentioned as a 
deterrent factor to uptake. 
‘When you have come to a certain level of training or age then it is very difficult to 
go for something new, it's treated with suspicion.’ (Participant 2) 
‘When new research recommends not to do something anymore, everyone 
immediately stops doing it, but when you're supposed to do something in addition to 
what you're already doing, uptake is a bit smaller.’ (Participant 4) 
 
Among the sub-theme of ‘practicalities’, the ability of EIS to free capacities was seen as 
a major facilitator to uptake as five respondents emphasised the existing pressure on 
ultrasound scanning and that anything to relieve that would be welcome. They also thought 
that EIS may be more efficient than ultrasound or offer some cost-savings compared to 
ultrasound.  
‘Anything that will reduce the pressure on ultrasound will be welcome.’ (Participant 
3) 
‘If you do it instead of [ultrasound] scans, then this is much quicker and there's 
efficiencies to be had.’ (Participant 4) 
‘Ultrasound seems to be such a scarce resource that any alternative would be 
welcome.’ (Participant 7) 
 
Several other aspects were aggregated under the ‘practicalities’ theme: the need for 
training certain personnel, having a chaperone when performing the exam, and the time 
pressure caused by the additional work that would need fitting in with consultants’ schedules.  
‘You can't do anything now, without someone being on a training course.’ 
(Participant 2) 
‘You may need someone to chaperone you and that can be an issue in an antenatal 
clinic.’ (Participant 5) 
‘If I need to do it to every patient that I see in antenatal clinic, that is going to add 
15 minutes and reduce my clinic by a third.’ (Participant 6) 
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Midwives’ support was mentioned and that getting them on board could have an effect 
on uptake. 
‘The midwives are often the ones who see it, they'll suggest why don't you do this test, 
so I think it's important to engage them.’ (Participant 5) 
 
The last sub-theme within the organisational set-up was the organisation’s budget that 
may prevent EIS from being purchased.  
‘Budget is an issue, for example trusts or health funders might decide to buy 4 
rather than 8 devices.’ (Participant 1) 
 
It was furthermore mentioned that there are different budgets for different purposes and 
that there is a certain flexibility as to what budget might be used: 
‘It is about whether it is capital or revenue budget. We could be totally broke and 
load the costs at the front end because it's not our directorate's budget, but it's still 
the trust's budget.’ (Participant 7) 
 
One respondent mentioned the fact that tariffs often only poorly reflect the actual costs 
in a directorate and where those costs occur (participant 7). The existence of perverse 
incentives was noted, where a less invasive lower cost procedure leads to a lower tariff 
despite it being difficult to reduce the actual costs associated with this procedure. 
 
5.3.4 External factors 
The theme of ‘external factors’ comprised five sub-themes: ‘scientific dissemination’, 
‘guidance’, ‘peer influence’, ‘patient demand’ and ‘media’ (Figure 5.5). 
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Figure 5.5 Theme 4: External factors 
 
 
Within the sub-theme of ‘scientific dissemination’, respondents placed importance on 
publicising research in different channels, e.g. in scientific meetings.  
‘Research needs to be publicised and the more it is, the more likely people are to 
think that this might be helpful.’ (Participant 4) 
 
The sub-theme ‘guidance’ was mentioned by all respondents. They referred to different 
types of guidance such as those issued by local networks, the Royal College of Obstetricians 
and Gynaecologists, the national screening programme and NICE. NICE guidelines were the 
ones mentioned most often and a few times with a special emphasis on the ability of NICE 
guidance to make a significant difference to uptake, for example: 
‘The essential factor for the diffusion of a device is the reception that the NICE gives 
to it.’ (Participant 3) 
 
Respondents mentioned that it was difficult not to adopt something once there were 
guidelines of any type and justification would have to be provided. 
‘If the Royal College or NICE said everyone must have this then it would be difficult 
to say No.’ (Participant 4) 
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The importance of ‘peer influence’ and actions of other hospitals was also emphasized: 
 ‘Bad experience elsewhere can bring uptake down.’ (Participant 6) 
 ‘The greatest rise in uptake will be from people who just follow the trend.’ 
(Participant 10) 
 
Patient demand was also seen to be vital for uptake. This could go in both directions, 
with patients not accepting EIS, thus hindering uptake or patients demanding screening for 
PTB, thus encouraging the uptake of EIS. 
‘If patients don't like it, it won't get taken up.’ (Participant 6) 
‘A lot of bits of equipment are bought because patients in support groups talk about 
it, ask for it and want to go somewhere where it's available.’ (Participant 5) 
 
The last theme was ‘media’ which, according to a few respondents, could have a 
significant influence through driving patient demand but could also highlight any potential 
problems associated with the use of a technology. 
‘User feedback can be a big influence and it can come from women's magazines, soft 
press stuff and patients. It's getting it out there.’ (Participant 6) 
‘The media can have a strange effect, in front of a paper would do wonders but it 
also picks up problems.’ (Participant 10) 
 
It should be noted that sub-themes belonging to the ‘external factors’ theme were often 
mentioned together. This follows from two issues: firstly, that there was a question 
specifically asking for external influencing factors to uptake and secondly, that only very 
few respondents mentioned any theme belonging to that category before that question came 
up (it was one of the last questions). While this suggests that respondents were prompted, I 
believe that there is validity to these responses nevertheless. This is because respondents did 
seem to realise that these factors had slipped their minds before, and they often highlighted 
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them as being among the most important drivers to uptake. This shows the complexity of the 
topic and the difficulty respondents had in calling to mind all the relevant factors.  
 
5.3.5 Transferability of results 
To put results into the context of other research and obtain pointers as to whether the 
present study findings are transferable, the study findings were compared with studies of 
Greenhalgh et al. (2004), the NHS barriers to implementation described in the report by the 
Department of Health (2011) and findings from a qualitative study (Barnett et al., 2011). 
Greenhalgh et al. (2004) describe nine major model components with many sub-categories 
that are the result of a synthesis of empirical and theoretical findings. As such, their model is 
much broader and it is not surprising that all the included themes from this study fit into the 
diffusion model presented by Greenhalgh et al. (2004). Apart from being more limited in 
numbers, this study’s themes differed from themes in Greenhalgh et al. (2004) in the way 
they were categorised. This is largely because a much more context-specific research 
question was used in this study. A comparison is provided in the following.  
Sub-themes of the themes ‘evidence’ and ‘product & service characteristics’ can be 
associated with the Greenhalgh model component of ‘Innovation’, more specifically the sub-
components of ‘relative advantage’ and ‘complexity’ (Greenhalgh et al., 2004). Sub-themes 
related to the ‘organisational set-up’ would mainly fall into Greenhalgh’s ‘implementation 
and routinisation’ component, such as ‘organisational structure’ and ‘intra-organisational 
communication’ although they could also be ascribed to other areas such as ‘system 
readiness for innovation’ (Greenhalgh et al., 2004). My themes of ‘external factors’ would 
fall into their ‘outer context’ (Greenhalgh et al., 2004). Many other of the Greenhalgh model 
components were not covered by the findings of this study. The following reasons for why 
not more of the Greenhalgh model components were covered came to mind. First, 
Greenhalgh et al. (2004) themselves assert that their model is not a prescriptive formula but 
rather a memory aide for considering the different aspects of diffusion. Second, every 
technology has a different set of features and will be employed in different contexts, thus 
making some of the Greenhalgh model components redundant for individual technologies.  
The present study findings can also fit with the diffusion facilitators identified by the 
Department of Health (2011). Those consisted of top-down, horizontal and bottom-up 
pressures and included guidance, skills development, incentives, peer influence, marketing, 
competition and patient demand, to name a few that predominantly match my identified 
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themes. The fact that sub-themes falling in the areas of ‘evidence’ and ‘product & service 
characteristics’ were not mentioned in the DH report, can be explained by its focus on 
existing innovations that have been shown effective but exhibit low implementation. As such, 
the DH report focused on a later stage of the product lifecycle than this study. 
The qualitative study on diffusion determinants in the NHS (Barnett et al., 2011), in 
contrast, featured ‘evidence’ as a main theme. The study by Barnett et al. (2011) also 
prominently featured ‘contextual factors’ that could be intra- or interorganisational, similar 
to the themes ‘organisational factors’ and ‘external factors’ identified in this study. The 
Barnett theme ‘people-based resources’ was alluded to in my sub-themes ‘midwives’ 
support’ and the ‘clinician’, although Barnett et al. (2011) mentioned a wider range of 
different people, including people in the local community and the senior management. These 
slight differences are owed to differing contexts of these studies. Lastly, Barnett et al.’s 
theme of ‘the role of partnerships’ was not extensively covered in this study. The sub-theme 
‘peer pressure’ in this study touches upon this but other than that, partnerships were not 
viewed as vital by the participants in this study. It is difficult to assess whether this 
disagreement is owed to the context, the participants or the methods used in this study.   
As was expected, study findings overlapped to a certain extent but not fully, due to 
different study contexts and potentially the methods of eliciting the relevant factors and the 
choice of participants. Despite this, I believe that study results captured well the potential 
barriers and facilitators to uptake of this particular technology and purpose and at this point 
in time. There are three arguments to back this up. First, the sampling frame which included 
interviewees from different hospital types and from different professions has been vital to 
covering different experiences. Second, the semi-structured topic guide was flexible enough 
to allow themes to emerge but pointed respondents in directions of where to search for 
possible factors when they did not come to mind easily. Third, framework analysis then 
ensured that all the themes were identified and categorised in a transparent manner.  
However, there are three restrictions to the transferability of results: 
1. Some of the uptake factors are certainly transferable to other technologies, but with 
the caveat that a technology-specific study such as this one cannot be a reliable source for 
informing diffusion determinants in other technologies. For example, it seems intuitive that 
there has to be strong evidence for any type of health technology, while other themes such as 
the easy to use design may be less applicable to other technologies. Also, the strength of a 
qualitative analysis such as this one is the detail it provides. While strength of evidence will 
be a factor for most health technologies, this study has provided a detailed description of 
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what evidence should look like; including potential endpoints and other features of study 
design that may not be transferable to other settings.  
2. The results may not be fully applicable for the same technology with a different 
purpose. A similar technology to this one already exists for cervical cancer screening. Again, 
the study results presented here may partly be transferable to that setting but it seems safe to 
assume that other factors would play a role as well.  
3. This study captures a snap-shot of the relevant uptake factors for EIS. Performing the 
same interviews at a later stage of product life, for example when EIS has already been 
available for a few years and the evidence base is greater, may bring up different factors. 
This is for three reasons: a) the setting in which the technology is employed may genuinely 
change, that is there may be new evidence, competitors, tariffs, budgets or guidance, 
amongst others. b) Some of the themes might not come to the minds of respondents anymore 
if they think that they are fulfilled; for example, they may deem the evidence base sufficient. 
c) The product itself may have changed and may, for example, have become more effective, 
cheaper or easier to use. Hence, even though the interviews covered all the factors that may 
be relevant at any point in time, they were based on current knowledge.  
 
5.3.6 Triangulation 
Triangulation with the results from the elicitation study revealed that the qualitative 
study had uncovered most of the relevant factors to uptake. Sub-themes belonging to all four 
themes were mentioned by experts in the elicitation study, with 12 out of 15 sub-themes 
mentioned. Unsurprisingly, the most important uptake factors identified from the interviews 
came up in the elicitation but there were also two new aspects that had not been mentioned 
before. One of these aspects was that respondents felt that the process of making a business 
case takes a long time which would delay the uptake of EIS, albeit not change its absolute 
size. This came up in the elicitation study because there was a specific question about 
timings of uptake which was not the case in the interviews. The other aspect was the size of 
the hospital or of the obstetrics unit that may have something to do with whether EIS would 
be adopted or not. This may mainly be related to the budget of such smaller units as well as 
the facilitation of the service (for instance, an arrangement could be made that high risk 
women could be treated in larger units only). At present, the way the service would be 
facilitated is unknown, but the finding is still relevant when estimating the total number of 
units that may adopt EIS. 
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5.3.7 Generation of evidence identified as effective implementation strategy 
Examining answers to the interview question about those factors that would have the 
greatest impact on uptake and the language that respondents used throughout the interviews, 
narrowed the pool of most effective uptake determinants down to ten factors, described in 
the following. All interviewees stated that generation of further evidence was one of the 
factors with the greatest impact. While some interviewees viewed evidence on the predictive 
ability of EIS as most important, others emphasised the relative treatment effect of 
progesterone compared with no treatment. The use of language confirmed the perceived 
importance of strong research evidence to diffusion throughout the interviews: evidence on 
the predictive ability of EIS and on the progesterone treatment effect were both mentioned 
by most respondents in phrases that contained words such as ‘crucial’, ‘the main thing’ and 
‘the biggest thing’.  
Other factors mentioned in response to this question mainly fell into the ‘costs’ and the 
‘easy to use design’ sub-themes, with five respondents each mentioning these. ‘Financial 
impact’ and ‘peer influence’ were mentioned by four and two respondents, respectively, and 
‘clinicians’ and ‘patient acceptability’ and the ‘applicability to the wider population of 
pregnant women’ were each mentioned once. Some of these were also associated with the 
use of superlatives. Especially participant 10 emphasised the importance of several different 
factors by using phrases such as ‘the greatest factor’ referring to an ‘easy to use design’; 
‘the biggest thing’ referring to ‘evidence and the cost benefit’ and ‘the greatest rise in 
uptake’ being caused by ‘peer influence’. Unsurprisingly, participant 10 mentioned evidence, 
cost-benefit and ease of use as the most important uptake factors.  
Factors that were not mentioned in response to the final question but came up as very 
important throughout the interviews were the ‘clinician’s awareness’, that could ‘influence 
its use in practice more than anything else’ (Participant 5) and ‘guidance’, for instance by 
NICE, that was described as the ‘essential factor for the diffusion of a device’ (Participant 3).  
These ten factors fell into the seven sub-themes of ‘easy to use design’, ‘evidence on 
predictive ability’, ‘evidence on progesterone treatment effect’, ‘costs’, ‘guidance’, 
‘practicalities’ and ‘clinician’. As I could not assess the value of all of these through 
elicitation due to time constraints, I had to make a final choice on the implementation 
strategies to evaluate in Chapter 6. For this, I based the decision on the relevance that these 
factors had at an early stage of product life. I developed a diagram that shows at which 
points of the product lifecycle, as presented by Kotler and Keller (2012), the potential 
implementation strategies would have the greatest effect (Figure 5.6). For this, I placed the 
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sub-themes identified above along the lifecycle arrow where I thought them to be the most 
effective. The limitation of this diagram is that the lifecycle stages are arbitrary in their 
shape and their duration, a common criticism of product lifecycle diagrams (Kotler and 
Keller, 2012). It follows that the placement of the uptake factors along the lifecycle stages is 
also arbitrary. However, the diagram illustrates what uptake factors may be targeted first in 
order to increase implementation of EIS throughout its lifecycle. 
According to the interviewees, evidence on the predictive ability of EIS and the 
progesterone treatment effect would have to be right first. Unless the evidence was right and 
of high quality, other factors such as guidance or the ease of use would not significantly 
influence uptake and I therefore thought that getting the evidence right has to be made a 
priority in the early stages of life; that is, pre-introduction up to shortly after introduction. Of 
course evidence that emerges later on will still have an impact on uptake. At the same time 
as developing the evidence, the technology developer can adapt the design of EIS to make it 
more user-friendly and thus influence uptake. Again, the technology can be developed 
further at any stage of its life, but any actions would likely be more effective if they were 
taken before technology introduction. Costs can also influence uptake throughout the 
product lifecycle. Guidance and activities to address practical issues within the organisation 
will be developed most likely after technology introduction in the growth phase of EIS, as 
they are contingent on evidence being available and the product development to be more or 
less concluded. The clinician’s awareness and motivation would also most likely be 
addressed during the growth phase of a technology. 
I conclude that predictive ability of EIS and the effect of subsequent treatment are the 
most important factors to uptake at this stage of product development for the following 
reasons: 1. they were named as the most important factors in the final question. 2. Analysis 
of the language used in the interviews showed that they were considered most important. 3. 
Development of a strong evidence base precedes many other activities targeting the wide 
implementation of EIS. 
Research evidence has the potential to affect diffusion in two ways: through reduction in 
uncertainty and through the produced study results. If a subsequent study showed that the 
predictive ability was worse than the current estimate, this would presumably result in lower 
uptake. Both effects should ideally be examined in subsequent studies. In the remainder of 
this thesis I focus on the reduction of uncertainty. I will also illustrate both effects, of 
reduction in uncertainty and study results, on diffusion and subsequent EVII analysis in a 
stylised example.
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Figure 5.6 EIS lifecycle and possible relevance of implementation strategies 
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5.4 Discussion 
5.4.1 Findings 
In this chapter, I have provided an overview of relevant uptake factors for EIS and 
identified potentially effective implementation strategies at this stage of product 
development which were: research evidence on a) the predictive ability of EIS and b) 
treatment effect of progesterone compared with no treatment when EIS screening was 
performed. These findings are useful to product and study developers and policy-makers 
alike. The most important uptake factors are also relevant to health economists who may 
want to take the opportunity of assessing the value of implementation measures in expected 
value of implementation analyses.  
 
5.4.2 Relevance 
Although it is in the nature of a qualitative study to be context-specific instead of 
generalisable, these results highlight the potential importance of high quality research 
evidence to the adoption process, especially at an early stage of product development. This 
has implications for expected value of information analyses in which the assumption of 
independence of implementation and information was typically made (Fenwick et al., 2008). 
This assumption may still be satisfied if the evidence base is mature enough to not affect 
uptake anymore. This, however, raises the question of why EVI analysis should be 
performed in such a case: surely, the motivation of conducting further research is to 
ultimately affect implementation, whether in the shape of increasing implementation or 
encouraging the use of alternatives. 
This study also adds further insight into the recent investigations on adoption barriers in 
the NHS. Whilst some of the identified themes matched the barriers and facilitators to 
adoption identified by the Department of Health (2011), it became clear that that report 
focused on a later stage of the product lifecycle and that our study adds some insight into 
uptake factors at an earlier stage, albeit with limited generalisability. 
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5.4.3 Strengths, limitations and further research 
Qualitative methods appeared useful in identifying technology-specific uptake factors as 
they provide the freedom required to explore certain areas and the depth needed for 
exploring the detail. Strengths lay in the ability of eliciting the respondents’ thoughts, 
associations and justifications without limiting them in their responses. Although difficulty 
in calling some factors to mind were observed, interviewees mentioned a broad range of 
different factors and theoretical saturation was achieved relatively fast, with all themes and 
sub-themes having emerged at the sixth interview.  
It was not possible to identify the uptake determinant that can be translated into the most 
effective implementation strategies from the qualitative findings. A quantitative assessment 
of the effectiveness and costs associated with the different strategies is necessary for this. 
But with the aim being to select potentially effective implementation strategies for that 
quantitative assessment, I had to rely on some selection criteria that used the respondents’ 
opinions and language as well as the lifecycle stage the technology was at.  
Alternatives to these selection criteria would be performing a focus group to achieve 
consensus on the most effective implementation strategies or a survey in which all the 
different uptake factors could be rated in terms of their potential impact. I opted against a 
focus group or a survey because I thought that the gain in knowledge would have been 
minimal. This is because the potential impact of uptake determinants is context-dependent; 
for instance, it is dependent on the lifecycle stage that the technology is at. Furthermore, it 
would not have contributed anything to the purpose of this study, as the ‘wrong’ choice of 
uptake determinant would not impair the quality of the elicitation study, just yield the effect 
of a strategy that may not be the most effective. But even a focus group or a survey would 
not necessarily have given me the most effective, let alone, the most cost-effective 
implementation strategy, as a quantitative assessment of the potential effectiveness and costs 
of the implementation strategies would be needed for that.  
Framework appeared to be an effective way of analysing and illustrating the data. It 
helped with getting an overview as well as a deep understanding of the themes and sub-
themes. The subsequent analysis of effective uptake factors according to the respondents’ 
statements and use of language helped identify potentially effective implementation 
strategies. Being a qualitative study, there is a certain degree of subjectivity in the data 
analysis. I did my utmost to work in a transparent way and document every step of the 
analysis in order to avoid my own potential bias to enter the analysis. 
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There is a possibility that not all factors relevant to uptake have been covered given that 
the sample size was relatively small and that the sampling frame was limited to two trusts. 
One respondent in the elicitation study expressed the view that some smaller units may be 
less likely to adopt innovation and although both University Teaching Hospital and District 
General Hospital types were covered, the included trusts were both large ones. However, the 
benefit of performing further interviews at different hospitals was considered to be relatively 
small compared to the time and effort required. This is because it was not particularly likely 
that smaller trusts would be driven by different factors. Instead it could be expected that 
some of the included factors would have a stronger influence on smaller units. Also, 
assuming that other themes did emerge, it is unlikely that these would change the overall 
result of this study. To verify this it would, however, be interesting to focus on smaller trusts 
in another study. The inclusion of more business managers may also be worthwhile to reflect 
their experience in different trusts.  
A limitation was noted with the interview guide: when asking the question on external 
factors influencing uptake most respondents did not understand the relevance of this 
question and asked for more explanation. In an attempt to explain, the example of guidance 
or policies was provided. This type of leading question could prove problematic and 
therefore interviewees’ responses were carefully examined. The result of this showed that 
respondents were genuinely convinced that guidance would play a major role and for most 
participants, other external factors then came to mind as well, such as the influence of media. 
In future studies, it would be worthwhile thinking about a better way of explaining external 
factors that avoids prompting, such as the description of influences that come from outside 
the local organisation, for example from authorities, other stakeholders and even other 
jurisdictions.  
Scope for further research lies in quantifying the effect of the identified factors on uptake 
through elicitation of expert opinion. 
 
5.4.4 Conclusion  
In conclusion, qualitative interviews with framework analysis and the use of selection 
criteria can help identify those factors that influence uptake of individual health technologies 
and that may be targets of effective implementation strategies that can subsequently be 
evaluated in the context of economic evaluation. 
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CHAPTER 6. PREDICTING DIFFUSION OF ELECTRICAL 
IMPEDANCE SPECTROSCOPY 
6.1 Introduction 
One objective of this thesis was to identify a prediction method for diffusion that (a) 
could be used prior to technology introduction; (b) is relevant to the health technology 
context; and (c) yields probabilistic diffusion estimates. Literature reviews in Chapter 3 
identified an expert judgement method based on a formal diffusion model to be the most 
appropriate method for this task in the health technology setting. In Chapter 3, I also showed 
that, so far, no such method has been described in the literature. Furthermore the Bass model 
of diffusion was identified as one such formal diffusion model, and I proposed the Satoh 
adaptation of it to address limitations associated with the Bass model.   
In Chapter 5, the most relevant factors to the uptake of EIS were identified. When 
examining these factors for their ability to be turned into implementation strategies, I found 
that two different research studies, one on the predictive ability of EIS and one on the 
treatment effect of progesterone treatment after EIS screening, were important 
implementation strategies at this stage of technology life. In order to evaluate further 
research as an implementation strategy, counterfactual estimates of diffusion with and 
without the effect of further research are needed.   
In this chapter, I wish to develop an elicitation of expert beliefs method that uses the 
Bass model of new product growth and the Satoh application of it, and to apply this method 
in the EIS for PTB screening case study. I predict natural diffusion and its uncertainty, as 
well as the effect of further research, in terms of its reduction of uncertainty, on future 
diffusion. Results of this study are used in health economic analyses that are presented in 
Chapters 7 and 8. The place of this chapter within the thesis is illustrated in Figure 1.2 in 
Chapter 1. 
This chapter is structured as follows: Section 6.2 describes the methods used to develop 
the quantities to be elicited and to perform the elicitation of experts’ beliefs exercise. In 
Section 6.3, I present the results of the elicitation study, including the individual and pooled 
estimates of diffusion and a comparison of the Satoh and the classic Bass model approaches 
in producing usable and realistic diffusion curves, as well as a reflection on the exercise. I 
conclude with a discussion and conclusion in Section 6.6. 
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6.2 Methods 
6.2.1 Elicitation of expert beliefs 
Elicitation is a widely-used method to obtain quantitative expert judgements reflecting 
uncertainty (O'Hagan et al., 2006). It describes ‘the process of capturing expert knowledge 
about one or more uncertain quantities in the form of a probability distribution’ (O'Hagan 
and Oakley, 2010). Elicitation of expert opinions is inherently a Bayesian approach: it is 
often used where there are no frequentist observations about a research question of interest. 
Although elicited evidence is viewed as having the potential to inform health economic 
analyses whilst realistically representing uncertainty (Stevens and O'Hagan, 2002), its use in 
health technology assessment (HTA) is not yet widespread. However, its use appears to be 
on the increase (Sullivan and Payne, 2011, Soares et al., 2011, Leal et al., 2007). 
 
6.2.2 What to elicit: re-parameterising the Bass model of diffusion  
In this section, I discuss different options and considerations for eliciting information to 
populate the Bass model. I noted in Chapter 3 that it is generally perceived as difficult to 
invert observable quantities into Bass model parameters. Observable quantities that can be 
elicited from experts need to fulfil certain criteria in order to minimise bias: for instance, it is 
important that the summaries chosen for elicitation can be grasped intuitively (O'Hagan et al., 
2006, Johnson et al., 2010). Care should also be taken not to confuse experts by eliciting too 
many different types of summaries, for example, eliciting a mix of absolute numbers, 
proportions and odds ratios (Soares et al., 2011).  
Whilst one of the advantages of the Bass model over other models of diffusion was its 
behavioural parameterisation where parameters had an intuitive purpose, this does not 
necessarily mean that these parameters are straightforward to elicit. The Bass model requires 
knowledge of three parameters: 1. the maximum number of adoptions that can be achieved 
for EIS based on the current state of evidence, in the following called m. 2. The so-called 
coefficient of external influence, or the growth in uptake that occurs without any peer 
influence taking place, p. 3. The coefficient of internal influence, which reflects peer 
influence in the speed of adoption, q. I deemed quantity m to be straightforward as I 
expected experts to have beliefs about it. Elicitation of parameters p and q, however, would 
not be straightforward given that there is no easy way of quantifying peer influence or 
external pressures. I therefore thought these to be infeasible to elicit directly.  
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Instead, I developed an approach to inverting observable quantities to yield the 
parameters p and q. Two observable quantities were chosen to achieve that: (a) the point of 
inflection of the s-shaped curve 𝑡′, i.e. the number of years at which the number of adoptions 
would start to decline, and (b) the initial number of adoptions in the first year after the 
technology was launched 𝑁1. To invert these quantities to yield parameters p and q, I used 
an approximation method that entailed minimising the sum of squared error term. The 
squared error terms referred to the distance between the tested diffusion curve and N1, t’ and 
m, respectively. The tested diffusion curves were obtained by using random parameter 
values for m, p and q to begin with. The curves were generated using two different versions 
of the Bass model, which I call the classic Bass model and the Satoh approach in the 
following. The classic approach was simply using the classic Bass model as presented in 
Chapter 4.4.1 to estimate per period adoptions. The Satoh approach used equations shown in 
Chapter 4.4.2 to estimate per period adoptions. It is worth noting that the classic approach 
required separate estimation of the number of adoptions for the first period using Equation 
(4.22) in Chapter 4. The Satoh approach avoided estimating first period purchases separately.  
The approximation method by minimisation of sum of squared error terms, given m, N1 
and t’ was performed in Excel Solver. This entailed calculating the error terms between the 
elicited information and the Solver trial run diffusion curve for the three elicited quantities, 
and minimising the sum of the squared error terms. Within Solver, constraints were put on 
the parameters p and q as Excel was overwhelmed with the number of possible solutions. 
The constraints were set as follows: 0.000001 < 𝑝 < 0.2 and 0.000001 < 𝑞 < 2.5. These 
ranges were chosen such that they included parameter value ranges used in another study by 
Meade and Islam (2006) that were presented in Chapter 4. Ranges of likely parameter values 
of 0.00005 < 𝑝 < 0.1 and 0.01 < 𝑞 < 0.99 were reported in that study (Meade and Islam, 
2006). While originally narrower ranges were chosen, they were widened to avoid truncating 
frequency plots when using the classic method. For both, the Satoh and the classic 
approaches, a number of 1,000 iterations of the solver algorithm was performed to obtain 
values for parameters p and q, by sampling from the distributions of the elicited parameters.  
Other ways of inverting the obtained summaries were tried but did not yield better 
results. Initially, I tried to invert quantities algebraically, which would have been the exact 
and preferred way of obtaining the Bass model parameters. I attempted to obtain algebraic 
solutions for the above inversion problem using Bass model equations provided by Mahajan 
and Sharma (1986) and Sultan et al. (1990). These were presented in Chapter 4, Equations 
(4.23) and (4.22), respectively. 
Solving both equations for p yielded, respectively: 
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 𝑝 ∗ 𝑒𝑝∗𝑡
′
=
𝑞
𝑒𝑞∗𝑡
′ (6.1)  
 
𝑝 ∗ 𝑒𝑝 =
1
𝑒𝑞 ∗
(𝑞𝑁1 +
1
𝑞
)
𝑚 − 𝑁1
 
(6.2)  
Equations (6.1) and (6.2) do not have an algebraic solution. There may be other possible 
solutions but I did not find any more approaches of obtaining the Bass model parameters 
from observable quantities through algebraic calculations. While superior to an estimation 
approach in terms of its precision, an algebraic solution hence proved infeasible.  
Another estimation approach using approximation was offered by Mahajan and Sharma 
(1986) who worked out p and q values using the following quantities: per period number of 
purchases at peak (n’) and cumulative number of purchases at peak (N’). For the Mahajan 
and Sharma (1986) approach to work, the cumulative number of purchases at peak was 
required to be smaller than 
1
2
𝑚 (half of total attainable adoptions), that is, 𝑁′ <
1
2
𝑚. This 
would result in diffusion curves that can only be asymmetrical in one way. There was no 
evidence to support this assumption, and I therefore discarded this option.  
 
6.2.3 Elicited quantities 
In summary, I chose three quantities that best informed the Bass model of diffusion 
based on current knowledge, and that matched the criteria of summaries suitable for 
elicitation. These quantities were: the maximum number of attainable adoptions (m), the 
number of years at which the number of adoptions would start to decline (t’) and the number 
of adoptions within the first year of technology launch (N1). These were elicited twice: 1. for 
the counterfactual scenario on which the currently undergoing trial would produce similar 
results for the predictive ability as were obtained from the pilot study; 2. given that two 
additional studies were performed, one on the predictive ability of EIS and the other on the 
relative treatment effect of progesterone versus no treatment after screening with EIS.  
Of further interest was the extent to which the different research studies would 
contribute to the increase in uptake. One way of eliciting this information would have been 
to elicit the three summaries that inform the Bass model another two times, for each of the 
two research studies separately. With the time constraints imposed by participants, this was 
not feasible. I instead elicited the proportion of the increase in diffusion with both research 
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studies that was contributed by the progesterone treatment effect trial, assuming 
independence of the effects of both trials on diffusion.  
As was mentioned in Chapter 1, another aspect to uptake that is not covered in this thesis 
is the extent to which a new technology is used once it is purchased. To obtain an idea of 
this utilisation in practice, I also elicited the proportion of patients being offered EIS once it 
is available at a hospital. The developers of EIS are currently studying the patient 
acceptability of EIS within the ongoing trial and I therefore did not deem it necessary to 
elicit this last aspect to technology uptake. 
Below is a summary of all elicited quantities: 
 the potential number of attainable adoptions (elicited twice, once given baseline 
evidence and once more given that both research studies have concluded) (m). 
 the initial number of adoptions in the first year within product launch (elicited twice, 
once given baseline evidence and one more time given that both research studies 
have concluded) (N1). 
 the number of years after which the number of adoptions starts to decline (elicited 
twice, once given baseline evidence and one more time given that both research 
studies have concluded) (t’).  
 the proportion of the increase in diffusion with both research studies that was 
contributed by the progesterone trial (compared with the study on the predictive 
ability of EIS) (κ).  
 the proportion of patients being offered EIS once it is available at a hospital (π).  
 
6.2.4 Individual elicitation meetings using SHELF 
When a number of experts are invited for an elicitation exercise, there are two options of 
synthesising the elicited evidence. One option is to hold a group session and try to reach 
consensus within the meeting, a process that is called behavioural aggregation (O'Hagan et 
al., 2006) and has received increased attention (Sullivan and Payne, 2011). The other option 
includes individual elicitation sessions, followed by a type of mathematical aggregation of 
opinions. It is important to note that behavioural aggregation, that is finding consensus 
among experts, and mathematical aggregation methods can lead to different results (Soares 
et al., 2011). Advantages of a group session include the opportunity of letting experts reach a 
consensus, rather than choosing a method of synthesising their probability distributions 
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(O'Hagan et al., 2006). A drawback of the behavioural method is that it tends to produce 
over-confident judgements (Soares et al., 2011).  
Without a consensus on the preferred method of aggregation, I conducted individual 
elicitation sessions which required mathematical aggregation of expert opinions. One reason 
for this choice was that it proved impossible to congregate experts at one place at the same 
time due to the participants’ availability. Another reason was that a group session required 
not only individual elicitation exercises but also finding a consensus through additional 
elicitation sessions after discussion, all of which would have caused the group session to be 
significantly longer than each individual session. To maintain a group session within a 
reasonable time that participants were agreeable to (two hours), this would have required 
cutting down the number of quantities to elicit.  
Previously, there were complaints about the lack of tools that facilitate elicitation 
methods (Leal et al., 2007). This research gap has now been addressed and there is a variety 
of tools and frameworks that can readily be used for elicitation of experts’ beliefs (Leal et al., 
2007, O'Hagan and Oakley, 2010). It was previously found that the use of a standardised 
script can help in establishing questions clearly (Johnson et al., 2010). I used the Sheffield 
Elicitation Framework (SHELF) in this elicitation study. SHELF is a formal procedure for 
elicitation of expert opinions (O'Hagan and Oakley, 2010), in particular focusing on group 
elicitation and finding consensus between experts. The decision to perform individual 
meetings rather than group meetings was made when some of the preparation was underway 
and therefore SHELF was kept as the package of choice. SHELF is a very straightforward 
package to use and although its greatest advantage lies in group elicitation, it performs well 
in individual elicitation and adds value through standardised guidance, processes and tools. 
SHELF provides tools that guide the facilitator through the process drawing on the insights 
of O'Hagan et al. (2006) but also on more recent practical experience (O'Hagan and Oakley, 
2010). Elicitation is conducted in an open and well-structured way, which is regarded as 
being in accordance with best practice in the field (O'Hagan and Oakley, 2010). Supporting 
documents are provided, such as a pre-session pro forma, briefing and elicitation records and 
a bespoke R software package.  
 
6.2.5 Population and sample 
The population of interest were experts in the field of obstetric technologies. With this 
definition, it was mainly consultants in obstetrics that were included in the sampling frame, 
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although there was a chance that business managers might contribute another perspective on 
the issue of technology uptake. In the qualitative study in Chapter 5, I found that the key 
people in the decision-making process for the adoption of new health technologies in 
obstetrics were consultants, making them the primary population of focus. 
The problem of overconfidence can be avoided by having a sample size greater than one 
(Johnson et al., 2010). A good sample size for an elicitation exercise is said to be no more 
than five experts, with three experts being sufficient as long as they are chosen based on 
their expertise (O'Hagan and Oakley, 2010). Table 6.1 summarises the professional 
categories that should be invited as well as the numbers to be included. 
 
Table 6.1 Elicitation sample frame 
Category to be included Number of individuals 
Obstetricians (UTH) At least 1 
Obstetricians (DGH) At least 1 
Business manager (UTH or DGH) 0-1 
Sum At least 2 
 
I contacted participants in the qualitative study who had expressed their agreement with 
being contacted for a follow-up study through the informed consent form. Three experts 
(two obstetricians from the UTH and one from the DGH) agreed to participate. Their 
availability was assessed via email communication as there was reluctance to use a doodle 
poll. When it turned out that a group meeting was not possible, places and times were 
booked for each individual expert. All meetings were held at the participants’ work places to 
ensure convenience.  
To make sure that the sample of experts represented knowledge of technology uptake in 
obstetrics, experts were chosen based on the following characteristics that experts for an 
elicitation study should demonstrate, developed by O’Hagan et al. (2006):  
 Tangible level of expertise: participants were selected if they had professional 
training and experience as an obstetrician and had experience in PTB screening. 
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Additionally, business managers of obstetric units were also considered for their 
experience with the purchasing of new equipment. 
 Understanding of the general problem area: experts should have an interest in and an 
understanding of the problem of uptake of health technologies in obstetrics and the 
factors that could influence it. I made sure this was the case by approaching 
participants in the qualitative study who had expressed their interest in participating 
in a follow-up study on this topic.  
 Reputation: experts should all be recognised as professionals in their area and should 
be deserving of other experts’ respect. I assumed that this was a given, with all 
experts having been medically trained and none of them being a junior member of 
staff. Whether they had published in the area of preterm birth was not seen as 
important as this study was not of strictly medical nature.  
 Lack of an economic or personal stake in research findings: if experts did have a 
stake in the findings of this research this would have to be laid open. Participants 
from the Sheffield Teaching Hospital could be suspected of having a stake in the 
study outcome as EIS was developed at their hospital. However, none of the invited 
consultants were directly involved with its development, or research surrounding it. 
Experts were also asked to highlight any stake or personal bias in the pre-elicitation 
pro forma and the issue was discussed at the introductory part of the elicitation. If 
potential biases had been identified, experts would have been encouraged to view 
the problem from different point of views or take other experiences into account. 
However, no biases were identified in any of the participants.  
 All available expertise should be covered: the available expertise in this study 
related to professional categories and hospital type. Consultants of obstetrics were 
seen as the most relevant group with the ability to assess future uptake. I thought 
that different hospital types may influence the likelihood of new technology uptake 
and therefore made sure to have both, University Teaching Hospitals and District 
General Hospitals, represented by a consultant.  
A pilot was conducted with one volunteer clinician. Garthwaite et al. (2005) flagged up 
the usefulness of a test run to obtain practice with the protocol. The pilot turned out to be 
helpful in practising the exercise because it featured a considerable number of quantities to 
be elicited and required a large amount of background information to be provided. The pilot 
also ensured effectiveness of the questions asked, gave me confidence with using the 
software and helped in assessing the time that the meetings would take to ensure that 
participants were adequately informed. The pilot was undertaken in November 2013 and 
three experts were interviewed in individual meetings between November 2013 and January 
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2014. Two weeks separated the pilot and the first meeting in order to ensure that all potential 
problems could be addressed. The elicitation meetings took between one and a half and two 
hours. 
 
6.2.6 Ethical considerations 
As with the qualitative study, the elicitation study had obtained ethics approval by the 
University of Sheffield Research Ethics Committee (UREC), as well as NHS R&D 
governance by the Sheffield Teaching Hospitals NHS Foundation Trust, the Rotherham 
NHS Foundation Trust and Barnsley Hospital NHS Foundation Trust. Confidentiality and 
anonymity were guaranteed. Written informed consent was obtained from all study 
participants after questions were addressed. The information sheet, informed consent form 
and elicitation briefing notes can be found in the appendix (Appendices D.1, D.5 and D.2, 
respectively). All information was sent well in advance of the meetings, at the recruitment 
stage. 
 
6.2.7 Elicitation study design 
The goal of an elicitation is to accurately represent an expert’s knowledge (Garthwaite et 
al., 2005). As with all other research, transparency in every step of the research is important 
and can contribute to minimisation of bias in elicitation of expert opinions. There are 
recommended steps and proceedings provided by SHELF (O'Hagan and Oakley, 2010), 
which are informed by O’Hagan et al. (2006) that help ensure transparency and rigor in 
performing and reporting elicitation exercises. These have been adopted and adapted to the 
present study and their application in this elicitation exercise is described below. 
 
 Preparation 6.2.7.1
It is important that participants know what to expect and are prepared for the tasks 
required of them in the elicitation meeting. Preliminary briefing materials were thus sent in 
advance of the meetings. These included three documents (see Appendix D): 1. an 
information sheet detailing the purpose of the study, expectations of participants and ethical 
questions, amongst others (Appendix D.1); 2. the pre-session briefing notes which are a 
general description of elicitation exercises and are provided by SHELF (O'Hagan and 
Oakley, 2010) (Appendix D.2); and 3. the pre-session pro forma, also provided by SHELF 
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(O'Hagan and Oakley, 2010), that has the purpose of asking participants about the scope of 
their expertise and any potential conflicts of interest (Appendix D.3). Participants were 
asked to fill in the pre-session pro forma ahead of the meeting and return it to me. In the 
event of it not being returned, the form was filled in at the meeting itself. A fourth document 
was sent closer to the meeting: the background information sheet (Appendix D.4). It is 
described in more detail in the section on structuring below. At each meeting, participants 
were again provided with the information sheet and given time to read through it and raise 
and have answered any questions. They were then asked to give their consent to participate 
via the elicitation consent form (Appendix D.5).  
 
 Training 6.2.7.2
Training was provided to all participants to familiarise them with the use of probability 
distributions and improve the normative goodness of their estimates (Johnson et al., 2010). 
The training exercise was conducted at the start of each individual session and one quantity 
was elicited. Training quantities are typically quantities that can in principle be known (and 
are known by the facilitator) but are not likely to be known exactly by the experts. O'Hagan 
and Oakley (2010) recommended the use of a quantity that lay in the domain of the expert. I 
thus chose the number of pregnant women with a preterm delivery in England. This quantity 
was deliberately elicited in absolute terms, given that most of the quantities of interest were 
absolute numbers. Experts were then shown their calibration, that is the match of their 
estimates with the real data, and given feedback on their performance.  
Offering training also provides an opportunity to discuss common heuristics, that is, 
strategies used for problem-solving that may induce bias. Such heuristics may be used by 
experts to assess probabilities. Hogarth (1987) as cited in Garthwaite et al. (2005) provided a 
more comprehensive overview of heuristics and biases and the more commonly used 
heuristics were described by O'Hagan et al. (2006), and are briefly summarised in Table 6.2. 
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Table 6.2 Commonly used heuristics 
Availability heuristic Describes how easily instances come to mind, a typical error 
being the over-estimation of probabilities of events that have, 
for instance, been covered in the news 
Representativeness heuristic Refers to the similarity between instances and expectations of 
those, common errors being: 
 1. Conjunction fallacy: where people tend to think that P(A)  <
 𝑃(𝐴 ∩ B). To give an example, people may think that the 
probability that someone is a smoker and delivers their baby 
prematurely is higher than the probability that someone delivers 
their baby prematurely. 
 2. Base-rate (neglect) effect: ignoring the a priori probability of 
an event. For instance, when someone over-estimates the 
probability of a patient delivering their baby prematurely 
because of the patient being a smoker and ignore the a priori 
likelihood of preterm delivery. 
 3. Small sample size inferences, also called hasty generalisation. 
 4. Confusion of the inverse: 𝑃(𝐴|𝐵) ≠ 𝑃(𝐵|𝐴). A popular 
example is that of there being a high probability that hard drug 
users also use marijuana. That does not lead to the conclusion 
that there is the same high probability that marijuana users also 
use hard drugs. 
 5. Insufficiently regressive predictions: people may change their 
predictions of an event based on new knowledge available but 
disregarding other factors that influence that event as well, thus 
over-estimating the change in the event. 
Anchor-and-adjustment 
heuristic 
Describes anchoring a decision at an initial starting value and 
just make small adjustments, with common errors including 
 1. Insufficient adjusting 
 2. Pruning effect: where having a certain number of categories 
implies an anchor at 
1
# 𝑐𝑎𝑡𝑒𝑔𝑜𝑟𝑖𝑒𝑠
 per category. 
Affect heuristic Describes when judgement is influenced by one’s mood or risk 
adversity. For example, high risk procedures may be judged as 
being less beneficial than low risk ones. 
 
134 
 
The use of these heuristics can lead to the introduction of bias in the elicited probability 
distributions. One way of avoiding the use of heuristics is making the experts aware of them. 
For a lack of time, not all of these heuristics could be explained and discussed but I was 
aware of them and tried to avoid their use by probing for rationales at the elicitation of every 
quantity. One of these heuristics seemed particularly likely to affect this exercise: 
insufficiently regressive predictions in the elicitation of the effect an implementation 
strategy would have on the participants’ uptake estimates. Participants may have been 
susceptible to focus on the effect of the implementation strategy and ascribe too big an 
impact to it by disregarding other factors at play. Participants were thus asked not to 
disregard all the other factors affecting uptake that they had identified previously when 
making their judgements.  
 
 Structuring: providing relevant background information 6.2.7.3
Relevant information and knowledge were brought to mind at this stage. The 
background information document (Appendix D.4) was thus presented to the participants 
and any questions they might have clarified. Background information included presentation 
of the evidence on the predictive ability of EIS obtained from the pilot, evidence on the 
progesterone treatment effect, a description of the device, an assumption that capital and 
disposable costs would not be prohibitively expensive and a plausible range of number of 
devices needed per hospital.  
It is worth noting that the uncertainty the experts described could be of aleatory nature, 
that is, it could be caused by inherent variabilities or randomness in the system, or it could 
be epistemic, that is, due to imperfect knowledge and can therefore be eliminated by 
specifying more conditions (O'Hagan and Oakley, 2004). Uncertainty in this context is more 
likely to be of epistemic nature: if the state of more independent variables were known, 
experts would likely be able to give a more accurate estimate of the probabilities they were 
asked for. Providing the background information described in this section was one way of 
specifying conditions that reduced this epistemic uncertainty. One of these specified 
conditions was that study results would be similar to existing evidence. This was to capture 
the effects a reduction in uncertainty rather than the effects of different study results but the 
caveat is that possible difference in study results are not explicitly considered in the 
diffusion estimates.   
To cover background on EIS and its evidence, I presented positive and negative 
predictive values and likelihood ratios that were available at that point in time, and the size 
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of the study that was being conducted at that point. Participants were asked to assume that 
the study currently underway would find similar results to the ones that were available from 
the pilot study while taking uncertainty about the mean estimates into account. The findings 
from the qualitative study were also briefly discussed, with a focus on further research 
influencing the diffusion of EIS. In accordance with the qualitative study findings, further 
research was broken down into evidence on the predictive ability of EIS and the relative 
treatment effect of progesterone compared to no treatment after using EIS screening. It was 
then agreed that both research studies would have a similar study design and sample size to 
existing or ongoing research studies that were cited in the background information sheet 
(Appendix D.4). Participants were informed of effectiveness estimates for progesterone 
when administered after testing positive with cervical length scans, bearing in mind that 
these estimates may differ after screening with EIS. 
As the price of the technology was not known at the time, it was assumed not to be 
prohibitively high but participants were asked to keep some uncertainty regarding that in 
mind, too. Information was provided on the number of obstetric units in England and the 
mean and range of their sizes in terms of patient numbers in order to enable experts to make 
judgements on the number of devices that could be purchased at maximum. 
Furthermore, evidence for the general shape of diffusion curves was presented in order 
to show respondents possible outputs of this study. Diffusion curves informed by a meta-
analysis as well as data for two other technologies were shown. These different diffusion 
curves were deliberately chosen to illustrate differences in the speed of diffusion. The main 
benefit in presenting these curves lay in visualising the elicited quantities and their potential 
effect on diffusion curves. There may have been a possibility that showing these curves 
made respondents more prone to using an anchor-and-adjustment heuristic and they were 
therefore encouraged to avoid using the presented diffusion curves as indicative of diffusion 
of EIS. In addition to that, when it came to eliciting the relevant quantities, experts were 
encouraged to think about their own experiences in this therapeutic area as well as about the 
background information on the number of obstetric units in the country (Appendix D.4). 
 
 Structuring: the elicitation 6.2.7.4
The first task was to elicit the ‘baseline’ diffusion; that is, diffusion of EIS conditional 
on 1. the ongoing trial delivering similar results to the pilot study and 2. the relative 
progesterone treatment effect being similar after EIS screening to after cervical length scans. 
The second task was to elicit diffusion conditional on the additional two studies that were 
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identified to have an impact on uptake having concluded. The third task was to elicit the 
contribution of the progesterone study to the change in diffusion. For this, it was assumed 
that the research studies were independent in their effect on diffusion (that is, research on the 
treatment effect would have a certain effect on diffusion regardless of what other research 
was conducted, and vice versa). The last task was to elicit the extent to which EIS was likely 
to be used by individuals after it had been purchased by the trust. 
All elicited quantities (m, N1, t’) were assumed to be independent. When eliciting 
multiple quantities from one expert, some thought has to be given to possible dependence 
between responses (Soares et al., 2011). There was some indication that quantities might be 
correlated, for example the number of attainable adoptions and the number of adoptions in 
the first year, but multivariate elicitation would have significantly increased the complexity 
of the exercise (O'Hagan et al., 2006) and experts may not have been able to provide the 
level of detail needed for eliciting joint probabilities (Soares et al., 2011) or other quantities 
required to assess correlation (that are described by Daneshkhah and Oakley (2010)). 
SHELF does not recommend elicitation of multivariate problems for the same reasons 
(O'Hagan and Oakley, 2010). I therefore excluded parameter inter-dependence from this 
analysis and elicited only the marginal distributions. This was discussed with the participants. 
 
 Probability distributions 6.2.7.5
A parametric method of fitting probability distributions was chosen for this study. 
Different methods of fitting probability distributions were discussed by Garthwaite et al. 
(2005). Parametric methods impose the structure of a member of a family of distributions by 
choosing appropriate hyperparameter values that represent the expert’s opinion (Garthwaite 
et al., 2005). Non-parametric methods of fitting distributions may pose the advantage of 
avoiding restrictive assumptions and forcing the elicited probability distribution to fit a 
parametric family (Oakley and O'Hagan, 2007) but they are more complex and may not 
actually yield a considerable benefit as imprecisions often have very little effect (Garthwaite 
et al., 2005). In this study, the obtained probability distributions were presented to the 
experts for them to confirm that they were consistent with their beliefs. I was satisfied that 
any slight imprecisions were not likely to significantly affect the cost-effectiveness model 
and expected value of implementation and information analysis that these data would feed 
into because imprecisions would have a small effect on cost-effectiveness and value of 
implementation. In summary, parametric methods were chosen for three reasons: first, to 
avoid the added complexity of non-parametric fitting; second, because the benefit of 
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obtaining a slightly more accurate distribution was questionable; and third, because 
parametric distribution fitting was embedded in SHELF and the resulting distributions were 
thus readily available. The SHELF software allows choosing the best fitting distributions 
from normal, log-normal, beta, scaled beta and gamma distributions. Gamma distributions 
were deemed appropriate for all parameters except for κ and π, for which beta distributions 
were used.  
The variable interval method was chosen as opposed to the fixed interval method 
(Garthwaite et al., 2005, Oakley et al., 2010). The former refers to experts making quantile 
judgements and the latter to the expert making judgements on the probability of the 
uncertain parameter θ falling into pre-specified intervals. Fixing pre-specified intervals 
constrains results compared to variable interval methods but fixed interval methods may be 
easier to complete. Which method performs best is debated and both Oakley et al. (2010) 
and Garthwaite et al. (2005) suggest that there is no conclusive evidence.  
SHELF provides different protocols for different methods, among them variable interval 
methods such as tertile and quartile methods and a fixed interval method that is called the 
roulette or histogram method (Soares et al., 2011, Bojke et al., 2010, Oakley et al., 2010). 
The roulette or histogram method divides the range into intervals (bins) and asks experts for 
the probabilities of those intervals. This method provides the advantage of being very visual 
and potentially easier to understand than variable interval methods. However, the process of 
assigning probabilities for many intervals and each quantity could become quite repetitive. 
In terms of variable interval methods where experts are asked to shift the interval to yield a 
certain probability, tertiles have been shown to yield better calibrated probability 
distributions than quartiles (O'Hagan et al., 2006). This is potentially a result of over-
confidence presenting a greater issue with the use of quartiles than with the use of tertiles 
(Garthwaite et al., 2005). Based on the greater flexibility and avoiding repetitive tasks and 
over-confidence, I chose to elicit tertiles.  
 
 Elicitation steps 6.2.7.6
For each elicited quantity, the first step entailed asking experts to define the lower and 
upper bound such that it was extremely unlikely to impossible that the quantity to be elicited 
fell outside this range (this was specified to be close to the 0.1
st
 and 99.9
th
 percentiles). 
Experts were asked to think carefully about that range so as not to choose a range too wide 
or narrow. I then asked for the median and for the upper and lower tertiles. All of these 
values were written down in the elicitation record 2 (D.7), with experts’ rationales added 
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wherever appropriate. A distribution could then be fitted to the experts’ assessments. At this 
stage, accuracy of the assessment was improved by verifying that experts were happy with 
their elicited distribution. This was done through presenting their probability density 
function and through confirming the implied values at the 10
th
 and 90
th
 percentiles. If experts 
were unhappy with these, the distribution was changed. After adjustments, the final 
distribution was recorded.  
All these steps were undertaken in all meetings and results were recorded in the 
elicitation record 1 and 2 forms (Appendices D.6 and D.7), provided by SHELF (O'Hagan 
and Oakley, 2010). The elicitation record 1 was filled in for each expert and contained a 
summary of the information available on the expert as well as on the summaries elicited. 
The elicitation record 2 was filled in for each expert and all of the quantities elicited from 
them. This served the purpose of recording the experts’ beliefs as well as any qualitative 
explanations. 
To enable reflection upon the exercise, I asked all the participants for brief feedback on 
the elicitation session at the end of the meeting. Together with my own observations on the 
meetings, this feedback was recorded in a post-elicitation record (Appendix D.8) to allow 
evaluation of expert elicitation as a method of obtaining diffusion estimates in this setting.  
 
6.2.8 Data analysis 
Once the elicitation meetings were conducted, several activities were undertaken to 
analyse the data. First, a closer examination of the resulting pooled diffusion curves was of 
greatest interest. Second, individual elicitation results were examined separately. Third, 
feedback and observations on the process of this study were evaluated.   
 
 Obtaining pooled estimates 6.2.8.1
Diffusion was presented in terms of number of adoptions in each period. I thought about 
representing uptake as a proportion of all desirable adoptions, however, it was not clear at 
what number of adoptions 100% was reached. For example, if it was assumed that, to make 
sure that all high risk patients in the country are covered, every obstetric unit would have to 
have at least two devices, then the desirable number of adoptions would be at least 462. 
However, some of the obstetric units are very small and may refer high risk patients to larger 
units. Some of the very large units may need a greater number of devices to ensure that one 
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is available for all patients at all times. I therefore opted against using proportional uptake 
going forward and focused on absolute numbers in the elicitation study. It is important to 
note that participants may have used their own assumptions on how many adoptions were 
desirable when providing their estimates on elicited quantities. 
Participants’ opinions on diffusion were aggregated mathematically. There are two 
methods of doing that: opinion pooling and Bayesian methods (Soares et al., 2011). 
Bayesian methods can be difficult to implement as they are based on the assumption that the 
aggregate distribution reflect the belief of a ‘supra Bayesian’ decision-maker (O'Hagan et al., 
2006, Genest and Zidek, 1986). Opinion pooling, and linear pooling in particular, was more 
commonly used in elicitation (Cooke, 1991) and was found to perform well (Clemen and 
Winkler, 1999). 
A linear opinion pool was chosen to be the most suitable type of mathematical 
aggregation. When using opinion pooling, there are two approaches: linear and logarithmic 
pooling. Logarithmic pooling offers an advantage when experts come from different 
backgrounds and it is expected that each of their experience adds to obtaining a more 
accurate estimate. Linear pooling on the other hand treats experts as being more fallible 
(O'Hagan et al., 2006) and thus reduces overconfidence (Johnson et al., 2010). The experts 
that contributed to this study had similar backgrounds and where dissimilarities occurred 
(for instance, in the length of time they had worked in their field) it was difficult to assess 
whether this might influence their calibration (none of the experts were very junior). The 
assumption that their ranges of knowledge would contribute to a better estimate did therefore 
not seem warranted. Hence, the more conservative option to use, that is the option that 
would result in greater uncertainty, was linear pooling.  
The arithmetic mean was not weighted in this study’s linear pool. A weighted arithmetic 
mean can be used where the expertise of some participants is clearly superior to those of 
others. This could not be attested through the preliminary questions asked in the pre-session 
pro forma (Appendix D.3). Another way of checking for participants’ superiority in 
expertise is through their calibration in the training exercise (Soares et al., 2011). Soares et 
al. (2011) highlighted that it was not clear how to choose appropriate seed questions and that 
research on how to obtain weights to reflect experts’ relative expertise was needed. In this 
particular elicitation, better calibration in the training exercise did not indicate better 
calibration with regards to future diffusion of EIS. With those difficulties of judging the 
expertise of each participant and the questionable benefit, I used an un-weighted arithmetic 
mean. For the linear pool, the arithmetic means of all elicited points of the distributions were 
taken. The latter included the lower and upper range, tertiles and the median.  
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 Analysing the pooled diffusion curves 6.2.8.2
i. Comparing the performance of the classic and the Satoh approach 
The Bass model parameters for the pooled diffusion curves that were estimated by 
inverting the probability distributions of elicited quantities using both the classic Bass and 
the Satoh approaches, as described above, were examined for the following: 
 How the individual parameters p and q affected the diffusion curve was examined 
through holding m and q (m and p) fixed at their means and exploring different 
values for the remaining parameter. These different values were the mean, maximum 
and minimum values that resulted from the simulation using excel solver. The 
impact of those different values for p (q, respectively) were plotted in figures 
showing diffusion curves with both the classic and the Satoh models.  
 Of particular interest were the parameters p and q as they were not elicited directly 
but approximated using solver. Their approximated distributions were plotted in 
density plots for both approaches.  
 The potential correlation of q and p while m was fixed at its mean was explored 
using smooth contour plots for both approaches.  
 In order to see whether q and p were correlated with m, scatter plots were created for 
both approaches.  
 Five examples of likely p and q combinations from the highest density level in the 
smooth contour plots were plotted in cumulative diffusion graphs for both 
approaches.  
 Thirty randomly sampled diffusion curves were plotted in graphs for both the classic 
Bass and the Satoh model. 
 
ii. Examining the cumulative diffusion of EIS with and without research 
Only the Satoh method was used for this part of the analysis as it was shown to perform 
better at obtaining realistic diffusion curves than the classic Bass model. The two curves for 
diffusion with and without further research were plotted in one graph. The proportional 
effect of the progesterone trial on diffusion when compared with the study on the predictive 
ability of EIS was applied to the difference of the adoptions in each period with and without 
research. The resulting diffusion curve was plotted on the same graph as well. One expert 
felt unable to give any estimate for this quantity and a weakly informative (flat) uniform 
distribution covering the range from 0 to 1 was thus used for the pooling. The mean 
diffusion estimates resulting from the pooled data and the solver algorithm applied to yield 
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parameters p and q were compared with the pooled elicited quantities. For this, the pooled 
mean values and standard deviations for each quantity were presented in a table and the 
pooled and individual probability distributions were plotted in probability density functions.  
 
 Examining individual diffusion data 6.2.8.3
Individual diffusion curves per participant were generated to examine how they differed 
amongst each other. For each elicitation, this required running 1,000 simulations of the 
solver algorithm for diffusion with and without further research to yield the likely space of 
diffusion curves. Qualitative explanations provided by the participants were analysed to shed 
light on how participants arrived at their estimates and how their rationales translated into 
different shapes of diffusion curves. 
 
 Reflection on the exercise 6.2.8.4
I considered how results of this study could be validated and assessed for any potential 
bias. It is not clear how validity, reliability and responsiveness can be measured in 
elicitations of probability distributions (Johnson et al., 2010) and I therefore attempted to 
ensure minimisation of bias through recommended measures, including my study design, the 
choice of experts, the type of elicited quantities and the use of a standardised elicitation tool 
(Johnson et al., 2010). Because elicitation of expert opinion can be a complex exercise and 
demanding on the participants who may not be used to thinking in terms of probability 
distributions, I also evaluated the use of this method by reflecting on it with the help of my 
own observations, feedback that was provided by the experts and elicitation results.  
 
6.3 Results 
6.3.1 Pooled distributions and performance of methods 
 Performance of the classic versus the Satoh approach 6.3.1.1
To enable an understanding of the effects of p and q values on the shape of the diffusion 
curve, the impact of different values of q and p in the classic Bass model are shown in 
Figure 6.1 and Figure 6.2. These values are derived from the solver algorithm applied to the 
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pooled elicited quantities. It appears that q has a more pronounced effect on the diffusion 
curve. While different values of p result in curves that mainly shift left or right, most 
significantly altering the number of adoptions in the earlier periods, different values of q can 
delay the process of diffusion to a very slow one (in the case of the minimum q it would take 
more than 50 years to reach the attainable number of adoptions) or even compromise the s-
shape altogether, as seen in Figure 6.2. 
The extreme and unrealistic shape of the diffusion curve caused by the maximum value 
of q stems from numerical problems caused by independent elicitation and the discrete 
nature of the continuous function. Parameters p and q were estimated by approximating to 
the number of initial adoptions and the time it takes to reach the maximum number of 
adoptions in one period. With the combination of high values of the former and low values 
of the latter, both p and q would be estimated at large values. The curve would grow very 
fast and exceed the maximum cumulative number of adoptions which then leads to negative 
adjustment in the following period. Of course, negative growth of cumulative adoptions is 
impossible, so this is an obvious limitation with the use of this model. 
 
Figure 6.1 Effect of minimum, maximum and mean p on the shape of the classic diffusion curve 
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Figure 6.2 Effect of minimum, maximum and mean q on the shape of the classic diffusion curve 
 
 
This limitation is a result of the univariate elicitation of a multivariate problem that 
results in implausible combinations of parameters as well as the fact that the Bass model is 
time-continuous but represents discrete data. The Satoh adaptation of it addresses these 
problems and the resulting diffusion curves with the simulated mean, minimum and 
maximum values for p and q are indeed s-shaped as plotted in Figure 6.3 and Figure 6.4. 
 
Figure 6.3 Effect of minimum, maximum and mean p on the shape of the Satoh diffusion curve 
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Figure 6.4 Effect of minimum, maximum and mean q on the shape of the Satoh diffusion curve 
 
 
Whilst the Satoh approach does not affect the estimation of the quantity of attainable 
adoptions which was elicited directly, its obvious impact is that the resulting parameters p 
and q fall into different ranges. Parameter q does not assume values greater than one with the 
Satoh approach while the classic approach allowed it to assume values as large as two. 
Parameter p on the other hand, assumes larger values with the Satoh approach. This can be 
seen in the distributions of parameters p and q resulting from applying the solver algorithm 
to the elicited values that are plotted in Figure 6.5 and Figure 6.6. Being conditional 
distributions, f(p|m) and f(q|m) do not follow any standard parametric distribution, and only 
the density plots for the marginal distributions of p and q are shown.  
 
Figure 6.5 Density plots of p and q for the classic Bass model 
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Figure 6.6 Density plots of p and q for the Satoh approach 
 
 
Despite the elicitation being performed univariately, the implied p and q distributions are 
correlated. This is illustrated in Figure 6.7, which shows concentrations of p and q 
combinations in smooth contour plots for the classic and the Satoh models. There is a trade-
off between parameters p and q. The larger p is, the more likely q is to be small and vice 
versa. The Satoh method results in p and q combinations that are more concentrated. One 
reason for this could be that the Satoh approach, while preventing unrealistic shapes of the 
diffusion curve, implicitly limits the value of q.  
 
Figure 6.7 Smooth contour plots for the correlation of q and p with the classic and the Satoh approach 
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The negative correlation between m and p that is illustrated in scatter plots on the left 
hand sides of Figure 6.8 and Figure 6.9 is a reflection of the functional relationship between 
p and the number of adoptions in the first period 𝑁1. Parameters p and q are functions of that 
number 𝑁1 and the time to the point of inflection of the diffusion curve t’. The quantity 𝑁1 
was obviously positively correlated with m, as the larger the attainable number of adoptions, 
the larger should be the number of adoptions in the first period. Because of the assumption 
of independence of 𝑁1, t’ and m, 𝑁1 would be distributed in the same way irrespective of any 
changes to m. So, if m adopted a smaller value, the resulting ratio of 𝑁1/m would become 
larger and, because p reflects larger numbers in initial periods, p would therefore adopt 
larger values.  
There is also a positive correlation between m and q, illustrated in Figure 6.8 and Figure 
6.9 on the right. This is less pronounced than the negative correlation of m and p. If the 
correlation between q and m was indeed positive, this could be explained through the 𝑁1/m 
ratio being smaller with larger values of m. Because q reflects a quick growth, this would 
result in q being larger to reach the attainable number of adoptions despite the small 𝑁1 (or 
p).  
 
Figure 6.8 Scatter plot showing the correlation of m and p, m and q for the classic approach 
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Figure 6.9 Scatter plot showing the correlation of m and p, m and q for the Satoh approach 
 
 
In order to examine likely shapes of the EIS diffusion curve, cumulative uptake with five 
likely combinations of p and q is presented in Figure 6.10 and Figure 6.11 for both 
approaches. The s-shape of the diffusion curve is retained when choosing likely 
combinations of p and q in both methods. While small differences in the approaches can be 
observed through visual inspection, it is difficult to assess whether they matter or which 
method leads to curves that fit the experts’ opinion better. Going forward, I used the Satoh 
adaptation of the Bass model, as it avoids the limitation of yielding unrealistic and unusable 
diffusion curves. 
 
Figure 6.10 Five likely shapes of diffusion curves using the classic approach 
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Figure 6.11 Five likely shapes of diffusion curves using the Satoh approach 
 
 
Randomly sampling 30 curves from both the Satoh and the classic Bass model shows 
that sampling from the classic model can result in unrealistic diffusion curves (Figure 6.12). 
There is a few curves in the left hand side of Figure 6.12 that appear to have a peak with a 
following decline. One curve is obviously oscillating. 
 
Figure 6.12 Thirty sampled diffusion curves from classic and Satoh model 
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research, although uncertainty is larger than for the estimate without research (Figure 6.13). 
Figure 6.13 shows density plots of the elicited quantities that are used to generate the Bass 
model. The left hand side of Figure 6.13 shows the estimated quantities of interest for the 
counterfactual scenario in which no further research is conducted. The right hand side shows 
the probability distributions of the same quantities conditional on both identified relevant 
trials being conducted. Table 6.3 shows the means and standard deviations of all the elicited 
quantities. 
The mean estimate of the attainable number of adoptions is relatively small. Given that 
there are 231 obstetric units in England and that some units would be expected to purchase 
more than one device (large units but also units that want to have a back-up when one of the 
devices is in maintenance), the number of 140 adoptions is not large. The first year will only 
see a very small number of adoptions, possibly by those units who developed the technology 
or have research grants for it. This was the rationale given by the experts for the number of 
adoptions being very small at a mean of five adoptions or ten adoptions if more research was 
conducted. More explanation will be given in the section on the individual elicitations. More 
research will make itself known more quickly. This was the underlying reasoning for the 
number of years at which the maximum number of per period adoptions is reached: it was 
estimated to be at a mean of six years, or five years with more research.  
Research on the relative treatment effect of progesterone compared with no treatment 
would contribute more to the overall increase in adoptions caused by further research than 
another study on the predictive ability of EIS (shown in Table 6.3 and Figure 6.14). This is 
expressed through the quantity κ being estimated at a mean of 61%, although there was 
considerable uncertainty surrounding it. Even when EIS is purchased, it will only ever be 
used on an expected 60% of patients (expressed by the quantity π). Experts commented on 
there being logistical difficulties that are hard to overcome, doctors’ scepticism and the cost 
of disposables that would affect usage after purchase. 
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Figure 6.13 Elicited probability distributions of diffusion quantities for each expert and linear pool 
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Figure 6.14 Elicited probability distributions of kappa and pi for each expert and linear pool 
 
 
Table 6.3 Pooled elicited quantities (mean, standard deviation (SD), median and 95% credible intervals 
(CIs)) 
Without further research With further research 
Variable Mean  SD Median CI Variable Mean  SD Median CI 
m1 140 69 129 (39-304) m2 146 66 136 
(46-
301) 
n1 4.99 2.04 4.71 (1.8-9.7) n2 
10.5
0 4.12 9.96 (4.0-20) 
t1 6.26 1.34 6.16 (3.9-9.1) t2 5.21 1.52 5.06 
(2.7-
8.6) 
The contribution of progesterone trial (κ) to increase in diffusion and utilisation (π) 
Variable Mean  SD Median CI Variable Mean  SD Median CI 
κ 0.61 0.14 0.62 
(0.33-
0.85) π 0.60 0.07 0.60 
(0.44-
0.74) 
 
The resulting means for Bass model parameters p, q and m with and without research 
obtained from the simulation that used the Satoh method are presented in Table 6.4.  
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Table 6.4 Values of simulated Bass model parameters (mean, SD, median and CIs) 
Bass model 
parameter 
Without further research With further research 
Mean SD Median CI Mean SD Median CI 
p 0.018 0.020 0.026 (0.005-
0.083) 
0.040 0.038 0.049 (0.013-
0.157) 
q 0.491 0.176 0.482 (0.2-
0.806) 
0.537 0.136 0.524 (0.313-
0.826) 
 
As per the definition of the Bass model, the cumulative diffusion of EIS exhibits an s-
shaped growth as can be observed from Figure 6.15. This shows the pooled mean 
cumulative diffusion curves with and without research. The blue and green lines were 
elicited and the red line was obtained by applying κ to the difference of with and without 
research adoptions in each period, as was discussed above.  
 
Figure 6.15 Cumulative mean number of adoptions without and with the availability of further research 
evidence 
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the elicitation). Note that the asterisk represents that these are approximated values, while 
the elicited values are represented by plain variable names, for instance, 𝑁1. The point of 
inflection occurs at 𝑡′
∗
= 5 years without further research and can be brought forward to 
𝑡′
∗
= 4 years with further research (𝑡′ = 6 and 𝑡′ = 5 years in the elicitation).  
Figure 6.15 shows that it takes approximately 14 years for EIS to be adopted by all the 
potential attainable adopters; with further research this is shortened to 10 years. With growth 
of the curve slowing down in the last periods, this means that 90% of the adoptions are 
achieved after nine or six years, without or with further research, respectively. Half of the 
adoptions are achieved at six or four years, respectively.  
The classic Bass model would have shown a slightly better fit in the mean values, but it 
is in the extreme values that p and q could adopt, where this method fails. For example, the 
approximated curve would have led to 𝑁1
∗ = 6.18 without further research and  𝑁1
∗ =
10.28 with further research, a more accurate fit with the elicited values in Table 6.3. The 
point of inflection would have been at 𝑡′
∗
= 6 and 𝑡′
∗
= 5 years, almost a perfect fit with 
the elicited values and certainly a better fit than provided by the Satoh approach. Despite this 
better fit near the mean, the classic Bass model could not be used going forward because 
unrealistic diffusion scenarios could not be prevented, as was shown in Figure 6.2. 
As highlighted above, the number of adoptions does not increase much with additional 
research. In fact, the cumulative number of adoptions only changes by six adoptions, or by 
four per cent. Diffusion appears to speed up with more research, with a reduction in the time 
to the maximum number of adoptions of one year or four percent. The number of adoptions 
in the first year is what changes the most, approximately doubling from six adoptions to 13 
with further research. The relatively small impact of research on diffusion in this case study 
is surprising given that the lack of research was identified as one of the barriers to diffusion 
in EIS. Possible reasons for this result will be discussed in the section on the individual 
elicitations where I present qualitative insights provided by the experts, as well as in the 
discussion.  
 
6.3.2 Individual diffusion curves and rationales 
Heterogeneity was observed in the individual diffusion curves elicited from each expert. 
These variations manifested themselves in the experts’ beliefs about the total attainable 
number of adoptions and the time that it would take until they are achieved as well as in the 
effect of further research on diffusion. These differences are going to be discussed below. 
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The diffusion curves resulting from the elicited mean parameter values with and without 
conducting further research are shown in Figure 6.16. Experts’ rationales for changes in the 
total number of purchases and the time at which purchases start to decline have been added 
to the figures but are explored more in depth in the following. 
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Figure 6.16 Individually elicited mean diffusion curves from 3 experts for with and without research scenarios 
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 The attainable number of adoptions (m) 6.3.2.1
Experts’ estimates of the attainable number of adoptions varied significantly (Table 6.5). 
Expert 1 predicted the lowest number of attainable adoptions both with and without further 
research evidence. The rationale for this low estimate was that, in their opinion, the positive 
predictive value of EIS was relatively small (currently estimated at 63%). The very good 
negative predictive value (currently estimated to be at 99%) could not offset this and this 
expert claimed that apart from reducing uncertainty, research would have to show a 
significantly improved predictive ability of EIS in order for the number of purchases to 
increase. In their opinion, the main driver for the adoptions that could be achieved despite 
this was the fact that EIS would alleviate the dependence on ultrasound. 
 
Table 6.5 Mean (95% credible interval) estimates of attainable number of adoptions 
Expert  1 2 3 
Without research 54.2 (10-150) 158.8 (30-230) 204.4 (30-410) 
With research 68.7 (20-150) 174.2 (60-250) 205.5 (30-410) 
 
Expert 2 on the other hand thought that the positive predictive value was good and that 
there was a lot of potential in the device. Reducing uncertainty through research would 
increase the number of attainable adoptions but, similarly to expert 1, expert 2 thought that 
improved results would have an even larger effect on it. Expert 2 furthermore thought that 
there was always going to be trusts that will not adopt the new technology and that further 
research could not change this. This innovation-adverse behaviour exhibited by certain trusts 
could only be changed through national guidance, in their opinion. 
The third expert estimated the largest values for the attainable number of adoptions 
despite expert 3 thinking that the positive predictive value was not that good. However, 
expert 3 stated that the strong negative predictive value would be of great help providing 
certainty for women testing negative. EIS was also perceived to be less costly and easier to 
apply than ultrasound. Expert 3 stated that the number of attainable purchases would not 
change with the availability of more research, as there are some trusts that do not adopt new 
technologies for reasons of budgets and lack of knowledge. 
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 The time at which the number of adoptions starts to decline (t’) 6.3.2.2
The time it takes to achieve the maximum per period number of adoptions was estimated 
to be quite different depending on which expert was asked (Table 6.6). 
 
Table 6.6 Mean (95% credible interval) estimate of number of years up to the peak of the per period 
diffusion curve 
Expert  1 2 3 
Without research 5.13 (3-8) 9.88 (7-13) 3.53 (2-6) 
With research 5.11 (3-8) 8.16 (5-11) 2.57 (1-5) 
 
Expert 2 was the one with the largest estimate. Their rationale for it taking so long was 
that the NHS is known to move slowly. The time would be shortened by more than a year 
with more research available as people would be convinced more easily and it would be 
easier to make a business case. The first expert found a shorter time to the peak of adoptions. 
Expert 1 explained this with the relatively low success they thought EIS would have. The 
expert’s rationale was that those who adopt would do it relatively fast, although they did 
concede that it takes time until a new device gets talked about. Expert 1 also believed that 
further research showing the same results would not change the speed of diffusion, which 
could only be improved through evidence that shows improved predictive ability or 
treatment effect of progesterone.   
Expert 3 provided the shortest estimates. This coincided with them being the expert with 
the highest attainable number of purchases suggesting that they believed in a much greater 
success than the other participants. Their rationale was that the problem of preterm 
deliveries is viewed as a great clinical need, which people are desperate to address. They 
thought that further research would help shorten the time further by reducing some of the 
uncertainty.  
 
 The number of adoptions in the first year (N1) 6.3.2.3
Two experts thought that no change would occur in the number of adoptions in the first 
year when further research was conducted (see Table 6.7). Both their rationale was that those 
early adopters would be people involved with the research and that this would not change 
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with the availability of further research. Expert 1 thought the initial purchases to be very low 
due to the purchasing process taking very long, a year at minimum. Expert 2 thought the 
same but added that early meetings and presentation of findings at conferences could lead to 
higher numbers in the first year.   
The other expert, however, believed that there was going to be a major change (expert 
3). Expert 3 believed in the largest number of purchases in the first year and further believed 
in a stark increase with the availability of further research evidence. The rationale provided 
was that a greater number of research studies would enter public consciousness sooner. 
Expert 3 also thought that initial purchases would largely stem from those units involved 
with research or associated with them. Expert 3 shared the other experts’ views that the 
purchasing process can be very lengthy and also voiced the opinion that people are generally 
reluctant to change and that the numbers depended on costs and presentations at 
conferences. 
 
Table 6.7 Mean (95% credible interval) estimate of number of adoptions in the first year 
Expert  1 2 3 
Without research 2.25 (0-5) 5.7 (2-15) 7.1 (2-10) 
With research 2.2 (0-5) 5.5 (2-15) 23.7 (10-40) 
 
One avenue worth considering for synthesising these different estimates is an approach 
by which the anonymised experts’ estimates and underlying rationales are fed back to all the 
experts and by giving experts the opportunity to adjust their views. The advantage of this 
could be that experts may reach a more informed estimate by considering other experts’ 
views. The drawbacks are the additional time and potentially resource requirements on the 
part of the researcher and the experts. Furthermore, I am not aware of any problems of over-
confidence resulting from this approach, but the possibility would need to be considered.  
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6.4 Reflection on the exercise 
As Soares et al. (2011) stated, it is impossible to assess the face validity of an elicitation 
exercise as the expert’s true beliefs are unknown. What can be done is reflect on the exercise 
as well as on feedback provided by the experts. The present elicitation exercise had certain 
characteristics that perhaps made it especially challenging. The topic of the exercise, future 
diffusion of a not yet existing health technology, may have lain out of the comfort zone of 
the participating experts. While experts were selected based on the belief that they were 
suitable candidates for providing estimates of diffusion, diffusion was certainly not 
something they could be expected to think about in their daily lives. The fact that future 
diffusion is dependent on many other variables further increased the complexity of the 
exercise.  
These difficulties made it necessary to conduct relatively lengthy briefing. This briefing 
included, as mentioned above, agreement with regards to assumptions made on the variables 
influencing diffusion. The values for the predictive ability of EIS and the treatment effect of 
progesterone after EIS screening, subject to uncertainty, were only two of many assumptions 
made. It was impossible to share assumptions on all the factors that may influence future 
diffusion (as identified in the previous chapter) in the briefing. This may have led to experts 
making different assumptions on some of the factors, such as costs, and some of those may 
have been made subconsciously.  
It is therefore especially hard to evaluate the effectiveness of such an elicitation. Experts’ 
calibration may be related to their knowledge but also to assumptions they made regarding 
the future environment which may result in experts’ estimates being more accurate in certain 
settings that may or may not realise in the future. While calibration cannot be checked at this 
point in time, there was suggestive evidence for experts using different assumptions to 
obtain their estimates of diffusion. This became evident when examining the rationales for 
their beliefs in certain parameter values. However, this uncertainty was presumably captured 
in the probability distributions. 
In one case, the same rationale translated into quite different probability distributions for 
a certain parameter. For the number of purchases in the first year, expert 3’s estimate 
significantly diverged from the other experts despite them stating more or less the same 
rationale. This may be an indication that it was difficult for the experts to think about this 
particular quantity, or that experts made different underlying assumptions that they did not 
make explicit. This is not surprising given that these prior distributions characterise the 
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experts’ beliefs in the face of limited knowledge, which means that their distributions can 
only converge as more evidence becomes available. 
Interestingly, different rationales could also lead to similar quantitative beliefs. The time 
until the number of purchases declined was estimated to be shorter by two experts who had 
opposed views on the overall success of EIS. Expert 1 thought that it would not take long for 
EIS to reach its peak, given the low number of attainable purchases. In contrast, expert 3 
believed in a very fast product growth given the overall success of EIS. This suggests that 
the time to the peak number of adoptions does not indicate a successful or unsuccessful 
technology. Another insight is that this quantity was unlikely to be strongly correlated with 
the attainable number of purchases. 
Although the process encouraged the participants to voice all their rationales and I made 
sure to record them, it cannot be guaranteed that all of these rationales and underlying 
assumptions were captured. This may have to do with the fact that experts themselves might 
not have been aware of the assumptions they were making and that they were therefore not 
making them explicit. 
The above observations are supported by one expert’s feedback on this exercise: 
‘It was difficult to predict future events like this but I’m relatively confident with the 
estimates given that the conditions set for the task remain true.’ (Expert 1) 
The others merely stated that they found the task interesting and in one case, the 
software clever. All of them were happy to participate and understood the task well after the 
training was conducted. The experts also commented on difficulties they had with the 
following:  
 The use of tertiles: all experts initially thought of tertiles being closer to the upper 
and lower limits of the range than to the median; suggesting a bimodal distribution 
would make the best fit. Showing them the fit of their distribution in a histogram 
and how the choice of tertiles affected the shape of the distribution was one step to 
clarifying their meaning. It was also explained that the closer the tertiles were to the 
median, the more likely the values close to the median became and the narrower the 
resulting distribution. It was explained that tertiles should be chosen such that there 
was a 33% certainty that the value fell into that range between the two tertiles. Even 
after that explanation, the participants found it difficult to come up with numbers for 
the tertiles and relied more on the visual representation of their resulting 
distribution. An iterative approach, by which participants shifted tertiles and 
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checked the effect on the visual, gave them the opportunity to achieve the shape of 
distribution they wanted, that is the desired uncertainty and skew. In some cases, 
experts realised that their range might have been too narrow. In such cases, the range 
was widened. The use of quartiles may be more intuitive and should be considered 
in future studies. 
 Difficulty with underlying assumptions: experts found it difficult to make 
judgements considering the lack of information there was on all the influencing 
factors to uptake in the future. Experts were encouraged to widen their ranges if they 
felt great uncertainty. One particular assumption caused difficulty for one expert: the 
one that the current EIS trial would remain the only one. This was seen as unrealistic 
by this expert but I encouraged them to keep that assumption for the purpose of this 
exercise. The lack of information on the quality of the current EIS trial caused a 
problem for the elicitation of the relative importance of the progesterone trial over 
another EIS trial. One expert felt unable to give a judgement because of that. This 
needed addressing in the data analysis: a flat beta(1,1) distribution representing this 
expert’s opinion was thus used in the linear pool.  
 Thinking about the number of years at which the number of purchases peak: this was 
viewed as the most difficult quantity to estimate. A conversation on potential 
rationales for different lengths of time helped clarify thoughts. Also, the possibility 
of reflecting their uncertainty through selecting a wider range or through the choice 
of tertiles was highlighted again. Peculiarly, experts did not choose particularly 
weakly informative distributions. It is hard to tell whether this might have been due 
to over-confidence (it is important to bear in mind that expert knowledge is fallible 
(O'Hagan and Oakley, 2004)) or whether this represented their true beliefs. Over-
confidence would have, at least partially, been addressed by linear pooling of the 
three experts’ beliefs (Johnson et al., 2010). 
The above shows that it is difficult to develop a way of eliciting diffusion that minimises 
bias and avoids the use of certain heuristics and assumptions but that appropriate preparation, 
briefing and training have the potential to support such an exercise.  
 
6.5 Exploring the impact of trial results on diffusion 
In this chapter, I examined the impact of reduction of uncertainty through the generation 
of research evidence on diffusion. For this task it was implicitly assumed that study results 
162 
 
of both simulated studies would be similar to existing evidence (experts were asked to bear 
some uncertainty in mind). Given that experts diverged significantly in their estimates of 
attainable number of adoptions (m) and the time to the peak number of adoptions (t’), and 
given that the experts expressed differing views on the quality of the existing evidence, it 
can be hypothesised that experts’ estimated diffusion curves would take different shapes 
conditional on the data generated by the respective studies. For instance, if EIS was shown 
to have a better predictive ability than that so far observed (in terms of positive and negative 
predictive values, for example), diffusion may be quicker or a greater number of attainable 
adoptions could be achieved. If, in another example, the relative treatment effect of 
progesterone versus no treatment was much worse after EIS scans than after CL scans, then 
diffusion may turn out to achieve fewer attainable adoptions. 
This means that diffusion estimates should not only be elicited for the counterfactual 
with and without research scenarios, but also for different possible study results. Continuing 
with the example on the progesterone trial, one could elicit three different scenarios: that 
progesterone treatment effect after EIS screening turns out to be similar to that predicted for 
CL scans (for instance, within the two middle quartiles of the prior distribution), that it turns 
out to be significantly worse (in the lowest quartile of the prior distribution), and that it turns 
out significantly better (in the uppermost quartile). Of course, a more detailed breakdown of 
different research study outcomes is desirable (for example, quintiles), but elicitation 
exercises only work well with a small number of elicited quantities. Assuming that the value 
of one well-defined trial is going to be assessed, elicitation of a counterfactual without 
research diffusion curve is required, as well as elicitation of three with research diffusion 
curves, resulting in 12 quantities to be elicited. Using quintiles would drive this up to 18 
quantities, which may lead to exceeding the time that experts’ are able and willing to 
allocate to an elicitation meeting. 
When diffusion is elicited conditional on study results, it may also be worthwhile to 
provide information on the potential cost-effectiveness associated with each of the possible 
sets of study results, because knowledge of cost-effectiveness may also influence the 
diffusion curves.  
 
 
163 
 
6.6 Discussion 
6.6.1 Findings 
In this chapter, I presented a method for eliciting expert beliefs about technology 
diffusion using adaptations of the Bass model of diffusion. This method was used in 
estimating diffusion of EIS for use in PTB screening. I demonstrated an approximation 
method for converting experts’ beliefs on observable quantities into Bass model parameters 
using two different specifications of the Bass model: the Satoh adaptation and the classic 
Bass model. The Satoh specification of the Bass model performed better than the classic 
model with respect to the resulting parameter space, enabling the generation of s-shaped 
diffusion curves. The classic model reflected experts’ beliefs slightly better near the mean 
estimates but caused problems in extreme parameter values that could not be overcome. The 
model parameters p and q were shown to be negatively correlated and also correlated with 
parameter m. The correlation is a feature of inverting a non-linear function.  
Results for EIS showed that the attainable number of adoptions was relatively low. 
While no authoritative figure on the desirable number of adoptions exist, an average of two 
devices per obstetric unit in England could be plausible, resulting in a tentative value of 462 
desirable adoptions. A mean of 140 attainable adoptions without further research evidence is 
therefore low, resulting in 30% of desirable adoptions only. The experts’ main rationales 
were: the predictive ability of EIS being less good than the experts would like it to be at 
present and the general adversity to change that was thought to be present in the English 
NHS. It would take approximately 14 years for EIS to reach all attainable adoptions without, 
or 10 years with further research evidence available. Once EIS is purchased by the hospital, 
only an expected 61% of patients would be offered the screening with it. Assuming that all 
hospitals saw the same number of patients, this would result in only 5,000 of 27,000 patients 
being offered EIS screening. As stated previously, I will not use utilisation for the remainder 
of the thesis. However, the decision-maker and the developer of EIS may wish to bear this 
low utilisation in mind when devising implementation strategies. These findings do not take 
into account the potential differences in diffusion curves conditional on different trial results.  
 
6.6.2 Relevance 
This study adds to current knowledge by offering an approach to obtaining probabilistic, 
technology-specific predictive estimates of diffusion even before technology launch. The 
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reviews in Chapter 2 showed that predictive estimates of diffusion are rarely used in health 
economic evaluation. In Chapter 3, the reviews identified no existing methods for obtaining 
probabilistic health technology diffusion estimates prior to technology introduction but did 
highlight that an expert judgement exercise should use formal diffusion models, such as the 
Bass model, as the underlying structure. The method commonly used for predicting future 
diffusion included guessing by analogy, which was not deemed suitable in health 
technologies for a lack of data on analogous technologies, and because it would ignore the 
technology-specific factors influencing uptake. The method of elicitation of experts’ beliefs 
together with specifications of the Bass model used in this study therefore fills this research 
gap. It is useful in health technologies, because there usually is not sufficient data for a 
guessing by analogy exercise, but it can also be useful for other types of technologies 
because this method allows taking into account the very distinctly individual environmental 
and technology-specific conditions in estimating diffusion. Although the Bass model of new 
product growth itself is not new, its use has been limited to predict future uptake when data 
on the first few periods were available or to guessing by analogy studies. 
The contribution of probabilistic estimates of diffusion for EIS as a PTB screening tool 
may prove important for further cost-effectiveness and value of information and 
implementation analyses, examples of which will be presented in Chapters 7 and 8. The 
presented approach enables researchers to obtain better representations of uptake patterns 
and thus may help direct public funds to the most efficient implementation strategies. This 
approach could also be of interest to manufacturers who may want to assess the value of 
investing into technology development at an early stage, as technology uptake is strongly 
linked to potential profit through revenues.  
 
6.6.3 Strengths and limitations 
The strengths of this approach relate to the representation of experts’ uncertainty. 
Experts could also take factors influencing future uptake into account, leading to the best 
guess that we can obtain at present. Experts were encouraged to provide insights into their 
thought process and describe those factors that influenced their estimates the most. These 
additional data provided the opportunity of analysing the implicit assumptions experts were 
making.  
The use of the Bass model enabled me to predict future diffusion with a minimum 
number of elicited quantities. Rather than eliciting uptake levels for every year, only three 
points sufficed to obtain uptake dynamics that are coherent with the theory of diffusion of 
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innovations and that have been shown to more or less accurately predict diffusion of other 
technologies. Reducing the number of elicited quantities is important: not only is recruitment 
harder with increased meeting lengths, but experts’ calibration may also suffer as the task 
goes on. 
Limitations of this approach were mainly related to the complexity of diffusion and its 
dependence on a diverse set of factors. In particular, the present elicitation exercise did not 
consider the different possible study results. However, during this exercise, experts flagged 
up that diffusion would be different conditional on different study results. This means that a 
major part of the uncertainty associated with diffusion is potentially not reflected in the 
elicited distributions. I have therefore proposed a way of structuring the elicitation exercise 
to account for different diffusion curves conditional on study results in Section 6.5. 
A caveat of the use of the Bass model is that the joint parameter space may contain 
implausible values because I was unable to multivariately elicit beliefs about the observable 
quantities. Ideally, these correlations should have been quantified using multivariate 
elicitation but this was beyond the scope of this research because of the increased difficulty 
and meeting length of a multivariate elicitation. Another drawback of using the Satoh 
approach to inverting observable quantities into Bass model parameters was that the 
resulting range for parameter q was smaller compared with the classic Bass model parameter. 
Unfortunately, it was not possible for me to assess whether this led to introduction of bias, 
let alone quantify the bias.  
Difficulties were noted in the elicitation of certain quantities: while the quantity m and 
𝑁1 (that is, the number of attainable adoptions and the number of adoptions in the first 
period, respectively) were intuitively easy to grasp, respondents found it more difficult to 
come up with an estimate of t’ (the time until the per-period adoptions start to decline). The 
quantity κ (the proportion of uptake increase caused by the study on the treatment effect of 
progesterone) posed another problem that might have been caused by the parameter’s 
definition, which was confusing to respondents. The assumption that the effects of different 
types of research on diffusion were additive was another limitation and will limit the use of 
κ in further analysis. Ideally, the contribution of each study would have been elicited 
separately.  
It should also be highlighted that elicitation of future diffusion, not unlike elicitation in 
general, requires a significant amount of preparation and planning. The particular challenges 
in this elicitation lay in briefing experts on uptake of health technologies and explaining the 
elicited quantities as well as presenting the different research findings relevant to this 
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technology. As well as gathering the information for the briefing, time should be taken to 
phrase questions asked in the elicitation and practising the use of software as well as 
providing training to experts. Conducting elicitation to inform an uptake model may thus not 
be feasible in all research settings. 
One of the greatest difficulties was associated with finding a balance between guiding 
the experts in the assumptions they were making about the underlying conditions of 
diffusion and giving them absolute freedom. The former could produce probability 
distributions that are too narrowly defined; the latter could lead to weakly informative 
probability distributions including unrealistic scenarios. I decided to set out conditions, but 
even these few conditions meant lengthy briefing of experts before the elicitation was started. 
Another drawback of setting out these conditions was that the resulting diffusion curves may 
contain a bias or false certainty. I do not believe that briefing was avoidable for the simple 
reason that experts were not familiar with EIS at all. I also found that experts may refuse to 
provide any estimates if they feel too uncertain about pivotal factors that would influence 
their beliefs. This is an area for further research in the field of elicitation.  
With the trial still ongoing, no results were available to present to the experts and it had 
was assumed that estimates of the predictive ability obtained from the pilot would hold true. 
This may compromise the usability of the resulting diffusion curves for health economic 
decision-making because the evidence that will be produced in the ongoing trial may alter 
the experts’ views of future diffusion. It can be argued, however, that experts’ estimates of 
diffusion reflected uncertainty, also about the trial outcomes. In Section 6.5, I outlined a 
more sophisticated approach to reflect the impact of different trial results on diffusion. The 
fact that the elicitation was conducted early on also showed that it is possible to elicit 
diffusion estimates at an early stage of product development, which may be relevant in 
instances in which the manufacturer wishes to find out about potential diffusion of a 
technology early in product development to help decide whether to pursue that technology or 
not.  
The use of the tertile method proved difficult for the experts. While elicitation of the 
range and the median did not pose any problems, experts found it hard to provide opinions 
on tertiles, possibly due to their unfamiliarity with probability distributions. I addressed their 
questions by showing visuals of histograms or density curves, showing examples of different 
tertiles. The main benefit of using tertiles was that no intervals had to be pre-specified and 
the expert therefore had greater flexibility in deciding on the shape of their probability 
distribution with the estimation of very few points. This greater flexibility came at the 
expense of simplicity associated with fixed interval estimation methods. Since this initial 
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lack of understanding could be overcome, it does not present a problem for the task in 
general, but it is worth bearing this trade-off of flexibility versus simplicity in mind when 
designing future studies. The use of quartiles may be more intuitive for participants and 
should be explored in further research. 
It would have been desirable to show the effect of elicited parameters on the diffusion 
curve during the meeting as a means of providing feedback and to improve the fit of 
probability distributions with experts’ opinions. It was not possible to do this in this study as 
running solver with the elicited quantities to yield the Bass model parameters and produce a 
mean diffusion curve would have resulted in exceeding the available time for the meeting.  
 
6.6.4 Further research 
Scope for further research lies in addressing the limitations of this study, particularly the 
elicitation of different diffusion scenarios conditional on trial results as was outlined in 
Section 6.5. Furthermore, the correlation of parameters could be explored through 
multivariate elicitation, poses its own set of challenges that was beyond the scope of this 
study. Whether experts are truly unable to provide the covariance structure should ideally be 
explored through performing research on this but this may not be feasible because of the 
increased lengths of elicitation meetings. 
It would be interesting to repeat this study once the first trial results are available and 
examine any changes to diffusion with potential changes to the predictive ability of EIS. I 
did not examine the potential increase in uptake that could be caused by better effectiveness 
results for EIS because this is not directive for action as, presumably, the device’s predictive 
ability cannot be improved. This study revealed, however, that the device’s predictive 
ability, especially its positive predictive value, may pose a significant barrier to 
implementation. Eliciting uptake estimates conditional on what if scenarios with different 
levels of efficacy could thus be useful to manufacturers who wish to make a decision on 
whether to develop a technology further and for obtaining a more accurate and complete 
picture of the value of implementation that appropriately reflects uncertainty around 
implementation. In this case study, predictive ability may indeed be improved, as EIS has 
been developed further since the pilot study, on which the positive and negative predictive 
values used in this exercise were based. 
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6.6.5 Conclusion 
In conclusion, I recommend elicitation of expert opinions to inform the Satoh 
modification of the Bass model of diffusion as a way of obtaining probabilistic, dynamic and 
technology-specific estimates of uptake. The estimates of diffusion obtained through 
application of this method to EIS for use in PTB screening can be used for cost-effectiveness 
and value of information and implementation analyses, although further exploration of 
different study results and their impact on diffusion is desirable.  
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CHAPTER 7. THE DYNAMIC EVII FRAMEWORK APPLIED IN AN 
ECONOMIC EVALUATION OF EIS FOR USE IN PTB SCREENING 
7.1 Introduction 
The aim of this chapter was to illustrate the dynamic expected value of information and 
implementation framework that was developed in Chapter 4 in the exemplary case study of 
electrical impedance spectroscopy (EIS) for preterm birth (PTB) screening. Background on 
the case study technology, the therapeutic area and health need was provided in Chapter 1. 
The latest trial evidence on the predictive ability for EIS was not available upon writing this 
thesis because it was still ongoing, and any results are therefore preliminary and based on 
pilot study data. I drew on insights from the qualitative study on potential implementation 
strategies presented in Chapter 5. I also used the estimates of counterfactual with and 
without research implementation dynamics obtained from the elicitation study described in 
Chapter 6. The flow of the thesis and the place of this chapter in it are shown in Figure 1.2 in 
Chapter 1. 
In this chapter, I wish to address the following objectives:  
1. To demonstrate the use and usefulness of the concepts related to the dynamic expected 
value of information and implementation in the context of HTA. 
2. To compare static implementation estimates with the elicited diffusion estimates with 
respect to their impact on health economic outcomes and implications for decision-making. 
This chapter will follow these steps: I describe the PTB screening model that I developed 
for the economic evaluation of EIS in Section 7.2. The dynamic EVII framework that was 
developed in Chapter 4 is applied in the PTB screening model in Section 7.3. I present 
results of the decision-analytic model for EIS and compare static with dynamic results in 
Section 7.4. I conclude with a discussion in Section 7.5. 
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7.2 The preterm birth screening model 
This section describes the conceptualisation of and data inputs used for the economic 
model of EIS for use in PTB screening. For the model conceptualisation, I followed the steps 
outlined by Gray et al. (2011) to build a decision-analytical model and guidance by Squires 
(2014) to conceptualise the model. 
 
7.2.1 Defining the research question  
 Review of existing health economic models for PTB screening 7.2.1.1
I started model development with a review of other economic evaluations for PTB 
screening as Squires (2014) highlighted the potential helpfulness in reviewing previous 
economic evaluations in the therapeutic area. With EIS still being under development at the 
time of writing, there was no economic evaluation of EIS for use in PTB screening. There 
were, however, two existing economic evaluations of screening interventions combined with 
treatments in the therapeutic area of preventing PTB: one HTA by Honest et al. (2009), and 
one cost-effectiveness analysis by Werner et al. (2011) that was updated by the authors in a 
later publication (Werner et al., 2015). I briefly discuss these two economic evaluations in 
terms of their strengths and limitations for use in assessing EIS: 
The HTA report by Honest et al. (2009) assessed a large number of different screening 
tests (22) and interventions (40) for their effectiveness in predicting and preventing preterm 
birth in asymptomatic women and women with symptoms of preterm labour. Cervical length 
ultrasound scans were among the screening tests and progesterone was assessed as an 
intervention to prevent preterm birth. The model structure used was a decision tree model for 
both asymptomatic and symptomatic women. Four options (test no one and treat all, test all 
and treat no one, test all and treat only with positive test and test all and treat all) were 
compared to test no one and treat no one. The model outcome in asymptomatic women was 
the cost per threatened PTB avoided; in symptomatic women it was the cost of preterm birth 
avoided. Effectiveness was thus not measured in QALYs but only in threatened preterm 
birth or actual preterm birth avoided. The average cost associated with a woman tested and 
treated in the symptomatic analysis was the cost that screening and treatment of 
asymptomatic women is attempting to avoid – hence the symptomatic analysis was 
necessary for the analysis in asymptomatic women. 
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The economic evaluation performed by Honest et al. (2009) was useful for the purpose 
of this study in that it provided a systematic review of the effectiveness and costs associated 
with different screening and treatment interventions. The fact that it adopted a very short-
term time horizon by ignoring costs and QALYs associated with the future life-times of the 
affected babies is a limitation. The lack of QALYs also limits the EVI analysis as there is no 
accepted monetary valuation for the outcome measures used in their analysis. 
Werner et al. (2011) assessed the cost-effectiveness of a single routine transvaginal 
cervical length measurement at 18-24 weeks of gestation followed by daily vaginal 
progesterone treatment for those women identified at risk against no screening and no 
treatment. Like the study by Honest et al. (2009), the model has a decision tree structure. 
This analysis used costs and QALYs as the model outcomes. There were only three possible 
health states that were associated with four different lengths of gestation: full health, severe 
disability and death. The advantage of this analysis was that it took a life-time horizon and 
quality of life into account. However, evidence used on the effectiveness of progesterone 
and the predictive ability of cervical length (CL) scans was based on single trials rather than 
a systematic review and evidence synthesis and health outcomes were crudely modelled 
reflecting only three health states.  
The study by Werner et al. (2011) found cervical length scans combined with 
progesterone treatment to be a dominating strategy in comparison to test nobody and treat 
nobody. In a subsequent revision of some of their input parameters (Werner et al., 2015), the 
authors still found this strategy to be cost-effective, though not dominating. The same 
strategy did not come out to be the most cost-effective in the model by Honest et al. (2009). 
This difference in model results appears to be caused by the difference in the time horizon 
that is considered for the studies as well as by the costs associated with preterm birth. Both 
studies used a decision tree model, which is appropriate to answer the research question (see 
justification below in step 2). Werner et al. (2011) considered the impact of four different 
lengths of gestation on costs and health outcomes while Honest et al. (2009) only considered 
two different lengths of gestation and their impact on costs.  
In summary, the two studies differed in terms of the use of evidence, modelled health 
states, and length of time for which costs and health outcomes were modelled. Both studies 
could be helpful in providing data for the present economic model, although some of the 
input data needed updating. 
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 Research questions for EIS for use in PTB screening model  7.2.1.2
The present model aimed to estimate the costs and effects of EIS screening followed by 
progesterone treatment in women with a singleton pregnancy and a history of PTB or mid-
trimester loss; and to compare these outcomes to those of comparator screening 
interventions followed by progesterone treatment. PTB was defined as birth before 34 weeks 
of gestation, at which time the threat to the baby is the most significant (Werner et al., 2011). 
The comparator screening interventions used in this model were cervical length ultrasound 
scans and no screening. The comparators CL scans and No screening had been identified as 
the most relevant comparators in the interviews with experts and based on communication 
with the developers of EIS. The interviews also identified progesterone as the only likely 
prevention strategy for those who tested positive. A no screening, treat all strategy was 
deemed improbable to occur in practice and was therefore not assessed. In contrast to the 
study by Honest et al. (2009), all strategies were only assessed in high risk women, 
following the identification of parous women at risk of preterm birth based on previous 
history of at least one preterm birth.  
The analysis was conducted from the payer’s perspective, and within the jurisdiction of 
England, therefore taking the viewpoint of the England NHS. If also a personal social 
services (PSS) perspective was adopted, EIS would likely be more cost-effective because 
fewer personal and social services would be needed in the case of averted PTB. It is also 
worth noting that decision-makers at a local level may be more interested in the cost-saving 
in the pregnancy and delivery pathway than the lifetime costs. A scenario analysis from local 
level decision-maker perspective could therefore omit the lifetime costs and utilities and 
focus on the cost-saving associated with PTBs averted. Because the purpose of this thesis 
was to explore the dynamic EVII model in a case study, this scenario analysis does not form 
part of this thesis.  
 
7.2.2 Deciding on the most appropriate type of decision model 
The model used in this analysis was a decision tree model. This is usually appropriate 
when recurring events are not important (Gray et al., 2011). Brennan et al. (2006) stated in 
their taxonomy of model structures that a decision tree is an appropriate model choice when 
interaction between individuals is not needed; the model does not need to be timed; and a 
cohort model reflects the decision problem accurately. The present decision problem 
justified the model choice because: 1. interactions between individuals in the model were not 
likely. 2. Timing would not affect model outcomes, as the time at which the intervention is 
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used and at which future health outcomes are determined is limited to one year, and health 
outcomes can be extrapolated for a life-time horizon without the need for accounting for any 
recursive health states. 3. Individual patient characteristics are not foreseen to change model 
outcomes significantly.  
I developed the decision tree for this decision problem by following the steps proposed 
by Gray et al. (2011): 
a) Tree structure 
A decision tree model has a square decision node which indicates a decision point 
between alternative options (Briggs et al., 2006). A circular chance node shows a point 
where two or more alternative events are possible for a patient. Each chance node is 
associated with a probability that shows the likelihood of a particular event occurring at that 
node. Patients then follow pathways through the decision tree, which are mutually exclusive 
sequences of events, each associated with a probability of occurring. To the very left of the 
decision tree, the first probabilities show the probability of an event, but moving to the right, 
these probabilities become conditional on the previous events.  
The PTB decision tree model (Figure 7.1) starts out with parous pregnant women that 
are deemed to be at high risk of PTB based on their history of previous PTB. This includes 
all pregnant women that have had a previous pregnancy of at least 20 weeks’ gestation. In a 
proportion of these women, preterm birth as defined as birth before 34 weeks’ gestation is 
prevalent, if the woman remains untreated. This is determined by the prevalence in all 
pregnant women and the sensitivity of previous history as a predictor for PTB. I assume that 
the history of previous PTB will be known for each of these women, which should be a 
reasonably realistic assumption in the English NHS. If a woman has a history of PTB, she is 
sent for EIS screening; or a CL scan or no screening in the comparator strategies. Figure 7.1 
only presents one arm of the decision tree, only for EIS screening, for reasons of space.  
If a woman tested positive, she would be recommended vaginal progesterone in the form 
of pessaries for the duration of up to 34 weeks of gestation. With progesterone treatment, the 
relative risk of having a PTB is reduced. That means that out of the women who were going 
to have a PTB, a proportion will not have a premature delivery because of the treatment. 
This results in two branches coming out of that node – the women who give birth prior to 34 
weeks of gestation and those who give birth after that.  
Costs and health outcomes associated with PTB are significantly influenced by the 
length of gestation (Boyle et al., 2012). I therefore adopted the approach by Werner et al. 
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(2011) and divided the length of gestation up further. Among the women who give birth 
prior to 34 weeks’ gestation, a proportion would give birth prior to 28 weeks, and the 
remainder between 28 and 34 weeks. Among those who give birth after 34 weeks’ gestation, 
a proportion would go on until more than 37 weeks and the remainder would give birth 
between 34 and 37 weeks. At each different length of gestation, there are three different 
health states for the baby: full health, severe and lifelong neurological disability and death. 
Each length of gestation is also associated with a cost of neonatal and maternal care. 
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Figure 7.1 Illustration of EIS decision tree structure  
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b) Order of events in the decision tree 
For screening tests, there are two possible ways of ordering events (Gray et al., 2011). 
One is starting with the prevalence of the disease and continuing with the patients that test 
positive. For this, one needs the disease prevalence and values for sensitivity and specificity. 
The other way, which may be more intuitive for clinicians but is usually more difficult to 
populate (Gray et al., 2011), starts out with screening and dividing patients into those who 
test positive and those who test negative and then continue with those who have the disease. 
For the latter approach, the positive and negative predictive values are required, and the 
prevalence of the disease in those who tested positive and negative. The availability of data 
thus often influences the approach for ordering the events in the decision tree. I followed the 
more commonly used approach of starting with the prevalence of the disease and let this be 
followed by the sensitivity and specificity of the respective test because I lacked the data to 
populate the alternative model for CL scans.  
To obtain the number of women with a history of preterm birth to start the decision tree, 
I used the prevalence of PTB and the sensitivity and specificity of a PTB history, which was 
obtained from Honest et al. (2009). This resulted in a new estimate for the prevalence of 
PTB in all high risk pregnant women. EIS, or its comparator interventions CL scans or No 
screening, would then be used on all the women who had a history of PTB, whether PTB 
was imminent or not. The remainder of the tree after the different screening interventions 
was straight forward. Women who tested positive with EIS or CL scans would undergo 
treatment with progesterone and that would reduce their chance of having a PTB.  
 
c) Estimating probabilities 
Each chance node is associated with a probability. As mentioned above, the probabilities 
after the first chance node are conditional probabilities. With pathways being mutually 
exclusive, all probabilities coming out of one chance node must sum up to 1. The end of a 
pathway is therefore associated with a joint probability of all the events in one branch 
occurring. 
 
d) Payoffs 
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The term ‘payoffs’ describes costs and utilities that are associated with each final node. 
Chance nodes along the pathway can also be associated with costs. These costs are summed 
up to yield the total cost associated with the strategy. 
 
7.2.3 Identifying the evidence and populating the model 
Evidence to populate the model was obtained from different sources, mainly the 
previously described studies (Honest et al., 2009, Werner et al., 2011), but also from other 
sources, as shown in Table 7.1. For some parameters, obtaining evidence proved challenging 
and the assumptions made to address this and the impact on model outcomes are discussed 
below. 
There was no data on the number of parous pregnant women and this number was 
therefore estimated using the number of births per year in England (The Health and Social 
Care Information Centre, 2012a) and the proportion of parous pregnant women found in a 
trial on the relative treatment effect of progesterone versus no treatment in preventing PTB 
by Fonseca et al. (2007). While the data on EIS and CL scans (Honest et al., 2009, Werner et 
al., 2011) was for singleton pregnancies and this is what is examined in this model, the 
number of births includes multiple pregnancies. The bias this may cause is fairly small, as 
over- or underestimation of the numbers of patients in the model would affect only the cost 
per screening with EIS, and only in very small orders of magnitude. 
A preterm birth, as mentioned above, is defined as a birth before 34 weeks of gestation. 
If the baby is born before 28 weeks’ gestation, the risk of the baby dying or having a severe 
disability is even higher. The prevalence of preterm births (that is, prior to 34 weeks of 
gestation) in pregnant women was taken from Honest et al. (2009). A word of caution 
applies here: an estimate of the prevalence of preterm births in parous pregnant women was 
not available and I therefore assumed that this would be the same as in all pregnant women.  
The likelihood ratios for previous history as an indicator for PTB were obtained from 
Honest et al. (2009) as were the likelihood ratios associated with CL scans, which the 
authors obtained by performing an evidence synthesis on relevant trials. As an explanatory 
note, the positive likelihood ratio is the ratio of sensitivity over (1-specificity) (or 
alternatively the probability of positive test conditional on prevalent disease over probability 
of positive test conditional on no disease), and the negative likelihood ratio is the ratio of (1-
sensitivity) over specificity (or alternatively, the probability of negative test conditional on 
disease over probability of negative test conditional on no disease). The greater the positive 
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likelihood ration the better (e.g. greater than 10 is considered good) and the smaller the 
negative likelihood ratio, the better (e.g. negative likelihood ratios are between 0 and 1, but 
the closer to 0, the better). The threshold for a positive test result with CL scans was 25mm, 
which was described as the most common threshold evaluated in asymptomatic women at 20 
weeks of gestation (Honest et al., 2009): a shorter cervix than that would indicate that there 
was an increased risk of having a PTB. A word of caution for the latter: these likelihood 
ratios applied to screening of all pregnant women regardless of their risk factors and they 
may over- or underestimate the likelihood ratios in the population of high risk women based 
on their history of previous PTBs. To be used in this model, likelihood ratios were converted 
to sensitivity and specificity.  
Sensitivity and specificity of EIS were obtained from a pilot study that had not been 
published and was provided to me via personal communication with the developers of EIS 
(Anumba, 2013). These data were preliminary and will be updated once the ongoing trial has 
reported. Because the pilot study was small, I generated posterior distributions for the 
sensitivity and specificity parameters by assuming a binomial likelihood for the sample 
‘number of events’ and by using a reference conjugate Beta(1,1) prior distribution.  
The relative risk of having a PTB before 34 weeks’ gestation when treated with 
progesterone compared with no treatment was approximately 0.55 (95% credible interval: 
0.34, 0.88) in singleton pregnancies, as reported in a trial by Fonseca et al. (2007). This was 
equivalent to women treated with progesterone having a probability of PTB of 18.1%, 
conditional on a positive CL scan. The caveat of these data was that the identification of 
women with potential PTB was based on cervical length shorter than 15mm, that is different 
from the 25mm used for the predictive ability in the Honest et al. (2009) study. This trial 
also did not undertake any pre-screening using previous history – and thus represents a 
sample from a different population of women than what is used in the present model. 
Furthermore, the lack of data forced me to make the assumption that the relative risk was 
similar in women who underwent screening with EIS. A Bayesian reference prior was used 
to account for this added uncertainty, resulting in a probability of PTB when treated with 
progesterone of 18.6%. The implications for the uncertainty surrounding this parameter are 
discussed in Section 7.2.4. I was not aware of any negative effects of progesterone treatment 
on utilities.  
There was some evidence from a Chochrane review I decided not to use on the 
relevative risk associated with progesterone treatment against no treatment in women who 
had a history of PTB of 0.31 [95% CI 0.14 to 0.69] based on 11 studies (Dodd et al., 2013) 
and women with a short cervix of 0.64 [95% CI 0.45 to 0.95] based on two studies. The 
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former was not of use for this model, because treatment of women with history only does not 
occur in practice. The latter included the study by Fonseca et al. (2007) and another study, 
but did not report the probability of PTB with no treatment. I therefore used the Fonseca et 
al. (2007) estimates because the detail provided in the article enabled me to calculate the 
probability of PTB with progesterone treatment. The implication is that the real relative risk 
of progesterone against no treatment may be underestimated here, causing potential bias 
against the no screening, no treatment strategy.  
The probabilities associated with the length of gestation and the health states have all 
been informed by the Werner et al. (2011) study, but were originally reported by Clements et 
al. (2007) and Moster et al. (2008). The probability of severe disability was an estimate of 
probabilities of the most prevalent disabilities grouped together. The probability of delivery 
prior to 28 weeks, which was conditional on a delivery prior to 34 weeks and the probability 
of delivery prior to 37 weeks conditional on delivery after 34 weeks were obtained from 
Fonseca et al. (2007). The underlying assumption is that these probabilities are not changed 
by treatment with progesterone.  
The cost associated with each EIS scan was indicative because the price had not been set 
yet. I assumed costs of £15 in consumables in every patient plus £1 training and 
maintenance costs per scan and I assumed it would take a consultant 15 minutes at 
approximately £9.40 to perform the test. The £9.40 estimate was based on inflated 
consultant costing in the Honest et al. (2009) study. The capital cost per device was assumed 
at £5,000. The capital cost was annuitised over an assumed time horizon of five years, with 
the annuity factor calculated using 
1−(1+𝑟)−𝑛
𝑟
, where r is the discount rate and n is the 
number of years the technology will be in use (Drummond et al., 2005). Based on 
participants’ statements in the qualitative study, it was assumed that two devices would be 
purchased per each obstetric unit, the thinking behind which was that there should be at least 
one spare unit in case one goes to maintenance.  
With that information, the number of scans per year per device could be calculated using 
the number of parous pregnancies that were determined at risk based on the women’s history 
of PTB, which would be approximately 27,000 women in England per year. The number of 
obstetric units in England was 231 (UNICEF, 2013), which led to a total potential number of 
EIS devices in hospitals of 462 and 59 scans per device per year, based on having each 
woman screened once in their pregnancy. The annuitised price (which was £1,107 based on 
a purchase price of £5000 for five years) was then divided over the number of scans per year 
to yield the capital cost per scan, to which training, maintenance and manpower were added 
to yield the cost per scan of £44 (Table 7.1). This is slightly higher than the cost per scan for 
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a similar device (Electrical Impedance Spectroscopy for use in cervical cancer screening) 
which could reflect the further development that has gone into the device. 
Where costs were obtained from sources that reported them in US Dollars, they were 
converted to GBP by using health-care specific purchasing power parities by the World 
Health Organisation (2015). Costs were inflated to 2014 costs using the Personal Social 
Services Research Unit (PSSRU) inflation tables (Personal Social Services Research Unit, 
2015).  
The maternal costs associated with early delivery were reported by Werner et al. (2011) 
but originally taken from Gilbert et al. (2003). Neonatal costs associated with PTB were 
informed by Honest et al. (2009) who obtained their estimates by calculating the cost at 
different lengths of gestation based on the cost associated with different birth weights 
reported by Petrou (2003), assigning average birth weight to lengths of gestation. 
Werner et al. (2011) used costs associated with early intervention in the first three years 
of a child’s life. These included costs of special education, which were not relevant for the 
payer perspective adopted here. Instead, I used costs reported by Petrou and Khan (2012) 
that were only of medical nature and estimated for the first 18 years of the babies’ lives 
using a Markov model. The evidence used by the authors stemmed from various countries, 
including the UK. If a societal perspective were to be adopted, special education costs as 
well as potential productivity losses could be incorporated in the model (Werner et al., 2011) 
but this does not apply here.  
I also explored medical care cost data of children with low birth weight that was 
available from a UK study (Stevenson et al., 1996), which could be used by converting the 
duration of gestation into average birthweight, as was done by Honest et al. (2009). These 
costs were, however, reported in 1979 values and stemmed from data collection prior to 
1980. Major changes in resourcing and management may have occurred since then that 
would have an impact on these costs, thus making them less applicable than the above costs 
reported by Petrou and Khan (2012). If the Stevenson et al. (1996) costs were used and 
inflated to today’s value, they exceeded those reported by Petrou and Khan (2012) 
significantly, leading to potential bias in favour of EIS and CL scans.  
The cost for severe disability per year was based on the medical costs associated with 
cerebral palsy, one of the most common disabilities in premature babies (Werner et al., 2011, 
US Department of Health and Human Services and Centers for Disease Control and 
Prevention, 2004).   
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The cost of single CL scans was taken from the review by Honest et al. (2009), in which 
it was assumed that one scan would take up to ten minutes of the time of a consultant and 
one hour of the time of a lab technician doing the analysis. The purchasing cost of 
ultrasound machines was assumed to be zero, as ultrasound scans with the purpose of 
preterm birth screening are performed on existing machines in the NHS, in line with the 
analysis in Honest et al. (2009). If this analysis were to be carried out for other countries, the 
purchasing cost of ultrasound machines might have to be factored into the analysis. The cost 
of taking the history of a pregnant woman was assumed to be zero, as this is part of the 
standard routine assessment of each pregnant woman. 
The cost of progesterone injections was reported by Honest et al. (2009) to be at £923.55 
for 15 injections. It was anticipated that progesterone would be administered via pessaries 
following screening with EIS but, for the lack of other cost data, I used the inflated costs 
reported by Honest et al. (2009) for injections.  
Quality-of-life values associated with the three possible health states were based on 
Werner et al. (2011). The QALY value for severe disability was taken from Odibo et al. 
(2006) and included the conditions ‘cerebral palsy, mental retardation, blindness, deafness 
and epilepsy’ (Werner et al., 2011) that were identified as the most prevalent conditions 
following a preterm birth by Moster et al. (2008).  
Costs associated with severe disability and quality-of-life data were extrapolated over an 
expected time horizon of 76 years (Werner et al., 2011) and discounted at 3.5% according to 
the NICE reference case (NICE, 2013), assuming that life expectancy would be the same for 
babies with and without disabilities. This is a simplifying assumption that may make the cost 
and the utilities of disability look larger than they actually are. When extrapolated over the 
lifetime horizon, utility values for both full health and disability were adjusted by population 
norm utility values (Hawthorme and Osborne, 2005) by multiplication. 
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Table 7.1 Data inputs used in PTB model 
Parameters Mean 
values 
Reference 
Number of births in England 668,936  NHS maternity statistics 
report (England) (2012) 
Proportion of parous women (given birth at least 
once) 
0.44  Fonseca et al. (2007) 
Prevalence delivery before 34wks 0.04 Honest et al. (2009) 
LR+ of History 4.620 Honest et al. (2009) 
LR- of History 0.68 Honest et al. (2009) 
EIS sensitivity 0.44 EIS pilot data 
EIS specificity 0.9 EIS pilot data 
LR+ CL scan (sensitivity) 13.38 
(0.21) 
Honest et al. (2009) 
LR- CL scan (specificity) 0.8 (0.98) Honest et al. (2009) 
Prob. of PTB with progesterone after CL scan 0.181 Fonseca et al. (2007) 
Prob. of PTB with progesterone after EIS test 0.186 Assumption 
Prob. of PTB with no treatment 0.3214 Fonseca et al. (2007) 
Cond. prob. of birth before 28 wks 0.206 Werner et al. (2011) 
Cond. Prob. of birth after 37 wks 0.084 Werner et al. (2011) 
Prob. disability before 28 wks 0.106 Werner et al. (2011) 
Prob. disability 28-34 wks 0.05 Werner et al. (2011) 
Prob. disability 34-37 wks 0.024 Werner et al. (2011) 
Prob. disability after 37 wks 0.017 Werner et al. (2011) 
Prob. death before 28 wks 0.179 Werner et al. (2011) 
Prob. death 28-34 wks 0.009 Werner et al. (2011) 
Prob. death 34-37 wks 0.002 Werner et al. (2011) 
Prob. death after 37 wks 0.0007 Werner et al. (2011) 
Cost per EIS screening £ 44 Based on assumptions 
Cost per CL scan £ 14.38 Honest et al. (2009) 
Cost vaginal progesterone £ 1,115 Honest et al. (2009) 
Cost maternal care if delivery at <28 wks $10,953 Werner et al. (2011) 
Cost maternal care if delivery btw. 28-34 wks $8,153 Werner et al. (2011) 
Cost maternal care if delivery at 34-37 wks $4,627 Werner et al. (2011) 
Cost maternal care if delivery at >37 wks $3,577 Werner et al. (2011) 
Cost neonatal care if delivery at <28 wks  Honest et al. (2009) 
Cost neonatal care if delivery btw 28-34 wks £ 19,618 Honest et al. (2009) 
Cost neonatal care if delivery at 34-37 wks £ 15,137 Honest et al. (2009) 
Cost neonatal care if delivery at >37 wks £ 0 Honest et al. (2009) 
Cost medical intervention if delivery at <28 wks £ 123,213 Petrou and Khan (2012) 
Cost medical intervention if delivery betw 28-34wks £ 135,868 Petrou and Khan (2012) 
Cost medical intervention if delivery at 34-37 wks £ 22,829 Petrou and Khan (2012) 
Cost medical intervention if delivery at >37 wks £ 9,700 Petrou and Khan (2012) 
Cost severe disability (per year) $1,175 US Department of 
Health and Human 
Services (2004) 
Utility death (per year) 0 Werner et al. (2011) 
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Utility severe neurological disability (per year, these 
are adj. by pop. norms) 
0.61  Werner et al. (2011) 
Utility Health (per year, these are adj. by pop. 
norms) 
1  Werner et al. (2011) 
Life expectancy (years) 76 Werner et al. (2011) 
 
7.2.4 Synthesizing evidence 
For the purposes of this case study, I used available estimates of the required parameters 
that were obtained mostly from previous economic evaluations or trials as described above. 
This may mean that relevant evidence was missed. The potential lack of precision 
introduced by this will not impair this study that seeks to explore the effects of 
implementation dynamics on economic evaluation outcomes. For the final health economic 
model on the use of EIS for PTB screening, the model will be updated and it was therefore 
important to describe the model in sufficient detail to enable the updating of the model at a 
later stage. This is what I have attempted in Sections 7.2.2 and 7.2.3 and I will continue to 
describe the handling of uncertainty and simplifying assumptions transparently in this 
section.  
To reflect the uncertainty about the input parameters, I performed probabilistic 
sensitivity analysis (PSA) varying the uncertain parameter values over a number of 10,000 
simulations. I chose beta distributions for all probabilities and QALYs and gamma 
distributions for all costs, based on guidance by Briggs et al. (2006). I also used the log-
normal distribution for likelihood ratios. The probability distributions used in the PSA and 
shown in Table 7.2 were generated using the data sources shown in Table 7.1, with a few 
exceptions. All estimates obtained from Werner et al. (2011) were reported with ranges. I 
assumed that these ranges were 95% credible interval estimates although Werner et al. (2011) 
did not go into that detail.  
The sensitivity and specificity data for EIS were taken from the classification table of the 
pilot study. I used beta distributions to model each. However, because sensitivity and 
specificity measures are typically correlated, I also explored the use of a bivariate normal 
distribution on the log scale. Knowing that there is some correlation, of which the magnitude 
is currently unknown, I expressed my belief about the correlation (as was done by O'Hagan 
et al. (2001)) by assigning a covariance to the two measures that I assumed to lie between 
the individual variances in magnitude, resulting in 𝑚 = (
0.44
0.9
) , 𝑉 = (
0.0247 0.01
0.01 0.00309
). 
The resulting correlation coefficient then allowed the calculation of the joint and the 
conditional distributions of sensitivity and specificity. Using the bivariate lognormal 
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distribution on the log scale led to the marginal distributions of sensitivity and specificity to 
exhibit smaller variation compared with the separate simulation of these parameters using 
the beta distribution. For this reason, I continued using the separate simulation of sensitivity 
and specificity parameters for this illustrative example. 
As was done in the Honest et al. (2009) study, I used log-normal distributions for 
likelihood ratios of CL scans, restricted to a minimum of 1.0001 for the positive likelihood 
ratio and to a maximum of 0.9999 for the negative likelihood ratio. It needs to be mentioned 
that the estimates obtained from Honest et al. (2009) reflect a slightly different population, 
the non-high risk population. I assumed that the diagnostic accuracy may be similar to a high 
risk population but reflected the greater uncertainty in widened credible intervals.  
Instead of using the relative risk estimates in the PSA, I used the probabilities of giving 
PTB with and without progesterone treatment. This prevented the problem of yielding 
relative risk ratios greater than one in a small number of samples. The evidence used to 
generate the posterior distribution for the probabilities of PTB with and without 
progesterone treatment was obtained directly from Fonseca et al. (2007). To account for 
uncertainty associated with this estimate, I used a Beta(1,1) reference prior distribution to 
generate the posterior distribution for relative effectiveness of progesterone treatment after 
EIS screening.  
For lack of data, the credible intervals surrounding the capital costs of purchasing EIS 
were based on my assumption.  
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Table 7.2 Uncertain parameters varied in the PSA 
Parameters Mean 
estimates 
95% Credible 
Interval 
Distribution 
EIS sensitivity 0.44 (0.16, 0.76) Beta 
EIS specificity 0.9 (0.76, 0.98) Beta 
LR+ CL scan 13.38 (3, 26) Log-normal 
LR- CL scan 0.8 (0.65, 0.9) Log-normal 
Probability of PTB with progesterone after 
CL scan 
0.181 (0.117,0.256) Beta 
Probability of PTB with progesterone after 
EIS test 
0.186 (0.121,0.261) Beta 
Prob disability bef28wks 0.106 (0.091, 0.171) Beta 
Prob disability 28-34wks 0.05 (0.033, 0.097) Beta 
Prob disability 34-37wks 0.024 (0.021, 0.026) Beta 
Prob disability aft37wks 0.017 (0.015, 0.018) Beta 
Prob death bef28wks 0.179 (0.08, 0.493) Beta 
Prob death 28-34wks 0.009 (0.002, 0.086) Beta 
Prob death 34-37wks 0.002 (0.001, 0.004) Beta 
Prob death aft37wks 0.0007 (0.0005, 0.0009) Beta 
EIS cost £5,000 (£3,000, £15,000) Gamma 
Cost Maternal care if delivery at <28wks £7,345 (£1,341, £10,728) Gamma 
Cost Maternal care if delivery 28-34wks £5,467 (£670, £8,046) Gamma 
Cost Maternal care if delivery at 34-37wks £3,103 (£536, £4,694) Gamma 
Cost Maternal care if delivery at >37wks £2,399 (£469, £4,023) Gamma 
Cost Neonatal care if delivery at <28wks £19,618 (£12,505, £50,022) Gamma 
Cost Neonatal care if delivery 28-34wks £19,618 (£12,505, £50,022) Gamma 
Cost Neonatal care if delivery at 34-37wks £15,137 (£6,253, £37,516) Gamma 
Cost Medical intervention if delivery at 
<28wks 
£123,213 (£50,022, £150,065) Gamma 
Cost Medical intervention if delivery 28-
34wks 
£135,868 (£62,527, £187,581) Gamma 
Cost Medical intervention if delivery at 34-
37wks 
£22,829 (£3,752, £37,516) Gamma 
Cost Medical intervention if delivery at 
>37wks 
£9,700 (£2,501, £18,758) Gamma 
Cost Severe disability (per year) £941 (£401, £4,006) Gamma  
QALY Severe Neurological Disability (per 
year) 
0.61 (0.5, 0.8) Beta 
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7.2.5 Analysing the model  
The process of evaluating model outcomes is described by ‘folding back’ the decision 
tree. By folding it back, the expected values for each strategy can be calculated. Probabilistic 
analysis was performed by sampling from probability distributions in Table 7.2. I generated 
the posterior distribution for incremental costs and benefits, which is commonly represented 
as a cost-effectiveness plane (Drummond et al., 2005) and presented the probability of the 
different technologies being cost-effective in the cost-effectiveness acceptability curve 
(CEAC).  
 
7.2.6 Model evaluation 
Model evaluation should be centred around the assumptions and the model structure, the 
input parameters, distributions that reflect uncertainty, and the output and conclusions (Gray 
et al., 2011). There are three key processes that aid model evaluation (Gray et al., 2011) that 
I attempted to follow:  
1. Face or descriptive validity, which can be established if assumptions, the model 
structure and results can be described intuitively: I attempted an intuitive description of the 
model structure in Section 7.2.2 and described assumptions in the sections on data inputs 
(7.2.3) and on handling uncertainty (7.2.7). 
2. Internal validation and calibration, which tells us whether model inputs relate to 
outputs with a certain logic. To test this, extreme values and null values can be put into the 
model to explore whether they would have the expected effects on model results. I used null 
values for all costs but the costs associated with EIS, CL scans and progesterone and 
checked whether results and parameters related to each other logically by doing a few PSA 
runs and checking the relationship between all the PSA run specific parameter values and 
the resulting costs and QALYs. I also assumed the same distributions for the predictive 
ability of EIS and CL scans at (at the distribution of the likelihood ratios of CL scans) and 
re-ran the PSA with a small number of simulations to see whether in each simulation, the 
resulting costs and QALYs related to the parameter inputs logically.  
3. External validity and consistency can be shown if findings can be generalised beyond 
the evidence used for the model and can be demonstrated to apply in the real world. This is 
beyond the scope of this thesis.  
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7.2.7 Handling uncertainty 
In addition to presenting parameter uncertainty in the cost-effectiveness plane and 
CEAC, I also calculated the EVPI, which represents the expected opportunity loss of 
decision uncertainty. Uncertainty in the output can be broken down into those parameters 
that contribute the most to it by an EVPPI analysis.  
Structural uncertainty reflects assumptions made in building the model. Because this 
model is immature and needs updating at a later stage, I did not undertake any formal 
methods of addressing structural uncertainty, such as the model discrepancy method (Strong 
et al., 2012) or model averaging (Bojke et al., 2009). Instead, I summarise all the 
assumptions in this model in the list below: 
1. The number of births used includes multiple pregnancies but the analysis applies to 
singleton pregnancies. 
2. The incidence of PTB is the same across parous and nulliparous women. 
3. The likelihood ratios associated with CL scans in the low risk pregnant population 
are the same as the likelihood ratios associated with CL scans in the high risk 
population used here. 
4. The relative treatment effect of progesterone compared to no treatment after 
screening with EIS and after screening with CL scans are approximately the same, 
apart from adding a reference beta distribution. 
5. The relative treatment effect of progesterone compared to no treatment is the same 
regardless of whether pre-screening with previous history was performed or not. 
6. Only a single CL scan is conducted rather than a series of scans. This may have 
implications in terms of test accuracy and cost. 
7. Patients are only screened once using EIS, rather than being exposed to a series of 
tests. This may have implications in terms of test accuracy and cost.  
8. The cost of progesterone injections was used even though pessaries might be 
recommended in practice.  
9. The probability of giving birth prior to 28 weeks conditional on the probability of 
giving birth prior to 34 weeks was assumed to be independent of changes to the 
probability of giving birth prior to 34 weeks due to treatment. The same applied to 
the probability of giving birth prior to 37 weeks conditional on the probability of 
giving birth posterior to 34 weeks. 
10. No difference in life expectancy was assumed for patients in full health and those 
with any disability.  
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11. CL scans were assumed not to have any capital costs as ultrasound machines are 
mainly used for many other purposes and have a long lifetime. This may introduce a 
slight bias in favour of CL scans. 
12. I assumed that each obstetric unit in the country would purchase two EIS devices. 
13. Health outcomes were crudely modelled: different conditions were grouped and the 
same probability, QALY value and cost assumed for all of them. 
14. Estimates for likelihood ratios for CL scans were based on a cut-off of 25 mm but 
the estimate for the relative risk associated with progesterone treatment versus no 
treatment was based on a 15 mm cut-off. 
 
7.3 Methods for estimating the dynamic expected value of 
implementation and information illustrated in the PTB screening 
model 
7.3.1 Calculating the value of implementation measures 
In this section, I describe how the extended EVII framework introduced in Chapter 4 
was applied in the EIS screening case study. I first present results for a static analysis, in 
which diffusion was ignored and only time-fixed implementation estimates were used. Then, 
I present results for the dynamic analysis that took account of diffusion. Static and dynamic 
estimates of implementation were therefore needed to facilitate comparison of the static and 
the dynamic method. The additional implementation data requirements affected the 
estimation of the expected value of implementation measures only (see Chapter 4 Table 4.3 
for a summary of the different value measures). The diffusion curves required for the 
dynamic analysis were obtained from the elicitation study described in Chapter 6. I also 
derived static estimates from there.  
To calculate the expected value of perfect implementation, an estimate of optimal 
implementation levels was needed. I assumed this to be 462 devices, based on the number of 
obstetric units in England (231 according to UNICEF (2013)) and assuming that two devices 
are needed for each obstetric unit (see Chapter 6), resulting in 462 adoptions for England. In 
the absence of information to suggest otherwise, I assumed that the share of the other two 
technologies over the remaining adoptions was equal, as was detailed in Section 4.2.4 in 
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Chapter 4. Table 7.3 shows a summary of the data used for each of the expected value 
measures. 
Calculating the EVPIM also required knowledge of current implementation of the 
alternative technologies. Current implementation refers to the level of implementation that 
can be achieved currently, that is, without the performance of any further research or 
implementation initiatives. For the dynamic EVPIM analysis, the elicited baseline diffusion 
curve was used (see Table 7.3). For the static analysis, I used the estimate of the maximum 
attainable number of adoptions from that elicited diffusion curve (the mean estimate was 
140). At the time of technology appraisals, implementation of a new technology is 
commonly zero percent. Using this as the baseline implementation level would, however, 
over-inflate the EVPIM, as the recommendation decision alone is commonly assumed to 
trigger a certain level of implementation (this was backed up by findings from the review of 
diffusion curves in Chapter 3). Of course, the assumption of a sudden jump in 
implementation is not necessarily realistic, highlighting the limitations of using static 
analysis.  
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Table 7.3 Data requirements for estimation of Expected Value measures 
Value concept Implementation 
data required 
Data used in static analysis Data used in 
dynamic analysis 
EVPIM  
Current 
implementation  
140 adoptions (=30.3%) 
(elicited ‘current’ maximum 
attainable adoptions) 
Elicited current 
diffusion curve 
Perfect 
implementation 
100% 100% in each period 
EVPIM
R 
Current 
implementation 
140 adoptions (=30.3%) 
(elicited ‘current’ maximum 
attainable adoptions) 
Elicited current 
diffusion curve 
Implementation at 
perfect information 
200 adoptions (=43.3%) 
(assumed) 
Elicited ‘Both 
research studies’ 
diffusion curve 
parameters, but with 
maximum adoptions 
of 200 
EVSIM
Rpp 
Current 
implementation 
140 adoptions (=30.3%) 
(elicited ‘current’ maximum 
attainable adoptions) 
Elicited current 
diffusion curve 
Implementation at 
perfect parameter 
information for EIS 
+ Prog parameters 
150 adoptions (=32.5%) 
(assumed) 
Elicited ‘Both 
research studies’ 
diffusion curve 
parameters, but with 
maximum adoptions 
of 150 
EVSIM
S1+S2 
Current 
implementation 
140 adoptions (=30.3%) 
(elicited ‘current’ maximum 
attainable adoptions) 
Elicited current 
diffusion curve 
Implementation 
with respective 
research evidence 
available 
142 adoptions for EIS trial 
and 144 adoptions for 
Progesterone trial (elicited 
study specific maximum 
attainable adoptions) 
Elicited study specific 
diffusion curve 
 
To calculate the EVPIM
R
, estimates of implementation levels that would occur when all 
decision uncertainty had been resolved were needed. This was not elicited and I assumed 
that 200 adoptions (43%) could be achieved by resolving all uncertainty for illustration 
purposes. The number of 200 out of 462 possible adoptions achievable through research was 
deliberately low, because the qualitative study reported in Chapter 5 revealed that there were 
many factors affecting the implementation of EIS, not only research. This finding was 
confirmed in the elicitation study in which experts pointed out that ‘some trusts never adopt 
new technology’ or that the predictive ability of EIS was too low to warrant greater 
implementation. 
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Calculation of the respective EVSIM of the two research studies on 1. the treatment 
effect of progesterone against no treatment after EIS screening and 2. the parameters 
associated with the predictive ability of EIS (sensitivity and specificity) required quantitative 
estimates on diffusion for each. These were obtained by applying the elicited proportional 
gain in implementation for each of the studies κ to each period of the difference between the 
‘with further research’ diffusion curve and the ‘without further research’ diffusion curve (61% 
for the relative treatment effect of progesterone versus no treatment after screening with EIS 
study, and 39% for the EIS predictive ability study). For the static analysis, I used the 
elicited study-specific maximum attainable number of adoptions, which resulted in an 
increase of approximately four purchases for the progesterone trial and of approximately two 
purchases for the EIS screening trial. It is important to note here that the with research 
diffusion estimates were based on the elicitation exercise in which the effects of possible 
study results were not considered. The EVSI is therefore calculated assuming that diffusion 
and expected net benefit are independent of each other, as was shown in Equation (4.12) in 
Chapter 4. This limitation needs to be addressed in future research. To obtain an intuition of 
the potential impact on EVSIM results, I explore this issue in Section 7.4.4, where I apply 
Equation (4.11) from Chapter 4 in an extension to this case study. 
For the EVSIM
Rpp
 analysis, knowledge of the level of implementation when uncertainty 
surrounding these parameters is completely resolved was required. This was not elicited but 
I assumed it to be at 150 adoptions. This was based on assuming diminishing marginal 
returns to research on the same parameters and knowledge of the maximum attainable 
adoptions with both research studies, and without further research.  
 
7.3.2 Calculating the value of information measures 
The calculation of EVPI and EVPPI are straightforward and methods are described 
elsewhere (Briggs et al., 2006, Claxton et al., 2012, Strong et al., 2014). The evaluation of a 
specific research study using the EVSI, however, deserves a more detailed description. To 
calculate the EVSI, it was necessary to simulate the research that was planned. The process 
of trial data simulation has been described previously (Ades et al., 2004, Strong et al., 2015, 
Brennan and Kharroubi, 2007) and I follow the steps outlined there. The two planned 
research studies were 1. to investigate the relative treatment effect of progesterone compared 
with no treatment after screening with EIS, and 2. to study the predictive ability of EIS in 
identifying women that would give PTB. 
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For 1., one possible research design after recommendation of EIS could be an 
observational study in which progesterone treatment was given to those patients who tested 
positive. The omission of a control arm could be caused by ethical issues in recruiting 
patients for the no treatment arm, once screening and treatment are recommended. To 
simulate such a one-arm observational study, the response to treatment with progesterone 
after screening with EIS was estimated. A statistical model for the data that would be 
collected had to be specified, together with the sample size, and then a dataset from the 
proposed study could be simulated for each ‘row’ of the PSA on that parameter. The 
probability of having a PTB after treatment with progesterone was represented by a beta 
distribution. For the trial simulation, a sample size of 150 patients was assumed. For each 
row of the PSA, I generated a sample of data 𝑥(𝑘) for those 150 patients (where k is the 
number of draws from the PSA), sampling from a 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑃𝑃𝑇𝐵.𝑃
(𝑘) , 150) distribution 
(where 𝑃𝑃𝑇𝐵.𝑃 is the probability of having a PTB given treatment with progesterone). Given 
the simulated data, the implied model parameters for the decision model could be calculated. 
I calculated the EVSI using the Generalized Additive Model (GAM) regression method 
developed by Strong et al. (2015), which entailed regressing the incremental net benefits on 
the simulated data for each run of the PSA and estimating the EVSI using Equation (4.4) in 
Chapter 4.  
I followed the same process for simulating a study of the predictive ability of EIS. For 
this, I used the PSA output for the sensitivity and specificity of EIS and assumed that the 
prevalence of 13% PTB was fixed. I assumed that sensitivity and specificity were 
uncorrelated for simulating the data, as I have also done within the PSA. I simulated a trial 
with a sample size of 300 non-randomised high risk pregnant women. All pregnant women 
would be tested for PTB using EIS screening. There are therefore four different possible 
outcomes: patients could have tested positive and had a PTB (quantified by the sensitivity 
times the prevalence), patients could have tested negative and had a PTB (1-sensitivity times 
prevalence), or patients could have tested positive or negative and not had a PTB (1-
specificity or specificity times prevalence, respectively). Assuming the prevalence was fixed, 
I generated data for sensitivity and specificity in independent simulations. This enabled me 
to know the sample size in each data simulation: for the sensitivity simulation, the sample 
size was determined by the prevalence in the high risk population (approximately 13% based 
on prevalence in all pregnant women of 0.04 and number of parous pregnant women with 
history of PTB as well as sensitivity and specificity of history) times the overall trial 
population, resulting in 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑃𝐸𝐼𝑆.𝑆𝑒𝑛𝑠
(𝑘) , 39). For the specificity, the sample size was 
the remainder, resulting in 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑃𝐸𝐼𝑆.𝑆𝑝𝑒𝑐
(𝑘) , 261).  
 193 
 
 
7.3.3 Accruing the EVII measures over the population and decision relevance 
horizon 
In order to compare the EVII measures with the cost of a research study, the above value 
measures need to be accrued over the relevant population and decision relevance horizon. 
The population of women screened annually was approximately 27,000 women. I assumed a 
decision relevance horizon of five years. 
When specific implementation measures or research studies are to be evaluated against 
their cost, their value will only accrue for the proportion of the population that can be 
reached with the cost-effective technology, which will be shown to be EIS. This proportion 
of the population is achieved by adjusting the overall population by the implementation that 
can be achieved with the implementation measure.  
 
7.3.4 The timing of implementation measures and their effects  
To calculate the EVSIM of both research studies with a delay in time, I assumed the 
study on the predictive ability of EIS would report within two years of the decision, and the 
progesterone treatment effect study would report within three years of the recommendation 
decision. I assumed that the reported research evidence would have an effect on 
implementation right away. In the first years up to the point at which the research reported 
(two or three years after the decision), implementation would follow the elicited baseline 
uptake curve and after that it would follow the curves that were elicited for the two research 
studies. This jump is a simplification because the post-research curves were elicited under 
the assumption that those research results were available at the start of the implementation 
process. The bias that may result from this simplification is an over-estimation of the 
EVSIM, stemming mainly from the first periods after the jump in the implementation curve. 
Ideally, different implementation curves for different timings at which the research reports 
would have been elicited to solve this problem. 
 
7.3.5 Assessing the residual EVP with implementation measures 
The residual EVP with implementation measures can be calculated by subtracting the 
EVSIM associated with the planned implementation measure from the EVP. If the 
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implementation measure is research, it is important to evaluate its value in terms of both, the 
EVSI and the EVSIM and subtract both from the EVP. For this evaluation, the population 
values of the EVP aggregated over all periods until the decision relevance horizon should be 
used to reflect the value of the implementation measure to the payer. The implementation 
measure is then worth doing if the population EVSIM exceeds its cost.  
 
 
7.3.6 Practicalities of building the model and the EVII analysis 
The cost-effectiveness model was built using MS Excel. The PSA was performed in 
Excel using VBA. The individual and grouped EVPPI results were obtained using the SAVI 
online tool (http://savi.shef.ac.uk/SAVI/). Further analysis on the other value measures (for 
instance, the EVSI, EVPIM, EVSIM) were performed in R. 
The EVPPI and EVSI analyses were accomplished using the GAM regression to 
estimate the EVPPI developed by Strong et al. (2014). EVPPI analysis has so far been a 
computationally expensive exercise because the analysis required sampling from all 
uncertain parameters for a certain number of times within an inner loop when the parameter 
of interest was fixed and sampling again from all uncertain parameters with a new value for 
the parameter of interest in an outer loop (Briggs et al., 2006). The problem of the 
computational burden was even larger when calculating the EVSI in cases where the prior 
distribution was not conjugate to the data likelihood, because a Markov Chain Monte Carlo 
simulation would be required to obtain the posterior (Strong et al., 2015). With the 
nonparametric regression-based methods developed by Strong et al. (2014) and Strong et al. 
(2015), computation times of the EVPPI and EVSI are significantly reduced by avoiding the 
nested two-level approach. 
 
7.4 Results of the EVII analysis applied in the PTB screening model  
7.4.1 Cost-effectiveness results and uncertainty in PTB screening model 
Based on the PSA, EIS was expected to be dominating against both CL scans and no 
screening strategies. The PSA with 10,000 simulations resulted in EIS being the technology 
with the highest expected net benefit (Table 7.4). All costs and QALYs were scaled down to 
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a per person level based on all screened persons. Each screening strategy was associated 
with approximately 22 QALYs – these were discounted QALYs the average baby born 
would accrue over their lifetimes. EIS screening provided a small QALY gain over CL scans 
and over no screening. This was caused by the identification of more women going on to 
give PTB who could then be treated. In some of these treated women, PTB could be averted. 
For all screened women, this translated into a gain of 2,192 QALYs that EIS provided over 
CL scans, and a gain of 2,601 QALYs that EIS provided over the no screening strategy.   
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Table 7.4 PSA results for EIS in PTB model (based on 10,000 simulations), scaled to per person screened 
Threshold = £20,000 / 
QALY 
EIS CL scans No screening 
Expected Costs £32,649 £35,774 £38,493 
Expected QALYs 22.36 22.33 22.30 
Expected number of 
PTBs* 
3,279 3,888 4,418 
Expected number of 
detected PTBs* 
1,963 939 0 
Expected number of 
PTBs averted* 
1,139 529 0 
Expected number of 
false negatives* 
2,454 3,478 0 
Expected number of 
false positives* 
2,374 365 0 
Cost per screening 
strategy without 
treatment or 
consequences* 
£1.2m £0.4m £0 
Cost of consequences: 
disability* 
 
£15.5m 
 
£16.2m  
 
£16.8m 
Maternal and neonatal 
treatment and delivery* 
£870m £958m £1.03bn 
ICER against CL scans Dominating - NA 
ICER against no 
screening 
Dominating Dominating - 
Expected Net Monetary 
Benefit 
£414,481 £410,735 £407,488 
* not scaled to per person screened 
 
EIS was associated with expected costs that were smaller than those associated with CL 
scans and no screening strategies (Table 7.4). For all screened women the expected saving 
that EIS provided over CL scans was £136.77 million; and the expected saving of EIS over 
no screening was £161.76 million.  
Since EIS was still in development, the maximum price under which EIS would still be 
cost-effective against its comparators may be of interest to the manufacturer. I therefore 
performed a threshold analysis and found that the maximum price of EIS, at which EIS was 
still cost-effective against CL scans at £20,000 per QALY, was £991,507 (rather than 
£5,000). This was the price per device conditional on the other costs per scan being fixed at: 
£15 for disposables, £9 for manpower, £1 for maintenance and training. The resulting cost 
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per scan of capital and other costs would be £3,733. Against no screening, the maximum 
price would be at £1.87 million, resulting in a maximum permissible cost per scan of £7,002. 
The PSA results indicate that the expected values presented in Table 7.4 were associated 
with uncertainty. This is shown in the cost-effectiveness planes in Figure 7.2 and Figure 7.3 
in which part of the distribution of the incremental net benefit when comparing against CL 
scans lies in the North West (the dominated) quadrant (11%). A very small part of the 
incremental net benefit distribution lies in the North East quadrant in which the location 
above or below the threshold diagonal determined whether EIS was cost-effective against 
CL scans in that particular run of the simulation. This is reflected in the CEAC in Figure 7.5, 
in which the probability of EIS being cost-effective appears to be slightly lower at low 
thresholds than at higher thresholds. The largest part of the incremental net benefit 
distribution of EIS against CL scans lies in the South East (the dominating) quadrant (Figure 
7.2). Against no screening, all of the distribution lies in the South East quadrant (Figure 7.3). 
CL scans are clearly dominating against no screening (Figure 7.4), with only 0.4% of the 
incremental net benefit distribution lying in the North West quadrant. Figure 7.4 also shows 
a smaller spread of the incremental net benefit distribution of CL scans against no screening 
compared with the EIS comparisons, indicating greater certainty for the CL scans versus no 
screening comparison. 
The EVPI associated with this decision is £141.92 per person (see Table 7.5). Accrued 
over the population of women screened in England (approximately 27,000 women screened), 
the annual population EVPI is £3.83 million. Over a decision relevance horizon of five years, 
the population EVPI amounts to £19.16 million. 
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Figure 7.2 Cost-effectiveness plane of EIS against CL scans 
 
 
Figure 7.3 Cost-effectiveness plane of EIS against no screening 
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Figure 7.4 Cost-effectiveness plane of CL scans against no screening 
 
 
Figure 7.5 Cost-Effectiveness Acceptability Curve for EIS against CL scans and no screening 
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The reason for EIS being so clearly dominating lay in the fact that its use implied little 
additional costs (estimated at £44 per person screened, compared with £12 for CL scans and 
£0 for no screening) and saved some women from having a very costly PTB. The facts that 
1. the predictive ability of EIS was not perfect (especially the sensitivity was low at 
approximately 44%) and that 2. the treatment effect of progesterone compared with no 
treatment was not very large do not impair this strategy’s dominance over no screening, no 
treatment. This was because one PTB averted could prevent the payer from incurring a cost 
of up to £150,000 for maternal care, neonatal care and medical intervention in 18 years of 
the child’s life (this is ignoring the potential cost of disability), in the worst case of a PTB 
prior to 28 weeks of gestation.  
The main cause for EIS performing strongly compared with CL ultrasound scans was 
that the negative likelihood ratio associated with CL scans was very high (at 0.8). This 
meant that CL scans were not very useful in ruling out that a woman would have a PTB 
because they produced a large number of false negatives (almost 80% of the women in 
whom a PTB was imminent, compared to 56% false negatives with EIS, based on the mean 
estimates from the model). This led to many fewer women treated (940 women out of the 
ones with PTB imminent with CL scans compared with 1,960 with EIS screening) and fewer 
avoided cases of PTB as a result (529 compared to 1,139).  
To explain the clear-cut results against no screening, one aspect in which EIS could 
perform worse than no screening was that a woman could falsely be tested positive and 
treated with progesterone at a cost of approximately £1,100. The cost of even one PTB 
averted would however be much larger, because, only in terms of neonatal care, maternal 
care and early intervention and ignoring lifelong costs, the cost-saving per PTB averted 
would be at approximately £72,000 (when a weighted average for the costs prior and 
posterior to 28 weeks’ and 37 weeks’ gestation was taken). In order for no screening to 
perform better than EIS screening, EIS would therefore have to produce at least 65 False 
Positives for each PTB averted. On average, however, EIS produced only 2False Positives 
for each PTB averted (in combination with progesterone treatment).   
It is no surprise, given the decision problem, that costs and QALYs appeared to be 
strongly correlated in the cost-effectiveness planes in Figure 7.2 to Figure 7.4. The 
correlation was explained by large parts of the costs arising with poor health outcomes for 
the child.  
To summarise this section, EIS for use in PTB screening together with progesterone 
treatment of women that tested positive was shown to be a dominating strategy against the 
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strategies of CL scans and progesterone treatment and no screening and no treatment. The 
results of the cost-effectiveness model were insensitive to the price of EIS. In fact, based on 
this model, the manufacturer could charge up to almost £1 million per device, given that the 
other cost parameters were reflected accurately. 
 
7.4.2 The static EVII analysis applied in the PTB screening model 
The above analyses showed the per person EVPI to be at approximately £142 per person, 
or £19 million for the population and a decision relevance horizon of five years (Table 7.5). 
The EVPPI analysis identified the sensitivity of EIS as the parameter driving the largest part 
of the EVPI (39%). Other individual parameters causing uncertainty were the relative risk 
ratio of treating with progesterone compared to not treating the women who tested positive 
with EIS and the negative likelihood ratio of CL scans, but both contributed less than 1% of 
the EVPI. I selected a few combinations of parameters based on my beliefs on what may 
contribute most to decision uncertainty and evaluated the grouped EVPPI. The result was 
that parameters for the predictive ability of both CL scans and EIS screening together with 
the treatment effect of progesterone after both types of screening explained approximately 
100% of the EVPI.  
The burden caused by low implementation was larger than the burden caused by 
uncertainty, costing the payer £3,742 per patient, which, over the population of women 
screened and the decision relevance horizon of five years, amounted to £472 million (Table 
7.5). A significant part of the EVPIM could be addressed using research. This was revealed 
by the Research EVPIM, which was large, at £700 per person which translated into £88 
million for the affected population in England over a five year decision relevance horizon. 
This EVPIMR meant that the value of resolving all decision uncertainty in terms of changing 
implementation was at £88 million. This suggests that it may be worthwhile to consider 
research studies as a means of increasing implementation, thus reducing the burden to the 
payer of financing other sub-optimal screening technologies. It needs to be mentioned, 
however, that the EVPIMR was based on assumptions surrounding the level of 
implementation that could be achieved when all uncertainty had been resolved. The EVSIM 
is more specific in telling us what the value of an actual research study would be in terms of 
increasing implementation. The possible reduction in the EVPIM that could be achieved by 
complete elimination of all parameter uncertainty around the predictive ability of EIS and 
the progesterone treatment effect had a value of approximately £116 per person or £1.55 
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million for the affected England population over five years (see the perfect parameter 
information Research EVSIM in Table 7.5). 
The research study on the progesterone treatment effect after screening with EIS in a 
two-arm randomised controlled trial with 300 patients recruited had an EVSI of 
approximately 21p per person. The EVSI of the other research study on the predictive ability 
of EIS was £52 per person. The EVSIM associated with both studies were £42 and £28 per 
person, respectively. Note that the EVSI, EVSIM and EVPIMR population values were 
adjusted by implementation. 
Together, the EVP therefore was £3,884 per person, or £491 million for the affected 
England population over five years. The Expected Value of Research was £3.23 million for 
the EIS study and £1.65 million for the progesterone study for the England population over 
five years. Compared to the EVP, these are small numbers. This is mainly explained by 
implementation remaining small even with further research evidence becoming available. 
This has two effects: 1. on the adjusted population estimate that the value measures accrue 
for and 2. on the implementation-related value measures themselves.  
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Table 7.5 The static EVII results in the PTB screening model 
  Per 
person 
Population 
per annum  
Population over time 
horizon of 5 years 
(discounted) 
U
n
c
er
ta
in
ty
 
EVPI £142 £3.83 million £19.16 million 
EVPPI (EIS sens+spec) £58 £1.56 million £7.3 million 
EVPPI (Tx effect Pg) £0.32 £8,733 £40,811 
EVSI (EIS) £52 £428,433 £2.15 million 
EVSI (Pg) £0.21 £1,577 £8,862 
Im
p
le
m
e
n
ta
ti
o
n
 
EVPIM  £3,742 £101 million £472 million 
EVPIM
R
 £697 £18.83 million £88 million 
EVSIMRpp (EIS + Pg) £116 £327,922 £1.55 million 
EVSIM (EIS)  £28 £232,127 £1.08 million 
EVSIM (Pg)  £42 £351,126 £1.64 million 
B
o
th
 
EVP £3,884 £105 million £491 million 
EVR (EIS) £80 £660,560 £3.23 million 
EVR (Pg) £42 £352,703 £1.65 million 
 
 
Figure 7.6 The EVII analysis chart for the static EIS analysis 
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The static EVP and possible reductions in it with the two research studies are presented 
in Figure 7.6. The residual EVPs with research studies were not considerably smaller than 
the without research EVP because the Research EVPIM was only reduced by between 1-2% 
for both studies. Of course, it may be worthwhile conducting these research studies as long 
as the costs of the planned study do not exceed the respective expected value of research, 
that is, the sum of EVSIM and EVSI. At EVRs of £3 million and £1.65 million for the two 
research studies respectively, this could be possible. At a crude cost estimate of £2 million 
for either of the trials, the study on the predictive ability of EIS would provide a positive net 
gain, while the study on the relative treatment effect would not. 
To summarise this section, the large EVPIM together with the relatively smaller EVPI 
resulted in a large burden of EVP of £491 million for the affected England population over 
five years. This large burden was caused mainly by two factors: that EIS was clearly better 
than the comparative strategies, exhibiting a much larger expected net benefit, and that 
implementation of EIS was expected to be relatively low at approximately 30% throughout 
its lifetime. The proposed research studies only caused a relatively small reduction in the 
EVP by the EVR because 1.) the EVPI was small and reductions in it posed a negligible 
improvement in the overall EVP and 2.) the gain in implementation that could be achieved 
by those research studies was small, resulting in an improvement of implementation of only 
3%. In absolute terms, the EVRs of the respective research studies may still be large enough 
at £1.65 and £3.23 million to potentially make them worthwhile if their costs fell below the 
expected value of research. These results indicate that other implementation measures may 
reduce the large EVPIM further. The static analysis was based on static baseline 
implementation estimates that were unrealistic. Dynamic analysis is therefore required and 
will be demonstrated in the next section. 
 
7.4.3 The dynamic EVII analysis applied in the PTB screening model 
 Dynamic analysis when research evidence is available at the time of 7.4.3.1
recommendation 
The above analysis ignored the dynamics of implementation that occur with and without 
the investment in implementation measures and research. In this section, I present the results 
when these dynamics were considered (Table 7.6) and the new residual EVPs in Figure 7.7. 
Results of the dynamic analysis only differed in the EVPIM
R
, the EVSIMRpp, the EVPIM, 
EVP and the EVSIM values but not in the EVPI and EVPPI (Table 7.8).  
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The dynamic analysis considered the difference in expected net benefits in each period, 
resulting in different estimates for the implementation-related expected value measures in 
each period. These differing values are illustrated in Table 7.7. To obtain the expected 
population values presented in Table 7.6, I multiplied the average value measures over all 
periods up to the decision relevance horizon (shown in Table 7.7) with the expected patient 
population. In the case of EVSIM and EVSI the population values were adjusted by the 
achievable uptake in each period. 
The trends of the different EVII measures are explained by the following: The EVPIM is 
falling in each future period because the gap between perfect implementation and the 
increasing uptake curve is closing. The Research EVPIM, EVSIMRpp, and the EVSIMs of 
both studies rise over time as the gap between the with and without research diffusion curves 
widens.  
In this case study, results for the measures influenced by implementation obtained from 
the dynamic analysis differed from those from the static analysis (Table 7.8). In some cases 
they were larger (EVPIM, EVSIMRpp and both EVSIMs) and in one case the dynamic value 
was smaller (EVPIM
R
). The reason for the differing values is illustrated through the example 
of the two research studies and their effect on implementation in Figure 7.8. In the static 
analysis, it was assumed that the recommendation decision was followed by an immediate 
implementation of the baseline uptake, shown by the dashed grey line. Further research 
studies on the progesterone treatment effect and the predictive ability of EIS before the 
research recommendation would result in immediate implementation shown by the solid 
grey line in Figure 7.8. More realistically, a recommendation decision would trigger the 
much slower implementation process illustrated by the dashed blue line for no further 
research and the solid blue line for further research studies having completed (Figure 7.8). It 
becomes evident from Figure 7.8 that the gap between the blue lines is much larger than 
between the grey lines, even when the average over all periods is taken. This led to the 
dynamic analysis exhibiting larger values for the EVSIM associated with the different 
research strategies. This finding is not generalisable as the difference between dynamic and 
static results depends on the static before and after implementation values as well as the 
distance between the dynamic curves in each period. For the EVPIM
R
, for instance, a jump 
from 140 to 200 adoptions was assumed in the static analysis, leading to a greater difference 
between the static solid lines than between the dynamic curves. 
Figure 7.7 shows that the reduction in the EVP achievable with the designed research 
studies remained small. This was because the EVP increased. The EVSIM also increased but 
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the reduction in the EVP that is achievable with the research studies, that is the EVR, 
remained comparatively small and posed only just above 1% of the EVP. 
 
Table 7.6 The dynamic EVII results in the PTB model 
  Per 
person 
Population 
per annum 
(average) 
Population over time 
horizon of 5 years 
(discounted) 
U
n
c
er
ta
in
ty
 
EVPI £142 £3.83 million £19.16 million 
EVPPI (EIS sens+spec) £58 £1.56 million £7.3 million 
EVPPI (Tx effect Pg) £0.32 £8,733 £40,811 
EVSI (EIS) £52 £428,433 £2.15 million 
EVSI (Pg) £0.21 £1,577 £8,862 
Im
p
le
m
e
n
ta
ti
o
n
 
EVPIM  £4,988 £126 million £631 million 
EVPIM
R 
£582 £3.30 million £16.5 million 
EVSIMRpp (EIS + Pg)  £343 £1.43 million £7.15 million 
EVSIM (EIS)  £129 £383,811 £1.92 million 
EVSIM (Pg)  £193 £645,862 £3.23 million 
B
o
th
 EVP £5,130 £130 million £650 million 
EVR (EIS) £181 £812,244 £4.07 million 
EVR (Pg) £193 £647,439 £3.23 million 
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Table 7.7 Per period EVII estimates in dynamic analysis 
Period EVPIM EVPIM
R 
𝐄𝐕𝐒𝐈𝐌𝐑𝐩𝐩  
EVSIM 
EIS trial 
EVSIM 
Prog trial 
1 £5,299  £136  £85  £32 £48 
2 £5,190  £348  £217  £82 £123 
3 £5,032  £609  £374  £142 £212 
4 £4,827  £843  £499  £188  £281 
5 £4,592  £974  £538  £200  £301  
Average £4,988  £582  £343  £129 £193 
 
 
Table 7.8 Comparison of static and dynamic analysis in the PTB model 
Per person values Static analysis Dynamic analysis 
EVPIM  £3,742 £4,988 
EVPIM
R
 £697 £582 
𝐄𝐕𝐒𝐈𝐌𝐑𝐩𝐩 (EIS + PG) £116 £343 
EVSIM (EIS)  £28 £129 
EVSIM (Pg)  £42 £193 
EVP £3,884 £5,130 
EVR (EIS) £80 £181 
EVR (Pg) £42 £193 
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Figure 7.7 The EVII analysis chart for the dynamic analysis 
 
 
Figure 7.8 Comparison of static and dynamic implementation estimates 
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 Dynamic analysis when considering the timing at which research reports 7.4.3.2
When the timing of research was considered and the results of the research only became 
available after the recommendation decision, the values of the EVSIM were lower than the 
values of the EVSIM when research reported before the recommendation decision (Table 
7.9) because the payer would not accrue any benefit from it for some years. This is presented 
in more detail in Table 7.10. The newly calculated EVSIM values, however, were still larger 
than the values obtained from the static analysis.  
The fact that the decrease was considerable could be explained by the relatively large 
difference between diffusion curves especially in the first few periods and the discounting 
that would result in greater importance being placed on the periods in the near future. This is 
shown through the implementation curves for the two studies and the kinks they exhibit at 
the time of reporting of the results compared with the (dotted) curves that could have been 
obtained if research reported now, presented in Figure 7.9. This illustrates that the time at 
which research reports could have a large effect on the EVSIM. For example, if research 
reported only after the five year decision relevance horizon, the EVSIM would be zero.  
 
Table 7.9 EVSIM values at future reporting times 
Study – time to 
reporting 
Per 
person 
Population 
per annum  
Population over decision 
relevance horizon of 5 
years (discounted) 
EVSIM (EIS) – 2 yrs £106 £33,798 £168,992 
EVSIM (Pg) – 3 yrs £116 £36,626 £183,132 
 
Table 7.10 Per period and person EVSIM estimates in dynamic analysis 
Period 
EVSIM EIS trial with 
2 years reporting time 
EVSIM Prog trial with 3 
years reporting time 
1 £0     £0    
2 £0    £0    
3 £141.50 £0    
4 £187.57  £281.35  
5 £200.42  £300.63  
Average  £106  £116 
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Figure 7.9 Implementation curves with different research studies and reporting times 
 
 
In summary, using dynamic implementation estimates, as opposed to their static 
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mainly larger with implementation dynamics than with a static analysis. It is worth noting 
that dynamic analysis does not always generate larger or smaller results than the static 
analysis – the sign of the change depends on the assumptions made about the static 
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7.4.4 Exploring the impact of different study results on the EVSIM 
In this thesis, the impact of different study results on the EVSIM and subsequently on 
the EVR has been largely ignored. The reason for this was to capture the effect of a 
reduction in uncertainty on diffusion, as was done in previous studies (Willan and 
Eckermann, 2010). However, a full consideration of the effects of research on diffusion must 
include the potential for different study results. When this is considered, diffusion is no 
longer independent of the net benefit function and Equation (4.11) described in Chapter 4 
must be used to calculate EVSIM and EVR instead of Equation (4.12).  
Implementation of this requires estimates of different diffusion curves conditional on 
study outcomes. Ideally, a meta model of diffusion as a function of study outcomes would be 
available. Such a model could be informed by an elicitation of expert opinions on diffusion 
in which a functional relationship between study outcomes and diffusion is established. To 
inform this functional relationship it is necessary to elicit a number of different diffusion 
scenarios conditional on different study outcomes, as was described in Section 6.5.  
In this section, I explore the impact of different study results on the Research EVSIM 
and EVR using an extension to the model shown in Section 7.3.4 and using both proposed 
studies, on the predictive ability of EIS and the progesterone trial for illustration purposes. 
For this, I use the individually elicited diffusion curves from each of the three experts as a 
proxy to diffusion curves for the following three cases: 
1. study results are in the lowest quartile of the original distribution, i.e. the predictive 
ability of EIS is much worse than the previously expected value / the progesterone treatment 
effect relative to no treatment is worse than for CLS. 
2. study results fall within the two mid quartiles of the original distribution, i.e. the 
predictive ability of EIS falls into 50% credible interval of the previously expected value / 
the progesterone treatment effect relative to no treatment falls into the 50% credible interval 
of the previously expected value. 
3. study results fall in the uppermost quartile of the original distribution, i.e. the 
predictive ability of EIS / progesterone treatment effect is much better than the previously 
expected value. 
Implementing Equation (4.11) requires applying the different diffusion curves to each 
run of the PSA, based on the simulated study results in that PSA run. For illustration 
purposes, I simplify this by using a different with-research diffusion curve conditional on the 
expected net benefit associated with EIS. For this, I divide the net benefit distribution up into 
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quartiles. If net benefit in a PSA run falls into the lowest quartile, I use expert 1’s diffusion 
curve; if it falls into the middle two quartiles, I use expert 2’s curve and expert 3’s curve for 
net benefit falling into the uppermost quartile. The counterfactual without research diffusion 
curve is that based on all (pooled) experts’ estimates. The diffusion curves relating to the 
other two technologies are calculated by using an equal share over the remainder of the 
market share after EIS has been taken up.  
Results of this analysis show that the conditional EVSIMs on study outcomes for both 
the progesterone and the EIS studies are larger than those calculated independently of the 
study outcomes (Table 7.11). 
 
Table 7.11. EVSIM of studies with uptake conditional on simulated trial outcomes 
Period 
Cond. 
EVSIM Prog 
trial 
Cond. 
EVSIM EIS 
trial
 
Previous 
EVSIM 
Prog trial 
Previous 
EVSIM 
EIS trial 
1 £53 £40 £48 £32 
2 £156 £129 £123 £82 
3 £296 £264 £212 £142 
4 £426 £395 £281 £188  
5 £504 £471 £301  £200  
Average £287 £259 £193 £129 
 
This in turn leads to the following values for the conditional EVSIMs and EVRs accrued 
over the population and over time (Table 7.12). The expected value of research accrued for 
the population and the time horizon is now larger than originally, when study outcomes were 
not considered in the calculation of the Research EVSIM (£4.07m and £3.23m for EIS and 
Progesterone studies, respectively). Of course, these results come with the caveat that 
diffusion curves conditional on study outcomes were not elicited. Furthermore, the net 
benefit distribution was used as a proxy for study outcomes.  
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Table 7.12. Accruing conditional EVSIM and EVR over population and time 
Study  Per 
person 
Population 
per annum  
Population over decision 
relevance horizon of 5 
years (discounted) 
Cond. EVSIM (EIS)  £259 £877,766 £4.39m 
Cond. EVSIM (Pg) £287 £997,430 £4.99m 
EVR (EIS) £311 £1.3m £6.54m 
EVR (Pg) £288 £860,968 £4.99m 
 
 
7.5 Discussion  
7.5.1 Findings  
In this chapter, I illustrated the application of the dynamic expected value of information 
and implementation method in an exemplary case study on electrical impedance 
spectroscopy for use in preterm birth screening. This analysis can help assess the losses the 
health care payer incurs when there is decision uncertainty and predicted low 
implementation of the cost-effective health technology. Findings of this chapter include that 
the value of research may be larger than what is commonly assessed with expected value of 
sample information analysis because the latter typically ignores the effect of research on 
implementation. When this is accounted for, the value of research can be larger than the 
EVSI, as was shown in this case study example. When EVR and EVSIM are accrued for the 
England population, the estimated number of affected patients should be adjusted by 
proportional uptake. Results of the dynamic analysis differed considerably from the results 
of the static analysis which means that ignoring implementation dynamics in value of 
implementation and information analysis leads to erroneous estimates. The timing of 
research and implementation measures and their effects also alters results and needs to be 
considered in the dynamic value of information and implementation analysis. 
Further findings relate to the case study technology and decision problem. EIS for use in 
PTB screening together with progesterone treatment of women that test positive was shown 
to be a dominating strategy against the CL scans and progesterone treatment strategy and 
against the no screening, no treatment strategy. This was because each PTB averted 
presented a cost-saving to the payer that, even when few cases were averted, exceeded any 
expenditure incurred on the purchase of the equipment and on progesterone treatment. 
Furthermore, EIS appeared to identify more women that would go on to have a PTB than CL 
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scans, enabling them to receive preventative treatment and thus reduce the number of PTBs. 
The cost-effectiveness results were largely insensitive to the price of EIS. EIS would be 
cost-effective up to a capital cost for each EIS device of almost £1 million. 
The dynamic EVP was large, at potentially £650 million for the England population over a 
five year decision relevance horizon. This was caused by low implementation of EIS 
resulting in a large EVPIM (£631 million). The identified research studies could be 
worthwhile undertaking if their cost fell below the expected value of research of £3.23 
million and £4.07 million for the studies on EIS and progesterone, respectively. When the 
study results report with a delay in time, these values would be smaller. Compared with the 
EVP, the EVRs of the two identified research studies only achieved a relatively small 
reduction in the EVP (of 1-2% of the EVP). The largest part of the EVP was made up of the 
EVPIM. This points to the fact that there must be other barriers to implementation that have 
a larger impact than the uncertainty that is contributed by the identified parameters.  
 
7.5.2 Relevance  
This chapter illustrates an extension to the EVII framework presented by Fenwick et al. 
(2008). The present work built on their framework by allowing states of information and 
implementation other than ‘current’ and ‘perfect’, by allowing research to have an effect on 
implementation and by considering the dynamics and the timing of implementation. This is 
foreseen to be of value to decision-makers, analysts and manufacturers who wish to perform 
such analyses. The findings of this case study are relevant to the developer of EIS and 
decision-makers that may assess EIS for PTB screening in the future. The cost-effectiveness 
findings for EIS for the use in PTB screening, albeit premature, support the developer’s 
hypothesis that EIS screening together with progesterone treatment could help reduce the 
incidence of PTBs. As such, this model can be further developed to help the developer build 
a case for EIS when it is scrutinised by different stakeholders, including potential adopters, 
once the technology is introduced. It may further be in the interest of the developer and the 
health care payer to help fund implementation measures or further research to reduce the 
large burdens of uncertainty and implementation.  
The EVRs of the respective research studies were low in comparison to the EVP. There 
may be different reasons for this: 1. that the main barriers to implementation are not 
evidence-related; 2. that the study design was not optimal in terms of improving the EVSI 
and EVSIM such that these studies contributed only little to an increase in implementation; 
and 3. that there is other evidence that could result in a greater increase in implementation. 
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The latter would indicate that there potentially is a distinction to be made between the 
evidence required for demonstrating cost-effectiveness of a new technology and evidence 
required to promote implementation. An example could be that larger trials or a greater 
number of trials would be required for promoting implementation than what may be 
sufficient for demonstrating cost-effectiveness, or vice versa. 
Findings also need to be viewed in the context of the evidence that is currently available. 
Diffusion was elicited under the assumption that the evidence for EIS sensitivity, specificity 
and progesterone treatment effect would be similar to the evidence available from the pilot 
study and the evidence available from progesterone after CL scan research studies. If new 
trials produced different results, this may impact on implementation. A closer examination 
of other barriers to implementation could also be worthwhile. These have been identified in 
the qualitative study and include the lack of clinical guidelines, junior staff on rotation, as 
well as financial issues associated with the purchase of new equipment, amongst others. 
 
7.5.3 Strengths, limitations and future research 
The strength of this chapter was the incorporation of diffusion in EVII analysis, the 
estimation of which was based on the theory of diffusion of innovative technologies 
(Rogers, 2003) and the Bass model of new product growth (Bass, 1969) via a method of 
eliciting expert opinions that was proposed in Chapter 6. The extended dynamic EVII 
analysis was illustrated in a case study of a technology that is still in development. This is 
relevant because technology assessments commonly occur before technology introduction 
and when there is still funding for research. I argued that addressing the issue of potentially 
low implementation at the time of HTA would save the health care system resources and 
therefore provide health gains for patients. This notion has been quantified in this chapter. 
The main limitation is that EVR results do not account for changes in study outcomes. I 
attempted to illustrate such an analysis in Section 7.4.4. Due to there not being any elicited 
information on diffusion conditional on study outcomes, these results are only illustrative in 
nature. There are a number of limitations that relate to the case study model used, especially 
in terms of simplifying assumptions that were made, all of which have been described in the 
previous sections. I also did not take side effects of tests and treatments into account. 
Positive EIS test results may have adverse effects, including anxiety, on mothers, and 
therefore could cause problems in the pregnancy. This could work in favour of the no 
screening, no treatment strategy. However, there was no evidence to support this but it 
should be considered when this model is developed further. In some cases, I had limited data 
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and based my parameter inputs on assumptions. For further development of the model, a 
more thorough search of the literature on the predictive ability of CL scans in high risk 
women and the treatment effect of progesterone in high risk women and after being screened 
with EIS in particular would be valuable, although the chance of finding data may be slim. 
Alternatively, elicitation of expert opinion could be performed to obtain better estimates than 
the ones I have used.  
A further limitation is that this chapter focused only on the number of attainable versus 
desirable purchases, as opposed to the utilisation by clinicians and acceptance by patients. In 
practice, the value of implementation would need to take all of these into account. 
Implementation strategies could then be devised to address the low number of purchases and 
the low utilisation separately. Of course, some implementation strategies would have an 
effect on both quantities. To simplify the illustration in this case study, I therefore ignored 
utilisation, but further research should be done on this and on the effect of research studies 
on utilisation and number of purchases.  
The restriction of the economic model to an NHS perspective could also be considered a 
potential limitation, given that there are likely to be obvious costs to patients, family and 
society that go beyond the health-care sector. The main argument against using a broader, 
societal, perspective was that because most assessments of cost-effectiveness are performed 
from the perspective of the healthcare payer, designing the economic model from the NHS 
perspective remains most relevant to facilitate comparison with other uses of healthcare 
resources.  
Further research could concentrate on identifying other implementation measures and 
quantifying their effect on implementation using expert opinion. The extension of the model 
to all pregnant women rather than women with a history of PTB may be worth doing, given 
that the findings of this study are encouraging. Of course, such a model would require 
knowledge of the predictive ability of EIS in that population, something that may be 
examined in future research studies. Expected value of information analysis on that 
extension of the model can quantify the value of such research studies. 
 
7.5.4 Conclusion  
In conclusion, this chapter showed that diffusion estimates can be included in the EVII 
analysis framework and can help provide more realistic estimates of the value of research 
and the dynamic values of information and implementation than available to date. EIS for 
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use in PTB screening was shown to be a cost-effective, even dominating strategy based on 
preliminary evidence, but implementation was predicted to be low, resulting in a large 
burden to the health system. The evaluated research studies alone were not likely to resolve 
this burden.   
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CHAPTER 8. THE DYNAMIC COST-EFFECTIVENESS ANALYSIS 
MODEL ILLUSTRATED IN A HYPOTHETICAL EXAMPLE 
8.1 Background 
In Chapter 7, I illustrated the dynamic EVII framework in the case study on EIS for 
preterm birth screening. The aim of the present chapter is to explore the impact of the 
dynamic cost-effectiveness analysis (DCEA) model that incorporates the experience curve, 
which was developed in Chapter 4. Originally, this approach was going to be applied in the 
same case study of EIS for PTB screening. However, Chapter 7 showed that the cost-
effectiveness results for EIS were insensitive to price. This results in the experience curve 
model having no effect on cost-effectiveness results. Based on the current parameterisation 
of the EIS model, the relationship of implementation and price dynamics with cost-
effectiveness cannot be fully explored. Consequently, an alternative parameterisation is used 
to examine this relationship. With the resulting model no longer representing EIS, cervical 
length ultrasound, or indeed PTB screening, this chapter presents the application in a 
hypothetical example in which Technology T1 is compared with Technology T2 and no 
screening (T0). The flow of the thesis and the place of this chapter in it are shown in Figure 
1.2 in Chapter 1. 
 
8.2 Application of the DCEA model in hypothetical example 
The hypothetical example used in this chapter is based on the decision tree model for 
PTB screening presented in Chapter 7. While many parameter values, and hence the 
evaluated interventions, changed, it was not necessary to change the model structure. The 
new hypothetical screening technology (T1) used in this example is evaluated against 
technology T2 and T0 (no screening). The parameter estimates that were changed compared 
with the model in Chapter 7 are shown in Table 8.1.  
Modelling the experience curve requires information on diffusion and on the price 
change that is associated with diffusion. I used the diffusion parameters obtained from the 
elicitation study described in Chapter 6 for the ‘natural’ diffusion curve, that is, without 
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performing further research. The parameters informing the price change element of the 
experience curve were based on assumptions. For experience curve alpha, I assumed a value 
of 0.9, such that it fell in the range reported in the study by Brown et al. (2008). This value 
means that the price of T1 drops to 90% of its previous price every time the initial 
production quantity doubles. I assumed the initial production quantity at ten produced units, 
based on the demand predicted by the diffusion curve for the first period plus an additional 
50% of stock in case demand exceeded expectations. Another important piece of information 
for this dynamic analysis was the decision relevance horizon. Despite evidence for very 
short technology life spans in medical devices (Chapman et al., 2014), I chose a mean of 15 
years and varied the decision relevance horizon between 1 and 60 years to explore its effect 
on cost-effectiveness.  
 
Table 8.1 Parameters used in hypothetical example to illustrate the DCEA model 
Parameters Mean 
values 
Reference 
T1 sensitivity 0.44 Assumption 
T1 specificity 0.72 Assumption 
T2 sensitivity 0.4 Assumption 
T2 specificity 0.7 Assumption 
Cost per T1 screening £ 168 Assumption 
Cost per T2 screening £ 31 Assumption 
Cost of care if condition not prevented £ 3,000 Assumption 
Cost of care if condition partially prevented  £ 1,000 Assumption 
Cost of care if condition diagnosed and prevented £ 0 Assumption 
Experience curve alpha 0.9 Assumption based on Brown et 
al. (2008) 
Experience curve initial production quantity 10  Assumption 
Uptake parameter p 0.018 Elicitation study 
Uptake parameter q 0.491 Elicitation study 
Uptake parameter m 140 Elicitation study 
Decision relevance horizon 15 Assumption 
 
Operationalising experience curve dynamics over the decision relevance horizon 
required an additional modelling step: the calculation of prices based on the implementation 
estimate for each future period. In this instance of a fairly short-term decision tree model, 
each period (in years in this example) also represents one future cohort. In other, more long-
term conditions, several patient cohorts could potentially receive the new technology each 
year. In that case, price changes in each year have to be applied to multiple co-existing 
cohorts for technologies in which costs occur in more than one cohort. For many medical 
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devices, which the experience curve model is most relevant for, costs of medical devices 
often occur at one point in time. In such cases, a period equals a cohort. In situations where 
costs of the device are incurred for more than one year, a period equals multiple cohorts. 
Price changes are not only incurred for future cohorts, but also for the first cohort in future 
periods.  
For intervention T1, price changes in each year are a function of implementation in that 
year. The decision tree then incorporates the price change to calculate the new cost for each 
year. The costs and effects for each year are recorded up to the decision relevance horizon 
and are discounted. The average cost (the sum of each year’s costs divided by the employed 
decision relevance horizon) is then the final cost associated with the respective technologies. 
If there was no discount, the cost per person associated with T2 and T0 would be equal with 
or without the dynamic model. I assumed that there were no future price changes for 
technologies T2 and T0. This makes sense for T0 which represents no screening. It also 
makes sense for the comparator T2, if it is assumed that it is a well-established technology 
that is predominantly in use for other conditions – even if there were a price change resulting 
from the additional use for this hypothetical condition, this would likely be negligible.  
I first present results from this hypothetical example without the modelling of the 
experience curve – which I call the static results. Then I present results for the dynamic 
example with the experience curve; explore the potential effects of diffusion and experience 
curve parameters on the technology price; illustrate the effect of the decision relevance 
horizon on the ICER and finally analyse decision uncertainty in the dynamic model. 
Both, the static and the dynamic models were programmed in Excel. To represent 
uncertainty about the parameter estimates, a PSA with 1,000 iterations was performed. The 
PSA was conducted in Excel using VBA. The uptake parameters p and q were sampled from 
lookup tables that were generated by sampling from the probability distributions of elicited 
quantities and by fitting appropriate p and q values. These did not fit any parametric 
distribution and using the lookup tables was therefore deemed the best way of representing 
the uncertainty about the mean.  
Uncertainty without and with incorporation of the experience curve was analysed using 
the EVPI. EVPPI analysis was performed to analyse whether uptake and experience curve 
parameters and the decision relevance horizon were drivers of decision uncertainty in the 
dynamic model. EVPPI results were obtained using GAM regression and Gaussian Process 
regression (Strong et al., 2014).  
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8.3 Results of the DCEA model applied in the hypothetical example 
8.3.1 Static results of hypothetical example  
Technology T2 was the technology with the highest expected net benefit in this example 
due to its cheaper price, despite producing slightly fewer QALYs than T1. Table 8.2 presents 
the costs and effects associated with all the technologies in the static analysis of the 
hypothetical example. Whilst T0 was cheaper than both T1 and T2, it was also significantly 
less effective resulting in ICERs that fell below the threshold when comparing both T1 and 
T2 with it (Table 8.2).  
 
Table 8.2 Cost-effectiveness data in hypothetical example – static analysis 
Threshold = £20,000 / 
QALY 
T1 T2 T0 
Expected Costs £1,227 £1,091 £769 
Expected QALYs 22.33 22.32 22.27 
ICER T1 against… - £28,243/QALY £8,401/QALY 
ICER T2 against… - - £6,479/QALY 
Expected Net 
Monetary Benefits 
£445,332 £445,371 £444,699 
 
These results are associated with uncertainty. The CEAC in Figure 8.1 shows that from 
thresholds above £9,000 per QALY there is uncertainty mainly between technologies T2 and 
T1. This is further illustrated in the cost-effectiveness plane of T1 against T2 in Figure 8.2 in 
which part of the joint costs and effects distribution is located to the North-West of the 
threshold value diagonal, and part to the South-East, indicating uncertainty as to whether T2 
is truly the most cost-effective technology. The EVPI also indicates decision uncertainty 
valued at £112 per person which translates into approximately £3 million per annum 
(assuming a patient population of 27,000 patients, as in the preterm birth model in Chapter 
7).  
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Figure 8.1 CEAC in hypothetical example - static analysis 
 
 
Figure 8.2 Cost-effectiveness plane of T1 vs T2 in hypothetical example - static analysis 
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8.3.2 Dynamic results of hypothetical example  
 Cost-effectiveness analysis results 8.3.2.1
In the dynamic analysis, costs and effects have decreased for all three interventions due 
to the discounting of future periods (Table 8.3). For this reason, effects of the experience 
curve model on the cost-effectiveness data are not obvious but it can be seen from the 
expected net monetary benefits in Table 8.3 that the decision between T1 and T2 is closer in 
the dynamic analysis than in the static analysis.  
 
Table 8.3 Cost-effectiveness data in hypothetical example - dynamic analysis 
Threshold = £20,000 / QALY T1 T2 T0 
Expected Costs £967 £877 £618 
Expected QALYs 17.98 17.97 17.93 
ICER T1 against… - £23,044/QALY £8,011/QALY 
ICER T2 against… - - £6,531/QALY 
Expected Net Monetary 
Benefits 
£358,564 £358,576 £358,041 
 
The expected opportunity loss associated with decision uncertainty as quantified by the 
EVPI is smaller in the dynamic than in the static analysis (EVPI of £103 per person, or £2.8 
million for the patient population). This may seem paradoxical but is explained by the 
discounting of future periods’ costs and effects that reduces the expected net monetary 
benefits of the dynamic compared to the static analysis. The EVPI, being a function of the 
incremental net benefits and the number of times one would make the ‘wrong’ decision, 
consequently decreases. This, however, does not mean that we are more certain about what 
the truly best decision option is; it just does not matter as much because the cost associated 
with a wrong decision is now smaller. The CEAC shows that T1 becomes the technology 
most likely to be cost-effective at a threshold that is lower than that in the static analysis 
(approximately £28,000 as opposed to £40,000 per QALY) (Figure 8.3). The shape of the 
joint distribution of the incremental costs and effects of T1 against T2 in the cost-
effectiveness plane is altered with the dynamic analysis (Figure 8.4) compared to the static 
analysis. Incremental QALY gains are now less variable, owing to discounting of future 
periods. The wider spread of incremental costs is caused by the inclusion of the experience 
curve which in some of the iterations of the PSA results in T1 being cheaper than T2 (Figure 
8.4).  
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Figure 8.3 CEAC in hypothetical example - dynamic analysis 
 
 
Figure 8.4 Cost-effectiveness plane of T1 vs T2 in hypothetical example - dynamic analysis 
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 Exploring the potential for future price changes in the hypothetical example 8.3.2.2
This hypothetical example shows the potential shape of price declines when future 
periods with price changes contingent on implementation dynamics are modelled (Figure 
8.5). Figure 8.5 shows two different developments: one is that cumulative diffusion of the 
new screening technology T1 follows an s-shaped curve, as was already shown before. The 
maximum number of attainable adoptions is reached after approximately 15 years, 
emphasising the word ‘attainable’ as opposed to ‘desirable’. The second development is that 
price starts to decline after approximately 12% of the attainable adoptions have been 
achieved (Figure 8.5). Price remains stable for a short period of time (two years), which is 
followed by a quick price decline. With uptake exhibiting diminishing marginal growth 
towards the later periods, price converges to an asymptote of £3,348 after 22 years. More 
intuitively, when uptake growth slows down, the reduction in technology price decreases 
until the lowest possible level of price is reached. Price is shown as a function of the 
cumulative number of adoptions in the traditional experience curve chart in Figure 8.6 
(Brown et al., 2008). These developments are explained by the parameterisation in this 
example, particularly the initial production run, and the experience curve alpha and diffusion 
parameters. The initial production run was assumed to produce small quantities (10 devices 
in the first year) in response to the predicted low uptake. With uptake growing quickly in 
this example, the initial production run is used up in the second year; that is, at the time at 
which implementation levels increase exponentially.  
 
Figure 8.5 Price and uptake developments in hypothetical example  
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Figure 8.6 Traditional experience curve chart for hypothetical example 
 
 
With different parameter values, such as larger initial production runs or slower 
diffusion curves, the price decline could be less drastic. I show examples with a larger initial 
production run of 65 produced units and the same diffusion curve in Figure 8.7 a), and small 
and large initial production runs (10 and 65 units) with a much slower diffusion curve with 
parameters taken from ultrasound scans (Gobok et al., 2009) in Figure 8.7 b) and c), 
respectively. These graphs show that price declines could happen later in the lifetime of a 
new technology and may be less pronounced with different initial quantities produced.  
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Figure 8.7 Potential impact of parameter values on price and uptake: initial production run and diffusion 
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Figure 8.8 Potential impact of parameter values on price and uptake: experience curve alpha 
 
 
Choosing different magnitudes for the experience curve parameter alpha, which is the 
percentage to which price declines every time initial production quantity doubles, can result 
in large differences in the magnitude of price reduction that can be achieved. This is 
illustrated in Figure 8.8, where, given that all else remains equal, an alpha of 80% could 
reduce future price to less than half of its starting value while an alpha of 95% would still 
reduce the future price to just more than 80% of its starting value (Figure 8.8) (noting that 
the initial production run was very small in this hypothetical example). The effects of these 
different variations to the parameter values are also shown in Figure 8.9 in the traditional 
experience curve chart, in which price is plotted against number of adoptions instead of time. 
Of course, slow diffusion makes no difference to the experience curve shape, which is the 
rationale for a presentation in a chart that shows both, price and uptake developments as, for 
instance, in Figure 8.5.  
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Figure 8.9 Traditional experience curve chart for variations in parameterisation 
 
 
The significant effect that the experience curve alpha parameter has on the experience 
curve also translates into different ICERs. This is shown in Table 8.4, where I present the 
resulting ICERs when different sizes for experience curve alpha are assumed. Alphas 
between 70% and 95% could make a difference of almost £4,000 to the ICER in this 
example. 
 
Table 8.4 ICERs with different values for experience curve alpha 
Experience curve parameter 
alpha 
Deterministic ICER of T1 vs 
T2 (per QALY gained) 
60% £21,310 
70% £22,204 
80% £23,433 
90% £25,068 
95% £26,063 
100% (no change in price) £27,190 
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 The effect of the decision relevance horizon on the dynamic ICER 8.3.2.3
As was shown above, the extent to which price changes occur largely depends on the 
parameter values of the pivotal diffusion and experience curves. These effects translate into 
changes in cost-effectiveness. In addition to those effects, the dynamic ICER is affected by 
the decision relevance horizon which crucially determines how much lower the dynamic 
ICER is compared to the static ICER. Figure 8.10 shows different dynamic ICERs (which 
are the averages over the respective decision relevance horizon) plotted against the number 
of periods up to the chosen decision relevance horizon. A decision relevance horizon of 15 
years results in the lowest dynamic ICER compared to decision relevance horizons of five 
and ten years. This negative relationship between the dynamic ICER and decision relevance 
horizon exhibits diminishing marginal returns. This is best explained by the per-period 
dynamic ICER decreasing with diminishing marginal returns (Figure 8.10). The diminishing 
rate is caused by prices stagnating at a certain time period, with the effect of the per-period 
ICER not being significantly lowered by modelling more periods in the future.  
When a decision relevance horizon of 15 years is chosen, the dynamic ICER is lower 
than the static ICER, at just below £25,000 per QALY as opposed to the static ICER of just 
above £27,000 per QALY. Choosing a shorter decision relevance horizon of five years, in 
contrast, may mean that price changes have not yet been realised and that the dynamic ICER 
remains closer to the commonly used static ICER at just above £26,000 per QALY (Figure 
8.10). While the decision relevance horizon is not a factor that alters the decision in this 
hypothetical example (if the threshold is £20,000 per QALY), this analysis shows that the 
employed decision relevance horizon could be influential when the experience curve is 
modelled in cost-effectiveness analysis. 
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Figure 8.10 ICER results in hypothetical example with and without experience curve 
 
 
 How does the addition of experience curves affect decision uncertainty in the 8.3.2.4
hypothetical example? 
As was mentioned above, the EVPI reduced with the dynamic analysis compared with 
the static analysis (£103 and £112 per person, respectively). This was explained by 
discounting of future periods. Whilst it makes sense to value future price less than the 
starting price in the first period, I explored the expected opportunity loss associated with 
decision uncertainty when future periods were not discounted for illustration purposes. The 
resulting EVPI was £124, which is larger than the EVPI resulting from the static analysis.  
The analysis including discounting of future periods resulted in diffusion parameters 
accounting for approximately 4% of the EVPI at £6 per person (Table 8.5). The EVPPI of 
the experience curve parameter alpha is only worth £0.01, and that of the decision relevance 
horizon £0.06. Together, the diffusion and experience curve parameters have a grouped 
EVPPI of £9 and the diffusion and decision relevance horizon parameters a grouped EVPPI 
of £10. Diffusion parameters p and m have an individual EVPPI of £3.55 and £3.64, 
respectively; diffusion parameter q only has an EVPPI of £0.64. Standard errors of the 
EVPPI are relatively large, indicating difficulties in estimating the EVPPI that may be 
caused by the nonlinear nature of this model. The large standard errors may explain why the 
grouped EVPPI of all the newly introduced parameters is smaller than the grouped EVPPI of 
a subset of four of them. Furthermore, 1,000 simulations of the PSA may not be sufficient to 
provide accurate estimates but model run times were prohibitively long. Lastly, the 
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estimation method used was different for the five parameters: instead of the GAM regression, 
the Gaussian process regression was used because the GAM regression becomes 
increasingly inaccurate as the number of parameters increases (Strong et al., 2014). 
 
Table 8.5 EVPPI results for hypothetical example - dynamic analysis 
Parameter(s) Per person 
EVPPI (£) 
Standard 
error 
Percentage of 
EVPI (%) 
Grouped diffusion parameters 6 3.8 4 
Experience curve parameter α 0.01 1.62 0 
Decision relevance horizon 0.06 1.79 0 
Grouped diffusion and 
experience curve α parameters 
9.4 4.05 9 
Grouped diffusion and decision 
relevance horizon parameters 
10.4 4.37 10 
Grouped experience curve α and 
decision relevance horizon 
parameters 
0.1 2.2 0 
Grouped diffusion, experience 
curve α and decision relevance 
horizon parameters* 
4.13 3.66 4 
* For this analysis, a Gaussian process regression was used instead of a GAM regression. 
 
8.4 Discussion 
8.4.1 Findings 
In this chapter, I have applied the DCEA model in a hypothetical example. This analysis 
shows that changes in price precipitated by changes in uptake significantly affect cost-
effectiveness results and have the potential to alter decisions. The adopted decision 
relevance horizon plays a significant role in determining whether price changes reverse the 
cost-effectiveness outcome, as short decision relevance horizons may not be sufficient to 
allow price changes to take effect. EVPI results were also affected, with the new parameters 
contributing to decision uncertainty. Furthermore, taking the average of future discounted 
periods resulted in a lowered EVPI compared with the static analysis. Results of the partial 
EVPI analysis imply that, at least in this example, there is value in reducing uncertainty 
surrounding diffusion, experience curve and decision relevance horizon parameters; 
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although with the caveat that estimating the true EVPPI is made difficult by the nonlinear 
structure of the model.  
 
8.4.2 Relevance 
These results call into question the commonly made assumption of the first cohort being 
representative of future periods until re-appraisal is undertaken, and the common disregard 
for changes that are precipitated by the reimbursement decision itself. The proposed model 
is especially useful in technologies that may be rejected at the common cost-effectiveness 
threshold but that may exhibit a decline in price with increasing uptake. As such, it may be 
useful to present this analysis as a scenario analysis in a submission. In technologies, for 
which price does not represent a substantial part of its cost to the health care system, this 
analysis may not affect model outcomes considerably. It is necessary to reiterate that I am 
only aware of empirical evidence supporting the experience curve in medical devices. Whilst 
such price changes may exist for other technologies, the lack of evidence may mean that the 
pragmatic decision maker would prefer confining this additional analysis to medical devices. 
In principle, of course, this model can be used in all technologies, with parameter 
distributions reflecting whether a price change is expected or not.  
It is important to recognise that, when modelling future cohorts, there is a trade-off of 
present against future welfare. I assumed here that discounted future welfare gains of one 
technology could offset present welfare gains of another technology. The key problem with 
this is the uncertainty surrounding future events. Price changes might never materialise or 
another more cost-effective technology could become available. Careful consideration of 
competitor technologies to be launched subsequently is therefore advisable. It is furthermore 
important to treat the experience curve alpha parameter just as any other uncertain parameter 
and reflect that uncertainty. 
 
8.4.3 Strengths, limitations and further research 
The strength of this chapter lies in the exploration of the effects of the experience curve, 
diffusion and decision relevance horizon parameters. The choice of a decision relevance 
horizon was shown crucial for the value of the dynamic ICER. There is differing literature 
on the appropriate time horizon. Hoyle (2010) estimated the mean drug lifetime to be 57 
years (95% confidence interval 39-79 years) and used this as a proxy to a time horizon. In 
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contrast, medical devices seem to have much shorter lifespans, estimated as short as 18 
months (Chapman et al., 2014). While the ISPOR Good Research Practices task force (Caro 
et al., 2012) recommends a time horizon long enough to capture all relevant outcomes, 
noting that this may result in a lifetime horizon, the interpretation of this refers to the within-
cohort time horizon rather than to the number of periods that should be modelled in the 
future for cohorts that start at different times. No matter what decision relevance horizon is 
chosen, it is appropriate to include this within the PSA because of the uncertainty associated 
with its estimates.   
A limitation of this chapter is that the DCEA model was illustrated in a hypothetical 
example only, rather than in a real world example. Furthermore, the model structure was 
taken from the PTB model presented in Chapter 7 and, despite changes in the parameter 
values, resulted in technology price that made up only a fraction of the overall cost 
associated with the screening strategy T1 (6%). This chapter has therefore highlighted that 
the experience curve approach may be most important in higher cost technologies, and 
certainly in those in which technology cost makes up for a major part of the overall cost 
associated with a strategy.  
Furthermore, I did not illustrate the EVR here, because this was done in Chapter 7 and 
the workings of calculating the EVSIM and EVSI are not different in this analysis, with the 
exception that net benefit is time-dependent. So, for each future period that the EVSIM is 
calculated for, the net monetary benefit of that period is based on that period’s price, which 
is conditional on diffusion.  
For the purpose of illustration, experience curve parameter alpha (that is the percentage 
of price to which price changes with diffusion) has been assumed to be at 90%. It is not clear 
what the true value of this alpha would be for EIS, or any technology, apart from those 
where the actual price change has been empirically estimated. (Brown et al., 2008) reported 
that alphas in most published experience curves fall into the 70-80% range. Assuming an 
alpha of 90% was therefore conservative, resulting in a smaller change in the ICER than 
lower values for ICER, compared to no future price changes. However, the chosen value 
would crucially affect the shape of the experience curve and consequently the ICER. I 
addressed the uncertainty associated with it by varying alpha in the PSA. If such analysis 
were used for decision-making, however, a better estimate of this parameter would be 
desirable. This could be obtained through elicitation of expert opinion, but ideally a 
commitment to a price change conditional on uptake would be obtained from the company, 
in the form of a price-volume agreement scheme. Such a scheme would eliminate substantial 
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uncertainty for the decision-making body and the NHS, whilst also ensuring that the 
company only has to lower their price when a certain sales volume is reached.  
Further research should be conducted to generate evidence for or against the existence of 
the experience curve in a greater sample of medical devices; and in other health technologies 
as well. 
 
8.4.4 Conclusion 
In conclusion, the DCEA framework that includes modelling the experience curve has 
the potential to alter decision-making. The framework is especially relevant for those 
technologies for which there is empirical evidence of experience curves (that is, medical 
devices) and those technologies for which price is a main contributor of overall costs 
associated with the strategy. Furthermore, this analysis is most relevant when the technology 
in question is not cost-effective and when there is decision uncertainty. Otherwise, future 
price reductions are not likely to have an impact on cost-effectiveness outcomes. 
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CHAPTER 9. DISCUSSION AND CONCLUSION 
9.1 Summary of findings 
In this thesis, I explored the impact that estimates of health technology diffusion have on 
cost-effectiveness and value of information and implementation analyses. Four hypotheses 
motivated this thesis: (A) consideration of implementation could be beneficial to the 
reimbursement authority and the health-care payer at the time of HTA. (B) Implementation 
estimates may be correlated with other parameters in the cost-effectiveness model and 
influence health economic outcomes. (C) It is possible to acquire estimates of 
implementation that are compatible with diffusion theory; and incorporate these in an HTA. 
Lastly, hypothesis (D) was that a better understanding of the technology-specific causes of 
low implementation is required to improve implementation. 
I tested hypothesis (A) by extending the EVII framework to include dynamic 
implementation estimates and accounting for the effect of research evidence on 
implementation. I found that knowledge of low implementation and its associated 
opportunity loss at the time of HTA presents an opportunity to recommend research studies 
that serve both the reduction in uncertainty and improving implementation. The opportunity 
loss incurred by the payer when the most cost-effective technology experienced low 
implementation and its cost-ineffective comparators remained in use could be assessed using 
the value of implementation. Furthermore, I found that the value of research is under-
estimated with traditional EVSI methods, if the research also has an effect on 
implementation. The expected value of research that consists of both its value of information 
and implementation allows for these two separate effects. The value of research may, 
however, be over-estimated if its calculation involves scaling up over the entire eligible 
patient population rather than over the population that will receive the technology. If 
different study results are considered, EVR results may differ further.   
Price can be influenced by diffusion and I found that this relationship could be 
represented by experience curves. Incorporating experience curves in the dynamic cost-
effectiveness analysis framework led to potential differences between traditional cost-
effectiveness and dynamic results (hypothesis (B)) (see Chapter 8). These differences in 
cost-effectiveness are caused by price decreasing with increasing uptake, a relationship that 
has been observed in medical devices.  
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I demonstrated that it was possible to obtain estimates of future diffusion (hypothesis 
(C)). Literature reviews presented in Chapter 3 highlighted that methods were needed to 
estimate diffusion without prior data available. I proposed a method that, with elicitation of 
three quantities only, can generate diffusion curves over the life-span of a technology. This 
method was based on diffusion theory and an existing diffusion model. Diffusion curves 
were elicited for EIS, assuming availability of different sets of evidence. 
Effective implementation strategies are best devised if there is knowledge of the 
technology- and lifecycle-specific factors influencing diffusion, but it can be challenging to 
identify those strategies with the largest effect sizes without an elicitation of expert opinion 
(hypothesis (D)). Barriers and facilitators to diffusion were shown to be highly specific to 
individual technologies. To identify EIS specific diffusion determinants and determine the 
design of potential implementation strategies, a qualitative study was therefore more 
appropriate than drawing on an existing catalogue of diffusion determinants (Greenhalgh et 
al., 2004) or on other studies examining diffusion patterns and determinants (Barnett et al., 
2011, Department of Health, 2011).  
With respect to the case study on EIS for PTB screening, EIS was shown to be 
dominating against the alternative cervical length ultrasound scans and against no screening 
with relatively high certainty, based on current evidence. This outcome was shown to be 
insensitive to the price of EIS, and the experience curve model was therefore illustrated in a 
hypothetical example. Relevant implementation strategies to EIS would be related to 
establishing evidence in the first instance. Diffusion of EIS was estimated for counterfactual 
with or without research scenarios and it was shown that in all scenarios, EIS would not 
reach the maximum desirable adoptions, and diffuse over a period of 10 to 14 years. Low 
implementation resulted in a large expected value of implementation; and the expected value 
of information was relatively smaller. The expected value of research associated with the 
two defined research studies may warrant performing these studies, if their value falls below 
costs. Further implementation measures may need to be considered in order to address low 
implementation. 
 
9.2 Novel contributions to knowledge 
This thesis made four main novel contributions to knowledge:  
1. Incorporating estimates of health technology diffusion in health economic methods 
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This thesis has, for the first time, incorporated a formal technology diffusion model in 
EVII analysis and cost-effectiveness analysis. In cost-effectiveness analysis, diffusion was 
ignored and static estimates of implementation were used in the few studies that considered 
uptake. When this thesis began, methods of obtaining implementation estimates for use in 
expected value of information and implementation research were rudimentary and often did 
not account for any dynamics. In fact, in value of implementation analyses, all 
implementation estimates found through reviews reported in Chapter 2 were of static nature. 
The counterfactual, that is ‘natural’ diffusion that would occur without any implementation 
measures, was also largely ignored. Since then, other studies have been published that 
included developments of implementation over time (Whyte et al., 2016, Faria et al., 2014, 
Andronis and Barton, 2016), but none of them used elicited data that was based on diffusion 
theory. Whilst implementation changes over time were used in EVIM analyses prior to 
finishing this thesis, this work remains the only one that based diffusion estimates upon 
theory and established models. The emergence of this other literature highlights the 
importance and timely nature of this thesis.  
 
2. The expected value of research as a combination of value of information and 
implementation 
I developed the expected value of research that explicitly considers effects of 
information on implementation. This has not been done before based on the reviews reported 
in Chapter 2. Within this, this research has also contributed to clarifying a misunderstanding 
of the realisable EVPI and the implementation-adjusted EVSI: these are measures of the 
value of implementation and not value of information measures as was suggested in the 
study by Andronis and Barton (2016). This thesis makes the distinction between value of 
implementation measures and value of information measures much clearer. I also highlight 
that the value of research can be larger when both, expected value of information and 
implementation, are considered than in traditional EVSI analyses. 
 
3. New method to elicit diffusion prior to technology introduction 
The method of predicting health technology diffusion developed in this thesis is the first 
method that does not require data of initial periods or data on analogous technologies to be 
available. The literature review in Chapter 3 showed that the only methods of forecasting 
using an established quantitative model without any diffusion data available were reliant on 
diffusion data of analogous technologies (Goodwin et al., 2014). The use of analogous 
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technologies is, however, associated with many limitations. First, it is not obvious what 
discerns an analogous technology and multiple factors need to be assessed in order to decide 
whether another technology may be an appropriate analogy. Second, the probability of an 
analogous product being available in the health care industry may be smaller than with many 
other goods and especially consumer goods, because of patenting that prevents very similar 
technologies from entering a market. Being able to predict diffusion independently of the 
availability of diffusion data for analogous technologies is therefore important. The 
structuring of the diffusion model using the maximum attainable number of adoptions, the 
number of adoptions in the first year and the time to the inflection point of the diffusion 
curve will be particularly useful to analysts who wish to model diffusion as an s-shaped 
curve, with theoretical and empirical foundation. 
 
4. Extended cost-effectiveness analysis framework accounting for changes in 
implementation and price 
While evidence on the existence of experience curves in health technologies was 
presented before (Brown et al., 2008, Brown et al., 2007), the relevance of these 
developments to the economic evaluation of health technologies was and remains 
unexplored by other studies, as was shown in Chapter 2. This work is novel in that it 
provides the DCEA framework, which enables calculation of ICERs with future periods that 
account for changes in implementation and price that are precipitated by the reimbursement 
decision. 
 
9.3 Relevance and implications for decision-making and the 
manufacturer 
9.3.1 Preventing the burden of low implementation 
As was demonstrated in this thesis, there could be considerable value in preventing the 
burden of low implementation to the health system. This could be achieved by assessing this 
burden and evaluating measures to reduce it at the time of technology appraisal. The benefits 
that can be made by improving implementation can, in some circumstances, exceed those 
that can be made by reduction of uncertainty. Assessing this early on may therefore be in the 
interest of the payer and the decision maker. 
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Research projects may become more attractive when their value in improving 
implementation is considered. Whilst reimbursement authorities such as NICE typically do 
not have the mandate to recommend implementation initiatives, they can recommend further 
research being conducted if there is large decision uncertainty (NICE, 2013). In practical 
terms this could have a substantial effect on recommendation with research (RwR) decisions, 
which are a type of managed entry agreement used by reimbursement authorities and 
manufacturers to agree on a process of recommending a new technology (Walker et al., 
2012a, Walker et al., 2012b, Grimm et al., 2016). With this analysis, the value of research is 
not limited to its impact on decision uncertainty, which can be estimated by the EVSI, but 
includes the associated value of increased implementation and may thus be of particular 
relevance to reimbursement authorities. Of course, a RwR decision requires other preceding 
analyses (Walker et al., 2012a, Walker et al., 2012b) to ensure it produces a positive net 
monetary benefit; otherwise the faster implementation can inflate opportunity costs 
associated with ineffective schemes. 
The dynamic EVII analysis presented here can inform the design of evidence generation 
schemes, thus producing a more appropriate estimate of the value of research to the payer. 
For instance, it might not be the research scheme with the largest EVSI that provides the 
highest value of implementation. This can occur when the main drivers of decision 
uncertainty do not coincide with the main evidence-related drivers of diffusion. Evidence for 
such a situation was presented in the case study of this thesis where experts interviewed in 
the qualitative study stated that they perceived the clinical uncertainty surrounding EIS for 
use in PTB as being large and a perceived barrier to implementation (Chapter 5). The health 
economic model, in contrast, showed that decision uncertainty associated with EIS for use in 
PTB was small and related to uncertainty surrounding a combination of many different 
model parameters instead of mainly the predictive ability of EIS and the treatment effect of 
progesterone. In such a situation, where there is potential value in different research studies, 
calculation of the EVSIMs and EVSIs of these research schemes needs to be undertaken and 
the research project chosen that exhibits the largest EVR relative to its cost. Where the main 
drivers of uncertainty are the same as the main evidence-related drivers of diffusion, the 
EVR analysis could still affect the research scheme design through different sample sizes 
being indicated. To design eligible research schemes for assessment via EVR methods, it is 
worth watching out for study results of a currently ongoing study on how evidence 
influences decisions in the UK NHS, including what defines ‘strength’ and ‘credibility’ of 
research in the eyes of different stakeholders involved in decision-making in the NHS 
(Turner et al., 2016).  
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Lastly, performing EVII analysis may lead to the more realistic assessment of evidence 
generation schemes because the uptake-adjusted population values result in smaller values of 
research. The difference between the full population values of research and the uptake-
adjusted values of research are largest in the first few periods modelled, with the per-period 
estimates in the later periods converging because of discounting. The uptake-adjustment is 
hence most relevant when shorter decision relevance horizons are used.  
 
9.3.2 Recommending technologies based on future prices 
Analyses that incorporate price changes precipitated by the reimbursement decision and 
subsequent diffusion may pose a useful scenario analysis for a decision-maker. The 
proposed DCEA model is especially useful in technologies that may be rejected at the cost-
effectiveness threshold but that may exhibit a decline in price with increasing uptake. It can 
help avoid a situation in which a potentially cost-effective technology is rejected. Such 
analysis is relevant when price changes are triggered by a reimbursement decision in the 
jurisdiction of interest and when there is no re-appraisal scheduled for the time when those 
price changes occur.  
The proposed DCEA framework entails a trade-off of present against future welfare and 
has implications for the ongoing debate on pharmaceutical pricing. Whilst there is support 
for higher prices for new drugs that reflect the benefit of future innovation (Jena and 
Philipson, 2007), another view is that such future benefits are uncertain and that gains 
appear once future prices reduce because of generic competition (Claxton et al., 2008). This 
framework suggests that these price changes can occur prior to generic competition and as 
such can support higher prices at product launch. However, the size of the premium at 
launch suggested by our framework would depend on a number of factors and would require 
further research. Reimbursement bodies may want to consider reducing the uncertainty 
around initial pricing and future price changes by making reimbursement contingent on the 
establishment of price and volume agreements. Whilst the precise mechanism by which this 
could be enacted is beyond the scope of this thesis, this analysis can help in assessing 
whether price volume agreements are mutually beneficial by making the relationship 
between implementation and price over time explicit and enabling uncertainty to be 
captured.  
It is noteworthy that health technology assessments of medical devices and other 
technologies including diagnostics follow different rules from typical NICE technology 
appraisals. For instance, the NICE medical technologies evaluation programme requires for 
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recommended devices to be cost-saving (NICE, 2011b). But these different requirements do 
not make the proposed analysis redundant: future price reductions precipitated by the 
reimbursement decision could make a technology that is not cost-saving at current price 
cost-saving at future price developments and as such the proposed analysis would be 
relevant to such a setting. 
 
9.3.3 Using diffusion estimates in health technology assessments: 
considerations for decision makers 
To offer pragmatic guidance as to when these proposed approaches are most valuable in 
the context of HTA, the following conditions need to be met: they are broadly summarised 
as (1) technologies that experience low implementation (in at least one period) and (2) 
technologies that experience price changes that are precipitated by and relevant to the 
recommendation decision. Only the first condition has to be met for expected value of 
implementation analysis to become relevant and for making population estimates of value of 
information analysis more realistic. In addition to the first condition, the second condition 
needs to be fulfilled to warrant calculation of the future periods ICER.  
Assessing whether these conditions hold for a new health technology is not trivial. There 
may be some idea of whether a technology may be prone to low implementation. There may 
be certain health technologies that are generally less prone to low implementation. To my 
knowledge, however, there is no standard way of identifying technologies with potentially 
low implementation, which suggests the need for a screening process that should precede 
any further analysis and that will help identify future implementation levels. This screening 
process could entail qualitative interviews with relevant stakeholders and ideally an 
elicitation exercise, the kind that were described in the previous chapters. Evidence from the 
diffusion curves review in Chapter 3 showed, however, that none of the health technologies 
had full instant implementation. Even after NICE guidance with recommendation decisions, 
no sudden jump to full implementation occurred. For lack of other experience, and in order 
to avoid the complexities and time and resource requirements associated with preceding 
qualitative and elicitation studies, I therefore recommend assuming that condition (1) holds 
for all health technologies.  
In the context of value of implementation analysis, there is still a judgement to be made 
on whether the extent to which low implementation occurs for a technology of interest 
warrants performing further analyses and potentially conducting qualitative and elicitation 
studies. Whether the burden on the health system that results from low implementation is 
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large depends on three factors: a) how low implementation is going to be, that is the 
implementation discrepancy, b) the magnitude of the incremental net benefit of the new 
technology over its comparators, c) the size of the population affected. Factors b) and c) will 
be known to decision-makers at the time of the appraisal. Factor a) could be addressed by 
using diffusion estimates that are estimated in the context of budget impact analysis. The 
ISPOR guide to budget impact analysis already recommends that estimates of natural 
diffusion be submitted (Mauskopf et al., 2007). A full set of value of information and 
implementation estimates should be produced using these diffusion estimates. This would 
then allow future research to be prioritised and potentially built into a RwR scheme. 
Assessing whether condition (2) holds, that is, whether a technology will experience 
price reductions that are precipitated by, and are relevant to, the reimbursement decision, is 
no less complex. Such price reductions may be most applicable to medical devices as there 
is no evidence on experience curves occurring in pharmaceuticals, although there is evidence 
on price changes in pharmaceuticals (Hoyle, 2010). Existing evidence on pharmaceutical 
price changes does not explain whether these would occur independently of the 
reimbursement decision in the same jurisdiction (Hoyle, 2011). More research on the nature 
of price reductions in pharmaceuticals may therefore aid in this decision. With experience 
curves evidence existing only for medical devices, these technologies should potentially be 
singled out for this analysis until further evidence emerges. Furthermore, the experience 
curve analysis is only relevant to assessments in which the health economic output, 
commonly the ICER, is sensitive to technology price. Only then would the DCEA and 
experience curve analysis influence results, and hence, become relevant for decision-making.  
 
9.3.4 The manufacturer’s perspective 
This study could contribute to the perspective of the pharmaceutical and medical device 
industries by providing estimates of health technology diffusion that could inform profit 
calculations and the return on investment in a clinical trial. The manufacturer’s objective 
function has been described as a profitability index that is a ratio of the net present value of 
all costs and benefits over the investment costs, amongst other objectives by Phillips and 
Bana e Costa (2007) in their work on corporate and not-for-profit decision-making. 
Considering all development options, the manufacturer thus faces a portfolio analysis and 
option value decision problem whereby the investment in product and evidence development 
programmes associated with each option have to be accounted for and weighed against 
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future profits. To be able to forecast future profits for each option, it is essential to know the 
expected sales volume, which should be informed by diffusion estimates.  
Funding for clinical trials comes mostly out of the pharmaceutical industry (Breeze and 
Brennan, 2014) and several studies have incorporated the pharmaceutical perspective in, 
commonly health care provider perspective oriented, value of information analyses (Breeze 
and Brennan, 2014, Willan and Eckermann, 2010, Pezeshk and Gittins, 2006). The study by 
Breeze and Brennan (2014) is a useful contribution in that the authors calculated expected 
profits incurred by the manufacturer based on sales volume and price. The authors’ 
estimation of sales volume included incidence, market share and a deflation factor on price. 
The research performed in this thesis could inform such a study further by providing a better 
estimate of health technology diffusion that could be used instead of a time-fixed market 
share estimate. Willan and Eckermann (2010) and Pezeshk and Gittins (2006) estimated the 
relationship between the strength of evidence and future number of users of the new 
treatment. The net benefit resulting from the trial then depended on the strength of evidence. 
The functional relationships used in each of the analyses were dependent on assumptions 
that I avoid by eliciting the effect of research on diffusion from experts. I therefore see the 
potential of this analysis in being relevant to different purposes in industrial decision-
making, predominantly in the calculation of profits and in the design of valuable research 
schemes. 
 
9.4 Strengths and limitations 
9.4.1 Strengths 
The strengths of this thesis relate mainly to the following points:  
1. The use of diffusion theory and an established diffusion model 
The use of an established diffusion model based on diffusion theory was the only 
approach to predicting future implementation or forecasting that was grounded in theory and 
substantiated by a large evidence base. This body of literature stood in comparison with 
other forecasting methods that were deemed to be less accurate and did not have the same 
theoretical foundations or evidence to support them (Goodwin et al., 2014).  
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2. Methods are technology-specific 
Diffusion among technologies is heterogeneous and using pre-existing data on 
alternative technologies may not be appropriate. I addressed this by eliciting technology-
specific diffusion data. In doing so, any factors affecting diffusion that were relevant to EIS 
in PTB screening could be taken into account by the experts. Furthermore, diffusion 
determinants relevant to EIS were elicited using semi-structured interviews that allowed 
participants to freely name anything they deemed relevant and to list the most important 
drivers to EIS diffusion. 
 
3. Applicability to different technologies 
While the methods used to obtain diffusion estimates and identify diffusion drivers took 
account of the individuality of the technology of interest, these methods are generalisable to 
many types of different technologies. The modelling frameworks presented in Chapter 4 are 
generic. The interview guide used for identifying drivers to diffusion would require no 
adaptation to different settings, except in the introductory part in which background of the 
technology in question is presented. The elicitation protocol does not need altering any more 
than the interview guide. It is flexible enough to allow elicitation of any different number of 
diffusion scenarios conditional on different implementation strategies. It is, however, 
important to consider the choice of experts for each technology. I included clinicians and 
one business manager but other professional groups could be relevant, too, for example a 
representative of the manufacturer. The sample of experts should include people who will be 
involved in the use, purchasing or sales process of the technology in question. Furthermore, 
the use of tertiles was deemed difficult by experts. Quartiles are an alternative to tertiles that 
may be more intuitive.  
 
4. Validity of findings on diffusion determinants and their impact on diffusion  
The methodology that included both a qualitative and an elicitation study enabled 
validity checks through triangulation of results. Results from the triangulation process 
suggested that no new themes were identified through the expert elicitation. They further 
showed that, while evidence on EIS and the progesterone treatment effect had been deemed 
most important diffusion factors by a few experts in the interviews, evidence generation 
schemes proved to have limited effects on improving implementation. This leads to the 
conclusion that the qualitative study can identify diffusion factors but it cannot tell us 
anything about the extent to which these factors affect diffusion. The elicitation study 
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therefore is indispensable in obtaining diffusion estimates. The elicitation of expert beliefs 
paired with a diffusion model provides a robust framework that stands in stark contrast to 
previously used static or hypothetical estimates (Willan and Eckermann, 2010) or 
extrapolation methods that do not make use of established diffusion models (Whyte et al., 
2016). 
 
9.4.2 Limitations 
1. Assumption of diffusion being independent of study results 
The Research EVSIM and subsequently the EVR were calculated using diffusion estimates 
that did not account for different study results. The result is that this thesis describes the 
effects of a reduction of uncertainty on diffusion only. I have outlined an approach how this 
can be incorporated in Chapters 4, 6 and 7. This approach is entails the following steps: 
(i) Propose a research study. 
(ii) Define cut-off points for plausible research outputs. I suggested using 25% and 75% 
quartiles and the middle range, but this could be divided up further.  
(iii) Report a range of cost-effectiveness outputs for each of these defined ranges.  
(iv) For each of these, elicit a diffusion curve using the approach described in Chapter 6, but 
conditional on the different research and cost-effectiveness outputs. 
(v) Based on the elicited diffusion curves, define a relationship between research study 
results and diffusion.  
(vi) Simulate the study in question, with a large number of simulations.  
(vii) Apply the appropriate diffusion curve in each of these simulations, conditional on 
simulated study outcomes. 
(viii) Calculate the Research EVSIM using Equation (4.11). 
The potential impact on Research EVSIM results have been explored in Chapter 7. However, 
this was done without having elicited the appropriate diffusion curves conditional on study 
results, and these results are therefore only illustrative in nature. 
 
2. Resource and time requirements associated with proposed methods 
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Incorporating diffusion estimates in health technology assessments entails additional 
resource and time requirements. These are associated with identifying implementation 
measures, quantifying implementation levels and modelling both, experience curves and the 
value of implementation. There are two modelling tasks that are the most time-consuming: 
the simulation of research and the two-stage model for the experience curve. Simulation of 
trial data entails a few days of analyst time for conceptualising the statistical model for the 
planned evidence generation scheme and simulating the data. Methods such as the Sheffield 
Accelerated Value of Information (SAVI) tool (Strong et al., 2015) make the calculation of 
the EVSI much simpler than it used to be. Modelling the experience curve requires an 
extension to commonly used models, which entails modelling future periods. 
Conceptualising this is not difficult, but a PSA could take significantly longer because of it. 
In the hypothetical example presented in Chapter 8, which was a simple decision tree model 
with a small number of parameters, the PSA without the experience curve took 
approximately one hour to run in MS Excel (on a machine with 8GB memory). With the 
two-stage experience curve model, the PSA ran for more than 12 hours. 
Qualitative and elicitation methods are time-consuming, as they require careful planning, 
ethics approvals (for the qualitative study), scheduling of interviews and data analysis. The 
elicitation study, now that its design and analysis are in place, can be conducted relatively 
quicker than the qualitative study. A few days for adapting the design of the protocol and 
familiarisation with the software and process are sufficient to prepare for this study and the 
data analysis only takes a couple of days, too. A qualitative study can be a greater 
undertaking in that ethics approval or R&D governance approvals in the respective trusts are 
typically required. The interview guide presented here can be used for all health technologies 
and study preparation, apart from ethics application, is therefore straightforward. However, 
data analysis is never standardised in qualitative research. Transcribing interviews and going 
through the various phases of data analysis can take up weeks of a researcher’s time.    
The additional resource and time requirements can be mitigated by using the proposed 
analyses only when the conditions described in Section 9.3 hold. When more diffusion data 
on health technologies becomes available in the future, using diffusion estimates of 
analogous technologies or meta-analysed data could be a shortcut to doing an elicitation 
study. Qualitative research to explore factors influencing diffusion may not be needed if the 
researcher already has a clear idea on what may be causing low uptake in the future. 
Searching existing catalogues of diffusion factors could help the researcher in assessing 
what the relevant diffusion drivers are for different technologies. It just has to be borne in 
mind that taking these shortcuts potentially results in sacrificing accuracy. 
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3. Deterministic diffusion estimates used in expected value of research calculations 
The calculations of the expected value of implementation were performed using the 
mean diffusion estimates obtained from the elicitation study. With probabilistic diffusion 
estimates available, further analysis could entail simulations of the EVII measures that take 
uncertainty surrounding diffusion estimates into account. This was not done due to time 
constraints in this study, but is an area that could be explored in further research. 
 
4. Only one case study used 
The use of one case study only is a limitation as this means that the range of results that 
could be obtained by performing EVII and DCEA analyses was not fully explored. The 
reason for which only one case study was chosen was because this enabled the use of 
qualitative and elicitation research methods to identify and quantify factors influencing the 
diffusion of EIS. As mentioned above, the qualitative and elicitation studies were time-
consuming and could not have been performed multiple times within the scope of this thesis.  
 
5. Reality-check of s-shaped diffusion curves 
It was highlighted before that s-shaped diffusion curves are not always reflective of 
reality. Heterogeneity of technologies and external influencing factors may cause a diffusion 
curve to exhibit kinks, plateaus or sudden flattening off (Goodwin et al., 2014). Predicting 
diffusion with an s-shaped curve is therefore to be understood as an approximation to what 
will happen in the future, a best guess, resulting from the desire to achieve a sensible trade-
off of realism and feasibility. Whether the generated diffusion curves are predictive of actual 
diffusion will have to be established through applying the method and comparing generated 
curves with actual diffusion data in the future.  
 
6. Utilisation by clinicians ignored 
Lastly, I ignored the uptake levels of utilisation by clinicians, which was estimated to be 
low (Chapter 6). The value of implementation should incorporate this in further research. I 
did not research learning effects brought about by increased usage because my focus was on 
the number of purchases as opposed to utilisation and individual usage. An example of users’ 
learning curves in surgery is the reduction of patient’s blood loss that occurs with physicians’ 
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experience (Hopper et al., 2007). With EIS, it is not entirely clear yet, whether there will be 
learning effects in the sense of improving the predictive ability of EIS, and consequently the 
QALY gain, by increased usage. The pilot study on the predictive ability of EIS had flagged 
up that impedance results were sensitive to the pressure exerted by the operator of EIS 
during measurement. But, with the newly developed transducer-based force gauge, this 
potential problem and source for a learning curve would be eliminated. I therefore do not 
think that learning curves will play a significant role in EIS. The other reason for ignoring 
learning curves was that such analyses would require both, estimates of utilisation and 
purchases.   
 
9.5 Areas for further research 
Areas for further research relate to the limitations that are described above. The main 
limitation was that diffusion was assumed to be independent from study outcomes. I covered 
ways of addressing this in the previous section and explored potential results in Section 
7.4.4. Future research should cover this and explore a range of results. 
Furthermore, performing a PSA on the range of possible results of the dynamic EVII 
analysis in the EIS case study by using probabilistic diffusion estimates could be a 
worthwhile study. For more accurate value of implementation results, clinicians’ utilisation 
needs to be incorporated in uptake and an elicitation conducted on the effects of research or 
other implementation strategies on utilisation. This would also enable a study on clinicians’ 
learning curves.  
A further effect of diffusion that is worth studying is the potential for generating more 
evidence as cumulative use increases, which would increase the expected value of 
implementation further. For instance, if implementation increased and data on predictive 
ability was collected, then the decision problem could be revisited at a defined point in time 
and this data taken into account. This effect can be incorporated in value of information 
analysis by modelling the expected data collection and adjusting the sample size by uptake 
in each year, for instance within a recommendation with research scheme. A modelling 
framework for assessing the value of such schemes has recently been developed (Grimm et 
al., 2016). An increase in implementation would then increase the expected value of 
information of such a scheme. 
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Furthermore, applying the proposed qualitative, elicitation and modelling methods in 
further case studies could have benefits in validating the methods in other settings and gain 
greater experience with them. The objective of this would be to obtain a better overview of 
potential outcomes, uses of the framework and processes required to establish this analysis 
within technology assessments.  
The limitation of time and resource requirements for obtaining diffusion estimates could 
potentially be addressed by the NHS collecting more data on diffusion of health technologies 
which could then be analysed further to develop a database of diffusion estimates. If and 
when more diffusion data becomes available, diffusion data for the available periods could 
be extrapolated over time for a sample of health technologies using the Bass model to start a 
database on Bass model parameters within health technologies. This could be useful for 
health technology assessments and value of implementation analyses in which quick 
estimates of potential health technology diffusion are needed. The database could be used in 
two ways to populate such analyses: either by choosing an analogous technology, with or 
without adaptation, or by using meta-analysed diffusion data. Such a database could also 
inform analyses on the effects of diffusion factors such as the issue of NICE guidance on 
diffusion data from the UK health care setting. The caveat of this is that diffusion has been 
shown to be extremely heterogeneous in the review performed in Chapter 3 and huge 
amounts of data may be required to obtain meaningful results.  
 
9.6 Conclusion 
In conclusion, this thesis has contributed to knowledge by developing methods to predict 
diffusion of health technologies and to obtain more accurate dynamic estimates of the value 
of implementation, the value of research and cost-effectiveness. These developments are 
foreseen to be relevant in the context of health technology assessments of medical devices, 
diagnostics and drugs, particularly in decisions in which there is low implementation and 
uncertainty; or those technologies with potential for future price changes conditional on 
uptake. The proposed methods are also relevant to profit and return on investment 
calculations performed by manufacturers. Further research is needed to obtain diffusion 
estimates conditional on different study results. 
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APPENDIX 
A. Appendix to Chapter 2 
Table A.1 Review of health economic evaluations and use of implementation estimates 
Ent
ry  
Author, 
year 
Type of  
economic 
evaluatio
n 
Condition Comparato
rs 
Reason for 
implementation 
estimate 
Method of deriving 
implementation 
estimates 
Impact of 
implementation on 
result 
Mechanism by which 
ICER was affected by 
implementation 
Areas for future 
research relating 
to 
implementation 
in economic 
evaluation 
1 (Aballea 
et al., 
2007) 
Budget 
impact 
analysis, 
CEA, 
PSA 
Influenza 
vaccinatio
n 
Offering 
vaccination 
to 50-64 
year old 
population; 
to only high 
risk 50-64 
year old 
population 
To calculate 
incidence of 
influenza-like 
symptoms in 
unvaccinated 
population from 
average incidence; 
deaths avoided; 
gains in 
productivity 
Data on current uptake 
available, assumptions 
made about the uptake 
of low risk vs. high risk 
groups based on 
empirical findings 
Uptake affected 
population costs and 
effects, higher 
uptake rates 
produced lower 
ICER. 
Blended ICER. Age 
cohort consists of low 
risk and high risk 
patients: high risk 
patients are expected to 
benefit more from 
vaccination and uptake 
among high risk 
patients is higher - and 
higher with cohort 
vaccination than with 
high risk only. 
Potential for 
evaluating health 
promotion efforts 
to increase uptake  
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2 (Atherly 
et al., 
2009) 
Budget 
impact 
analysis, 
CEA for 
many 
countries 
Rotavirus 
vaccinatio
n 
Introducing 
rotavirus 
vaccine in 
GAVI 
(Vaccine 
alliance) 
eligible 
countries, 
no vaccine 
To explore how 
demand reacts to 
different price 
developments, using 
the Cennium 
demand forecasting 
software with other 
variables including 
coverage rates 
Vaccine coverage rates 
from demographic and 
health surveys and 
assumption, assuming 
that highest-risk 
children have less 
access to vaccine. 
Demand in different 
countries resulted from 
model that depended on 
coverage, price, etc. 
Population costs 
and effects and 
ICER: lower 
coverage rates lead 
to larger ICER. 
Blended ICER. Larger 
uptake increases uptake 
in high-risk groups as 
well which may affect 
ICER. No further 
details provided. 
- 
3 (Burr et 
al., 
2007) 
HTA Screening 
for open 
angle 
glaucoma 
Population 
screening, 
current 
practice 
Uptake of 
community eye test 
would affect cost-
effectiveness of 
OAG screening. 
Historical data and 
assumption 
The higher the 
uptake rate for no 
screening (eye test 
with community 
optometrist) the 
higher the ICER for 
OAG screening. 
Blended ICER. When 
community eye test 
visits have a high 
uptake, OAG will be 
discovered without 
OAG screening. 
Future research on 
whether uptake 
rates are realistic 
for relevant 
patient groups 
4 (Carlin 
et al., 
1999) 
CEA Rotavirus 
vaccinatio
n 
Rotavirus 
vaccination, 
current 
practice 
To estimate 
population effects 
Historical immunisation 
rates, 2 scenarios 
Not clear: ICER 
changed in 
sensitivity analysis 
but other parameters 
were varied at the 
same time. 
Not available. - 
5 (Castane
da-
Orjuela 
et al., 
2011) 
CEA Pneumoco
ccal 
polysacch
aride 
vaccine in 
elderly 
population 
Pneumococ
cal 
polysacchari
de vaccine, 
current 
practice 
To estimate 
population effects 
Historical rates of 
vaccination coverage 
among elderly 
population 
Uptake affected 
population effects 
but whether this 
affected the ICER is 
not clear, as no 
sensitivity analysis 
was conducted 
Not available. - 
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6 (Chew 
et al., 
2010) 
CEA Coronary 
heart 
disease 
(CHD) 
General 
practice-
based CHD 
initiative, 
current 
practice 
To estimate 
population effects 
and costs 
Assumption: Uptake 
was the proportion of 
patients with CHD 
visiting a GP, GPs 
willing to undertake 
programme, patients 
participating for costs, 
and effects only accrue 
for those patients who 
complete the full cycle. 
Estimates based on 
similar programmes in 
e.g. diabetes or 
assumptions (point 
estimate and range) 
Scenario testing 
with low and high 
uptake values was 
conducted and 
ICER was larger 
with lower uptake. 
Estimates of uptake are 
different for costs and 
effects because health 
benefits are only 
accrued for full 
completion which 
means that costs but no 
effects accrue for 
patients who do not 
complete the 
programme (30% in the 
basecase). No further 
details provided. 
Robust 
prospective data 
demonstrating the 
benefits and 
uptake of 
programme would 
be valuable in 
refining the CE 
model. 
7 (Claes et 
al., 
2009) 
CEA Heptavale
nt 
pneumoco
ccal 
conjugate 
vaccine 
Heptavalent 
pneumococc
al conjugate 
vaccine, 
current 
practice 
To estimate herd 
immunity effects 
Estimate based on US 
uptake rates and general 
immunisation rates in 
Germany for first and 
second year of life. 
Higher uptake rates 
were tested in 
scenario analysis 
and had an effect on 
ICER. 
Herd immunity - 
8 (Coffin 
et al., 
2012) 
CEA Chronic 
Hepatitis 
C 
1-time US 
adult 
population 
screening + 
high-risk 
screening, 
screening of 
only high-
risk 
individuals 
To estimate 
population effects 
Estimate based on 
reported uptake rates in 
screening 
recommendations.  
ICER changed with 
uptake rates. 
Not available. Authors 
were contacted but no 
reply was received. 
- 
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9 (Collins 
et al., 
2007) 
HTA Hormone-
refractory 
metastatic 
prostate 
cancer 
Docetaxel 
w/ 
prednisone, 
other 
chemothera
py regimens 
To conduct value of 
implementation 
analysis 
Estimate based on 
currently observed 
shares of treatments as 
all treatments are 
available at present 
The EVPIM was 
smaller with larger 
implementation of 
the cost-effective 
strategy. 
Straightforward in 
EVPIM. 
No 
implementation 
estimate used for 
ICER or EVPI 
10 (Coudev
ille et 
al., 
2009) 
CEA Pertussis 
vaccinatio
n 
Childhood, 
childhood+a
dolescent, 
childhood+a
dolescent+c
ocoon 
(parents of 
newborn), 
childhood+a
dolescent+c
ocoon+1 
dose at 40, 
childhood+a
dolescent+r
outine adult 
To estimate herd 
immunity effects 
Estimate based on 
assumption. Different 
coverage rates were 
assumed for different 
strategies. 
One strategy was 
always dominant 
independently of 
vaccine coverage 
rates. 
Herd immunity Limitation that 
changing 
coverage rates 
over time were 
not evaluated. 
11 (Coupe 
et al., 
2009) 
CEA Preventio
n of 
cervical 
cancer in 
the 
Netherlan
ds 
HPV 
vaccination 
for girls 
aged 12 and 
screening, 
just 
screening, 
just 
vaccination, 
do nothing 
To estimate 
population effects 
Vaccination coverage 
was based on 
assumption. Not varied 
or explored in 
sensitivity analysis. 
Screening compliance 
was based on 
assumption and varied 
in scenario analysis. 
To estimate the 
number of cervical 
cancer cases and 
deaths. Effect of 
vaccination 
coverage on ICER 
not shown. Change 
of ICER with 
screening 
compliance was 
only small, lower 
uptake of screening 
resulted in higher 
ICER for 
vaccination and 
Assumption that added 
vaccination reduced 
screening compliance - 
lower screening 
compliance increased 
ICER of adding 
vaccination. 
Conservative 
coverage rate 
assumed 
compared to data 
from Dutch 
national 
immunization 
programme.  
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screening. 
12 (Cuckle 
et al., 
1995) 
CEA Cystic 
fibrosis 
screening 
Sequential 
carrier 
testing, 
couple 
carrier 
testing 
To estimate the cost 
per affected 
pregnancy detected 
Range of uptake rates 
obtained from pilot 
study reports. 
Costs per affected 
pregnancy detected 
varied with different 
uptake rates in both 
screening strategies. 
Not available. - 
13 (de 
Vries et 
al., 
2010) 
CEA Pertussis 
vaccinatio
n 
Universal 
adolescence 
pertussis 
booster 
vaccination, 
current 
practice 
To estimate cost-
effectiveness 
Assumed that coverage 
rate is the same in 
adolescents as in infants 
which was available. 
Impact of vaccine 
coverage on result 
was not discussed 
Not available. - 
14 (De 
Wals et 
al., 
2004) 
CEA Serogroup 
C 
meningoc
occal 
disease 
Mass 
immunizatio
n campaign, 
routine 
vaccination 
1 or 3 dose, 
no vaccine 
To obtain 
population effects 
and costs 
Based on point 
estimates found in 
literature. 
Not available. Not available. - 
15 (Dee 
and 
Howell, 
2010) 
CEA HPV 
infection 
and 
cervical 
cancer in 
Ireland 
Quadrivalen
t, bivalent or 
no HPV 
vaccine 
additional to 
cervical 
cancer 
screening 
To estimate effects 
of vaccine uptake 
on use of services 
provided to those 
with genital warts, 
abnormal smear 
tests and cervical 
cancer 
Vaccination coverage 
and screening uptake 
rate based on 
assumption and 
vaccination coverage 
rate was varied in 
sensitivity analysis. 
ICER is influenced 
by vaccination 
coverage rates: the 
higher the coverage 
rate the lower the 
ICER. 
Not available - authors 
have been contacted, no 
reply. 
- 
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16 (Heitma
n et al., 
2010) 
CEA Colorectal 
cancer 
screening 
Fecal Occult 
Blood Test 
(FOBT), 
Fecal 
immunoche
mical test 
(FIT), fecal 
DNA every 
3 yrs, 
flexible 
sigmoidosco
py, no 
screening 
To estimate cost-
effectiveness 
Based on uptake 
reported in RCT on 
FOBT, assumed to be 
the same for all 
technologies, and was 
varied in sensitivity 
analysis. 
Different uptake 
rates affected the 
ICER, but not clear 
in which direction. 
Not available - authors 
have been contacted, no 
reply. 
Further 
information on 
long-term 
adherence rates 
for annual stool-
based tests is 
needed. 
17 (Quezad
a et al., 
2008) 
CEA Hepatitis 
A vaccine 
Vaccinate 
all children, 
no 
vaccination 
To estimate 
population effects 
and costs and herd 
immunity 
Scenarios based on 
assumptions 
Cost-savings and 
effectiveness were 
affected by different 
scenarios. 
Herd immunity - 
18 (Rein et 
al., 
2007) 
CEA Hepatitis 
A vaccine 
Vaccinate 
all US 
children, 
current 
policy, no 
vaccination 
To estimate 
population effects 
Based on coverage rates 
of haemophilus 
influenzae type b 
vaccine and from a 
2003 survey 
ICER changes were 
not reported, but 
population effects 
changed, e.g. deaths 
averted, 
productivity losses 
reduced. 
Straightforward for 
population effects. 
- 
19 (Retel et 
al., 
2009) 
CTA Breast 
cancer 
Gene 
expression 
profiling, 
current 
practice 
CTA framework 
demands forecasting 
future developments 
to enable, where 
appropriate, 
influencing these 
developments 
Diffusion scenarios, 
using timeline of 
diffusion phases by 
Rogers (2003) 
To be demonstrated 
in later publication 
(see Entry 20) 
See Entry 20 - 
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20 (Retel et 
al., 
2012) 
 
CTA Breast 
cancer 
Gene 
expression 
profiling, 
current 
practice 
To forecast future 
developments, 
specifically 
diffusion 
Scenario drafting, 
feedback by experts, 
followed by workshops 
with experts to choose 
most likely qualitative 
scenarios, uptake rates 
agreed to resemble the 
uptake rates of clinical 
guidelines in the 
Netherlands 
ICER changed with 
uptake. The higher 
uptake, the lower 
the ICER. 
Blended ICER: co-
existence of cost-
ineffective and cost-
effective technology 
when uptake was low. 
VOI to be 
conducted, more 
quantitative 
estimation of 
uptake is desirable 
21 (Roberts 
et al., 
2007a) 
CEA Chlamydi
a 
screening 
Opportunisti
c screening, 
proactive 
screening 
To examine 
dynamic effects on 
cost-effectiveness 
and consider 
transmission of 
infectious diseases 
Empirical data from 
Chlamydia screening 
studies project 
ICER highly 
sensitive to uptake 
(one-way sensitivity 
analysis), higher 
uptake, lower ICER. 
Transmission model 
considers effects 
beyond the screened 
individual. 
Incorporate 
differential uptake 
estimates 
according to 
characteristic; 
future research 
should focus on 
cost-effectiveness 
of measures to 
increase uptake 
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Table A.2 Review of PEVI estimates and the role of uptake in population estimates 
Ent
ry  
Author (Year) Condition Comparators Population 
estimate based 
on: 
PEVI 
uptake-
adjusted? 
Uptake level  or 
diffusion used 
Uptake estimate based on: Issue of  uncertainty 
around population 
estimate discussed? 
1 McCullagh et 
al. (2012) 
Prophylaxis of 
venous 
thromboembolysm 
after hip 
replacement 
Rivaroxaban, 
dagibatran etexilate, 
enoxaparin sodium 
THR procedures 
in acute public 
hospitals in 
Ireland and uptake 
Yes Out of those that 
received 
prevention, 50% 
received policy of 
choice 
Assumption It was acknowledged 
that population 
estimates for PEVI were 
themselves subject to 
uncertainty, however 
this was not explored. 
2 Welton et al. 
(2008) 
Low uptake of 
breast cancer 
screening 
Do nothing, send 
letter, flag in patient 
record, letter and flag 
Women eligible 
for screening  
No 100% (implicitly) - - 
3 Fleurence 
(2007) 
Two case studies: 1. 
risk of fracture in 
osteoporosis 
patients and 2. 
pressure ulcers 
1. Hormone 
replacement therapy, 
bisphosphonates, 
vitamin D with or 
without calcium, hip 
protectors, 2. High-
spec foam mattress, 
alternating pressure 
mattresses and 
overlays  
Number of 
patients entering 
the decision in 
each year 
No 100% (implicitly) - The implementation of 
research results will not 
automatically follow the 
logical implications of 
the cost-effectiveness 
evidence and should 
therefore be explored in 
further in EVI analysis. 
4 Pandor et al. 
(2004) 
Neonatal screening 
for inborn errors of 
metabolism 
Neonatal tandem 
mass spectrometry, no 
treatment 
Number of 
neonates per 
annum  
No 100% (implicitly) - - 
5 Soares et al. 
(2012) 
Severe sepsis and 
septic shock 
Adjuvant intravenous 
immunoglobulin, 
current care 
Incidence No 100% (implicitly) - - 
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6 Hall et al. 
(2012) 
Early stage lymph 
node positive breast 
cancer 
Oncotype DX 21-
gene assay directed 
chemotherapy, 
chemotherapy for all 
Incidence No 100% (implicitly) - - 
7 Gurusamy et al. 
(2012) 
Gallbladder and 
common bile duct 
stones (CBD) 
Intra-operative versus 
pre-operative 
endoscopic 
sphincterotomy (ES) 
Number of 
patients with 
laparoscopic 
cholecystectomy 
with CBD stones 
and the number of 
ES performed 
each year 
No 100% (implicitly) - - 
8 Pham et al. 
(2011) 
Pressure ulcers in 
elderly patients 
admitted through 
emergency 
departments 
Pressure re-
distributing foam 
mattresses, standard 
hospital mattresses 
Elderly admitted 
emergency 
department 
patients in Ontario 
No 100% (implicitly) - - 
9 Purmonen et al. 
(2011) 
Human epidermal 
growth factor 
Receptor 2 (HER2)-
positive early breast 
cancer 
Adjuvant 
trastuzumab, 
conventional 
treatment after 
chemotherapy 
Number of HER2-
positive breast 
cancer patients 
No 100% (implicitly) - - 
10 Nosyk et al. 
(2011) 
Influenza in patients 
with human 
immunodeficiency 
virus 
Three influenza 
vaccine dosing 
strategies, previous 
dosing strategy 
Prevalence of 
HIV positive 
individuals in 
Canada 
No 100% (implicitly) - - 
11 Hall et al. 
(2011) 
Human epidermal 
growth factor 
Receptor 2 (HER2)-
positive early breast 
cancer 
Adjuvant 
trastuzumab, 
conventional 
treatment after 
chemotherapy 
Annual incidence 
of breast cancer 
and rate of over-
expression of 
HER2 and uptake 
Yes 67% Estimates of use of 
chemotherapy with adjuvant 
trastuzumab from a study 
- 
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12 Petrou et al. 
(2010) 
Otitis media with 
effusion 
Topical intranasal 
steroids, no treatment 
Number of 
children 
potentially 
eligible based on 
a trial 
No 100% (implicitly) - - 
13 Wilson et al. 
(2010) 
Acute cholecystitis Early versus delayed 
laparoscopic 
cholecystectomy 
Number of 
laparoscopic 
cholecystectomy 
per annum 
No 100% (implicitly) - - 
14 Eddama et al. 
(2010) 
Pre-term birth in 
twins 
Progesterone gel, no 
treatment 
Estimated number 
of twin 
pregnancies per 
annum 
No 100% (implicitly) - - 
15 Stevenson et al. 
(2010) 
Post-natal 
depression (PND) 
Group Cognitive 
Behavioural Therapy, 
routine care 
Annual incidence 
of PND 
No 100% (implicitly) - - 
16 Genders et al. 
(2009) 
Suspected coronary 
artery disease 
Computer-
tomographic coronary 
angiography prior to 
conventional 
angiography, 
conventional coronary 
angiography 
Incidence No 100% (implicitly) - - 
17 Bansback et al. 
(2009) 
Rheumatoid arthritis 
(RA) 
Statin therapy in 
addition to 
conventional 
treatment, 
conventional 
treatment 
Number of RA 
patients 
No 100% (implicitly) - - 
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18 Ramsey et al. 
(2008) 
Emphysema Lung-volume 
reduction surgery, 
medical treatment 
Number of 
procedures per 
annum 
No 100% (implicitly) - Acknowledged that 
there was uncertainty 
associated with the 
number of procedures 
but did not address this 
in the model. 
19 
 
Wailoo et al. 
(2008) 
Influenza Amantadine, 
zanamivir, oseltamivir 
Influenza attack 
rate in healthy 
population and 
rate of influenza 
like illness 
No 100% (implicitly) - Acknowledged 
uncertainty associated 
with the population 
estimate but did not 
address this in the 
model. 
20 Singh et al. 
(2008) 
Patients with chest 
discomfort 
presenting to 
emergency 
department 
Early Disposition 
Prediction Rule, 
standard care 
Number of 
individuals 
presenting to 
emergency 
departments with 
chest discomfort 
each year 
No 100% (implicitly) - EVPI was reported with 
different levels of 
incidence; 
implementation was not 
discussed. 
21 Griebsch et al. 
(2007) 
Newborn screening 
for congenital heart 
defects 
Clinical examination, 
pulse oximetry, 
echocardiography 
Number of 
newborns 
No 100% (implicitly) - - 
22 Girling et al. 
(2007) 
End-stage heart 
failure 
Left-ventricular assist 
device implantation 
vs. optimal medical 
management 
Cases of ESHF 
per annum 
No 100% (implicitly) - - 
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23 Colbourn et al. 
(2007) 
Prevention of group 
B streptococcal and 
other bacterial 
infections in early 
infancy 
Prenatal screening 
and treatment 
strategies 
UK population No 100% (implicitly) - - 
24 Wight et al. 
(2003) 
Preserving kidneys 
prior to 
transplantation 
Pulsatile machine 
perfusion, cold 
storage 
Transplant 
population 
No 100% (implicitly) - - 
25 Maheswaran 
and Barton 
(2012) 
Tuberculosis in HIV 
infected individuals  
9 different screening 
strategies in 
combination with 
Isoniazid Preventative 
Therapy 
Annual HIV 
incidence 
No 100% (implicitly) - - 
26 McKenna et al. 
(2012) 
Post-myocardial 
infarction (MI) 
heart failure 
Eplerenone, 
spironolactone 
Prevalence and 
incidence of post-
MI heart failure 
No 100% (implicitly) - - 
27 Mohseninejad et 
al. (2013) 
Prevention of 
depression 
Opportunistic 
screening and contact 
psychotherapy, no 
screening 
Prevalence of 
subthreshold 
depression 
No 100% (implicitly) - - 
28 Dallat et al. 
(2013) 
Quality of life and 
absenteeism from 
work 
Monitoring physical 
activity at work, not 
monitoring 
All current 
Northern Ireland 
employees 
No 100% (implicitly) - - 
29 Murphy et al. 
(2013) 
Severe aortic 
stenosis 
Transcatheter aortic 
valve implantation, 
medical management 
Annual number of 
patients ineligible 
for surgery 
No 100% (implicitly) - - 
  
 279 
 
Table A.3 Results of the expected value of implementation review 
Entr
y 
Authors Title Aim Method Applied 
EVIM 
framework 
by Fenwick 
et al. (2008) 
in a case 
study? 
Developed 
EVIM 
framework 
by Fenwick 
et al. (2008) 
further? 
Effect of 
research on 
implementa
tion 
considered
? 
Dynamics of 
implementatio
n considered? 
Future research Comments 
1 (Fenwick 
et al., 
2008) 
The Value of 
Implementati
on and the 
Value of 
Information: 
Combined 
and Uneven 
Development 
To present a 
framework that 
simultaneously 
addresses the 
problem of 
allocating funds 
between 
investments in 
research and 
implementation. 
Simple four 
state world 
where both 
information 
and 
implementatio
n can be either 
at the current 
level or 
"perfect". 
Assessed 
EVPIM, EVPI 
and EVP in 
case studies 
on orlistat for 
obesity 
treatment, 
zanamivir for 
treatment of 
influenza and 
prophylactic 
extraction of 
wisdom teeth.  
Not 
applicable. 
No. No. Relax assumption 
that information has 
no effect on 
implementation and 
consider both, 
positive and negative 
effects. 
Incorporate 
uncertainty around 
the current level of 
implementation to 
estimate the EVPPI 
of it. 
Evaluate specific 
implementation 
measures, which 
requires estimation of 
the change in 
implementation that 
can be achieved. 
Application of 
framework in an 
ongoing technology 
appraisal.  
Additional 
research could 
focus on 
incorporating the 
dynamics of 
implementation in 
the analysis. 
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2 (Hoomans 
et al., 
2009b) 
Value of 
Information 
and Value of 
Implementati
on: 
Application 
of an 
Analytic 
Framework 
to Inform 
Resource 
Allocation 
Decisions in 
Metastatic 
Hormone-
Refractor y 
Prostate 
Cancer 
To develop a 
framework to 
inform the 
decisions of 
reimbursement, 
research and 
investing in 
implementation 
strategies.  
EVPI and 
EVPIM 
analysis and 
application of 
framework in 
metastatic 
hormone-
refractory 
prostate 
cancer. 
Sensitivity 
analysis to test 
effect of 
assumptions 
on results. 
Assessed 
EVPIM, EVPI 
and EVP in 
the case study 
example.  
No. No. No. Incorporate the cost 
of reversal in the 
framework. 
Calculate EVSI and 
EVSIM. 
This highlights 
the relevance of 
considering 
research and 
implementation 
recommendations 
at the time that a 
reimbursement 
decision is made 
but does not 
evaluate specific 
research or 
implementation 
measures. 
3 (Willan 
and 
Eckermann
, 2010) 
Optimal 
clinical trial 
design using 
value of 
information 
methods with 
imperfect 
implementati
on 
Relax the 
assumption of 
perfect 
implementation 
for EVSI 
analysis to 
inform optimal 
clinical trial 
design. 
Value of 
Information 
Analysis 
Applied EVSI 
with imperfect 
implementatio
n levels in the 
design of two 
trials: the 
early external 
cephalic 
version trial 
and the 
CADET-Hp 
trial. 
Allow sample 
size 
calculations 
when 
imperfect 
implementatio
n levels are 
considered in 
the EVSI 
analysis. 
Allow 
implementatio
n strategies to 
take a few 
years. Allow 
implementatio
n levels other 
than current or 
perfect. 
Yes. The 
effect of a 
research 
study with 
one study 
objective 
and 
different 
sample sizes 
was 
assessed on 
reduction of 
uncertainty 
and 
implementat
ion. 
No. Incorporate multi-
stage trial designs in 
the proposed 
framework. 
Assume 
functional 
relationship 
between the 
strength of 
research evidence 
and (static) 
implementation 
rather than using 
elicited diffusion 
data. 
Do not compare 
different studies 
in terms of their 
impact on 
implementation. 
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4 (Hoomans 
et al., 
2011) 
Implementin
g guidelines 
into clinical 
practice: 
what is the 
value? 
Inform decision 
making about 
guideline and 
specific 
implementation 
strategies using 
the total net 
benefit approach 
Total net 
benefit 
approach to 
calculate the 
EVPIM and 
EVSIM, that 
incorporates 
the costs and 
effects of 
implementatio
n strategies 
into the 
strategy's net 
benefit. 
Assessed 
EVPIM and 
EVSIM of 
specific 
implementatio
n measures.  
No. No. No. None identified that 
relate to the 
framework. 
The estimates 
used for prior and 
posterior 
implementation 
were static. 
5 (Soeteman 
et al., 
2011) 
Cost-
effective 
Psychotherap
y for 
Personality 
Disorders in 
the 
Netherlands: 
The Value of 
Further 
Research and 
Active 
Implementati
on 
To assess the 
societal value of 
conducting 
research and 
implementation 
of cost-effective 
psychotherapy 
for clusters B 
and C 
personality 
disorders 
EVPI and 
EVPIM 
analysis at 
population 
level. 
Assessed 
EVPIM, EVPI 
and EVP in 
psychotherapy 
case study. 
No. No.  No. Calculate the EVSI 
and EVSIM. 
An application of 
the four-state 
framework by 
Fenwick et al. 
(2008). 
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6 (Walker et 
al., 2014) 
Getting cost-
effective 
technologies 
into practice: 
the value of 
implementati
on. Report on 
framework 
on valuing 
implementati
on initiatives. 
Framework for 
allowing 
evaluation of 
different 
implementation 
strategies. 
EVSIM 
analysis and 
assessing the 
value against 
cost of 
implementatio
n measures. 
No. Yes. The 
framework 
was extended 
to allow for 
different 
levels of 
implementatio
n in each time 
period.  
No. Changes to 
implementation 
over time were 
considered 
possible but 
there was no 
application of 
the general 
framework.  
Use of appropriate 
time horizon. 
Elicitation of 
diffusion curves or 
using diffusion data 
of reference 
technologies. 
Incorporating 
uncertainty around 
implementation 
estimates into the 
value of 
implementation 
analysis. 
This is a 
framework that 
does not provide 
detailed guidance 
on data 
requirements and 
possible sources 
of the required 
data.  
7 (Faria et 
al., 2014) 
Getting cost-
effective 
technologies 
into practice: 
the value of 
implementati
on. An 
application to 
novel 
anticoagulant
s in the 
prevention of 
stroke and 
systemic 
embolism. 
Quantify the 
value of 
increasing 
uptake of novel 
anticoagulants 
for patients with 
atrial fibrillation 
by applying a 
value of 
implementation 
framework 
developed 
previously (see 
Entry 7). 
Value of 
Implementatio
n Analysis. 
Assessed 
implementatio
n measures for 
their value of 
actual 
implementatio
n (EVSIM).  
See Entry 7.  No. Extrapolated 
from available 
utilisation rate 
at present using 
linear and 
polynomial 
regression to 
yield utilisation 
rates over 
future time 
periods. 
Effectiveness over 
time and costs of 
implementation 
measures.  
Eligible population, 
current and target 
utilisation rates. 
How implementation 
will change without 
implementation 
measures 
Did not use an 
established model 
of diffusion and 
the two regression 
methods therefore 
differ 
significantly in 
terms of the 
implementation 
that can be 
achieved and the 
time it takes - 
completely 
different 
implementation 
dynamics could 
also be possible. 
8 (Whyte et 
al., 2014) 
Getting cost-
effective 
technologies 
into practice: 
the value of 
implementati
on. An 
application to 
Quantify the 
value of 
increasing 
uptake BNP 
testing by 
applying the 
value of 
implementation 
Value of 
Implementatio
n Analysis.  
Assessed 
implementatio
n measures for 
their value of 
actual 
implementatio
n (EVSIM).  
See Entry 7. No.  Assumed an s-
shaped curve 
for cumulative 
implementation 
based on 
diffusion theory 
which was 
fitted to two 
Exploring the use of 
diffusion curves for 
the estimation of 
implementation in 
future periods.  
There not much 
evidence on the 
effectiveness of 
implementation 
initiatives. The 
first periods of 
implementation of 
BNP testing 
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B-type 
natriuretic 
peptide 
(BNP) testing 
in diagnosing 
chronic heart 
failure 
framework 
developed 
previously (see 
Entry 7). 
periods of 
observed data 
for natural 
diffusion. An 
estimated effect 
size of the 
implementation 
initiative was 
applied to 
implementation 
in future 
periods. 
before 2010 were 
ignored. The way 
the s-shaped curve 
was fitted lacked 
evidence on the 
maximum number 
of attainable 
adoptions, as 
100% was 
implicitly 
assumed. 
9 (Tuffaha et 
al., 2014) 
Cost-
Effectiveness 
Analysis of 
Clinically 
Indicated 
Versus 
Routine 
Replacement 
of Peripheral 
Intravenous 
Catheters 
Assessing the 
cost-
effectiveness of 
clinically 
indicated versus 
routine 
replacement of 
peripheral 
intravenous 
catheters 
Cost-
effectiveness 
analysis 
alongside a 
clinical trial, 
EVPI and 
EVPIM 
analyses. 
Assessed 
EVPI and 
EVPIM.  
No. No. No. None identified that 
relate to the 
framework. 
Baseline 
implementation 
was assumed to 
be at 0%.  
10 (Revill et 
al., 2015) 
Opportunities 
for improving 
the efficiency 
of paediatric 
HIV 
treatment 
programmes 
To assess 
monitoring 
methods for 
HIV-infected 
children on ART 
therapy and the 
continuation of 
cotrimoxazole 
treatment when 
children are 
stabilised on 
ART. 
Incremental 
Cost-
Effectiveness 
Analysis and 
Value of 
Implementatio
n Analysis 
Assessed the 
maximum 
value of 
investing in 
any 
implementatio
n measure 
(e.g. 
strengthening 
procurement 
systems, 
improving 
drug supply 
chains and 
tracking 
systems 
No. No. No. None identified that 
relate to the 
framework. 
The method of 
using the 
difference in 
NMBs does not 
consider the value 
of specific 
implementation 
measures in terms 
of their effect on 
implementation 
nor their 
respective costs 
and more analysis 
is required to 
establish which 
IM could most 
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paying 
providers 
based on 
provision of 
cotrimoxazole
), using the 
EVPIM. 
Used the 
INMB to 
determine that 
value. 
cost-effectively 
improve 
implementation. 
11 (Andronis 
and Barton, 
2016) 
Adjusting 
Estimates of 
the Expected 
Value of 
Information 
for 
Implementati
on: 
Theoretical 
Framework 
and Practical 
Application 
To present a 
method of 
calculating the 
expected value 
of further 
research that 
accounts for the 
reality of 
implementation 
Extended 
Fenwick et 
al.’s 4-state 
world to a 6-
state world 
including 
sample 
information 
and improved 
implementatio
n and 
calculated an 
“implementati
on-adjusted” 
EVSI 
Applied the 
framework in 
a stylised 
illustrative 
case study on 
non-small 
lung cancer 
See methods Yes. Yes. Use better 
implementation 
dynamics 
The authors did 
not calculate the 
true effect of 
research on 
decision 
uncertainty but 
solely focused on 
the effect of 
research on 
implementation. 
Their IA-EVSI is 
therefore in fact 
the EVSIM of 
research. The 
conclusion from 
this work, that the 
EVSI always 
over-estimates the 
IA-EVSI when 
implementation is 
imperfect, is 
wrong. 
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B. Appendix to Chapter 3 
Table B.1 Results of the predicting diffusion methods review 
Entry 
# 
Authors 
(Year) 
Title Objectives Method used to predict 
diffusion with no 
available data 
Bass model of 
new product 
growth used? 
If expert 
judgement, is 
uncertainty 
reflected? 
Limitation of 
method 
Relevant authors' 
comments 
1 (Bass et al., 
2001) 
DIRECTV: 
Forecasting diffusion 
of a new technology 
prior to product launch 
Forecast diffusion 
prior to product 
launch 
Guessing by analogy and 
management decision on 
the most appropriate 
analogous product 
Yes Not applicable Choosing the right 
analogy is 
important but little 
is known about the 
best way of 
choosing the 
analogy 
None 
2 (Jiang et al., 
2006) 
Virtual Bass Model 
and the left-hand data-
truncation bias in 
diffusion of innovation 
studies 
Present a method for 
dealing with bias 
caused by left-hand 
truncation of data 
used for guessing by 
analogy: "the virtual 
Bass model" 
Guessing by analogy: the 
p and q parameter 
estimates for analogous 
products are used to 
forecast the diffusion 
pattern for the new 
product 
Yes Not applicable Left and right 
truncation of data 
used 
Guessing by analogy is 
an established method 
3 (Sugaris and 
Reljin, 
2012) 
DVB-T2 technology 
improvements 
challenge current 
strategic planning of 
ubiquitous media 
networks 
Estimating 
profitability of 
digital terrestrial TV 
Guessing by analogy Yes Not applicable None None 
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4 (Kim et al., 
2013) 
Forecasting diffusion 
of innovative 
technology at pre-
launch: a survey-based 
method 
Propose systematic 
method for the 
diffusion of 
forecasting 
technology at pre-
launch stage 
Design of expert survey 
with seven items that are 
both familiar to 
respondents and 
transformable into 
parameters of logistic 
diffusion model by means 
of algebraic 
transformation and local 
search methods 
No, logistic 
model used 
No Use of logistic 
model instead of 
the Bass model 
Deterministic 
estimates 
Guessing by analogy is 
difficult because it is 
hard to find truly 
analogous products, 
especially in the case 
of radical innovations.  
The Bass model is 
superior to the logistic 
model in most aspects 
of demand forecasting, 
but the logistic model 
has merit in terms of its 
simplicity. 
5 (Lee et al., 
2014) 
Pre-launch new 
product demand 
forecasting using the 
Bass model: A 
statistical and machine 
learning-based 
approach 
Propose novel 
approach to pre-
launch forecasting of 
new product demand 
Guessing by analogy but 
also establishing 
relationship between 
product attributes and 
diffusion characteristics 
through statistical and 
machine learning-based 
approaches applied to real-
world examples that are 
based on expert judgment 
of product attribute values 
Yes No Requires the 
maintenance of 
large databases on 
product attributes 
and diffusion data 
of similar 
technologies. 
Requires expert 
judgement to value 
product attributes 
A large number of 
analogous products is 
required for this to 
work. 
Authors excluded all 
products with fewer 
than 12 years worth of 
data for lack of 
accuracy of resulting 
estimates 
6 (Song et al., 
2015) 
A hybrid Bass–
Markov model for the 
diffusion of a dual-
type device-based 
telecommunication 
service: the case of 
WiBro service in 
Korea 
Develop a new 
approach, the hybrid 
Bass-Markov model, 
to forecast demand 
of a dual-type 
device-based service 
Guessing by analogy for 
Bass model, based on 
weighted average of 
existing services 
Yes Not applicable None None 
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Table B.2 Overview of diffusion curves in cancer 
Entry Condition, 
population 
Ref Technology Diffusion 
measures, 
proxies 
Time 
period 
(data 
available) 
Year of 
first 
guidance 
Data 
sources 
1 Colon cancer (NICE, 
2009d) 
Capecitabine Prescription 
costs 
2000-2009 2003 IMS Health 
Hospital 
Pharmacy 
Audit 
2 Colon cancer (NICE, 
2009d) 
Oxaliplatin Prescription 
costs 
2000-2009 2003 IMS Health 
Hospital 
Pharmacy 
Audit  
3 Colorectal 
cancer 
(NICE, 
2010a) 
Laparoscopic 
surgery 
% of colorectal 
resections 
performed 
laparoscopically 
2001-2009 2004 Hospital 
Episode 
Statistics 
national 
data 
warehouse  
4 Colorectal 
cancer 
(Cullum et 
al., 2004) 
Laparoscopic 
surgery 
% colorectal 
cancer patients 
having 
laparoscopic 
surgery 
1998-2001 2000 HES data 
5 Colorectal 
cancer 
(Green et al., 
2010) 
Laparoscopic 
surgery 
% of surgery 
done 
laparoscopically 
1998-2007 2000 HES data 
6 Advanced 
colorectal 
cancer 
(Howard and 
Harrison, 
2005) 
Oxaliplatin Patients 2001-2003 2002 IMS Health 
7 Advanced 
colorectal 
cancer 
(Howard and 
Harrison, 
2005) 
Irinotecan Patients 2001-2003 2002 IMS Health 
8 Non-small lung 
cancer 
(Cullum et 
al., 2004) 
Docetaxel Milligrammes 1997-2002 2000 Hospital 
pharmacies 
9 Non-small lung 
cancer 
(Cullum et 
al., 2004) 
Gemcitabine Milligrammes 1997-2002 2000 Hospital 
pharmacies 
10 Non-small lung 
cancer 
(Cullum et 
al., 2004) 
Paclitaxel Milligrammes 1997-2002 2000 Hospital 
pharmacies 
11 Non-small lung 
cancer 
(Cullum et 
al., 2004) 
Vinorelbine Milligrammes 1998-2002 2000 Hospital 
pharmacies 
12 Advanced 
ovarian cancer 
(Howard and 
Harrison, 
2005) 
2nd line: 
Topotecan  
Patients 2001-2003 2001 IMS Health 
Oncology 
13 Advanced 
ovarian cancer 
(Howard and 
Harrison, 
2005) 
2nd line: 
Carboplatin  
Patients 2001-2003 2001 IMS Health 
Oncology 
14 Advanced 
ovarian cancer 
(Howard and 
Harrison, 
2005) 
2nd line: 
Pegylated 
liposomal 
doxorubicin 
Patients 2001-2003 2001 IMS Health 
Oncology 
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Entry Condition, 
population 
Ref Technology Diffusion 
measures, 
proxies 
Time 
period 
(data 
available) 
Year of 
first 
guidance 
Data 
sources 
hydrochloride 
15 Malignant 
glioma 
(Howard and 
Harrison, 
2005) 
Temozolomide  Patients 2001-2003  2001 IMS Health 
16 Glioblastoma 
multiforme, 
malignant 
glioma 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Temozolomide NIC 2000-2011 2001 IMS HPAI 
system 
17 Glioblastoma 
multiforme, 
malignant 
glioma 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Carmustine 
implants 
Number of 
implants 
2004-2012 2007 IMS HPAI 
system 
18 Chronic 
lymphocytic 
leukaemia 
(Howard and 
Harrison, 
2005) 
Fludarabine  Patients 2001-2003 2001 IMS Health 
19 Chronic myeloid 
leukemia 
(Howard and 
Harrison, 
2005) 
Imatinib  Patients 2001-2003 2002 IMS Health 
20 Pancreatic 
cancer 
(Howard and 
Harrison, 
2005) 
Gemcitabine  Patients  2001-
2003 
 2001 IMS 
Oncology 
21 Metastatic 
pancreatic 
cancer 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Erlotinib Cost 2005-2011 2007 IMS HPAI 
system 
22 Cancer (Department 
of Health, 
2006) 
Trastuzumab Est number of 
mg (000) 
2000-2005 2002 IMS Health 
Hospital 
Pharmacy 
Audit data 
23 Early breast 
cancer, 
metastatic 
breast cancer 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Trastuzumab Cost 2000-2011 2002 IMS HPAI 
system 
24 Breast cancer 
(early & 
advanced) 
(The Health 
and Social 
Care 
Information 
Centre, 
2009) 
Trastuzumab Cost 2000-2009 2002 HPAI 
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Entry Condition, 
population 
Ref Technology Diffusion 
measures, 
proxies 
Time 
period 
(data 
available) 
Year of 
first 
guidance 
Data 
sources 
25 Cancer (Department 
of Health, 
2006) 
Imatinib Est number of 
mg (000) 
2001-2005 2002 IMS Health 
Hospital 
Pharmacy 
Audit data 
26 Cancer (Department 
of Health, 
2006) 
Rituximab Est number of 
mg (000) 
2000-2005 2002  IMS Health 
Hospital 
Pharmacy 
Audit data  
27 Cancer (Department 
of Health, 
2006) 
Oxaliplatin Est number of 
mg (000) 
2000-2005 2002  IMS Health 
Hospital 
Pharmacy 
Audit data 
28 Renal cell 
carcinoma, 
stromal 
gastrointestinal 
tumours 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Sunitinib Cost 2006-2011 2009 IMS HPAI 
system 
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Table B.3 Overview of diffusion curves in acute conditions 
Entr
y 
Condition, 
population 
Reference Technology Diffusion 
measures, 
proxies 
Time period 
(data available) 
Year of first 
guidance 
Data sources 
29 Hepatitis B (The Health 
and Social 
Care 
Information 
Centre, 
2009) 
Entecavir Cost 2006-2009 2008 ePACT & HPAI 
databases 
30 Severe sepsis (NICE, 2009f) Drotrecogin Prescription costs 2002-2009 2004 IMS Health 
Hospital 
Pharmacy Audit 
and 
Prescription 
cost analysis 
(PCA) system 
31 Severe sepsis (The Health 
and Social 
Care 
Information 
Centre, 
2009) 
Drotrecogin Cost 2002-2009 2004 HPAI 
32 Head Injury (NICE, 
2010h) 
MRI scanning No. of episodes 
from HES with 
investigations of 
head 
2006-2009  2007  HES national 
data 
33 Head Injury (NICE, 
2010h) 
CT scanning No. of episodes 
from HES with 
investigations of 
head 
2006-2009  2007  HES national 
data 
34 Head Injury (NICE, 
2010h) 
X-ray No. of episodes 
from HES with 
investigations of 
head 
2006-2008  2007  HES national 
data 
35 Urinary 
incontinence 
(NICE, 2009g) Oxybutynin Items prescribed 2005-2009  2006 ePACT 
36 Acute 
coronary 
syndromes 
(Howard and 
Harrison, 
2005) 
Tirofiban Units 1999-2003 2000 IMS Health 
37 Acute 
coronary 
syndromes 
(Howard and 
Harrison, 
2005) 
Eptifibatide Units 1999-2003 2000 IMS Health 
38 Hip 
replacement 
(Howard and 
Harrison, 
2005) 
Metal hips  Units  2000-2003 2002 IMS Health 
39 Hip 
replacement 
(Roberts et 
al., 2007b) 
Uncemented 
prostheses 
% of hip 
replacement that 
are uncemented 
or hybrid 
prostheses 
1990-2005 2000 TRENT Regional 
Arthroplasty 
study (Wales) 
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Entr
y 
Condition, 
population 
Reference Technology Diffusion 
measures, 
proxies 
Time period 
(data available) 
Year of first 
guidance 
Data sources 
40 Hip 
replacement 
(Roberts et 
al., 2007b) 
Hybrid 
prostheses 
% of hip 
replacement that 
are uncemented 
or hybrid 
prostheses 
1990-2005 2000 TRENT Regional 
Arthroplasty 
study (Wales) 
41 Wisdom 
teeth 
(Cullum et 
al., 2004) 
Wisdom teeth 
removal 
No. extractions 1992-2001 1997 HES, Dental 
practice board, 
Scottish 
morbidity 
records, 
Scottish 
Practitioner 
Services 
42 Angioplasty (Clinical 
Audit 
Support Unit, 
2010) 
Stents % Percutaneous 
coronary 
intervention (PCI) 
with drug eluting 
stents 
2002-2009 - Survey 
conducted by 
Clinical Audit 
Support Unit, all 
centre but 3 
submitted data 
43 Angioplasty (Clinical 
Audit 
Support Unit, 
2010) 
Arterial access 
route catheters 
% cases using 
radial arteries 
2004-2009 - Survey 
conducted by 
Clinical Audit 
Support Unit, all 
centre but 3 
submitted data 
44 Percutaneous 
coronary 
interventiona
l (PCI) 
procedures 
(National 
Institute for 
Cardiovascul
ar Outcomes, 
2011) 
Stents % PCI with drug 
eluting stents 
2002-2010   Survey 
conducted by 
Clinical Audit 
Support Unit, all 
centre but 3 
submitted data 
45 PCI 
procedures 
(National 
Institute for 
Cardiovascul
ar Outcomes, 
2011) 
Arterial access 
route catheters 
% cases using 
radial arteries 
2004-2010   Survey 
conducted by 
Clinical Audit 
Support Unit, all 
centre but 3 
submitted data 
46 PCI 
procedures 
(Booth-
Clibborn et 
al., 2000) 
Coronary stents Cumulative 
proportion of 
hospitals (%) 
6 years   Questionnaires 
to West 
Midlands 
hospitals 
47 Diagnosis 
(MRI) 
(Booth-
Clibborn et 
al., 2000) 
MRI Cumulative 
proportion of 
hospitals (%) 
17 years   Structured 
questionnaires 
to West 
Midlands 
hospitals 
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Table B.4 Overview of diffusion curves in chronic conditions 
Entr
y 
Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
48 Alzheimers (NICE, 2009e) Donepezil Items prescribed, 
costs 
1998-2008 2005 IMS Health Hospital 
Pharmacy Audit and 
Prescription cost 
analysis (PCA) 
system 
49 Alzheimers (NICE, 2009e) Galantamine Items prescribed, 
costs 
1998-2008 2005 IMS Health Hospital 
Pharmacy Audit and 
Prescription cost 
analysis (PCA) 
system 
50 Alzheimers (NICE, 2009e) Rivastigmine Items prescribed, 
costs 
1998-2008 2005 IMS Health Hospital 
Pharmacy Audit and 
Prescription cost 
analysis (PCA) 
system 
51 Alzheimers (NICE, 2009e) Memantine Items prescribed, 
costs 
1998-2008 2005 IMS Health Hospital 
Pharmacy Audit and 
Prescription cost 
analysis (PCA) 
system 
52 Alzheimer's (The Health 
and Social 
Care 
Information 
Centre, 2009) 
Donepezil Cost 2000-2009 2007 ePACT & HPAI 
databases 
53 Alzheimer's (The Health 
and Social 
Care 
Information 
Centre, 2009) 
Galantamine Cost 2000-2009 2007 ePACT & HPAI 
databases 
54 Alzheimer's (The Health 
and Social 
Care 
Information 
Centre, 2009) 
Rivastigmine Cost 2000-2009 2007 ePACT & HPAI 
databases 
55 Asthma (NICE, 2010d) Omalizumab Prescription costs 2006-2010 2007 IMS Health Hospital 
Pharmacy Audit  
56 Asthma  (The Health 
and Social 
Care 
Information 
Centre, 2009) 
Omalimuzab Cost 2005-2008 2007 HPAI 
57 Atopic 
Eczema 
(NICE, 
2009m) 
Tacrolimus Prescription costs 2002-2008 2004 IMS Health Hospital 
Pharmacy Audit  
58 Atopic 
Eczema 
(NICE, 
2009m) 
Pimecrolimus Prescription costs 2003-2008 2004 IMS Health Hospital 
Pharmacy Audit  
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Entr
y 
Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
59 Severe 
chronic hand 
ecxema 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Alitretinoin Cost 2008-2011 2009 PCA & HPAI 
databases 
60 ADHD (NICE, 2009b) Methylphenidat
e 
Prescription costs 
(NIC) 
1991-2009 2006 Prescription cost 
analysis (PCA) 
system 
61 ADHD (NICE, 2009b) Atomoxetine Prescription costs 
(NIC) 
1991-2009 2006 Prescription cost 
analysis (PCA) 
system 
62 ADHD (NICE, 2009b) Dexamfetamine Prescription costs 
(NIC) 
2003-2009 2006 Prescription cost 
analysis (PCA) 
system 
63 Chronic 
hepatitis B 
(NICE, 2009a) Adefovir 
dipivoxil 
Prescription costs 2003-2008 2003 IMS Health Hospital 
Pharmacy Audit  
64 Chronic 
hepatitis B 
(NICE, 2009a) Peginterferon 
alpha-2a 
Prescription costs 2002-2008 2003 IMS Health Hospital 
Pharmacy Audit  
65 Chronic 
hepatitis B 
(NICE, 2009a) Lamivudine Prescription costs 2003-2008 2003 IMS Health Hospital 
Pharmacy Audit  
66 Hepatitis C (NICE, 2009h) Ribavirin Prescription costs 2001-2008 2004 IMS Health Hospital 
Pharmacy Audit  
67 Motor 
neurone 
disease 
(NICE, 2010e) Riluzole Items prescribed, 
prescription costs 
2000-2009 2001 (<1 
yr) 
IMS Health Hospital 
Pharmacy Audit and 
Prescription cost 
analysis (PCA) 
system 
68 Motor 
neurone 
disease 
(Howard and 
Harrison, 
2005) 
Riluzole Units 1999-2003 2001 IMS Health 
69 Motor 
neurone 
disease 
(The Health 
and Social 
Care 
Information 
Centre, 2009) 
Riluzole Cost 1996-2009 2001 ePACT & HPAI 
databases 
70 Amyotrophic 
lateral 
sclerosis 
form of 
motor 
neurone 
disease 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Riluzole Cost 2000-2011 2001 PCA & HPAI 
databases 
71 Osteoarthriti
s, RA 
(NICE, 2006) Celecoxib Items prescribed 2000-2006 2001 (<1 
yr) 
Prescribing Analysis 
and Cost Tool 
(PACT)  
72 Osteoarthriti
s, RA 
(NICE, 2006) Etodolac Items prescribed 2000-2006 2001 (<1 
yr) 
Prescribing Analysis 
and Cost Tool 
(PACT)  
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Entr
y 
Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
73 Osteoarthriti
s, RA 
(NICE, 2006) Etoricoxib Items prescribed 2000-2006 2001 (<1 
yr) 
Prescribing Analysis 
and Cost Tool 
(PACT)  
74 Osteoarthriti
s, RA 
(NICE, 2006) Meloxicam Items prescribed 2000-2006 2001 (<1 
yr) 
Prescribing Analysis 
and Cost Tool 
(PACT)  
75 Osteoarthriti
s, RA 
(NICE, 2006) Rofecoxib Items prescribed 2000-2006 2001 (<1 
yr) 
Prescribing Analysis 
and Cost Tool 
(PACT)  
76 Osteoarthriti
s, RA 
(NICE, 2006) Valdecoxib Items prescribed 2000-2006 2001 (<1 
yr) 
Prescribing Analysis 
and Cost Tool 
(PACT)  
77 Bipolar 
disorder 
(NICE, 2009c) Lithium Items prescribed, 
prescription costs 
2001-2009  2003  PCA data 
78 Rheumatoid 
arthritis 
(NICE, 2009l) Sodium-
aurothiomalate  
Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
79 Rheumatoid 
arthritis 
(NICE, 2009l) Hydroxychloroc
hline sulphate 
Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
80 Rheumatoid 
arthritis 
(NICE, 2009l) Leflunomide Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
81 Rheumatoid 
arthritis 
(NICE, 2009l) Methotrexate Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
82 Rheumatoid 
arthritis 
(NICE, 2009l) Adalimumab Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
83 Rheumatoid 
arthritis 
(NICE, 2009l) Etanercept Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
84 Rheumatoid 
arthritis 
(NICE, 2009l) Infliximab Total net ingredient 
cost (NIC) 
2005-2009 2007 ePACT 
85 Rheumatoid 
arthritis 
(NICE, 2009l) Anakinra Total net ingredient 
cost (NIC) 
 2002-2009 2007 ePACT 
86 Rheumatoid 
arthritis 
(NICE, 2009l) Abatacept Total net ingredient 
cost (NIC) 
2007-2009 2007 ePACT 
87 Crohn's 
disease and 
Rheumatoid 
arthritis 
(Howard and 
Harrison, 
2005) 
Etanercept Units 1999-2003 2002 IMS Health 
88 Crohn's 
disease and 
Rheumatoid 
arthritis 
(Howard and 
Harrison, 
2005) 
Infliximab Units 1999-2003 2002 IMS Health 
89 Diabetes  (NICE, 2009k) Insulin glargine Items prescribed 2002-2008  2002 ePACT 
90 Diabetes  (NICE, 2011c) Metformin 
hydrochloride 
Items prescribed, 
NIC 
2006-2010  2009 ePACT 
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Entr
y 
Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
91 Diabetes  (NICE, 2011c) Chlorpropamid
e 
Items prescribed, 
NIC 
2006-2010  2009 ePACT 
92 Diabetes  (NICE, 2011c) Glibenclamide Items prescribed, 
NIC 
2006-2010  2009 ePACT 
93 Diabetes  (NICE, 2011c) Gliclazide Items prescribed, 
NIC 
2006-2010  2009 ePACT 
94 Diabetes  (NICE, 2011c) Glimeprimide Items prescribed, 
NIC 
2006-2010  2009 ePACT 
95 Diabetes  (NICE, 2011c) Glipizide Items prescribed, 
NIC 
2006-2010  2009 ePACT 
96 Diabetes  (NICE, 2011c) Gliquidone Items prescribed, 
NIC 
2006-2010  2009 ePACT 
97 Diabetes  (NICE, 2011c) Tolbutamide Items prescribed, 
NIC 
2006-2010  2009 ePACT 
98 Diabetes  (NICE, 2011c) Pioglitazone Items prescribed, 
NIC 
2007-2010  2009 ePACT 
99 Diabetes  (NICE, 2011c) Rosiglitazone Items prescribed, 
NIC 
2007-2010  2009 ePACT 
100 Type 2 
diabetes 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Pioglitazone Cost 2000-2011 2001 PCA database 
101 Type 2 
diabetes 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Rosiglitazone Cost 2000-2011 2001 PCA database 
102 Type 2 
diabetes 
(Howard and 
Harrison, 
2005) 
Sulphonyluria Patients 2000-2003 2000 IMS Health 
103 Type 2 
diabetes 
(Howard and 
Harrison, 
2005) 
Metformin Patients 2000-2003 2000 IMS Health 
104 Type 2 
diabetes 
(Howard and 
Harrison, 
2005) 
Pioglitazone Patients 2000-2004 2000 IMS Health 
105 Multiple 
sclerosis 
(Howard and 
Harrison, 
2005) 
Beta-interferon Units 1999-2003 2001 IMS Health 
106 Multiple 
sclerosis 
(8) Natalizumab Cost 2007-2009 2007 HPAI 
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Entr
y 
Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
107 Renal failure (Howard and 
Harrison, 
2005) 
Home dialysis  % of all 
haemodialysis 
patients 
1997-2002 2002 IMS Health 
108 Renal failure (Howard and 
Harrison, 
2005) 
Hospital dialysis  % of all 
haemodialysis 
patients 
1997-2002 2002 IMS Health 
109 Age-related 
macular 
degeneration 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Ranibizumab Cost 2007-2011 2008 IMS HPAI system 
110 AIDS (Murphy et 
al., 2004) 
Antiretroviral 
therapy (ART) 
Prevalent diagnosed 
HIV infections 
receiving ART (%) 
1997-2001   Henry et al (2000) 
'National 
assessment of HIV 
indections' 
111 HIV (Townsend et 
al., 2006) 
Antenatal HIV 
testing 
Routine offer (no. of 
units), uptake rates 
in units (%) 
2000-2003   Postal survey of 
unit-based obstetric 
respondents UK 
112 Several 
conditions: 
Proton pumb 
inhibitors & 
statins 
(Bennie et 
al., 2012) 
Omeprazole Defined daily dose 
per 1000 inhibitants 
(Scotland), number 
of tablets 
2001-2010 NA National Health 
Services Scotland 
Warehouse  
113 Several 
conditions: 
Proton pumb 
inhibitors & 
statins 
(Bennie et 
al., 2012) 
Pantoprazole Defined daily dose 
per 1000 inhibitants 
(Scotland), number 
of tablets 
2001-2010 NA National Health 
Services Scotland 
Warehouse  
114 Several 
conditions: 
Proton pumb 
inhibitors & 
statins 
(Bennie et 
al., 2012) 
Lanzoprazole Defined daily dose 
per 1000 inhibitants 
(Scotland), number 
of tablets 
2001-2010 NA National Health 
Services Scotland 
Warehouse  
115 Several 
conditions: 
Proton pumb 
inhibitors & 
statins 
(Bennie et 
al., 2012) 
Rabeprazole Defined daily dose 
per 1000 inhibitants 
(Scotland), number 
of tablets 
2001-2010 NA National Health 
Services Scotland 
Warehouse  
116 Several 
conditions: 
Proton pumb 
inhibitors & 
statins 
(Bennie et 
al., 2012) 
Esomeprazole Defined daily dose 
per 1000 inhibitants 
(Scotland), number 
of tablets 
2001-2010 NA National Health 
Services Scotland 
Warehouse  
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Entr
y 
Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
117 Several 
conditions: 
Proton pumb 
inhibitors & 
statins 
(Bennie et 
al., 2012) 
Simvastatin Defined daily dose 
per 1000 inhibitants 
(Scotland), number 
of tablets 
2001-2010 NA National Health 
Services Scotland 
Warehouse  
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Table B.5. Overview of diffusion curves in conditions that can be acute and chronic 
Entry Condition, 
population 
Reference Technology Diffusion 
measures, 
proxies 
Time period 
(data available) 
Year of 
first 
guidance 
Data sources 
118 CV events (NICE, 2008) Atorvastatin    Items 
prescribed 
2002-2008 2005 electronic 
Prescribing 
Analysis Cost Tool 
(ePACT) 
119 CV events (NICE, 2008) Fluvastatin Items 
prescribed 
2002-2008 2005 electronic 
Prescribing 
Analysis Cost Tool 
(ePACT) 
120 CV events (NICE, 2008) Pravastatin Items 
prescribed 
2002-2008 2005 electronic 
Prescribing 
Analysis Cost Tool 
(ePACT) 
121 CV events (NICE, 2008) Rosuvastatin Items 
prescribed 
2002-2008 2005 electronic 
Prescribing 
Analysis Cost Tool 
(ePACT) 
122 CV events (NICE, 2008) Simvastatin Items 
prescribed 
2002-2008 2005 electronic 
Prescribing 
Analysis Cost Tool 
(ePACT) 
123 Inguinal 
hernia repair 
(NICE, 2010b) Laparoscopic 
surgery 
% of hernia 
repairs 
performed 
laparoscopically 
2001-2009 2004 Hospital Episode 
Statistics national 
data warehouse 
(NHS Information 
Centre) 
124 Insomnia (The Health 
and Social Care 
Information 
Centre, 2009) 
Zolpidem Cost 2000-2009 2004 ePACT & PCA 
databases 
125 Insomnia (The Health 
and Social Care 
Information 
Centre, 2009) 
Zoplicone Cost 2000-2009 2004 ePACT & PCA 
databases 
126 Insomnia (The Health 
and Social Care 
Information 
Centre, 2009) 
Zaleplon Cost 2000-2009 2004 ePACT & PCA 
databases 
127 Primary 
hypercholest
erolemia 
(NICE, 2009i) Ezetimibe, 
combined with 
simvastatin 
Items 
prescribed 
2004-2008 2007 electronic 
Prescribing 
Analysis Cost Tool 
(ePACT) 
128 Hypercholest
erolaemia 
(The Health 
and Social Care 
Information 
Centre, 2012b) 
Ezetimibe DDDs 2003-2011 2007 PCA database 
129 Hypercholest
erolaemia 
(The Health 
and Social Care 
Information 
Ezetimibe Cost 2003-2009 2007 PCA & HPAI 
databases 
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Entry Condition, 
population 
Reference Technology Diffusion 
measures, 
proxies 
Time period 
(data available) 
Year of 
first 
guidance 
Data sources 
Centre, 2009) 
130 Patients in 
need for 
central 
venous 
catheters 
(Howard and 
Harrison, 2005) 
Ultrasound for 
placing central 
venous 
catheters 
 Units 1999-2004  2002 IMS Health 
131 Depression (Howard and 
Harrison, 2005) 
Computerised 
cognitive 
behavioural 
therapy 
 CCBT 
placements 
1999-2003 2002 IMS Health 
132 Arrhythmias (3) Implantable 
cardioverter-
defibrillator 
(ICD) 
total number of 
ICDs 
1995-2001 2000 British Pacing and 
Electrophysiology 
Group (BPEG) 
Register 
133 Arrhythmias (Cunningham 
et al., 2005) 
Implantable 
cardioverter-
defibrillator 
Total implants / 
million 
population 
1998-2002 2000 National 
Pacemaker 
Database 
134 Thrombolysis (Packer et al., 
2004) 
Streptokinase Patient doses 
purchased 
1981-2001   IMS Health 
England data 
135 Thrombolysis (Packer et al., 
2004) 
Alteplase Patient doses 
purchased 
1981-2001   IMS Health 
England data 
136 Thrombolysis (Packer et al., 
2004) 
Reteplase Patient doses 
purchased 
1981-2001   IMS Health 
England data 
137 Thrombolysis (Packer et al., 
2004) 
Tenecteplase Patient doses 
purchased 
1981-2001   IMS Health 
England data 
138 Thrombolysis (Packer et al., 
2004) 
Anistreplase Patient doses 
purchased 
1981-2001   IMS Health 
England data 
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Table B.6 Overview of diffusion curves in other conditions 
Entry Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
139 Heavy 
menstrual 
bleeding 
(NICE, 2009j) Hysterectomy No. of patients with 
at least one 
prescription 
1996-2008  2007 Sample of 
anonymised GP 
patient records data 
using IMS Disease 
Analyser 
140 Heavy 
menstrual 
bleeding 
(NICE, 2009j) Endometrial 
ablation 
No. of patients with 
at least one 
prescription 
1996-2008 2007 Sample of 
anonymised GP 
patient records data 
using IMS Disease 
Analyser 
141 Long-acting 
reversible 
contraception 
(NICE, 2010c) Implants Items prescribed 2004-2010  2005 Prescription 
Services Division of 
NHS Business 
Service Authority 
142 Long-acting 
reversible 
contraception 
(NICE, 2010c) Intrauterine 
devices 
Items prescribed 2004-2010  2005 Prescription 
Services Division of 
NHS Business 
Service Authority 
143 Long-acting 
reversible 
contraception 
(NICE, 2010c) Intrauterine 
systems 
Items prescribed 2004-2010  2005 Prescription 
Services Division of 
NHS Business 
Service Authority 
144 Obesity (NICE, 2010g) Orlistat Items prescribed 2000-2010  2006 ePACT 
145 Obesity (NICE, 2010g) Sibutramine Items prescribed 2001-2010  2006 ePACT 
146 Obesity (NICE, 2010g) Bariatric 
surgery 
Items prescribed 1999-2009  2006 ePACT 
147 Obesity (Howard and 
Harrison, 
2005) 
Sibutramine Number patients 2001-2004 2001 IMS Health 
148 Obesity (3) Orlistat Patient months 1997-2002 2001 PACT and hospital 
pharmacy data 
149 Obesity (The Health 
and Social 
Care 
Information 
Centre, 
2009) 
Orlistat Cost 2000-2009 2001 ePACT & HPAI & 
PCA databases 
150 Obesity (The Health 
and Social 
Care 
Information 
Centre, 
2009) 
Sibutramine Cost 2001-2009 2001 ePACT & HPAI & 
PCA databases 
151 Obesity (The Health 
and Social 
Care 
Information 
Rimonabant Cost 2006-2009 2001 ePACT & HPAI & 
PCA databases 
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Entry Condition, 
population 
Reference Technology Diffusion measures, 
proxies 
Time period 
(data 
available) 
Year of 
first 
guidance 
Data sources 
Centre, 
2009) 
152 Morbid 
obesity 
(Howard and 
Harrison, 
2005) 
Lap bands 
surgery 
Number 2001-2003 2002 IMS Health and 
reports from 7 out 
of 12 trusts 
153 Morbid 
obesity 
(Howard and 
Harrison, 
2005) 
Lap bypass Number 1997-2003 2002 IMS Health and 
reports from 7 out 
of 12 trusts 
154 Smoking 
cessation 
(NICE, 2010f) Varenicline Items prescribed 2006-2009 2007 ePACT 
155 Smoking 
cessation 
(NICE, 2010f) Buproprion Items prescribed 2002-2009 2007 ePACT 
156 Smoking 
cessation 
(NICE, 2010f) Nicotine 
replacement 
therapy (NRT) 
Items prescribed 2002-2009 2007 ePACT 
157 Smoking 
cessation 
(Howard and 
Harrison, 
2005) 
NRT Patients 2001-2003 2002 IMS Health 
158 Smoking 
cessation 
(Howard and 
Harrison, 
2005) 
Buproprion Patients 2001-2003 2002 IMS Health 
159 Smoking 
cessation 
(The Health 
and Social 
Care 
Information 
Centre, 
2012b) 
Varenicline Cost 2006-2011 2007 PCA database 
160 Smoking 
cessation 
(The Health 
and Social 
Care 
Information 
Centre, 
2009) 
Varenicline Cost 2006-2009 2007 ePACT 
161 Prophylaxis of 
Rhesus 
disease 
(Howard and 
Harrison, 
2005) 
Anti-D Units 1999-2003 2002 IMS Health 
162 Growth-
related 
diseases 
(Howard and 
Harrison, 
2005)  
Somatropin Units 1999-2003 2002 IMS Health 
163 Opioid 
dependence 
(6) Naltrexone Cost 2000-2011 2007 PCA & HPAI 
databases 
164 Measles 
mumps & 
rubella 
(Mason et 
al., 2002) 
Immunisation Uptake % of 
population 
1996-2000   Child Health System 
by Enhanced 
Surveillance 
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Table B.7 Results of the predicting diffusion methods review 
Entry 
# 
Authors 
(Year) 
Title Objectives Method used to predict 
diffusion with no 
available data 
Bass model of 
new product 
growth used? 
If expert 
judgement, is 
uncertainty 
reflected? 
Limitation of 
method 
Relevant authors' 
comments 
1 (Bass et al., 
2001) 
DIRECTV: 
Forecasting diffusion 
of a new technology 
prior to product launch 
Forecast diffusion 
prior to product 
launch 
Guessing by analogy and 
management decision on 
the most appropriate 
analogous product 
Yes Not applicable Choosing the right 
analogy is 
important but little 
is known about the 
best way of 
choosing the 
analogy 
None 
2 (Jiang et al., 
2006) 
Virtual Bass Model 
and the left-hand data-
truncation bias in 
diffusion of innovation 
studies 
Present a method for 
dealing with bias 
caused by left-hand 
truncation of data 
used for guessing by 
analogy: "the virtual 
Bass model" 
Guessing by analogy: the 
p and q parameter 
estimates for analogous 
products are used to 
forecast the diffusion 
pattern for the new 
product 
Yes Not applicable Left and right 
truncation of data 
used 
Guessing by analogy is 
an established method 
3 (Sugaris and 
Reljin, 
2012) 
DVB-T2 technology 
improvements 
challenge current 
strategic planning of 
ubiquitous media 
networks 
Estimating 
profitability of 
digital terrestrial TV 
Guessing by analogy Yes Not applicable None None 
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4 (Kim et al., 
2013) 
Forecasting diffusion 
of innovative 
technology at pre-
launch: a survey-based 
method 
Propose systematic 
method for the 
diffusion of 
forecasting 
technology at pre-
launch stage 
Design of expert survey 
with seven items that are 
both familiar to 
respondents and 
transformable into 
parameters of logistic 
diffusion model by means 
of algebraic 
transformation and local 
search methods 
No, logistic 
model used 
No Use of logistic 
model instead of 
the Bass model 
Deterministic 
estimates 
Guessing by analogy is 
difficult because it is 
hard to find truly 
analogous products, 
especially in the case 
of radical innovations.  
The Bass model is 
superior to the logistic 
model in most aspects 
of demand forecasting, 
but the logistic model 
has merit in terms of its 
simplicity. 
5 (Lee et al., 
2014) 
Pre-launch new 
product demand 
forecasting using the 
Bass model: A 
statistical and machine 
learning-based 
approach 
Propose novel 
approach to pre-
launch forecasting of 
new product demand 
Guessing by analogy but 
also establishing 
relationship between 
product attributes and 
diffusion characteristics 
through statistical and 
machine learning-based 
approaches applied to real-
world examples that are 
based on expert judgment 
of product attribute values 
Yes No Requires the 
maintenance of 
large databases on 
product attributes 
and diffusion data 
of similar 
technologies. 
Requires expert 
judgement to value 
product attributes 
A large number of 
analogous products is 
required for this to 
work. 
Authors excluded all 
products with fewer 
than 12 years worth of 
data for lack of 
accuracy of resulting 
estimates 
6 (Song et al., 
2015) 
A hybrid Bass–
Markov model for the 
diffusion of a dual-
type device-based 
telecommunication 
service: the case of 
WiBro service in 
Korea 
Develop a new 
approach, the hybrid 
Bass-Markov model, 
to forecast demand 
of a dual-type 
device-based service 
Guessing by analogy for 
Bass model, based on 
weighted average of 
existing services 
Yes Not applicable None None 
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C. Appendix to Chapter 5 
C.1. Topic guide 
 
Identifying factors that will influence usage of a new technology for pre-term 
birth screening in the UK 
 
TOPIC GUIDE 
Version 1 
 
1. Aim of interviews 
 To understand influencing factors of usage of a new technology for PTB screening 
in the UK.  
 
2. Introduction 
 Introduce yourself 
 Explain that this study will inform an economic model for a new technology that 
may diagnose likelihood of PTB 
 Explain that this is part of a PhD study that looks into how usage affects the 
evaluation of a technology  
 Explain that I wish to develop a standard approach by which experts are being asked 
about the usage of an innovative technology. 
 Highlight that you will briefly explain a few important concepts 
 Explain the concept of uptake as usage of technology at one point in time 
 Explain the concept of diffusion as the usage of a technology over a period of time 
- Show graph on first slide and explain that some technologies may never 
reach 100% of uptake 
- Explain that there is some natural diffusion and that it may be enhanced by 
implementation strategies 
 Explain that uptake and diffusion may be expressed in % of the total eligible patient 
population 
 Explain that a learning curve refers to learning how to use a technology better over 
time or with usage 
 Explain that the interviews will be conducted with different health care providers, 
business managers and representatives of the manufacturer in order to understand all 
perspectives 
 Reassure re: confidentiality and anonymity. 
– Confirm that the interview is solely for the use of the researchers  
– The report will pull together findings from all participants in the study and 
no individual will be identified. 
 Remind about length of interview – approximately 45 minutes, maximum of 1 hour 
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 Introduce tape recorder and explain transcription, data storage and destruction (post 
publication of findings) 
 Check if participant has any questions at all at this stage 
 Ask participant to sign consent form to provide written consent for participation 
 Thank the person for agreeing to participate 
 
3. General questions on PTB management (different versions for different respondent 
categories) 
 Ask about current way of managing PTB  
 Ask about point in time in pregnancy where PTB screening becomes relevant 
 Ask about different groups of pregnant women with regards to PTB 
– Ask about identification of higher risk women 
 Ask about available treatment of women prone to PTB 
4. General questions about EIS for PTB 
 Provide information and image on EIS technology – use slides 
 Ask about the type of patients EIS could be used for 
 Ask about the presence of a learning curve for the health care professional 
 Ask about ideas of how EIS could be improved 
 Ask about their perception of how pricy this technology may be 
 Ask about their thoughts on future price developments 
5. Main part (take field notes) 
 Ask about any characteristics of EIS that may influence uptake 
– Probe for explanations 
– Probe for other factors 
Notes: 
 
 
 
 
 
 Ask whether they can think of anything that is related to the user that may influence 
uptake 
– Probe: At health care provider level, e.g. skills, motivation, awareness, 
knowledge 
– Probe: At purchaser’s level 
– Probe: At patient level, e.g. acceptance and beliefs 
– Probe for explanations 
– Probe for other factors 
Notes: 
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 Ask whether they can think of anything related to their organization that may 
influence uptake 
– Probe for e.g. practicalities 
– Probe for explanations 
– Probe for other factors 
Notes: 
 
 
 
 Ask whether they can think of any characteristics of the external environment that 
may influence uptake 
– Probe for e.g. policies 
– Probe for explanations 
– Probe for other factors 
Notes: 
 
 
 
 Ask whether they can think of anything that could increase uptake? 
– Probe: usability, more evidence, communication between peers 
– Probe for explanations 
– If more evidence, probe what type of evidence may increase uptake 
– Probe for other factors 
Notes: 
 
 
 
 Ask about anything else at all that may influence uptake 
– Probe for explanations 
– Probe for other factors 
Notes: 
6. Conclusion 
 Repeat all the named factors and ask for those three that would affect uptake most 
Notes: 
 
Thank the participant for their time and contribution  
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C.2. Information sheet 
 
Identifying factors that will influence usage of a new technology for pre-term 
birth screening in the UK 
- Information sheet - 
 
You are being invited to take part in a research project. Before you decide, it is important for you 
to understand why the research is being done and what it will involve. Please read the following 
information carefully and discuss it with others if you wish. . If there is anything that is not 
clear or if you would like more information or share concerns you can do so contacting the 
researcher or a member of staff from the University of Sheffield (contact details below). 
Take time to decide whether or not you wish to take part. Thank you for reading this. 
What is the project’s purpose?  
The overall aim of this project is to understand factors that will influence usage of a new 
technology called Electrical Impedance Spectroscopy (EIS) with the purpose of pre-term birth 
(PTB) screening in the UK and to quantify future usage with the knowledge of these factors. 
The purpose of this is to test whether a technology’s usage affects evaluation in health economic 
models. 
We would like to talk to professionals who in future may be involved in purchasing, using, 
managing and/or maintaining EIS for PTB screening.  
Why have I been chosen?  
You have been asked to take part because you may be involved in either purchasing, using, 
managing or maintaining EIS for PTB screening. 
Do I have to take part?  
It is up to you whether or not to take part and there will be no negative consequences for you no 
matter what your decision is. If you do decide to take part you will be asked to sign a consent 
form and you can keep this information sheet. You are free to withdraw at any time and without 
giving a reason.  
What will happen to me if I take part?  
You will participate in an interview in which you will be asked about: 
1. Current diagnosis and management of pre-term birth. 
2. Your thoughts about the use of EIS for PTB (description of the technology will be provided at 
the interview). 
3. Potential factors that may influence the use of EIS for PTB. 
You may also be asked if you agree to be invited to participate in a study that will be held at a 
later date to elicit quantitative estimates of the technology’s use. Your agreement does not mean 
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that you have to take part, only that you are interested to hear from us. More information will be 
provided about this. 
How long will the study last? 
Your involvement will be for one interview of approximately 45 minutes, maximum 1 hour.  
What if I change my mind during the study? 
You are free to withdraw from the study at any time. You will not have to give any reasons for 
your withdrawal. 
Are there any risks or disadvantages to taking part in this study? 
We do not anticipate that there will be any risks or disadvantages to taking part. 
What are the possible benefits of taking part? 
The information you give us will help us inform an economic model of EIS for PTB screening 
that will assess cost-effectiveness and the value of investing in implementation measures, 
product development or further research. We think you will find your involvement interesting. 
We hope that in the future this will benefit people who deliver, use or receive EIS, as well as 
make good use of health care resources. 
Will my taking part in the study be kept confidential? 
All the information that we collect about you during the course of the research will be kept 
strictly confidential. You will not be able to be identified in any reports or publications. For data 
analysis, you will be identified by a code rather than a name and the information will be stored in 
password-protected computer files at the University of Sheffield which can only be accessed by 
the researchers. Comments made might be attributed to groups of participants, such as the type of 
hospital you work at, but your name will not be disclosed. 
What will happen to the results of the research project? 
The interview findings will inform a subsequent study that will serve to elicit quantitative 
estimates of the future use of EIS. We aim to publish results of the study in a health care journal 
and present our findings at professional conferences. If you would like a summary of the results 
on completion or details of any publications and presentations please let the researcher know 
through the consent form. 
Who has ethically reviewed this study? 
This project has obtained University Ethics approval by the School of Health and Related 
Research’s University Ethics committee and has obtained R&D governance approval by the 
Sheffield Teaching Hospital NHS Foundation Trust and Barnsley Hospital NHS Foundation 
Trust. The project is currently under review by the Rotherham NHS Foundation Trust review 
committee.  
What if I want to know more? 
If you want to know more or share concerns, you can get in touch with the researcher, Sabine 
Grimm or Dr John Stevens, a member of staff at University of Sheffield. 
Contact:  
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Sabine Grimm       Dr John Stevens 
Email: sabine.grimm@sheffield.ac.uk   Email : j.w.stevens@sheffield.ac.uk 
Phone: 0114 222 6382     Phone : 0114 222 6396 
ScHARR      HEDS, ScHARR 
Room 1.02, Innovation Centre    Regent Court 
217 Portobello Rd     30 Regent Street 
Sheffield S1 4DP     Sheffield S1 4DA 
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C.3. Consent form 
Identifying factors that will influence usage of a new technology for pre-term 
birth screening in the UK 
- Consent form - 
 
Please indicate your agreement with your initials in the right hand-side boxes. 
1. I confirm that I have read and understand the information sheet explaining 
the above research project and I have had the opportunity to ask questions 
about the project. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason and without there being any 
negative consequences. 
 
3. I understand that the information I provide will be securely stored and that 
access will be restricted to the researchers working on this project. I 
understand that my name will not be linked to research materials and I will 
not be identifiable in the report(s) that result from this research. 
 
4. I understand that, as part of the study, audio recordings of the interview 
will be made. 
 
5. I agree to take part in the above research project.  
 
The following statements are optional. Please indicate your choice by circling it. 
6. I agree that I wish to be informed about the study results. Yes No 
7. I agree that I can be informed about an elicitation exercise related to 
this study. 
Yes No 
 
 
Name of participant      Name of person taking 
consent 
 
Date        Date 
 
Signature       Signature 
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C.4. Participants’ statements  
 
Table C.1 Theme 1: Evidence 
Respondents Predictive ability  Treatment effect  Quality 
1 We want a highly 
predictive tool with 
good cut-off in 
impedance readings 
to distinguish those 
who will deliver early 
and those who don't. 
(p. 6) 
If it works we could 
screen all pregnant 
women at their 20 
week scan (p. 3) 
The ability for it to 
be used by all 
pregnant women 
would be crucial for 
uptake (p. 4) 
  The clinical dataset 
will have to be 
robust… (p. 5) 
It'll need validation 
in multi-centre 
studies across 
different settings (p. 
6) 
… how the 
performance of EIS 
compares with that 
of comparators (p. 4) 
2 There has to be 
overwhelming 
evidence, e.g. 
likelihood ratios in 
the 10s and 20s and 
good reproducibility. 
(p. 10)  
… you could instigate 
treatment to prevent 
them from having a 
PTB. (p. 9) 
It would have to 
have very good data 
to show that the cost 
of PTB decreased. (p. 
11) 
If a Cochrane review 
was done on the 
number of studies 
that looked at EIS, 
the prediction of PT 
labour and the cost-
savings, then it 
would involve local 
guideline 
committees and 
forums to say we are 
going to introduce 
this. (p. 11) 
 312 
 
3 If the research 
behind EIS is 
powerful enough, it 
could be made gold 
standard… (p.16) 
If the research shows 
that it could be used 
in the general 
population, then this 
would have 
implications for 
when and by whom 
it is used. (p. 16) 
 ...without trial 
evidence noone is 
going to introduce 
anything. (p. 19) 
If you see that it 
saves lives, and you 
get results in clinical 
practice. (p. 19) 
 
4 ...the main thing is 
whether it works and 
.... (p. 27) 
If the evidence came 
out that you would 
be screening every 
pregnant woman, 
that would have 
quite big training and 
logistical issues (p. 
30) 
Other people are not 
convinced that the 
existing treatment 
works and may need 
more evidence (p. 
24)  
...the main thing is … 
and whether it 
improves outcomes. 
(p. 27) 
Happy healthy 
babies is a valid 
endpoint. (p. 28) 
The more robust the 
evidence is, the more 
likely we are to do it. 
(p. 31) 
You don't need this 
many trials to say it 
works but you have 
to have a piece of 
research that, when 
you critically 
appraise it, you can't 
shoot holes through 
it. (p.31) 
So it has to have 
good external 
validity (p. 31) 
5 Reliability is the most 
important thing. (p. 
35) 
If you start using it in 
high risk groups, will 
it translate to low 
risk groups, will it get 
false positives, so I 
think you need a lot 
more studies (p. 37) 
The big thing is what 
do you do as a result 
of a positive test. (p. 
37) 
Evidence in the 
shape of 
randomised-
controlled trials, 
double-blind in fact, 
is essential. (p. 37) 
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6 Is there a way to 
screen everybody so 
that noone has to 
have PTB in the 
future (p. 41) 
The machine has to 
be reliable and show 
specific results... (p. 
46) 
From a clinical 
outcomes point of 
view, is this going to 
be better? (p. 40)  
If it gives us better 
health outcomes, it 
will be taken up 
quickly. (p. 42) 
I would want this 
information, that it is 
much better than 
what we currently 
have, to be well 
scrutinised and 
publicly used (p. 41) 
7 It's got to work. (p. 
48) 
It would have to 
have the research 
behind it… (p. 53) 
You have to have 
your research first. 
(p. 54)  
The clinical 
outcomes would 
have to be very 
robust. (p. 53) 
If the clinical 
evidence is strong 
enough, I think it's 
about engaging the 
health economy to 
try and adopt it. (p. 
54) 
8 I think that this 
would be the holy 
grail, that this test 
could be applied to 
everybody. (p. 57) 
Research has to 
show sensitivity and 
specificity to make 
sure that clinicians 
will use it correctly. 
(p. 58) 
If you can't do 
anything about the 
clinical outcome, and 
save unborn 
children, it may not 
be adopted. (p. 60) 
You'd have to have 
very good evidence 
before it might be 
widely adopted. (p. 
61) 
It's got to be 
grounded in good 
quality research, that 
was well conducted 
and peer-reviewed. 
(p. 63) 
Actually, there is a 
morbidity associated 
with this, putting 
patients under some 
degree of stress and 
telling some of them 
that they may have a 
PTB, a psychological 
morbidity that it 
could ruin your 
pregnancy (p. 60) 
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9 What I would like to 
see first is that this 
definitely predicts 
PTB (p. 66)  
That's why you've 
got to do the trials in 
women who've 
never had PTB 
before. (p. 66) 
It all depends on 
how good a 
predictor it was. (p. 
68) 
...if the treatment 
stopped PT labour 
then it would be 
taken on board. (p. 
68) 
It's a combination of 
how good the 
predictive value was 
and how good the 
treatment was. (p. 
71) 
Good research could 
convince me of 
whether this could 
make a difference. It 
has to be a good-
sized study with 
adequate power. 
And it needs to be 
randomised. I'm not 
bothered about lots 
of trials as long as it's 
good quality and it's 
big enough and not 
biased in any way by 
the people who are 
trying to make it. (p. 
72) 
10 The biggest thing 
would be the 
evidence, that it 
works, and if there 
was clear evidence 
on what the true 
positives, negatives 
and false positives, 
negatives were, that 
could drive uptake. 
(pp. 74-75) 
If you could prove 
that there was an 
intervention to 
improve the overall 
outcome, then that 
would send up the 
uptake. (pp. 74-75) 
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Table C.2 Theme 2: Product and service characteristics 
Respondents Easy to use design Costs Marketing 
1 What people need is 
a device that is easily 
used by operators. 
(p. 2) 
It must not look 
menacing or too big, 
if it looks sleek and 
nice it is likely that 
people would take it 
up. (p. 2) 
It should have 
disposable tips... (p. 
2) 
…should not need 
charging, whether 
it's a replaceable or 
rechargeable 
battery.  (p. 3) 
It should have 
wireless technology. 
(p. 2) 
Cost-effectiveness / 
pricing are vital for 
uptake as well. (p. 4, 
5) 
 
2 If everyone knew it 
was there and you 
could easily use it in 
clinic setting without 
other equipment. (p. 
11) 
If that stuff was all 
disposable, then it 
would be very 
simple. (p. 9) 
We want the best 
equipment but might 
not always get it 
because the initial 
outlay is very 
expensive. (p. 11) 
If this turned out to 
be effective, this 
would be what we 
are aiming for, as 
obviously PTB has a 
huge financial 
implication and 
every time you keep 
a baby out of the 
special care unit you 
are saving lots of 
money. (p. 9) 
Why should we 
spend X amount of 
money, if we are not 
going to improve our 
efficiency? (p. 11) 
It would have to be 
minimal outlay or it 
would be for the 
company to say we 
will  give you this on 
trial, completely free, 
with X many refills 
for 6 months... (p. 
12) 
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3 It should not need 
difficult procedures 
to do it. (p. 17) 
If the actual design 
of the device looks 
slick enough it may 
make it a winner. (p. 
17) 
It should be low 
maintenance and 
something that has 
to be calibrated 
every morning, is not 
going to work. (p. 17) 
What they are 
concerned about is 
recurrent 
expenditure (p. 20) 
If something can 
save money as well, 
the business case is a 
lot easier. (p. 20) 
If this saves 50 lives 
this year, they will 
say buy it. Even if it 
does not save any 
money. (p. 20) 
 
4 The easier it is to do, 
the more likely we 
are to do it. (p. 31) 
I've had issues in the 
past with devices 
that were too big 
and did not fit my 
hand. (p. 26) 
It needs to have a 
disposable cover. (p. 
23) 
It would be great if it 
had a docking station 
and you put it in and 
it downloads data to 
the computer. (p. 23) 
This is probably 
going to have better 
uptake, as long as it's 
not too expensive. 
(p. 25) 
The capital costs, the 
consumable costs… 
will influence uptake. 
(p. 26) 
You would need to 
budget maintenance 
into the overall costs. 
(p. 30) 
The cost of looking 
after pre-mature 
babies in the special 
care unit is just huge 
and then they are 
handicapped and 
need lifelong input 
and if we had a 
simple device that 
costs just £5,000 that 
we could use on 
everybody and 
predict the ones that 
deliver before 28 
weeks, then we 
could have some 
impact. (p. 26) 
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5 Ease of use is going 
to affect uptake of 
this technology. (p. 
34) 
The design is 
probably quite 
important, it should 
look sleek and easy 
to use and not big 
and threatening. (pp. 
34-35) 
If it's easy and quick 
to use it would 
influence uptake. (p. 
35) 
It would be what the 
initial cost is… It 
would make a big 
difference if you had 
to think very 
carefully about 
consumable cost. (p. 
33) 
Servicing costs and 
replacement are very 
important for the 
business case. (p. 36) 
 
6 Who can do it? Is it 
something that 
needs to be done by 
a consultant or can it 
be done by a nurse? 
(p. 41) 
I'd want to know 
how robust is the 
piece of kit. (p. 52) 
If you've got a probe 
that will link to a 
computer by 
bluetooth or wifi, 
people think that's 
wonderful. (p. 43) 
When things are 
expensive they are 
not taken up… (p. 42) 
If the kit only lasts a 
year it can't come in 
at 100,000 pounds. 
(p. 42) 
Affordability comes 
from two things, how 
much is it and how 
long do consumables 
last? (p. 41) 
Can this be done by a 
nurse who is much 
cheaper than a 
consultant? (p. 41) 
Can we prevent that 
woman from having 
a baby at 24 weeks 
and get it for delivery 
at 34 weeks, that's a 
hell of a lot of cost-
saving. (p. 43) 
I think it's how 
enthusiastic the sales 
person is, if they 
believe in what they 
do and they can put 
that over to you... (p. 
44) 
 318 
 
7 Is it easy to use, do 
they need to refer 
them to a specialist 
for it? (p. 51) 
Portability would 
influence the 
decision. (p. 52) 
If it's under 5,000 
pounds per item it 
can be a directorate 
local decision but if 
it's over it has to go 
to the capital 
investment team. (p. 
48) 
...know the cost 
outcomes and wider 
financial impact. (p. 
49) 
… it's about tariff 
payment catching up 
with what is 
happening clinically. 
If there's a saving in 
another clinical area 
it would not account 
towards our saving. 
(p. 50) 
Incentives can be 
perverse as they 
encourage you to 
keep higher cost 
procedures in order 
to not lose income 
because you may not 
be able to take out 
actual costs (p. 50) 
… negotiate things 
on maintenance, 
replacement is key. 
(p. 51) 
Some companies will 
work with you to do 
that [that the 
disposable bits are 
low]. (p. 50) 
8   If the disposables 
were costing 10s of 
pounds, let's say 30 
pounds every time 
you did it, people 
would think very 
carefully. (p. 58) 
… clinicians are 
increasingly aware of 
costs. (p. 59) 
… there is a cost 
associated with 
changing existing 
practice, it's quite 
difficult to introduce 
new technologies in 
the NHS (p. 62) 
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9 As long as the 
evidence said it was 
good and it was good 
in everybody's hands 
because it was easy 
to use, then I can see 
the potential. (p. 66) 
As long as it was 
robust and didn't 
break down at the 
first attempt of using 
it, that's what makes 
things usable. (p. 69) 
As long as it's quick it 
should be easily 
brought into clinical 
practice. (p. 69) 
 
… would have some 
probe covers that 
would need costing 
in (p. 67) 
How usable it was 
would depend on the 
initial outlay… (p. 67) 
… you would have to 
take into account 
whether you'd have 
to train someone (p. 
67) 
Cost is the biggest 
thing at the minute 
because all trusts are 
under pressure (p. 
68) 
You'd have to cost it 
up against the cost of 
PTB, the cost of 
steroids, the cost of 
treatments. (p. 67) 
It's how good care 
the manufacturer 
gives; that is also 
things like training 
packages. (p. 70) 
It's how good the 
representative is and 
how much care they 
give (p. 70) 
10 It should be 
something readily 
usable, with not 
much training 
required. (p. 75) 
An ergonomic and 
easy to use look is 
the greatest factor, 
along with the 
evidence for its use. 
(p. 75) 
Ease of use is 
important, how to 
store the 
information. (p. 75) 
The biggest thing 
would be evidence 
and working out the 
cost benefit, if you 
could save 3-5 PTBs 
per year, the impact 
that would have on 
drugs, special care 
baby units and long-
term effects. (p. 75) 
I think that the 
manufacturer would 
provide training 
initially because 
people will ask many 
questions and not all 
the information will 
be available (pp. 
75,76) 
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Table C.3 Theme 3: Organisational set-up 
Respondents Budget Practicalities Clinician Midwives’ support 
1 Budget is an issue, 
for example trusts or 
health funders might 
decide to buy 4 
rather than 8 
devices. (p.5) 
  There is a degree of 
scepticism in the 
clinical community. 
(p. 3) 
  
2 Everyone is having to 
make savings of 5% a 
year. We are having 
to cut down on this 
that and the other 
and then you want 
to introduce a new 
technology that's 
going to cost. (p. 12) 
You can't do 
anything now, 
without someone 
being on a training 
course. (p. 13) 
When you have 
come to a certain 
level of training or 
age then it is very 
difficult to go for 
something new, it's 
treated with 
suspicion. (p. 10-11) 
If you're ignorant of 
the data out there 
you are less likely to 
use it. (p. 11) 
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3  Anything that will 
reduce the pressure 
on ultrasound will be 
welcome. (p. 18) 
There are some 
people that are more 
enthusiastic than 
others. (p. 17) 
There are certain 
people who are up 
for innovation and 
some that aren't. (p. 
18) 
  
4   If you do it instead 
of scans, then this is 
much quicker and 
there's efficiencies to 
be had. (p. 29) 
When new research 
recommends not to 
do something 
anymore, everyone 
immediately stops 
doing it, but when 
you're supposed to 
do something in 
addition to what 
you're already doing, 
uptake is a bit 
smaller. (p. 31) 
A lot of people who 
do obstetrics in the 
UK are not 
obstetricians, they 
are primarily 
gynaecologists... And 
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a large chunk of 
them don't know 
that evidence exists 
because their 
interest is not in 
obstetrics. (p. 28) 
5   You may need 
someone to 
chaperone you and 
that can be an issue 
in an antenatal clinic. 
(p. 36) 
And who is 
responsible for 
maintaining it is 
quite an issue (p. 36) 
There'll be 
enthusiasts and 
there'll be people 
who will say, what 
am I going to do 
differently? So I 
think it takes a while 
for uptake to go up. 
(p. 34) 
We’re all a bit 
resistant to change, 
you always do the 
same thing that 
you've always done 
and it takes some 
time to get to it. (p. 
35) 
The fact that junior 
You need to buy the 
midwives' support into 
it. They are often the 
ones who see it, they'll 
suggest why don't you 
do this test, so I think 
it's important to 
engage them. (p. 35) 
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staff rotate between 
units can influence 
how it's used in 
practice more than 
anything else. (p. 36) 
6  If I need to do it to 
every patient that I 
see in antenatal 
clinic, that is going to 
add 15 minutes and 
reduce my clinic by a 
third. (p. 41) 
If you do it instead of 
transvaginal 
scanning, we may 
not need to buy 
transvaginal probes 
anymore. (p. 42) 
Where would you be 
if there is a drug or 
process that comes 
along, and I'm 
probably quite 
conservative with 
trying new things. (p. 
40) 
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7 It is about whether it 
is capital or revenue 
budget. We could be 
totally broke and 
load the costs at the 
front end because 
it's not our 
directorate's budget, 
but it's still the 
trust's budget. (p. 
53) 
Ultrasound seems to 
be such a scarce 
resource that any 
alternative would be 
welcome. (p. 50) 
   
8  It might save you 
money because you 
don't have to do 
other tests, such as 
ultrasound. (p. 62) 
And then you have 
some trusts, where 
they are more 
innovative and keen 
to innovate and 
introduce new 
technologies. (p. 62) 
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9 The cost-benefit will 
influence uptake, 
and at the minute, 
this trust is very 
financially bound. (p. 
70) 
  It's got mostly to do 
with awareness of 
how good the 
technology is. (p. 69) 
  
10     It depends on the 
group of doctors and 
particularly the lead 
doctor and how they 
feel about it. (p. 76) 
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Table C.4 Theme 4: External factors 
Respondents Guidance Scientific 
dissemination 
Peer influence Patient demand Media 
1 Obviously, if it's 
adopted by NICE that 
would dramatically 
improve uptake. (p. 
5) 
 Views of opinion 
leaders will increase 
uptake. (p. 5) 
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2 It would take local 
guideline 
committees to take it 
up and even better, 
NICE taking it up. (p. 
11) 
      
3 The essential factor 
for the diffusion of a 
device is the 
reception that the 
NICE gives to it (p. 
16) 
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4 If the Royal College 
or NICE said 
everyone must have 
this then it would be 
difficult for the trust 
to say No. (p. 30) 
Research needs to be 
publicised and the 
more it is, the more 
likely people are to 
think that this might 
be helpful. (p. 28) 
    
5 Local guidelines and 
national guidelines, 
in our case, the 
RCOG Green-top 
guidelines have a 
major influence on 
what is done. (p. 37) 
 If you have 
somebody who is 
well-respected 
talking at 
conferences, there is 
a take-home 
message. (p. 37) 
A lot of bits of 
equipment are 
bought because 
patients in support 
groups talk about it, 
ask for it and want to 
go somewhere 
where it's available. 
(p. 37) 
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6 If this goes through 
and it becomes NICE 
or college accredited 
that will encourage it 
to be taken up. (p. 
46) 
 Bad experience 
elsewhere can bring 
uptake down (p. 46) 
If patients don't like 
it, it won't get taken 
up. (p. 41) 
User feedback can be 
a big influence and it 
can come from 
women's magazines, 
soft press stuff and 
patients. It's getting 
it out there. (p. 47) 
7 When they come 
with NICE 
recommendations or 
are adopted for 
screening 
programmes then 
the funding is held 
differently. (p. 48) 
Clinicians go to 
conferences, they 
see all these new 
toys. (p. 48) 
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8 The shape of the 
uptake curve will 
alter according to 
things like evidence 
by NICE (p. 59) 
Publicity is going to 
be important, that is 
publicity in the 
medical fraternity 
and in the general 
public (p. 63) 
 It can become 
patient-driven, and 
patients may go to 
units because there 
is a degree of choice. 
(p. 62) 
Media is a big 
influence. (p. 62) 
9 If a local network 
says we're going to 
use this and you 
were an outlier then 
that would influence 
things. (p. 71) 
   Women are 
influenced by other 
women and they will 
want to access it… 
(p. 70) 
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10 NICE and the College 
guidelines would be 
what sparks a sharp 
rise in uptake. (p. 77) 
 The greatest rise in 
uptake will be from 
people who just 
follow the trend (p. 
74) 
 The media can have 
a strange effect, in 
front of a paper 
would do wonders 
but it also picks up 
problems (p. 76) 
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D. Appendix to Chapter 6 
D.1. Information sheet for elicitation study 
 
 
Quantifying factors that will influence usage of a new technology for pre-term 
birth screening in the UK 
- Information sheet - 
You are being invited to take part in a research project. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please read 
the following information carefully and discuss it with others if you wish. If there is 
anything that is not clear or if you would like more information or share concerns you can 
do so contacting the researcher or a member of staff from the University of Sheffield 
(contact details below). Take time to decide whether or not you wish to take part. Thank 
you for reading this. 
What is the project’s purpose?  
The overall aim of this project is to identify factors that will influence usage of a new 
technology called Electrical Impedance Spectroscopy (EIS) with the purpose of pre-term 
birth (PTB) screening in the UK and to quantify future usage with the knowledge of these 
factors. The purpose of this is to test whether a technology’s usage affects evaluation in 
health economic models. 
The relevant factors have already been identified. At this stage, future usage conditional on 
different levels of these factors will be quantified. 
For this exercise, we would like to seek opinions and subjective estimates of professionals 
who in future may be involved in purchasing, using, managing and/or maintaining EIS for 
PTB screening.  
Why have I been chosen?  
You have been asked to take part because you may be involved in either purchasing, using, 
managing or maintaining EIS for PTB screening. 
Do I have to take part?  
It is up to you whether or not to take part and there will be no negative consequences for 
you no matter what your decision is. If you do decide to take part you will be asked to sign 
a consent form and you can keep this information sheet. You are free to withdraw at any 
time and without giving a reason.  
What will happen to me if I take part?  
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You will participate in an elicitation exercise that will be conducted at a venue at the 
University of Sheffield. Elicitation is a widely used method for obtaining experts’ 
judgements. More information about your involvement and the nature of elicitation is 
provided in the separate ‘Elicitation briefing notes’ document. It is important that you fill in 
sections 2 and 4 in the document titled ‘Pre-elicitation meeting pro-forma’ before the 
elicitation meeting.  
How long will the study last? 
Your involvement will be for one elicitation session of approximately three hours.  
What if I change my mind during the study? 
You are free to withdraw from the study at any time. You will not have to give any reasons 
for your withdrawal. 
Are there any risks or disadvantages to taking part in this study? 
We do not anticipate that there will be any risks or disadvantages to taking part. 
What are the possible benefits of taking part? 
The information you give us will help us inform an economic model of EIS for PTB screening 
that will assess cost-effectiveness and the value of investing in implementation measures, 
product development or further research. We think you will find your involvement 
interesting. We hope that in the future this will benefit people who deliver, use or receive 
EIS, as well as make good use of health care resources. 
Will my taking part in the study be kept confidential? 
All the information that we collect about you during the course of the research will be kept 
strictly confidential. You will not be able to be identified in any reports or publications. For 
data analysis, you will be identified by a code rather than a name and the information will 
be stored in password-protected computer files at the University of Sheffield which can 
only be accessed by the researchers.  
To encourage exchange of information in the session it is vital that what is said during the 
session is treated as confidential and should not be repeated outside the session. 
What will happen to the results of the research project? 
The quantitative estimates of the future use of EIS will be used in an economic evaluation 
of EIS. We aim to publish results of the study in a health care journal and present our 
findings at professional conferences. If you would like a summary of the results on 
completion or details of any publications and presentations please let the researcher know 
through the consent form.  
Who has ethically reviewed this study? 
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This project is currently under review by the School of Health and Related Research’s 
University Ethics Review Procedure and under review of the Sheffield Teaching Hospital 
NHS Foundation Trust R&D governance procedure. [to be changed once approvals are 
obtained] 
What if I want to know more? 
If you want to know more or share concerns, you can get in touch with the researcher, 
Sabine Grimm or Dr John Stevens, a member of staff at University of Sheffield. 
Contact:  
Sabine Grimm     Dr John Stevens 
Email: sabine.grimm@sheffield.ac.uk Email : j.w.stevens@sheffield.ac.uk 
Phone: 0114 222 6382   Phone : 0114 222 6396 
Innovation Centre    HEDS, ScHARR 
217 Portobello Rd    Regent Court 
Sheffield S1 4DP    30 Regent Street 
      Sheffield S1 4DA 
 
  
 335 
 
D.2. Elicitation briefing notes 
Quantifying uptake determinants of Electrical Impedance Spectroscopy 
for use in pre-term birth screening in the UK 
Elicitation briefing notes 
The purpose of the elicitation meeting is to obtain probability distributions to represent 
your uncertainty about various quantities of interest. These are listed in section three of 
the attached pro forma. 
The elicitation will be conducted following the Sheffield Elicitation Framework (SHELF), 
based on elicitation practice recommended in O’Hagan et al (2006). You will be given 
training in the process of elicitation at the start of the meeting, which will include a 
practice exercise to familiarise you with the procedure. 
It is important to note that you will not be asked to provide single estimates of any of 
these quantities. The elicitation process will instead involve considerations such as what 
a plausible range of values would be for each unknown quantity, and whether, in your 
opinion, some values are more likely than others. You may have considerable 
uncertainty about some of these quantities (though less than that of a lay person). This 
will not be of concern during the elicitation itself, as the outputs from the elicitation will 
reflect large uncertainty when it is present. 
Due to the subjective nature of elicited probability distributions, it is important to make 
the elicitation process as transparent as possible. A written record will be kept of the 
meeting, which will include details of experts present at the meeting, a summary of each 
expert’s relevant expertise, and any declarations of interest. It would be helpful if you 
could complete sections 2 and 4 in the pro forma. A brief summary will be sufficient for 
section 4, covering expertise relevant to the parameters listed in section 3. 
Please note that declarations of interest are recorded for the purposes of transparency 
only, and will not be used as grounds for exclusion from the elicitation. It is common for 
experts to be stakeholders in the wider process. 
Suggested relevant evidence is listed in section 5. If you wish to add to this list you may 
do so. Where appropriate, publications/data listed in this section will be made available 
at the elicitation meeting. 
Reference: 
O'Hagan, A., Buck, C. E., Daneshkhah, A., Eiser, J. E., Garthwaite, P. H., Jenkinson, D. 
J., Oakley, J. E. and Rakow, T. (2006). Uncertain Judgements: Eliciting Expert 
Probabilities. Chichester: Wiley.  
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D.3. Pre-elicitation meeting pro forma 
Quantifying uptake determinants of Electrical Impedance Spectroscopy 
for use in pre-term birth screening in the UK 
Pre-elicitation meeting pro forma 
1) Background The purpose of this exercise is to obtain estimates of future 
purchases for Electrical Impedance Spectroscopy (EIS) for use in pre-
term birth screening. These estimates will then be used in an 
economic evaluation of this device that will show future cost-
effectiveness and help in setting research priorities. 
2) Declarations of 
interests 
[To be completed by the expert.  Please identify any personal 
interest that you might have in the outcome of this elicitation 
exercise, or in the wider context specified above – whether as an 
employee, consultant, shareholder or in any other capacity.] 
3) Parameter 
definitions 
1. The number of potential purchases of EIS in the NHS England (your 
expertise of adoption processes in the NHS in your field of work is 
needed). 
2. The number of potential purchases in the first period after 
introduction of EIS (your expertise of how fast hospitals adopt new 
technologies in your field of work is needed). 
3. The number of years at which the purchase rate peaks (your 
expertise of how long it takes to reach the majority of adopters in the 
NHS in your field of work is needed). 
4. The same 3 parameters as above assuming that there is more 
research available (your expertise of impact of research on adoptions 
in your field of work is needed). 
4) Participant’s 
expertise  
[To be completed by the expert.  Please briefly identify your 
expertise in relation to the parameters listed above.] 
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5) Key relevant 
evidence 
[The expert should add details of any key documents and studies that 
are relevant to the above parameters.] 
 
 
 
 
  
 338 
 
D.4. Quantifying factors that will influence usage of a new technology for pre-term birth 
screening in the UK 
- Background - 
 
1. Maternity care in the NHS 
- Number of hospital births in England: 669,0001 
- Number of hospital obstetrics units in England: 2312 
- Out of the above, number of teaching hospitals: ~ 603 
- Average number of beds per hospital obstetrics unit: 104 
- Average annual number of births per obstetrics unit in England: ~ 2,900 (Range: 10 - 
7000)
5
 
- Average annual number of births at Jessop wing: ~ 7,0006 
- Average annual number of births at Rotherham hospital: ~ 2,8007 
 
2. Electrical Impedance Spectroscopy for pre-term birth screening 
- Electrical Impedance Spectroscopy (EIS) has been used in cervical cancer screening 
- Currently in development for use in pre-term birth (PTB) with certain adaptations and 
improvements 
- EIS measures impedance of the cervix 
- Use:  
• On pregnant women at high risk based on their history (potentially extendable to 
women without risk factors but this is NOT in the focus of this exercise) 
• Speculum examination where electrical impedance probe is gently placed on the 
anterior lip of the cervix 
• Data is captured automatically when button is pressed 
- A single-centre clinical experimental study is underway:  
• Recruitment of 250 high risk women (and 250 women without risk factors) 
• Exclusion criteria: history of abnormal cervical smear in previous 3 years, cone 
biopsy or loop excision of the cervix, women with recent cervical infection or 
vaginal bleeding, multiple pregnancy or known fetal abnomaly 
• Inclusion criteria: at high risk based on ≥ 1 previous pre-term delivery (< 37 weeks 
gestation) 
• Cervical Impedance (CI) measurement at 20-22 weeks, repeated at 26-28 weeks 
                                                   
1 NHS maternity statistics England 2011-2012 
2 www.progress.babyfriendly.org.uk 
3 Wikipedia: Teaching hospitals England 
http://en.wikipedia.org/wiki/Category:Teaching_hospitals_in_England 
4 NIHR report “Mapping maternity care in England” (2011) 
5 www.birthchoiceuk.com 
6 www.sth.nhs.uk 
7 www.birthchoiceuk.com 
 339 
 
- For the purposes of this exercise, we will assume that the predictive values of EIS for 
pre-term birth measured between 14 and 28 weeks gestation obtained from above study 
are
8
: 
• Before 34 weeks: Positive predictive value (PPV) 63% (the proportion of positive 
test results that are true positives) and negative predictive value (NPV) ~100% (the 
proportion of negative test results that are true negatives) 
• Before 37 weeks: PPV 60% and NPV 96%  
• The proportion of negative tests is not known exactly but was similar to cervical 
length screening ~95%) 
- Costs: We do not know cost data at the moment. Although costs and budgets may, of 
course, be an issue, the capital and disposable costs of EIS are not going to be 
prohibitively expensive. 
- Number of units needed per hospital: 1-5 (results varied from interviews over 
respondents) 
 
3. Progesterone to reduce pre-term birth rates 
- A trial by Fonseca et al (2007)9 showed that progesterone reduced the rate of pre-term 
birth (44% reduction in pre-term birth rates before 34 weeks gestation) when used in 
women with a cervix shortened to 15mm or less (multi-centre, randomised, double-
blind, placebo-controlled, 250 patients with shortened cervix agreed to randomisation 
for 200mg vaginal progesterone or placebo) 
- The PREGNANT trial by Hassan et al (2011)10 found a 45% reduction in the rate of 
pre-term birth at less than 33 weeks of gestation when used in women with 10-20mm of 
cervix length (multi-centre, randomised, double-blind, placebo-controlled, 465 
randomised to 90mg vaginal progesterone or placebo) 
  
                                                   
8 Data was actually obtained from pilot within STH with 40 high risk women enrolled 
9 Fonseca et al (2007) The New England Journal of Medicine 357: 462-469 
10 Hassan et al (2011) Ultrasound Obstet Gynecol 38(1): 18-31 
 340 
 
4. Uptake in new health technologies 
- Uptake = number of adoptions = number of purchases of EIS 
- Uptake over time has been shown to follow s-shaped curves (when looked at 
cumulative adoptions over time)
11
 
1. in initial periods only a few early adopters or innovators will adopt the new 
technology 
2. the following periods see a larger acceptance and a sped up adoption process which 
is marked by increasing peer influence 
3. the last periods show a levelling off phase with only few more late adoptions 
- These curves can be described algebraically using 3 points of information12 (see figure 
below): 
• m: The maximum attainable number of EIS purchases (at the end of the period) 
• p: The number of EIS purchases that can be achieved in the first year (after product 
launch) 
• q: The point in time at which the rate of adoptions (or number of EIS purchases) 
peaks 
- Such s-shaped diffusion curves have been observed in many technologies, some 
examples: 
• Actual uptake curve of ultrasound in neonatal screening13 shows very low initial 
adoptions (p) and growth that starts only slowly; time of maximum number of 
adoptions (q) is at ~13-14 years: 
 
• Forecast uptake curves of new neuro-monitoring device (biomarker) used for 
neonatal monitoring
14
 suggest that initial adoptions would be low and the time of 
maximum adoptions would be just before 10 years: 
                                                   
11 Rogers (2003). Diffusion of Innovations. 5 ed. New York: Free Press 
12 Bass (1969). A new product growth model for consumer durables. Management Science 15: 
215 - 27 
13 Lilien & Rangaswamy (1998) Marketing engineering: computer-assisted marketing analysis 
and planning. Reading, Mass.: Addison-Wesley. 
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• Meta-analysis of uptake curves for different technologies in different industries15 has 
shown larger initial uptake and that time of maximum adoptions is achieved much 
sooner ~ in period 8: 
 
- An unsuccessful product could be reflected through decreasing the attainable number of 
adoptions m, but also through shifting the time where purchases peak left (presumably 
                                                                                                                                                
14 Gobok et al (2009) Forecasting for Biomedical Device Companies: Application of Techniques 
for a New Neuromonitoring Device. San Jose State University, Engineering FotDoG 
15 Sultan et al (1990) A Meta-Analysis of Applications of Diffusion Models. Journal of 
Marketing Research 27(1): 70 - 7 
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an unsuccessful product would prove unsuccessful relatively quickly whereas a 
successful product may need longer to prove itself) 
 
 
5. What will influence uptake of EIS? – Results of phase 1 
In phase 1 of this study, 10 interviews with experts (obstetricians and business managers 
from Teaching and District General Hospitals) were conducted in order to identify what 
factors may influence the uptake of EIS. Results encompass a wide range of different 
aspects that may drive adoptions. The most important drivers that were identified at this 
stage are: 1. Evidence on how predictive EIS impedance results will be of pre-term birth; 2. 
Evidence on progesterone treatment to improve pre-term birth outcomes after having 
identified at risk women with EIS. At a later stage, other factors such as costs, the cost-
benefit, usability or guidance may become more important – but most interviewees agreed 
that first the evidence has to be right. We therefore want to investigate the effect that 
additional trials on 1. and 2. can have on uptake.   
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D.5. Elicitation consent form 
Informed consent form 
 
Quantifying uptake determinants of Electrical Impedance Spectroscopy for use in 
pre-term birth screening in the UK 
Please indicate your agreement with your initials in the right hand-side boxes. 
1. I confirm that I have read and understand the elicitation information 
sheet, the briefing notes and I have had the opportunity to ask questions 
about the exercise. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason and without there being any 
negative consequences. 
 
3. I understand that the information I provide will be securely stored and 
that access will be restricted to the researchers working on this project. I 
understand that my name will not be linked to research materials and I will 
not be identifiable in the report(s) that result from this research. 
 
4. I agree to treating what is said during the elicitation session as 
confidential and not repeating it outside this session. 
 
5. I agree to take part in the above research project.  
 
The following statement is optional. Please indicate your choice by circling it. 
6. I agree that I wish to be informed about the study results. Yes No 
 
 
 
Name of participant      Name of person taking 
consent 
 
Date        Date 
 
Signature       Signature  
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D.6. SHELF Elicitation Record Part 1 
 
ELICITATION RECORD – Part 1 – Context 
To be filled in by the facilitator. 
Elicitation title  
Session  
Date  
Part 1 start time  
 
Attendance and 
roles 
 
Purpose of 
elicitation 
 
This record Participants are aware that this elicitation will be conducted using 
the Sheffield Elicitation Framework, and that this document, 
including attachments, will form a record of the session. 
Orientation and 
training 
 
Participants’ 
expertise  
 
Declarations of 
interests 
 
Strengths and 
weaknesses 
 
Evidence  
Structuring  
Definitions  
 
Part 1 end time  
Attachments  
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D.7. SHELF Elicitation Record Part 2  
ELICITATION RECORD – Part 2 – Distribution 
Tertile Method 
To be filled in by the facilitator. 
Elicitation title Quantifying factors that will influence usage of a new 
technology for pre-term birth screening in the UK 
Session  
Date  
Quantity  
Start time  
 
Definition  
Evidence As presented in background information sheet 
Plausible range  
Median  
Upper and lower 
tertiles 
 
Fitting  
Group elicitation  
Fitting and 
feedback 
 
Chosen 
distribution 
 
Discussion  
 
End time  
Attachments  
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D.8. Post elicitation record 
Post-elicitation record 
Elicitation session number  
Participants’ understanding of the elicitation 
exercise 
 
Difficulties   
How difficulties were overcome  
Description of participants’ experience  
 
 
 
